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Abstract 
Trypanosoma brucei, the eukaryotic parasite that causes human African 
trypanosomiasis in humans, evades the immune system through antigenic 
variation.  T. brucei antigenic variation involves the periodic switching of the 
variant surface glycoprotein (VSG) coat to an antigenically distinct variant.  A 
single VSG is expressed on the cell surface at any one time, but the T. brucei 
genome contains a vast number of silent VSGs.  To be expressed, a VSG must be 
located in a specialised VSG blood stream form expression site (VSG BES).  Silent 
VSGs are copied into VSG BES by homologous recombination.  Several proteins 
have been demonstrated to be involved in this process but how VSG switching is 
initiated remains unclear. 
Four putative DNA repair factors were identified in T. brucei, whose eukaryotic 
homologues play a range of roles in DNA repair and other aspects of genome 
maintenance.  These were two RecQ-like helicases, a Mus81 endonuclease and a 
Pif1 family helicase (PIF6).  To examine whether these factors play a role in DNA 
repair and VSG switching, mutants were generated in blood stream form 
T. brucei cells.  Analysis of RecQ1 by RNAi knockdown revealed it to be an 
essential gene in bloodstream form T. brucei, possibly involved in nuclear DNA 
replication.  Phenotypic analysis of recq2 mutants suggests that RECQ2 is 
involved in the repair of a range of DNA damaging agents.  Furthermore, analysis 
of survival following DSB induction suggests RECQ2 is involved in the repair of 
DNA DSBs, including those in the active VSG BES.  VSG switching analysis showed 
that recq2-/- mutants have an elevated VSG switching rate and increase in 
recombination events upstream of the active VSG.  These analyses suggest that 
RECQ2 suppresses VSG switching in T. brucei by suppressing recombination 
events near the active VSG.  Analysis of mus81 mutants showed mus81-/- mutants 
to be sensitive to agents inducing replication stalling and DNA breaks, and that 
MUS81 is important in the repair of DSBs.  PIF6 appears to be a complicated DNA 
repair factor, different from MUS81 and RECQ2.  pif6+/- and pif6-/- mutants 
appear to be more resistant to MMS than wild type cells, though more sensitive 
to the replication stalling agent hydroxyurea.  pif6 mutants do not appear to be 
more sensitive to DSBs than wild type cells and may even be more resistant.  It is 
unclear whether PIF6 is involved in VSG switching and more work is required on 
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this factor to attempt to understand its DNA repair and VSG switching function in 
T. brucei. 
These analyses shed light on the DNA repair functions of four previously 
uncharacterised T. brucei proteins.  In particular, observations that RECQ2 is 
deficient in repairing DSBs upstream of the active VSG and mutants exhibit an 
elevated VSG switching rate cannot be reconciled with current thinking that 
direct formation of DSBs in this location initiates VSG switching.  This suggests 
that the initiation of VSG switching is more complex than currently thought and 
requires careful further study and consideration of the relevance of using direct 
DSBs in this location to model VSG switching. 
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1 Introduction 
1.1 General Introduction 
Trypanosoma brucei is a eukaryotic parasite within the Trypanosomatidae 
family, a group of protozoan parasites belonging to the Kinetoplastida order.  
Kinetoplastids are distinguished by possession of a kinetoplast, a concatenated 
disc-shaped network of circular DNA molecules (kDNA) that comprise the genome 
of the single mitochondrion found in each cell, located adjacent to the flagellar 
basal body (Lukes et al., 2002).  Kinetoplastid organisms possess a number of 
unusual biological processes compared to other eukaryotes including extensive 
RNA-editing, a process that involves nucleotide insertion and deletion of 
mitochondrial (kDNA) transcripts.  This is necessary in order to produce mature 
transcripts for translation.  The Trypanosomatidae family includes the 
Leishmania and Trypanosoma genera, which contain a number of parasitic 
species that infect humans as well as other vertebrates (Simpson et al., 2006).  
T. brucei causes human African trypanosomiasis (HAT), commonly known as 
African sleeping sickness, in humans and nagana in cattle.  T. brucei is 
transmitted by the tsetse fly vector, thus restricting its distribution to areas of 
Africa the tsetse fly inhabits. 
African trypanosomes live exclusively extracellularly in the bloodstream and 
tissue fluids of mammals.  This extracellular lifestyle contrasts with the 
intracellular Trypanosoma cruzi, a trypanosome species found in South America 
causing Chagas disease.  The extracellular lifestyle of African trypanosomes is 
achieved by antigenic variation, the periodic switching in expression of their 
variant surface glycoprotein (VSG) coat, which enables the parasite population 
to continually evade destruction by the host’s immune system (discussed in 
Section 1.2).  This leads to chronic, and if untreated fatal, T. brucei infections.  
These Trypanosoma species are of substantial health and economic importance 
due to their impact upon humans, directly and indirectly through loss of 
livestock.  T. brucei is the African trypanosome species on which the greatest 
amount of research has been conducted, facilitated by its amenability to 
laboratory culture. 
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The T. brucei species is divided into the subspecies T. brucei brucei, T. brucei 
gambiense and T. brucei rhodesiense.  These subspecies also have a different 
geographical distribution and infection profile: T. brucei rhodesiense is present 
primarily in southern and eastern Africa and causes a fast onset HAT, while 
T. brucei gambiense is present in western and central Africa and causes a slow 
onset, chronic form of HAT (Barrett et al., 2003).  In contrast, T. brucei brucei is 
not infective to humans due to parasite uptake of trypanosome lytic factor 
(TLF), a toxic high-density lipoprotein (HDL) from human serum (Hajduk et al., 
1992; Harrington et al., 2009), composed of apolipoprotein A-I (apo A-I) and 
haptoglobin related protein (Hpr) (Shiflett et al., 2005).  T. brucei brucei is 
closely related to the human-infective subspecies of T. brucei and shares many 
important features with them, including VSG switching. It is therefore frequently 
used as a laboratory model for human trypanosomiasis.  T. brucei brucei is 
however infective to mice, thus providing an in vivo model for trypanosomiasis 
studies. 
1.1.1 Trypanosoma brucei life cycle 
For completion of its life cycle (Fig. 1-1), T. brucei must survive and proliferate 
in both mammals and the tsetse flies (genus Glossina).  The disparate 
environments of the mammalian bloodstream and the tsetse fly has necessitated 
T. brucei to evolve a complex life cycle with distinct stages adapted to the 
environments it inhabits. 
Mammalian hosts are infected via tsetse fly bites.  The saliva of infected tsetse 
flies contains metacyclic form trypanosomes, which are transmitted to the 
mammal when the fly takes its blood meal.  Metacyclic form trypanosomes are 
pre-adapted to infect mammals and cell cycle arrested until they enter the 
mammalian bloodstream (Matthews & Gull, 1997; Shapiro et al., 1984).  
Metacyclic cells possess a metacyclic variant surface glycoprotein (MVSG) coat to 
protect them from the immune response of the mammalian host they enter 
(Tetley et al., 1987; Turner et al., 1988). 
In the mammalian bloodstream, a series of morphological and biochemical 
changes in the metacyclic form cells occurs, leading to differentiation into ‘long 
slender’ bloodstream form (BSF) cells adapted for survival and proliferation in 
Chapter 1  24 
the mammalian bloodstream.  The MVSG surface coat is replaced with a BSF VSG 
(BVSG) coat to protect them from the innate and adaptive immune responses.  
Cells proliferate rapidly in the bloodstream.  The characteristic feature of BSF 
cells is the periodic switching of the single VSG type on the surface of a cell to 
an antigenically distinct VSG - the basis for immune evasion by antigenic 
variation that is shared by many pathogens (discussed in Section 1.2). 
 
Figure 1-1 T. brucei life cycle. 
The life cycle stages of T. brucei are shown, in the form of scanning electron micrograph 
(SEM) images (to scale).  The host animal of each stage and location of life cycle stages 
within the tsetse fly are indicated.  The name of each life cycle stage is shown, with straight 
arrows indicating progression from one stage to another and curved arrows indicating 
proliferative stages.  Figure from Barry & McCulloch (2001). 
Long slender BSF parasites differentiate into ‘short stumpy’ BSF trypanosomes, 
reviewed in Rico et al. (2013).  As parasitaemia increases, long slender form 
cells differentiate into short stumpy form cells that are cell cycle arrested 
(Reuner et al., 1997; Vassella et al., 1997).  Cell cycle arrested short stumpy BSF 
cells die if they are not transmitted to the insect vector (Turner et al., 1995), 
which occurs by ingestion when the fly takes a blood meal.  Trypanosomes pass 
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into the midgut of the fly, where they differentiate into replicative procyclic 
form (PCF) cells, then into proventricular mesocyclic forms that migrate to the 
salivary glands.  In the salivary glands epimastigotes and prometacyclics form, 
which differentiate into infective metacyclics.  The salivary glands are also the 
location of trypanosome meiosis (Peacock et al., 2014; Peacock et al., 2011).  
Metacyclic cells are transmitted back to a mammal when the fly takes its blood 
meal.  Though the mechanism driving the differentiation of PCF cells to 
metacyclic cells in the tsetse fly is unknown, it has been replicated in vitro by 
over expression of the RNA binding protein RBP6 (Kolev et al., 2012), suggesting 
a role for RBPs in this process.  PCF and BSF cells are the two T. brucei life cycle 
stages amenable to in vitro culture. 
1.1.2 Human African Trypanosomiasis: prevalence, symptoms 
and treatment  
African sleeping sickness occurs in 36 sub-Saharan African countries, areas where 
the tsetse fly vector is present to facilitate transmission.  Recent control efforts 
have resulted in fewer than 8000 reported cases in 2012, down from an 
estimated 300,000 cases in 1998 (World Health Organisation).  Approximately 
95% of HAT cases are due to T. brucei gambiense, with only a small minority 
caused by T. brucei rhodesiense (World Health Organisation). 
Human African Trypanosomiasis (HAT) is classed as either stage 1 
(haemolymphatic) or stage 2 (cerebral), depending on whether the trypanosome 
parasites have entered the central nervous system (CNS).  In Stage 1, 
trypanosomes proliferate in the blood and lymphatic tissue; it can last for weeks 
or years and can include asymptomatic periods (Jamonneau et al., 2012; Songa 
et al., 1991).  Stage 2 HAT is characterised by trypanosome invasion of internal 
organs, including the CNS.  This progression can take months or years in T. 
brucei gambiense infections but can occur within weeks in T. brucei rhodesiense 
infections (Barrett et al., 2003). 
There are currently only four drugs licensed for the treatment of HAT: 
pentamidine, suramin, melarsoprol and eflornithine (World Health Organisation).  
These drugs are associated with significant toxicity to the patient and/or dosing 
that is problematic for treatment of patients in under developed countries 
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(Milord et al., 1992; Pepin & Milord, 1991; Wilkinson & Kelly, 2009).  
Additionally, the dense, antigenically variant VSG surface coat means 
development of a vaccine is not promising (La Greca & Magez, 2011). 
1.1.3 T. brucei genome 
The haploid genome of T. brucei (strain TREU927; GeneDB version 2013-08-28) is 
~35 Mb in size and primarily comprised of 11 mega base-sized chromosomes.  
Genome sequencing (strain TREU927; GeneDB version 2013-08-28) revealed 
12094 predicted protein-coding genes, including 1458 pseudogenes.  The gene 
repertoire of strain Lister 427 is less than that of TREU 927, due to a greater 
degree of analysis having been performed on strain TREU927.  Analysis of strain 
Lister 427, which has revealed 9302 predicted protein coding genes, including 
524 pseudogenes and a total genome size of ~26 Mb (GeneDB, version 2010-10-
20). 
In their analysis of VSGs in the main contigs of the megabase chromosomes of 
TREU927, Marcello & Barry (2007) analysed 904 VSGs, whilst Cross et al. (2014) 
identified 2563 distinct VSG genes in the T. brucei Lister 427 genome.  The 11 
mega base chromosomes range in size from 0.9 Mb to >6 Mb and are numbered 1 
to 11, 1 being the smallest and 11 the largest in size.  However, chromosome 
size varies between and within strains, with differences of up to four-fold 
between chromosome homologue pairs in a single isolate (El-Sayed et al., 2000).  
Approximately 20% of the genome encodes subtelomeric sequences, the majority 
of which are T. brucei specific, and a large number of these are involved in 
antigenic variation (Berriman et al., 2005), with many of the telomeres linked to 
VSG bloodstream form expression sites (VSG BESs) (El-Sayed et al., 2000). 
Telomeres are nucleoprotein structures, located at the ends of chromosomes to 
protect them from processes such as exolnucleolytic degradation and end-to-end 
fusions (Stewart et al., 2012).  Eukaryotic telomeres are usually composed of 
TG-rich simple repetitive sequences that are replicated by the specialised 
telomerase enzyme (Nandakurnar & Cech, 2013; Stewart et al., 2012).  Between 
the telomere and the core chromosome sequence lies a region known as the 
subtelomere.  There is no absolute definition of what a subtelomere is, but is is 
agreed that subtelomere sequence is more complex than the simple repeats of 
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the telomere but lacks the degree of conservation between chromosomes that 
the chromosome core possesses, are highly polymorphic and contain an array of 
types of repeat element (Churikov, 2001; Louis & Vershinin, 2005).  Unlike 
telomeres, which do not contain genes, subtelomeres encode genes with 
important cellular functions and human subtelomere instability is associated 
with disease (Sacconi et al., 2013; Mefford et al., 2012).  A number of 
pathogenic organisms that undergo antigenic variation, including T. brucei, 
Plasmodium falciparum and Borrelia burgdorferi, express the genes encoding 
variant surface antigens from subtelomeric regions (Horn, 2014; Claessens et al., 
2014; Zhang et al., 1997).  Additionally, human subtelomeres encode human 
olfactory receptor genes (Mefford, 2001; Trask, 1998) and immunoglobulin heavy 
chains (Das et al., 2008), further evidence for subtelomeres as important 
locations for diverse gene families. 
Expression of the T. brucei genome is also unusual among eukaryotes.  T. brucei 
is the only known eukaryotic organism in which RNA polymerase I (RNAPI) 
transcribes not only rRNA genes but also the protein-coding VSG and procyclin 
genes (Gunzl et al., 2003).  The gene organisation of trypanosomes is also 
unusual, with virtually all genes organised into large directional gene clusters 
(DGCs) containing tens of genes polycistronically transcribed by RNAPII (Imboden 
et al., 1987).  Polytranscriptional units are bounded by variant histones (Siegel 
et al., 2009), transcriptional start sites are marked by histone H3K4 
trimethylation (Wright et al., 2010) and base J (β-d-glucosyl-
hydroxymethyluracil, a modification of thymine) maps to transcriptional 
terminators (Reynolds et al., 2014).  Furthermore, the T. brucei genome displays 
a segregation of gene types, with house-keeping genes clustered in DGCs in the 
core of the megabase chromosomes, VSG gene sequences clustered in the 
subtelomeres and BESs proximal to the telomeres (Barry et al., 2005).  The 
association of genes involved in antigenic variation with telomeres, an 
organisation found in other organisms, has been suggested to be due to the ease 
with which they ectopically recombine, thereby promoting VSG recombination 
(Horn & Barry, 2005). 
T. brucei also contain several intermediate chromosomes (200-900 Kb) and ~100 
mini-chromosomes (50-150 kb) (El-Sayed et al., 2000).  The only genes found so 
far on mini-chromosomes encode VSG and expression site associated genes 
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(ESAGs), though they do not contain VSG BESs (Wickstead et al., 2004).  This 
suggests that for expression of VSGs located on mini-chromosomes, 
recombination of the gene into a VSG BES elsewhere is necessary.  In contrast, 
many VSGs found in intermediate chromosomes are present in VSG BESs, some of 
which at least can be actively transcribed from VSG BESs (El-Sayed et al., 2000). 
1.2 T. brucei antigenic variation 
Though T. brucei is not the only pathogenic organism to undergo antigenic 
variation, it is arguably has the most complex and extensive antigenic variation 
system.  Antigenic variation is a common strategy for pathogenic organisms to 
prolong their survival in their host and enhance transmission and fitness (Barry & 
McCulloch, 2001; Deitsch et al., 2009; Morrison et al., 2009).  Antigenic variation 
is a process exclusively concerned with evasion of host acquired immunity.  In 
this process, an organism expresses a single surface antigen at one time and 
then switches among a series of antigenically distinct variants, each singly 
expressed over time.  The formation of such ‘families’ of surface antigen genes 
can be achieved by a number of mechanisms.  Recombination is a common 
mechanism of antigenic variation and is exclusively used in some pathogens such 
as Anaplasma marginale and Borrelia burgdoferi, which undergo antigenic 
variation of Msp2 (major surface protein 2) and VlsE, a surface lipoprotein 
respectively, both reviewed in Palmer et al. (2009).  Neisseria too uses gene 
conversion recombination (discussed in Section 1.3.2.1) to transfer 
transcriptionally silent PilS sequences to the single PilE expression site.  This 
creates antigenic diversity in the gene encoding pilin, the major subunit of the 
Neisseria type IV pilus, reviewed in Cahoon & Seifert (2011).  However, antigenic 
variation does not have to occur by recombination.  Several pathogens utilise 
transcriptional control to switch antigen variants.  P. falciparum switches 
between ~60 var genes, which encode erythrocyte membrane protein 1 (PfEMP1) 
proteins, by transcriptional control, reviewed in Guizetti & Scherf (2013).  
Giardia lamblia too, uses transcriptional control to switch between expression of 
~200 variant surface proteins (VSPs), reviewed in Prucca et al. (2011). 
Like Neisseria, T. brucei employs an antigenic variation system that uses 
multiple copies of a gene, the VSG, and switches between them.  However, the 
T. brucei system is far more elaborate.  While Neisseria possesses six variants of 
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the pilin gene (Hill & Davies, 2009), the T. brucei distinct VSG genes genome 
contains 2563 distinct VSG genes (Cross et al., 2014) that are expressed on the 
T. brucei cell surface.  In addition, T. brucei possesses >1 site of VSG expression, 
the VSG BESs, meaning that VSG switching is not limited to recombination, but 
can also employ transcriptional control mechanisms.  This huge VSG archive is 
much larger than any antigenically variant gene archive described elsewhere in 
nature (Morrison et al., 2009). 
It has until recently been thought that the VSG is the only antigen accessible to 
the adaptive immune system due to the dense packing of the VSGs in the coat 
(Fig. 1-6), therefore concealing the invariant surface molecules beneath as well 
as preventing complement-mediated lysis machinery from accessing the cell 
membrane.  The host can thus only generate an antibody response to the VSG 
expressed by the majority of the parasite population.  However, a small subset 
of cells switch expression to an antigenically different VSG and this 
subpopulation escapes the immune response targeted to the parental 
population.  This pattern is repeated, and together with the density-dependent 
differentiation of cells from long slender forms to short stumpy forms, produces 
characteristic parasitaemic waves and a prolonged infection (MacGregor et al., 
2011; MacGregor et al., 2012).  The view that the VSG coat shields all invariant 
T. brucei antigens has been challenged recently however, by the discovery that 
a Trypanosoma congolense haptoglobin-hemoglobin receptor is more elongated 
than a VSG protein and thus may extend beyond the VSG coat (Higgins et al., 
2013). 
1.2.1 T. brucei variant surface glycoproteins (VSGs) 
Homodimers of variant surface glycoprotein (VSG) cover the cell surface of 
T. brucei, forming a dense monolayer and hiding the invariant surface molecules 
beneath from the host immune system (Fig. 1-2).  VSGs are 400-500 amino acids 
in length and the majority are between 420 and 460 amino acids long 
(Hutchinson et al., 2003).  The C-terminal region is buried in the cell surface 
where it mediates attachment to the plasma membrane via a GPI anchor 
(Ferguson et al., 1988), while the N-terminal domain points outward, exposed to 
the immune system.  Although VSGs have a conserved structure dominated by 
alpha helices, they typically share less than 25% sequence identity with one 
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another (Hutchinson et al., 2003).  Variation is particularly high in the hyper 
variable N-terminal region of 350-400 residues that are exposed to the immune 
system (Berriman et al., 2005; Hutchinson et al., 2003). 
T. brucei contains an estimated 1600 VSGs in its megabase chromosomes, with 
most of these genes located in subtelomeric arrays (Berriman et al., 2005), as 
well as a further ~200 on the mini-chromosomes and ~20 VSGs located in BESs 
(see below) (Berriman et al., 2005; Marcello & Barry, 2007; Wickstead et al., 
2004).  Analysis of 940 silent VSG genes in TRUE927 by Marcello and Barry (2007) 
revealed that the vast majority of these were not intact genes capable of being 
expressed.  Fewer than 5% were fully intact VSGs and the remainder were full 
length or partial VSG pseudogenes.  Analysis of the VSGs of Lister 427 (Cross et 
al., 2014) revealed a similar picture: 80% of the 2563 distinct complete and 
partial VSGs analysed were incomplete or pseudogenes.  The large pseudogene 
repertoire acts as a resource for the generation of novel full-length mosaic VSGs 
through recombination reactions. 
 
Figure 1-2 The VSG surface coat of T. brucei 
The VSG coat covers the surface of the trypanosome, physically hindering immune access 
to invariant antigens beneath.  The VSG coat is composed of VSG dimers, (blue) composed 
of a C-terminal domain, N-terminal domain and N-terminal loops.  The N-terminal loops are 
exposed to the immune system and are the most variable regions of the VSG.  Figure 
adapted from James Hall, PhD Thesis, 2012 and originally assembled using PDB structures 
1vsg, 1xu6, 1rcj and 1igt, visualized using Pymol (Schrödinger, LLC). 
Trypanosomes also encode up to 27 distinct metacyclic variant surface 
glycoproteins (MVSGs) that are expressed on the surface of metacyclic cells 
(Turner et al., 1988) in the tsetse fly salivary gland.  This MVSG remains 
transcriptionally active until after the metacyclic from cell passes into a 
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mammalian host and begins to differentiate into the BSF (Ginger et al., 2002).  
The MVSG coat is then lost and replaced by a bloodstream VSG (BVSG) coat. 
1.2.2 VSG expression sites 
VSGs are transcribed from expression sites (ESs), polycistronic loci providing a 
mechanism for monoallelic VSG expression.  VSGs can only be expressed if they 
are recombined into the ES and only one ES is actively transcribed at any one 
time, resulting in expression of a single VSG in one cell.  Trypanosomes possess 
two types of ES: VSG blood stream expression sites (VSG BESs) and metacyclic 
expression sites (MESs).  T. brucei brucei EATRO 2340  possesses 23 distinct VSG 
BESs (Young et al., 2008), while Hertz-Fowler et al. (2008) identified 15 VSG 
BESs in the Lister 427 strain.  One suggestion for why T. brucei possesses 
multiple VSG BESs is that they may serve as sites for the construction of novel 
mosaic VSGs through recombination reactions (Marcello & Barry, 2007).  Another 
possibility is that multiple VSG BESs allow for adaptation to growth in different 
hosts through expression of different expression site associated genes (ESAGs) 
(Bitter et al., 1998; Cordon-Obras et al., 2013; Pays et al., 2001).  VSG BESs 
(Fig. 1-3) are between 40 kb and 70 kb in length (Becker et al., 2004) and are 
comprised of a telomere-proximal VSG, invariably flanked upstream by a number 
of 70 bp repeats as well as a number of promoter-proximal expression site 
associated genes (ESAGs) and a region of repeats known as 50 bp repeats.  The 
70 bp repeat region varies in size between 0.1 kbp and 7.0 kbp (McCulloch & 
Horn, 2009) and is not limited to the VSG BES, as over 90% of subtelomeric array 
VSGs have at least one 70 bp repeat 1-2 kbp upstream (Marcello & Barry, 2007).  
These repeats form the boundaries of gene conversion events that recombine 
intact, silent VSGs into active VSG BESs for expression (Alsford et al., 2009).  
Thus, these repeats provide 5’ sequence similarity between highly dissimilar 
VSGs, though it has been suggested that they may provide a more active function 
in recombination reactions (discussed in Section 1.2.4). 
ESAGs are co-transcribed with VSGs from the VSG BES; trans-splicing and 
polyadenylation is used to process the primary VSG BES transcript to produce 
monocistronic mRNAs.  The type of ESAGs present in a VSG BES varies, as does 
the number, though the relative order of the genes is rather conserved (Hertz-
Fowler et al., 2008; McCulloch & Horn, 2009).  Relatively little is known about 
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the function of ESAGs, although a number of functions have been proposed and 
it has been suggested that they may serve to allow for adaptation to different 
host environments (Bitter et al., 1998; Cordon-Obras et al., 2013; Pays et al., 
2001). 
 
Figure 1-3 Generalised schematic of a bloodstream VSG BES 
A typical bloodstream VSG expression site (BES) is shown.  The 50 bp repeat region 
(hatched box) is shown, followd by the promoter is shown (flag), a number of expression 
site associated genes (ESAGs) (turquoise boxes), the 70 bp repeat region (hatched box) and 
the VSG located most telomerically (pink box).  Telomeric repeats are indicated by triangles.  
Not to scale. 
Transcription of the VSG BES (and MES) is carried out by RNAPI, which appears to 
initiate transcription at both active and inactive VSG BES loci, though 
transcription is only fully processive at the single active VSG BES (Vanhamme et 
al., 2000), leading to monoallelic expression of only one VSG and its associated 
ESAGs.  In addition, there is evidence that there is also VSG BES regulation at 
the level of transcription initiation (Nguyen et al., 2014) and that VSG BESs are 
also regulated epigenetically (Figueiredo & Cross, 2010; Lopez-Farfan et al., 
2014; Stanne & Rudenko, 2010).  The expression site body (ESB) is another 
important explanation for monoallelic VSG expression.  The ESB is an 
extranucleolar RNA polymerase I-containing body that is associated specifically 
with the active VSG BES (Navarro & Gull, 2001).  This association of the ESB with 
a specific VSG BES is heritable and crucial for the inheritance of monoallelic VSG 
expression.  The means by which trypanosomes achieve monoallelic VSG 
expression has been recently reviewed by Günzl et al. (2015) and Glover et 
al. (2013b).  T. brucei also contains monoallelically expressed metacyclic 
expression sites (MES).  Although MESs are also transcribed by RNAPI, their 
promoter sequences are different to VSG BESs and they do not contain functional 
ESAGs (Ginger et al., 2002). 
1.2.3 Mechanisms of VSG switching in T. brucei 
T. brucei possesses multiple mechanisms to facilitate the switching of expression 
from one VSG to another.  These are categorised as either transcription-based 
switching or recombination-based switching. 
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1.2.3.1 Transcriptional VSG switching 
Transcriptional VSG switching, also termed in situ switching (Fig 1-4), involves 
the cessation of transcription from the single active BES accompanied by the 
activation of another single VSG BES, harbouring a distinct VSG, and resulting in 
a change in VSG expression.  Attempts to isolate T. brucei cells with two 
activate VSG BESs showed that this is a highly unstable state (Chaves et al., 
1999), illustrating the rigorous control of this process.  Transcriptional control 
thus appears to be coordinated such that the switching ‘off’ and ‘on’ of VSG 
BESs are events dependent on one another (Chaves et al., 1999). 
Work by Figueiredo et al. (2008) showed that epigenetic mechanisms are 
involved in transcriptional VSG switching.  Figueiredo et al. showed that DOT1B, 
a histone methyltransferase that methylates H3K79, is involved in transcriptional 
switching.  Deletion of DOT1B resulted in de-repression of silent VSGs at 
telomeric loci, indicating that histone methylation is important in maintaining 
monoallelic VSG transcription.  Additionally, nucleosomes are depleted at the 
active VSG BES compared to inactive VSG BESs (Figueiredo & Cross, 2010), 
indicating a role for chromatin remodelling in VSG BES regulation.  Depletion of 
cohesin results in loss of monoallelic VSG expression and also causes an increase 
in the rate of VSG transcriptional switching (Landeira et al., 2009), suggesting a 
possible link to DNA replication or cell division.  It is also possible that DNA 
repair plays a role in transcriptional switching since induction of DNA damage 
results in the transcriptional activation of silent VSG BESs (Sheader et al., 2004).  
Utilisation of the much larger number of VSGs outside the VSG BES, by 
recombinational VSG switching, is required for the chronic and fatal infections 
caused by T. brucei. 
Chapter 1  34 
 
Figure 1-4 Transcriptional VSG switching. 
Two VSG bloodstream expression sites (VSG BESs) are shown (A & B).  Initially, the VSG in 
BES (A) (pink box) is expressed, indicated by the red arrow and the VSG in BES (B) is 
inactive, indicated by a red cross.  The VSG in BES (B) (orange box) can be activated by 
turning off transcription of VSG BES (A) and turning on transcription of VSG BES (B).  Not 
to scale. 
1.2.3.2 Recombinational VSG switching  
VSG switching via recombination is the most common form of VSG switching, at 
least in pleomorphic lines, whereas monomorphic lines are believed to have a 
bias towards transcriptional switching  (Aitcheson et al., 2005; Robinson et al., 
1999) - see Section 1.3.2 for discussion of homologous recombination.  
Pleomorphic T. brucei cell lines are those that undergo differentiation from long 
slender BSF cells to short stumpy BSF cells.  In contrast, monomorphic lines do 
not readily undergo this differentiation.  It has been suggested that 
recombination is repressed in the monomorphic lines used in the laboratory such 
as Lister 427, though this is debated (Barry, 1997).  Recombination reactions 
allow the movement of silent VSGs from elsewhere in the genome into active 
VSG BES, leading to transcription of the new VSG.  Silent VSGs in the 
subtelomeric tandem arrays in the megabase chromosomes are the main source 
of VSGs moving into the active VSG BES.  However, silent VSGs in the mini-
chromosome subtelomeres and in silent VSG BESs in the megabase and 
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intermediate chromosomes can also provide new VSGs by recombination and 
appear to be preferentially used early in the course of an infection (Hall et al., 
2013; Morrison et al., 2005). 
A number of distinct reactions have been described in VSG switching by 
recombination: gene conversion (VSG GC), reciprocal telomere exchange 
(telomere crossover, telomere XO) and mosaic VSG formation (Fig. 1-5).  Gene 
conversion (see Section 1.3.2.1 for discussion) involves the duplicative 
transposition of a silent, intact VSG and surrounding sequence into the active 
VSG BES.  The boundaries of the duplicated region frequently extend beyond the 
VSG.  Upstream, the boundary of gene conversion can be the 70 bp repeats but 
can also extend beyond this when the donor VSG is in a BES (Liu et al., 1983; 
Timmers et al., 1987).  Downstream sequence similarity can involve conserved 
3’ VSG open reading frame (ORF) sequences, but often uses common sequences 
in the untranslated regions (UTRs) of the VSG (Bernards et al., 1981) or can 
extend beyond to the end of the chromosome if the silent VSG is telomeric 
(Delange et al., 1983).  The latter is known as telomere conversion.  Although 
70 bp repeats are used for homology, they are not indispensible for gene 
conversion, since VSG switching events by gene conversion are still observed 
when these repeats are deleted from the VSG BES or are inverted (McCulloch et 
al., 1997).  This is because, at least in monomorphic lines, such gene conversion 
reactions often utilise sequence similarity further upstream between VSG BES 
(Lee & Van der Ploeg, 1987), sometimes encompassing much of the ESAGs, even 
as far as the VSG promoter ~50 kb upstream (Hertz-Fowler et al., 2008).  
Synthesis-dependent strand annealing (SDSA) (Borst et al., 1996) and break-
induced replication (BIR) (Barry & McCulloch, 2001) (discussed in Sections 
1.3.2.2 & 1.3.2.3 respectively) have been proposed as specific recombination 
reactions that could account for such gene conversion events.  The involvement 
of BIR in T. brucei VSG switching was supported in a study Boothroyd et 
al. (2009) analysing switched clones (discussed in Section 1.2.4). 
Reciprocal telomere exchange (also called telomere crossover, telomere XO) 
involves the exchange of telomeres between chromosomes by crossing over and 
transfers a silent telomeric VSG into the active VSG BES (Pays et al., 1985), 
though they occur less frequently than other forms of VSG recombination and 
may even be suppressed (Kim & Cross, 2010; Kim & Cross, 2011).  The previously 
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active VSG is concurrently moved to the other chromosome telomere and is 
therefore retained intact on the other chromosome.  It is likely that this process 
is achieved by DNA double strand break repair (DSBR) (Morrison et al., 2009) - 
see Section 1.3 for discussion of DSBR. 
Mosaic VSG formation involves the assembly of mosaic VSG genes through a 
number of segmental gene conversion recombination reactions.  Portions of two 
or more donor VSG genes or pseudogenes are combined to form a novel, 
functional VSG gene by segmental VSG gene conversion (Barbet et al., 1982; 
Barbet et al., 1989; Kamper & Barbet, 1992; Thon et al., 1989; Thon et al., 
1990).  Mosaic gene formation allows an expansion of the number of possible 
VSG genes beyond those already encoded intact in the genome.  As with other 
instances of homologous recombination in T. brucei (Barnes & McCulloch, 2007), 
mosaic VSG formation relies on sequence similarity.  However, in this case the 
reaction must detect some sequence similarity within the VSG ORFs (Marcello & 
Barry, 2007), perhaps reflecting the preference for mosaic VSG donors sharing a 
high degree of sequence similarity (>73%) (Hall et al., 2013).  In contrast to VSG 
gene conversion, the formation of mosaic VSGs is inefficient (Marcello & Barry, 
2007), with mosaics expressed later in infections (Hall et al., 2013).  It is 
assumed that mosaic gene formation involves assembly intermediates, which has 
been suggested to occur in a silent VSG BES (Barry & McCulloch, 2001; Marcello 
& Barry, 2007), though assembly intermediates have not been described in these 
loci or elsewhere. 
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Figure 1-5 Pathways of VSG switching by recombination 
As described in the text, VSG switching by recombination can occur by mosaic VSG 
formation, telomere crossover and VSG gene conversion.  A VSG (pink box) in the active 
VSG BES is shown, a VSG (orange box) in a silent VSG BES and multiple silent VSGs and 
VSG pseudogenes (Ψ) elsewhere in the genome.  Hatched boxes depict 70 bp repeats and 
red arrows indicate transcription of the VSG BES.  A mosaic VSG formed from multiple 
silent VSG and VSG pseudogene donors is depicted by the green and purple box 
A number of proteins have now been identified to be involved in VSG switching 
by recombination.  These include RAD51 (McCulloch & Barry, 1999), the RAD51-3 
paralogue (Dobson et al., 2011; Proudfoot & McCulloch, 2005) and BRCA2 
(Hartley & McCulloch, 2008).  RAD51, RAD51-3 and BRCA2 are homologous 
recombination (HR) components and rad51-/-, rad51-3-/- and brca2-/- mutants 
have a reduced but not abolished rate of VSG switching (Dobson et al., 2011; 
McCulloch & Barry, 1999; Proudfoot & McCulloch, 2005).  In contrast, MRE11 and 
the RAD51 paralogues RAD51-4, -5 and -6, which are all involved in HR, are not 
involved in VSG switching (Bressan et al., 1999; Dobson et al., 2011; Proudfoot & 
McCulloch, 2005; Robinson et al., 1999).  This shows that not all HR factors have 
a role in T. brucei VSG switching.  The topoisomerase TOPO3α (Kim & Cross, 
2010) and RMI1 (Kim & Cross, 2011), components of a complex, which in yeast 
acts as a regulator of crossover (Bussen et al., 2007; Chelysheva et al., 2008; 
Raynard et al., 2008), are also involved in T. brucei VSG switching by 
recombination.  Unlike brca2, rad51 and rad51-3 mutants described above, 
topo3α-/- and rmi1-/- mutants display an elevated VSG switching rate, as well as 
an increase in VSG switching events involving recombination at the 70 bp repeats 
(Kim & Cross, 2010; Kim & Cross, 2011).  These studies demonstrate that factors 
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that act at multiple stages of HR can influence not only the rate of VSG 
switching, but the switching profile. 
1.2.4 T. brucei 70 bp repeats 
The majority (>90%) of VSG genes in T. brucei have one or more 70-bp repeats 
upstream of them.  These apparently VSG-specific repeats were first described 
by Liu et al. (1983), and sequence comparisons have shown that the repeat 
elements are quite variable in sequence and size between loci, though they are 
composed of three sections: a 5’ section, containing 5-116 TAA or TAA-like 
tandem repeats, a moderately conserved sequence with an alternating GT 
characteristic, and a highly conserved 3’ sequence that is mainly alternating TA 
repeats (Aline et al., 1985).  Much of the size variation is due to changes in 
numbers of (TAA)n repeat elements within each repeat (Aline et al., 1985), 
though sequence composition and length changes are found in other conserved 
sub-elements of these complex repeats (Shah et al., 1987). 
In their analysis of the VSG gene silent archive, Marcello & Barry (2007) found 
that 92% of full-length array VSGs have at least one 70 bp repeat 1-2 kbp 
upstream with 74% of these possessing only one, 14% possessing two and 5% 
three to fifteen copies.  However, the number of 70 bp repeats adjacent to VSG 
BES located VSGs is generally greater, comprising tens to over 100 repeats 
(Alsford et al., 2009).  MES VSGs are also flanked by 70 bp repeats, but the array 
lengths appear more comparable with subtelomeric VSGs (Ginger et al., 2002).  
It has long been thought that the 70 bp repeats play an important role in VSG 
switching, though whether they provide passive sequence similarity or are the 
focus for more active promotion of recombination is not clear. 
1.2.4.1 DNA double strand breaks at 70 bp repeats as initiators of VSG 
switching 
The 70 bp repeats are a ‘hot spot’ for recombination events, marking the 5’ 
border of many VSG gene conversion events (Campbell et al., 1984; Liu et al., 
1983).  This contrasts with the 3’ border, which is different depending on the 
type of conversion event.  In gene conversion of array VSGs the 3’ border is 
frequently within the 3’ UTR of the VSG (Bernards et al., 1981), whereas it is the 
chromosome end in the case of telomere conversion (Delange et al., 1983).  
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These conclusions were drawn from analysis and comparison of DNA sequencing 
data of the VSG and VSG BESs before and after VSG switching events.  Taken 
together, these data may suggest that the 70 bp repeats provide 5’ sequence 
specificity in VSG switching that is lacking at the 3’ VSG end.  Along with the 
high proportion of VSGs with 70 bp repeats upstream, in particular at VSG BESs, 
and the absence of significantly detectable numbers of 70 bp repeats elsewhere 
in the T. brucei genome, this has lead to the theory that they may be involved in 
VSG switching. 
Given the very limited sequence similarity between VSGs, one hypothesis is that 
the 70 bp repeats simply serve as stretches of sequence similarity for 
recombination (Delange et al., 1985).  Other authors have hypothesised that 
they serve as the initiation point for gene conversion reactions and are the 
location of the DNA double strand breaks (DSBs) or other lesions required for the 
reaction (Matthews et al., 1990; Pays et al., 1983).  It was suggested that such 
initiation could depend on unusual structures formed by the 70 bp repeats that 
lead to cleavage within the repeat tract (Campbell et al., 1984; Liu et al., 
1983).  Alternatively, they could be recognised by a structure- or sequence-
specific endonuclease (Matthews et al., 1990), both of which would lead to the 
DSB thought necessary to initiate gene conversion.  However, in experiments 
where the 70 bp repeats were removed from the active VSG BES, the overall VSG 
switching rate was not decreased and VSG gene conversion was still observed, 
nor was an effect observed when the repeats were mutated by inversion 
(McCulloch et al., 1997).  This suggests that the 70 bp repeats are not 
indispensible for VSG gene conversion reactions and it was hypothesized that 
mutation of the repeats made the involvement of a structure- or sequence-
specific nuclease or formation of unusual structures unlikely.  However, 
sequencing analysis of switched variants revealed that in cells lacking 70 bp 
repeats 22% had switched the VSG in a gene conversion reaction that utilised 
sequence similarity from an upstream ESAG, a pattern also observed in cells with 
inverted 70 bp repeats but not in wild type trypanosomes.  These findings 
indicate that although the 70 bp repeats are not absolutely required for VSG 
switching, they are a crucial determinant for efficient VSG switching by gene 
conversion (McCulloch et al., 1997). 
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Although DSBs were suggested to occur at 70 bp repeats, initiating gene 
conversion reactions and a homology search, physical evidence for this was 
lacking for a number of years.  A study by Boothroyd et al. (2009) experimentally 
investigated this hypothesis using an inducible yeast meganuclease, I-SceI.  The 
I-SceI meganuclease, originally isolated from Saccharomyces. cerevisiae, is a 
site-specific endonuclease that recognises and cleaves a specific 18 bp 
sequence.  A recognition site for the yeast meganuclease was placed adjacent to 
the 70 bp repeats of the active VSG BES and an inducible copy of the I-SceI gene 
also introduced.  The results of this study are summarised in Figure 1-6.  The 
researchers reported a 250-fold increase in VSG switching frequency upon 
induction of a DSB, a much higher switching rate than normally found in lab-
adapted T. brucei cell lines, and more closely resembling the switching rate of 
non-lab adapted trypanosomes.  This increase in switching was not recapitulated 
when the DSB was induced within an upstream VSG pseudogene, nor after DSB 
induction when the 70 bp repeats were replaced with an I-SceI site.  This 
indicates that the location of the DSB (adjacent to the 70 bp repeats) and the 
repeats themselves are important for the increase in VSG switching.  PCR 
amplification and sequence analysis of 18 of the switched variants revealed that 
all had lost the VSG at the active VSG BES and replaced it with a donor VSG from 
either a silent VSG BES or a mini-chromosome.  Furthermore, in all of the 
switched clones, the sub-telomeric region downstream of the active VSG was 
lost and likely replaced by the sub-telomeric region of the donor VSG.  The 
authors conclude that such a recombination reaction is likely to be a result of 
BIR (discussed in Section 1.3.2.2). 
Boothroyd et al. (2009) then investigated whether DSBs within the 70 bp repeats 
occur naturally in vivo.  Using ligation-mediated PCR on unmodified, wild type 
T. brucei, they detected putative DSBs distributed over the 70 bp repeats of the 
active VSG BES site as well as, though less frequently, upstream of the VSG 
pseudogene where another shorter set of 70 bp repeats is located.  Ligation-
mediated PCR did not detect breaks within an internal chromosome locus 
indicating that DSBs occur naturally and specifically within the 70 bp repeats of 
wild type trypanosomes.  Additionally, DSBs were not detected in a silent VSG 
BES, suggesting that transcription may play a role in DSB formation.  The authors 
suggest that presence of DSBs upstream of the VSG pseudogene could be due to 
Chapter 1  41 
DSBs occurring throughout the VSG BES but that only those in the 70 bp repeats 
last long enough to be detected. 
 
Figure 1-6 Effect of DSB induction at the 70 bp repeats on VSG switching 
Boothroyd et al. (2009) used an I-SceI recognition site and enzyme to induce a DSB adjacent 
to the active VSG BES 70 bp repeats.  Cells consequently switched VSG by recombining a 
silent VSG from elsewhere in the genome (other ESs, mini-chromosomes and silent VSG 
arrays) into the region of the DSB, replacing the previously expressed VSG.  Coloured 
arrows indicate different VSGs, black and white boxes upstream are regions of 70 bp 
repeats, grey arrows are non-VSG genes.  Percentages indicate the frequency of VSG 
switching events detected that utilised VSGs from each region.  Figure from Barry & 
McCulloch (2009). 
Further work by Glover et al. (2013a) supported the hypothesis that DSBs at the 
70 bp repeats initiate VSG switching.  Similarly to Boothroyd et al. (2009), 
Glover et al. (2013a) utilised the I-SceI meganuclease system to induce a DSB at 
one of three locations in the active BES: just downstream of the 70 bp repeats of 
the active VSG BES, adjacent to the BES promoter, or downstream of the VSG 
(proximal to the telomere).  Clonal cell survival following induction of a DSB 
adjacent to the promoter was <20% but was strikingly lower (~5%) when a DSB 
was induced downstream of the 70 bp repeats or proximal to the telomere.  This 
indicates that DSBs in the active VSG BES are typically lethal.  Glover et 
al. reported that DSBs induced near the active VSG BES promoter rarely 
triggered VSG switching and telomere proximal DSBs induced VSG switching in 
28% of surviving clones.  However, almost all surviving clones switched VSG when 
a DSB was induced adjacent to the 70 bp repeats.  Furthermore, DSBs induced 
adjacent to the 70 bp repeats triggered VSG switching mediated by 
recombination using the 70 bp repeats, indicated by retention of ESAG1, an 
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ESAG located upstream of the 70 bp repeats.  In contrast, telomere proximal 
DSBs triggered VSG switching through loss of the VSG BES.  Additionally, 
naturally occurring DSBs were reported in the VSG BES, but in contrast to the 
findings of Boothroyd et al. (2009), they were present at all three VSG BES 
regions assayed, irrespective of whether the site was transcriptionally active or 
inactive.  Similarly, Jehi et al. (2014b) also detected DSBs in inactive VSG BESs, 
suggesting the hypothesis that the breaks exclusively localise in the inactive VSG 
BES and in the 70 bp repeats may be inaccurate. 
The above studies demonstrate that an artificially induced DSB at the 70 bp 
repeats of the active VSG BES can induce VSG switching and that DSBs, or at 
least DNA breaks, naturally occur at the 70 bp repeats of the active VSG BES.  
Whether DSBs also occur within inactive VSG BESs is however, debated.  
Nonetheless, the current prevailing hypothesis for the initiation of VSG switching 
by recombination in T. brucei is that DSBs adjacent to the 70 bp repeats initiate 
VSG switching through a homology search (Boothroyd et al., 2009; Glover et al., 
2013a). 
1.2.4.2 70 bp instability 
A number of events can result in DSBs and the initiation of HR, including 
endonuclease cleavage at specific target sites (Arazoe et al., 2014; Malkova et 
al., 2000), replication fork instability or collapse (Labib & Hodgson, 2007), 
unusual secondary DNA structure (Bochman et al., 2012; Burrow et al., 2010) 
and transcription (Merrikh et al., 2011; Takeuchi et al., 2003).  As such, a 
number of hypotheses can be proposed to explain why the 70 bp repeats may be 
more prone to DSBs than other sites in the T. brucei genome.  It was first 
suggested a number of years ago (Matthews et al., 1990) that a sequence or 
structure –specific endonuclease may be responsible for generating DSBs 
specifically within the 70 bp repeats, similar to yeast mating type switching.  
The S. cerevisiae HO endonuclease makes a site-specific DSB to initiate mating 
type switching that occurs by HR, reviewed by Haber (1998).  However, such an 
endonuclease has yet to be identified. 
A number of alternative explanations exist for the occurrence of DSBs at 70 bp 
repeats based on the repetitive nature of the repeats.  The 70 bp repeats 
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contain a TAA·TTA motif, known to form a non H-bonded structure, which under 
certain conditions can destabilise the DNA helix – a property not shared by other 
triplet repeats (Ohshima et al., 1996b).  Several different triplet repeats are 
well established to cause repeat expansion and, when within or proximal to 
disease genes, genetic mutation resulting in disease in humans (Ohshima et al., 
1996a).  Such triplicate repeats are also associated with DNA polymerase pausing 
(Kang et al., 1995).  For example, DNA polymerase pausing occurs at the 
CTG·CAG triplet repeat whose expansion is associated with myotonic dystrophy 
(Kang et al., 1995), and is a hotspot for recombination (Jakupciak & Wells, 1999; 
Pluciennik et al., 2002).  Pausing of DNA polymerase on triplet repeats, including 
the CTG·CAG repeat, leads to replication slippage and rearrangement (Viguera 
et al., 2001).  However, the TAA·TTA repeat does not share similar properties to 
these repeats; it does not exhibit DNA polymerase pausing and overall has very 
different genetic and biochemical properties (Ohshima et al., 1996b), suggesting 
that its role in gene regulation may differ from other triplet repeats.  
Transcription of the highly repetitive 70 bp repeats in the active VSG BES, which 
have a propensity to form this unstable structure, may destabilise the active VSG 
BES leading to a DSB (Boothroyd et al., 2009). 
A further hypothesis proposes that the 70 bp repeat region is a ‘fragile site’ due 
to the repetitive sequences within the region and thus pre-disposed to 
replication stalling.  Replication fork stalling is associated with a number of 
elongation-blocking lesions including DNA damage, protein, transcription, DNA 
secondary structure or DNA repeats (Labib & Hodgson, 2007; Merrikh et al., 
2011).  Replication fork collapse results in single stranded DNA (ssDNA) gaps, 
which after processing could become structures able to undergo HR and 
potentially initiate VSG switching.  There are multiple ways a replication fork 
could stall in a VSG BES.  As already mentioned, TAA·TTA repeats present in the 
70 bp repeats predispose the region to forming unusual DNA structures.  Such 
structures, or indeed the repeats themselves, could lead to replication fork 
stalling, as has been observed at some sites (e.g. long genes) in other eukaryotes 
(Brewer, 1988; Helmrich et al., 2011; Tuduri et al., 2009).  This suggestion fits 
well with the findings by Boothroyd et al. (2009) who only detected DSBs in an 
actively transcribed VSG BES, though does not explain the presence of DSBs in 
inactive VSG BESs reported by others (Glover et al., 2013a; Jehi et al., 2014b).  
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Furthermore, replication stalling has been documented to initiate gene 
rearrangement.  For example, the induction of a DSB in the S. cerevisiae mat1 
locus is achieved through replication stalling, which leads to recombination and 
gene transposition, resulting in mating type switching (Klar, 2007).  Another 
interesting mechanism by which replication stalling may occur is demonstrated 
in the antigenic variation of the Neisseria PilE locus.  The formation of a 
DNA:RNA hybrid, brought about by expression of a small RNA (sRNA), is necessary 
for the formation of a guanine quadruplex (G4) secondary DNA structure 
required for switching of the downstream PilE locus (Cahoon & Seifert, 2009; 
Cahoon & Seifert, 2013).  G4 structures are guanine-rich regions of DNA capable 
of forming a four-stranded DNA structure (Huppert, 2008).  It is thought that the 
RNA:DNA hybrid forms on the C-rich strand, allowing the formation of the G4 
structure on the G-rich strand, possibly mediated by binding proteins.  G4 
structures can impair replication, leading to replication instability (Lopes et al., 
2011; Rizzo et al., 2009; Weitzmann et al., 1996). 
1.3 Double Strand Break Repair (DSBR) 
The genome is subjected to various types of DNA damage including DSBs, which 
are frequently described (Jackson, 2002; Lees-Miller & Meek, 2003b; Polo & 
Jackson, 2011; Zhang et al., 2009) as the most serious form of DNA damage due 
to loss of integrity of both strands.  DSBs can be caused by a number of events, 
including UV (Greinert et al., 2012) and ionising radiation (Costes et al., 2010), 
replication stalling (Unno et al., 2013), mutagenic chemicals (Driessens et al., 
2009; Ma et al., 2011; Morel et al., 2008) and endogenously generated free 
radicals (Albino et al., 2006).  DSBs that arise must be repaired to prevent 
serious mutations such as gross chromosomal rearrangements, which are 
detrimental and possibly lethal to single-celled organisms.  T. brucei, like all 
eukaryotes, possess multiple mechanisms to repair DSBs.  Non-homologous end 
joining (NHEJ) and HR are the two principle pathways used by most eukaryotes 
to repair DSBs.  These two pathways differ in their requirement for a 
homologous template to repair DSBs and in the fidelity of the repair they 
catalyse.  Both pathways are found in almost all eukaryotes, but whether they 
both act in T. brucei is unclear. 
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1.3.1 Non-homologous end-joining (NHEJ) 
Non-homologous end joining (NHEJ) is a DSBR pathway that is conserved in 
virtually all eukaryotes and is also found in some bacteria (Weller et al., 2002).  
The pathway requires no template and little (2 or 3 bp) or no homology for 
repair, and thus can lead to mutations through the re-joining of resected DNA at 
DSB ends or the re-joining of incorrect DSB ends.  Despite this, evidence 
indicates that most mammalian cells utilise NHEJ more than HR, as NHEJ is 
favoured in G0 and G1 cell cycle stages (Lees-Miller & Meek, 2003b).  NHEJ is 
also favoured when DSBs are located proximal to the telomere (Ricchetti et al., 
2003).  The regulation of pathway choice (HR vs NHEJ) is reviewed in Symington 
& Gautier (2011) and Chapman et al. (2012). 
The primary proteins responsible for NHEJ (Fig. 1-7) are the Ku70/80 
heterodimer and DNA ligase IV, which acts in association with the protein XRCC4 
(Grawunder et al., 1997; McElhinny et al., 2000).  Beyond these core proteins, 
NHEJ in mammals also requires the DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) (Smith & Jackson, 1999), while at least in yeast, the Rad50-
Mre11-Xrs2 (MRX) complex, an endoexonuclease, is necessary (Chen et al., 
2001a). 
The first step of NHEJ is DSB end binding.  The Ku70/80 heterodimer binds the 
DSB ends and can be translocated from the DNA ends in an ATP dependent 
manner (Dynan & Yoo, 1998).  In mammals, this is thought to be important for 
stabilising and recruiting the DNA-PKcs, which also binds to each side of the 
break; DNA-PKcs is recruited by Ku70/80 and forms the DNA-PK complex (Dynan 
& Yoo, 1998).  In yeast, MRX (MRN, Mre11-Rad50-Nbs1 in humans) processes the 
DSB ends (Khanna & Jackson, 2001; Paull & Gellert, 1998).  This role appears to 
have been supplanted by DNA-PKcs in mammals.  Some bacteria, such as Bacillus 
subtilis, possess a NHEJ pathway and Ku homologues have been found, 
suggesting that the pathway arose before the divergence of the prokaryotic and 
eukaryotic lineages (Weller et al., 2002).  The molecules of DNA-PKcs either side 
of the break bridge the ends together prior to re-ligation (DeFazio et al., 2002). 
The final stage of NHEJ is ligation.  In eukaryotes, the NHEJ-specific DNA ligase 
IV/XRCC4 complex is recruited to the DNA ends and catalyses the ligation of the 
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two ends (Chen et al., 2000).  This process often results in loss of nucleotides at 
the two ends of the break, resulting in inaccurate repair. 
 
Figure 1-7 Schematic of the steps of non-homologous end joining 
The steps of NHEJ are shown, as described in the text.  Black lines represent duplex DNA.  
Ku70/80 heterodimers bind the DNA ends (turquoise circles), recruiting DNA PKcs (yellow 
oval) to the DSB ends.  The DNA ligase IV-XRCC4 complex (grey semi-circle and pink 
hexagon respectively) completes the ligation of the DSB ends.  Figure adapted from Claire 
Hartley, PhD Thesis (2008). 
No evidence has so far been found that NHEJ takes place in T. brucei; the 
genome does not encode a detectable DNA ligase IV-XRCC4 complex, though 
Ku70/80 is conserved (Burton et al., 2007; Conway et al., 2002a).  In addition, 
transformation experiments (Conway et al., 2002b), induction of a DSB  (Glover 
et al., 2011; Glover et al., 2008) and analysis of end joining in cell extracts 
(Burton et al., 2007) has each failed to provide evidence for NHEJ. T. brucei 
does however possess an ‘MMEJ’ repair system (microhomology-mediated end 
joining, see below) capable of joining the free ends that is readily seen in each 
of the above experimental settings, perhaps suggesting that it has evolved to 
supplant NHEJ. 
1.3.2 Homologous recombination (HR) 
DSB repair by homologous recombination (HR) involves the utilisation of an 
intact, sequence-related DNA molecule located elsewhere in the genome as a 
template for repair.  For this reason, HR normally results in fewer mutations 
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compared to NHEJ.  In contrast to NHEJ, which predominantly acts in G0/G1 
(Lees-Miller & Meek, 2003a), HR acts primarily in late S-phase/G2 in vertebrate 
cells (Takata et al., 1998), reviewed in Branzei & Folani (2008).  HR can be 
considered to occur in stages, as shown in Figure 1-8. 
The first stage of HR, termed synapsis, involves the invasion of one strand of the 
broken DNA duplex into a homologous sequence, normally an intact duplex, 
elsewhere in the genome.  This requires a 3’ ssDNA overhang coated with a 
filament of the protein RAD51, a eukaryotic homologue of the bacterial RecA 
protein and a key protein in HR, permitting strand exchange to take place.  The 
5’-3’ exonuclease ExoI, MRX (Mre11-Rad50-Xrs2) complex and Sae2 resect the 5’ 
DNA ends to produce 3’ ssDNA overhangs necessary for binding of Rad51 
(Cannavo et al., 2013; Fiorentini et al., 1997; Nicolette et al., 2010).  The ssDNA 
in eukaryotes is coated with replication protein A (RPA), which protects the 
ssDNA from nucleases and removes secondary structure but is also inhibitory to 
nucleoprotein filament formation (Sugiyama et al., 1997).  RPA removal is 
therefore required for RAD51 filament formation.  The RAD52 recombinase, 
which is not detectably present in T. brucei, facilitates this in S. cerevisiae 
(Sugiyama & Kowalczykowski, 2002; Sung, 1997) and BRCA2 has been 
demonstrated to bind RAD51 and promote RAD51 filament formation (Jensen et 
al., 2010; Liu et al., 2010b; Thorslund et al., 2010). 
Following assembly of the RAD51-nucleoprotein filament, strand exchange 
occurs.  RAD51 catalyses the 3’ ssDNA end invasion of an undamaged, 
homologous DNA molecule forming a three-way junction (D-loop).  Though RAD51 
is the catalytic enzyme in strand invasion, it is supported by other proteins 
including RAD52, RAD54, so-called ‘RAD51 paralogues’ (such as RAD55 and RAD57 
in yeast) and BRCA2 (Llorente et al., 2008).  T. brucei encodes four Rad51 
paralogues that act in HR (Dobson et al., 2011; Proudfoot & McCulloch, 2005).  
DNA synthesis then occurs using the D-loop 3’ DSB end as the primer and the 
homologous DNA strand as the template (Paques & Haber, 1999).  After priming 
DNA synthesis on the 3’ DSB end, repair of the DSB can proceed in one of several 
pathways: gene conversion, synthesis dependent strand annealing (SDSA) or BIR. 
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Figure 1-8 Schematic of homologous recombination in eukaryotes 
The stages of HR, as described in the text.  Black lines represent duplex DNA and grey lines 
represent duplex DNA used as the template for repair.  The 3’ ends of the DSB are resected 
by the MRN complex (turquoise arrow) and RPA (pink circles) binds the ssDNA.  RAD51 
(orange ovals) is loaded onto the 3’ ssDNA by BRCA2 (purple oval) and the RAD51 filament 
invades a homologous DNA template (grey line). 
1.3.2.1 Gene conversion 
Gene conversion is the main route of DSB repair by HR (Chen et al., 2007) and 
allows the unidirectional transfer of genetic information from homologous 
sequences to the site of the DSB.  Gene conversion can occur via the formation 
of a Holliday junction (HJ) (Fig. 1-9), or alternatively by synthesis-dependent 
strand annealing (SDSA) or BIR (not depicted, described below).  In both 
pathways, the 3’ DSB end invades the homologous sequence forming a D-loop.  
Gene conversion by HJ resolution then proceeds by the other 3’ ssDNA tail 
pairing with the D-loop, resulting in the formation of two HJs (Holliday, 1964).  
This intermediate is resolved by cleavage of the Holliday junctions to yield 
either a product with or without crossover of flanking regions, depending on the 
axis along which the HJ is cleaved.  Gene conversion by SDSA produces non-
crossover products (Sung & Klein, 2006). 
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1.3.2.2 Break-induced replication (BIR) 
Break-induced replication (BIR) (Fig. 1-9) occurs when only one of the 3’ ssDNA 
strands invades a homologous DNA duplex, forming a D-loop.  BIR can be used to 
repair DSBs when only one end is available for strand invasion and D-loop 
formation, such as when homology only exists at one end of the DSB (Llorente et 
al., 2008).  The D-loop assembles into a replication fork and copies the 
downstream sequence, leading to long gene conversion tracts that can be 
hundreds of kilobases in length or even to the chromosome end (Esposito, 1978; 
Malkova et al., 1996; Paques & Haber, 1999).  The frequent and long gene 
conversions cause BIR reactions to often go undetected in cells (Paques & Haber, 
1999).  Such gene conversion events differ from SDSA (see Section 1.2.2.3) and 
DSB repair because resolution is by establishment of a bubble-like replication 
fork that moves along the chromosome (Saini et al., 2013) rather than through a 
process driven by recombination.  BIR can occur through Rad51-dependent and 
Rad51-indepenedent mechanisms (Malkova et al., 1996; McEachern & Haber, 
2006); Rad51-independent BIR requires shorter homologous sequences (30 bp) 
than Rad51-dependent BIR (Ira & Haber, 2002). 
1.3.2.3 Synthesis-dependent strand annealing (SDSA) 
In contrast to BIR and gene conversion, in synthesis-dependent strand annealing 
(SDSA) the D-loop migrates and the invading DNA strand (forming the D-loop) is 
ejected from the D-loop after priming DNA synthesis.  The ejected strand 
anneals with the complementary strand associated with the other end of the DSB 
(Nassif et al., 1994) (Fig. 1-9).  DNA synthesis and ligation complete the repair.  
As no HJ is formed, only non-crossover products result from SDSA (San Filippo et 
al., 2008). 
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Figure 1-9 Pathways of DSB repair 
Three mechanisms, described in the text, used to repair DSBs by homologous 
recombination are shown.  Solid lines indicate duplex DNA, grey lines represent template 
DNA and dashed lines indicate newly replicated DNA.  Top: a DSB is shown that has been 
processed and one ssDNA end has invaded a homologous template.  Repair of the DSB by 
gene conversion, BIR and SDSA are shown. 
1.3.3 Single strand annealing (SSA) 
A fourth mechanism, single strand annealing (SSA) (Fig. 1-10), can be employed 
to repair DSBs.  It occurs when a DSB is flanked by direct repeats and involves 
repair of the DNA using the repeated DNA sequences.  SSA is independent of 
Rad51 (Ivanov et al., 1996), does not involve the strand invasion and D-loop 
formation described in the mechanisms above and does not produce HJs.  
Instead, following resection of the DSB ends to produce 3’ ssDNA, the 3’ DSB 
ends anneal to one another rather than invading a homologous DNA sequence.  
The Rad52 recombinase is required for SSA (Ivanov et al., 1996).  Glover & Horn 
(2009) found that repair of DSBs within the RRNA spacer locus, which is flanked 
by stretches of duplicated sequence, was consistent with SSA, suggesting this 
process operates in T. brucei. 
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Figure 1-10 DSB repair by single strand annealing (SSR) 
Duplex DNA is represented by black lines and direct repeat sequences are indicated in 
yellow.  Resection of the non-homologous 5’ ends of the DSB is followed by annealing of 
the direct repeats.  The overhangs are resected and ligation completes repair of the DSB, 
resulting in loss of the sequence between the direct repeats. 
1.3.4 Microhomology-mediated end joining (MMEJ) 
Microhomology-mediated end joining (MMEJ) (Fig. 1-11) is another DSB repair 
pathway, potentially distinct from NHEJ and HR, though the enzymatic 
machinery remains unknown.  Although it was initially thought that MMEJ 
functioned only in the absence of NHEJ machinery, it has been established that 
MMEJ occurs even when the NHEJ pathway is not compromised (McVey & Lee, 
2008; Nussenzweig & Nussenzweig, 2007).  In contrast to NHEJ, which requires 
no homology to repair DSBs, MMEJ requires short stretches of homology, typically 
~6-20 bases, though (as with NHEJ) it is error prone and loss of sequence occurs 
(McVey & Lee, 2008).  It has been proposed (McVey & Lee, 2008) that MMEJ 
repair begins with the removal of Ku70/80 and Rad51 (which inhibit MMEJ) from 
the DNA, followed by resection of the 5’ DNA ends by the MRX complex and the 
nuclease Exo1 and endonuclease Sae2.  This promotes resection to reveal micro-
homologous sequences.  These micro-homologous sequences anneal to one 
another and repair is completed by DNA synthesis and ligation.  The enzymes 
responsible for the short homology base-pairing are unclear and the process can 
be very imprecise, leading to repair products containing numerous base 
mismatches.  MMEJ is readily detected in T. brucei in vivo (Conway et al., 
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2002b; Glover et al., 2011) and in vitro using nuclear cell extracts (Burton et 
al., 2007), and may therefore be a robust process in T. brucei. 
 
Figure 1-11 Microhomology-mediated end joining (MMEJ) 
Duplex DNA is represented by black lines and yellow boxes indicate microhomologous 
sequences.  After removal of Ku70/80 and RAD51, repair by MMEJ proceeds by resection of 
the 5’ DNA ends to reveal 3’ ssDNA and microhomologous sequence.  These 
microhomologies anneal and repair is completed by trimming of 3’ ssDNA flaps, gap filling 
DNA synthesis and ligation of ends to produce dsDNA, with loss of sequence between the 
microhomologies. 
 
1.4 DNA Helicases in DNA repair 
Helicases are molecular motors that unwind polynucleic acids using energy 
released from nucleoside triphosphate (NTP) hydrolysis, most commonly ATP.  
This process results in the translocation of the helicase along the polynucleic 
acid in a 5’!3’ or 3’!5’ direction.  Helicases are divided into two major 
superfamilies: superfamily 1 (SF1) and superfamily 2 (SF2), along with the 
smaller superfamilies 3 to 6.  Different types of helicase act on different nucleic 
acid substrates.  DNA helicases unwind DNA, RNA helicases unwind RNA and some 
helicases unwind DNA:RNA hybrids.  DNA helicases function in a wide range of 
nucleic acid processes.  Some examples of roles helicases play in DNA 
replication, transcription, repair and recombination are described below. 
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Helicases are crucial for the replication of DNA.  For example, the MCM2-3 (mini 
chromosome maintenance complex) helicase is the eukaryotic replicative 
helicase (Labib et al., 2000).  Other helicases facilitate replication of specific 
regions, such as the role of the Srs2 helicase in replication of hairpins (Anand et 
al., 2012).  The recovery of replication forks that have stalled, reversed or 
collapsed also require helicases.  For example, the Werner helicase, along with 
the Dna2 nuclease, functions in the recovery and restart of reversed replication 
forks in human cells (Thangavel et al., 2015). 
Transcription and transcriptional regulation also utilises helicases.  The TFIIH 
(transcription factor II human) complex, which is part of the transcription 
initiation apparatus, also functions in DNA repair, and contains two DNA 
helicases, XPD and XPB (xeroderma pigmentosum group D and xeroderma 
pigmentosum type B) – reviewed in Egly & Coin (2011).  Another family of 
helicases with important roles in transcription is the DExD/H box RNA helicases.  
These helicases regulate transcription in a variety of ways, reviewed in Fuller-
Pace (2006), including acting as transcriptional co-activators or repressors, 
acting as bridging factors to recruit transcription factors and stabilising 
transcription initiation complexes. 
XPB and XPD helicases, as part of the TFIIH complex, also function in nucleotide 
excision repair (NER) (Coin et al., 2004; Kuper et al., 2014; Timmins & 
McSweeney, 2006).  NER is a DNA repair pathway that repairs single-stranded 
DNA damage, such as UV damage, which distorts the DNA helix, reviewed in 
Kamileri et al. (2012).  Helicases also participate in other DNA repair pathways.  
Human RECQL5 (RecQ-like 5) is involved in base excision repair (BER) (Tadokoro 
et al., 2012), a repair pathway that corrects lesions resulting processes such as 
alkylation, oxidation and deamination, reviewed in Robertson et al. (2009). In 
addition, a number of helicases including Sgs1/BLM and human helicase B are 
involved in DNA repair by homologous recombination (Liu et al., 2015; Wu & 
Hickson, 2003).  Helicases can play both stimulatory and inhibitory roles in 
homologous recombination.  For instance, the Sgs1 helicase in yeast (Bloom 
helicase in humans) is part of the machinery that resects DNA ends, a necessary 
step for HR (Mimitou & Symington, 2008; Nimonkar et al., 2011).  In contrast, 
the Srs2 helicase has an anti-recombinogenic effect due to its disruption of 
RAD51-ssDNA filaments (Krejci et al., 2003; Veaute et al., 2003). 
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1.4.1 RecQ helicases in DNA repair and two putative T. brucei 
RecQ-like helicases 
RecQ-like helicases are an SF2 family (Gorbalenya & Koonin, 1993) of DNA 
helicases so-called due to the homologous region they share with the E. coli 
RecQ helicase, first described by Umezu et al, (1990).  The RecQ family is 
conserved from bacteria to humans (Fig. 1-12) and unwind DNA in a 3’!5’ 
direction (Bachrati & Hickson, 2008).  Schizosaccharomyces pombe and 
S. cerevisiae each possess a single RecQ helicase, Rqh1 and Sgs1 respectively.  In 
contrast, multicellular eukaryotes such as humans and Drosophila possess 
multiple RecQ helicases (Adams et al., 2003; Bernstein et al., 2010; Capp et al., 
2009; Chen et al., 2010). 
 
Figure 1-12 Domains and features of bacterial and eukaryotic RecQ helicases 
Typical domains and features found in RecQ helicases are shown.  All RecQ helicases share 
a conserved helicase (DEAD/DEAH box helicase) domain.  RQC (RecQ C-terminal) and 
HRDC (helicase and RNAse D C-terminal) domains are present in most RecQ family 
members and mediate protein and nucleic acid interactions.  Some members contain a 
strand exchange domain, exonuclease domain or nuclear localisation signal.  The number 
of amino acids in each protein sequence is indicated on the right.  Accession numbers can 
be found in Appendix 7.2.  Not to scale. 
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RecQ helicases participate in DNA replication, recombination and repair 
(Croteau et al., 2014).  RecQ proteins interact with many DNA repair proteins to 
play multiple roles in multiple types and stages of DNA repair.  They also 
participate in DSB NHEJ, where the Werner syndrome RecQ protein (WRN) 
interacts with the XRCC4-ligase IV complex (Kusumoto et al., 2008).  In addition, 
human RECQ1 interacts with Ku70/80, with depletion of RECQ1 leading to 
reduced NHEJ (Parvathaneni et al., 2013).  HR involves RecQ proteins such as 
the yeast Sgs1 and human Bloom syndrome RecQ protein (BLM) helicases, which 
promotion resection of DNA ends (Gravel et al., 2008; Mimitou & Symington, 
2008; Zhu et al., 2008).  Yeast Sgs1 also interacts with Rad51 to inhibit Rad51 
filament formation (Wu et al., 2001).  S. cerevisiae Sgs1 interacts with the HR 
nuclease Mre11 (Chiolo et al., 2005).  Addtionally, Sgs1/BLM interact with 
mismatch repair proteins Mlh1 and Mlh3 (Argueso et al., 2003; Dherin et al., 
2009; Langland et al., 2001; Wang & Kung, 2002).  The function of these RecQ-
mismatch repair interactions is unclear, though it has been suggested it could be 
to promote resolution of meiotic crossovers (Wang & Kung, 2002).  
RecQ helicases also interact with many proteins involved in DNA replication.  For 
example, human RECQ4 interacts with the replisome factors MCM10 and MCM2-7 
helicase and RECQL4 interacts with CDC45 and GINS (Go, Ichi, Nii, and San; five, 
one, two, and three in Japanese) (Im et al., 2009; Xu et al., 2009b).  Due to 
their direct role in DNA replication, absence of RecQ helicases can lead to 
replicative damage.  For example, WRN co-purifies with the DNA replication 
complex in embryonic stem cells (Lebel et al., 1999), and absence of BLM and 
WRN leads to accumulation of replication intermediates (Lonn et al., 1990).  
RecQ helicases also act in the repair of replicative damage, as in the case of 
yeast Sgs1, a function that interestingly can be uncoupled from its function in 
DNA recombination (Bernstein et al., 2009). 
RecQ helicases play an important role in the processing of double Holliday 
junctions (dHJs) as part of the RTR (also known as BTR) complex.  The complex 
is composed of a RecQ helicase (BLM in mammals, SGS1 in yeast), a 
topoisomerase IIIα and RMI1 (RecQ mediated genome instability 1; also known as 
BLAP75/18) (Johnson et al., 2000; Wu et al., 2000; Yin et al., 2005).  The RTR 
complex is an important regulator in the processing of dHJ recombination 
intermediates, to produce exclusively non-crossover products, known as dHJ 
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dissolution (Bussen et al., 2007; Chelysheva et al., 2008; Raynard et al., 2008) 
(Wu & Hickson, 2003) (Fig. 1-13).  This in contrast to the alternative pathway of 
processing dHJs by resolvases (such as Mus81), which can produce both non-
crossover and crossover products, known as dHJ resolution.  In dissolution, the 
RecQ helicase in the RTR complex branch migrates the two HJs closer to one 
another to form a hemicatenane intermediate, a structure in which one strand 
of a DNA duplex is wound around a strand of another DNA duplex.  TOPO3α then 
processes the hemicatenane, making a nick in one strand and passing the other 
strand through to dissolve the dHJ (Yang et al., 2010). RMI1 possesses no 
catalytic activity but its presence is essential for the stability of the complex 
and loss of RMI1 results in an increase in crossover events similar to that 
observed after BLM/SGS1 loss (Chang et al., 2005; Yin et al., 2005).  
Alternatively, resolvases can process dHJs by cleaving the dHJs and depending 
on the the orientation of the nucleolytic cleavage the result is either a crossover 
or non-crossover product.  In humans this can be achieved with either the 
MUS81-EME1 (MUS81-MMS4 in S. cerevisiae) complex acting together with SLX1-
SLX2, or by GEN1 (YEN1 in S. cerevisiae).  As crossovers are potentially 
deleterious to the cell, the processing of dHJs by resolution is tightly regulated 
during the cell cycle.  Dissolution via the RTR complex is favoured throughout 
most of the cell cycle, with resolvase activity limited to the end of the cell cycle 
to resolve any remaining recombination intermediates that would be a barrier to 
chromosome segregation (West et al., 2015). 
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Figure 1-13 Resolution and dissolution of double Holliday junctions 
A double Holliday junction (dHJ) is shown following resection of a DSB, D-loop formation 
and pairing of the other 3’ ssDNA tail to form a dHJ.  Processing by resolution involves a 
resolvase such as the MUS81-EME1/SLX1-SLX4 complex or GEN1 and can result in 
crossover or non-crossover products depending on the orientation of cleavage (coloured 
arrows).  Alternatively, the RTR can dissolve the dHJs using the branch migration activity of 
the RecQ-like helicase and the decatenating activity of the topoisomerase, producing only 
non-crossover products. 
Trypanosoma brucei is unusual among unicellular organisms with respect to its 
RecQ helicases.  The T. brucei genome contains two genes annotated as putative 
RecQ-like helicases: Tb427.06.3580 (here referred to as RECQ1) and 
Tb427.08.6690 (here referred to as RECQ2) (TriTrypDB.org).  These two T. brucei 
putative RecQ helicases are two of the factors examined in this thesis, neither 
having been characterised prior to this work.  Most multicellular organisms 
possess multiple RecQ helicases (discussed below).  Humans encode five: WRN 
(Werner syndrome protein), BLM (Bloom syndrome protein), RECQ1, RECQ4 and 
RECQ5 (Bernstein et al., 2010).  C. elegans encode four, named HIM-6, WRN-1, 
Chapter 1  58 
RECQ5 and RECQ1, though only the first three have been functionally 
characterised (Hyun et al., 2012; Jeong et al., 2003; Jung et al., 2014).  In 
contrast, unicellular organisms generally only contain one RecQ helicase: e.g. 
RecQ in E. coli, Rqh1 in S pombe and Sgs1 in S. cerevisiae (Bachrati & Hickson, 
2008; Myung et al., 2001; Umezu et al., 1990).  T. brucei is therefore unusual 
among unicellular organisms in containing more than one RecQ helicase, though 
this would appear to be common among kinetoplastids, since searches conducted 
on the TriTryp database (TriTrypDB.org) show that most Trypanosoma and 
Leishmania spp, as well as Crithidia fasciculata, contain more than one gene 
annotated as a RecQ-like helicase. 
Kinetoplastids have evolved expanded gene families to carry out kinetoplastid 
DNA (kDNA) repair and replication.  For example, the Pif1 helicase gene family, 
restricted to one or two genes in most eukaryotes, is expanded in T. brucei to 
eight genes, six of which localise to the mitochondria and three of which have 
been demonstrated to function in kDNA replication or maintenance (Liu et al., 
2009a; Liu et al., 2009b; Liu et al., 2010a; Wang et al., 2012).  Kinetoplastids 
also contain an expansion in bacterial-like DNA Polymerase I-related enzymes 
that all act in kDNA replication or maintenance (Bruhn et al., 2010; Chandler et 
al., 2008; Concepcion-Acevedo et al., 2012; Klingbeil et al., 2002).  Given this, 
it is possible that TbRECQ1 has evolved to provide a specialised kDNA function. 
1.4.2 Pif1 family helicases in DNA repair 
First described in S. cerevisiae (Foury & Kolodynski, 1983), and since shown to 
be present in almost all eukaryotes, Pif1 family helicases (Fig. 1-14) belong to 
the SF1B helicase family and move in a 5’!3’ direction (Bochman et al., 2010).  
S. cerevisiae possesses two Pif1 helicases, Pif1 and Rrm3, though most 
eukaryotes studied to date possess only a single Pif1 helicase (Bochman et al., 
2010).  The founding member of the PIf1 helicase family is S. cerevisiae Pif1 
(ScPif1), which was discovered in a genetic screen for genes affecting 
mitochondrial DNA (Foury & Kolodynski, 1983). 
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Figure 1-14 Pif1 family helicases 
Pif1 helicase domains in various eukaryotic Pif1 helicases and predicted protein domains in 
all eight T. brucei PIF1 helicases.  The number of amino acids in each sequence is shown on 
the right.  Accession numbers can be found in Appendix 7.2.  Not to scale. 
 
As with RecQ helicases (Section 1.4.1), Pif1 helicases participate in a wide 
variety of nucleic acid processes.  S. cerevisiae Pif1 inhibits telomerase, with 
pif1 null mutants possessing longer telomeres and repairing DSBs by aberrantly 
adding telomeres to the DSB ends (Makovets & Blackburn, 2009; Schulz & Zakian, 
1994; Zhou et al., 2000).  Several lines of data suggest that the S. pombe Pif1 
protein and one of the three isoforms of the S. pombe Pif1 protein Pfh1p 
functions in the DNA damage response.  Pfh1p levels increase following 
camptothecin treatment (Pinter et al., 2008), an inducer of DNA lesions through 
its inhibition of topoisomerase I (Hsiang et al., 1985; Liu et al., 2000).  In 
addition, Pfh1 mutants in S. pombe and Pif1 mutants in S. cerevisiae are both 
more sensitive to the DNA damaging agents MMS and hydroxyurea (Tanaka et al., 
2002; Wagner et al., 2006).  Both Pif1 and Pfh1 localise to DNA damage foci, 
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Pfh1 after gamma irradiation and Pif1 after treatment with the DNA damaging 
agent camptothecin (Pinter et al., 2008; Wagner et al., 2006).  Furthermore, S. 
cerevisiae Pif1 has been proposed to play a direct role in the repair of DSBs by 
BIR (Chung et al., 2010; Wilson et al., 2013). 
G4 structures are thought to be acted upon by Pif1 helicases.  S. cerevisiae Pif1 
suppresses G4-associated genomic instability (Paeschke et al., 2013) and 
recombinant S. cerevisiae PIF1, along with over 20 other Pif1 helicases, have 
been shown to bind and/or unwind G4 structures in vitro (Paeschke et al., 2013; 
Ribeyre et al., 2009). 
Pif1 helicases play a number of roles in replication.  Nuclear S. cerevisiae Pif1 
participates in the processing of Okazaki fragments and some reports suggest 
that S. cerevisiae Rrm3 is a component of the replisome (Azvolinsky et al., 2006; 
Matsuda et al., 2007).  However, there is debate as to whether Rrm3 is a part of 
the replisome or if it is specifically recruited to stalled replication forks (Calzada 
et al., 2005).  A major function of S. cerevisiae Rrm3 is in the disruption of 
protein-DNA complexes at certain genomic loci, known as Rrm3-sensitive sites.  
In the absence of Rrm3, the replication fork pauses at these sites (Ivessa et al., 
2002).   
Lastly, Pif1 helicases also perform mitochondrial functions.  S. cerevisiae Pif1 
has two isoforms, produced by initiation of translation from two different start 
sites.  Translation initiation from the first start site results in the inclusion of a 
mitochondrial targeting sequence in the protein and synthesis of the 
mitochondrial isoform (mtPif1) (Zhou et al., 2002).  S. cerevisiae mitochondrial 
Pif1 is required for the maintenance of mitochondrial (mt) DNA, with 
mitochondrial DNA being lost more quickly in Pif1 mutant strains (Schulz & 
Zakian, 1994; Vandyck et al., 1992) 
S. cerevisiae mtPif1 may be part of the mitochondrial replisome (Cheng et al., 
2007; Foury & Vandyck, 1985) and be involved in mitochondrial DNA replication 
and recombination, though it plays a non-essential role (Cheng et al., 2009). 
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1.4.2.1 Pif1 helicases in T. brucei 
In contrast to the single Pif1 family helicase possessed by most eukaryotes, 
T.  brucei has eight Pif1 helicases, TbPIF1-8.  The predicted protein domain 
organisation of Tb1-8 are shown in Fig. 1-14.  The majority of T. brucei Pif1 
helicases (TbPif1-2 and TbPif4-7) contain a predicted Pif1 family domain, as 
predicted using InterProScan sequence search.  Two helicase domains (though 
not specifically Pif1 helicase domains) are predicted in TbPif3 and TbPif8 
contains a P-loop containing nucleotide triphosphatase hydrolase domain.  The 
absence of a detectable Pif1 helicase domain in two T. brucei Pif1 helicases 
demonstrates the divergent nature of T. brucei.  The majority of these Pif1 
helicases have been shown to play a kinetoplast role: TbPIF1, 2, 5 and 8 have 
been characterised and are involved in kinetoplast replication (Liu et al., 2009a; 
Liu et al., 2009b; Liu et al., 2010a; Wang et al., 2012).  TbPIF3, 4 and 7 yet to 
be characterised, but TbPIF3 localises to the cytoplasm while TbPIF4 and 7 
localise mainly in the kDNA disc (Liu et al., 2009a).  TbPIF6 has been 
demonstrated to localise to the nucleus (Liu et al., 2009a) but otherwise has not 
been characterised.  All three proteins play roles in genome maintenance, 
stability or repair in other organisms but have not been characterised in T. 
brucei. 
1.5 Mus81 endonucleases in DNA repair and a putative 
T. brucei Mus81 homologue 
Mus81 (MMS UV Sensitive) is a structure specific endonuclease first identified in 
S. cerevisiae (Boddy et al., 2000; Interthal & Heyer, 2000).  It acts in complex 
with its partner protein (Eme1 in humans and S. pombe, Mms4 in S. cerevisiae), 
which is essential for Mus81 nuclease activity (Boddy et al., 2001; Ciccia et al., 
2003; Kaliraman et al., 2001; Ogrunc & Sancar, 2003).  Mus81 proteins of S. 
cerevisiae, S. pombe and H. sapiens are shown in Figure 1-15.  MUS81 proteins 
contain an ERCC4 domain.  ERCC4 domains are involved in nucleic acid binding 
and are found in a number of DNA repair proteins, including RAD1 and XPF, as 
well as in MUS81 and another crossover junction endonuclease, EME1 (Ciccia et 
al., 2008). 
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Mus81 acts with its partner protein to perform a number DNA repair functions 
involving resolution of recombination intermediates arising from replication and 
recombination by DNA cleavage (Hanada et al., 2007; Regairaz et al., 2011b).  
Mus81 resolves stalled and collapsed replication intermediates in human and 
yeast cells (Doe et al., 2002; Hanada et al., 2007; Regairaz et al., 2011a) and 
promotes the restart of stalled replication forks by fork cleavage (Pepe & West, 
2014a).  Mus81 also acts on 3’ DNA flaps and nicked HJs (Pepe & West, 2014b) 
and also acts on intact HJs (Boddy et al., 2001; Chen et al., 2001b; Gaillard et 
al., 2003).  Resolution of recombination intermediates by Mus81 results in 
crossover and yeast mus81 mutants have a lower rate of meiotic crossover 
(Boddy et al., 2001; Kaliraman et al., 2001; Osman et al., 2003).  Mus81-
mediated meiotic crossover has also been observed in mice (Holloway et al., 
2008).  Additionally, Mus81 acts to promote BIR repair of DSBs by its recruitment 
to the invading DNA strand, where its endonuclease activity facilitates the 
establishment of the replication fork required to complete BIR (discussed in 
Section 1.2.2.2).  In this process, Mus81 also promotes template switching, 
where the invading DNA strand ‘switches’ to a new homologous template, which 
frequently results chromosomal translocations (Pardo & Aguilera, 2012; Štafa et 
al., 2014). 
MUS81 is also involved in the response to some forms of DNA damage such as 
methylation and UV-induced DNA damage in S. cerevisiae (Interthal & Heyer, 
2000), and interstrand crosslinks in mammalian cells as part of the MUS81-EME1 
complex (Hanada et al., 2006).  Budding and fission yeast toleration of 
replication defects also requires Mus81, where Mus81 allows replication through 
damaged DNA and helps recruit Cds1, a protein that modulates the activity of 
damage tolerance enzymes (Boddy et al., 2000; Interthal & Heyer, 2000). 
The T. brucei genome encodes one gene (Tb427.08.6740; TbMUS81) that BLAST 
(basic local alignment search tool) analysis conducted prior to this work 
suggested is a Mus81 homologue but that has not been characterised or 
examined. 
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Figure 1-15 Illustration of yeast and human Mus81 proteins. 
Comparison of the size of eukaryotic Mus81 proteins and and location of ERCC4 domains. 
The number of amino acids in each protein sequence is indicated on the right.  Accession 
numbers can be found in Appendix 7.2.  Not to scale. 
 
1.6 Aims of this project 
The overall aim of this thesis was to investigate the role of several 
uncharacterised factors in DNA repair and VSG switching in T. brucei.  In 
particular, it was aimed to investigate the hypothesis proposed by Boothroyd et 
al. (2009), and since commencing this work supported by Glover et al. (2013a), 
that DSBs at the 70 bp repeats of the active VSG BES initiate VSG switching by 
recombination.  These factors were selected based on the DNA repair and 
replication functions of their equivalent proteins in other eukaryotes, notably 
humans and yeast. 
The aforementioned uncharacterised T. brucei factors were: TbRECQ1 and 
TbRECQ2 (Tb427.06.3580& Tb427.08.6690; RecQ-like helicases), TbMUS81 
(Tb427.08.6740; structure-specific endonuclease) and TbPIF1 (Tb427.10.910; 
Pif1 family helicase).  The specific aims of this work and the approaches taken 
to address each are detailed below. 
1.6.1 Roles of four factors in DNA repair 
Aim 1: Investigate whether each of these four factors are involved in T. brucei 
DNA repair. 
Approach: Generation of heterozygous and null knockout mutants in wild type 
cells and analysis of their DNA damage phenotypes. 
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1.6.2 Roles of four factors in DSB repair 
Aim 2: Establish whether each of the four factors are involved in the repair of 
DSBs, including DSBs at the 70 bp repeats, the location hypothesised to be where 
VSG switching-initiating DSBs occur. 
Approach: Generate heterozygous and null knockout mutants in cell lines that 
allow the induction of DSBs at specific locations using the I-SceI meganuclease 
system, and analyse survival and repair of DSBs in these mutants. 
1.6.3 Roles of four factors in VSG switching 
Aim 3: Assess whether and how the four factors function in VSG switching. 
Approach: Generate heterozygous and null knockout mutants in a cell line 
permitting the VSG switching rate and profile of T. brucei cells to be assayed in 
vitro and perform VSG switching experiments using these mutants. 
1.6.4 DSBs at the 70 bp repeats as the initiators of VSG switching 
These aims sought to investigate the role of these four factors in DSB repair at 
the site hypothesised to initiate VSG switching (using I-SceI directed DSBs), while 
also investigating their role in VSG switching in an unbiased fashion (using a VSG 
switching assay).  This concurrent analysis was designed to not only investigate 
whether and how these factors are involved in DNA repair and VSG switching, 
but also further our understanding of the initiation of VSG switching and explore 
the hypothesis that DSBs at the 70 bp repeats are the initiating lesion. 
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2 Materials and Methods 
2.1 Trypanosome culture 
2.1.1 Trypanosome strains and their growth 
The trypanosome strain used in this thesis is Lister 427 (McCulloch et al., 1997; 
Rudenko et al., 1996).  This is a monomorphic T. brucei brucei strain, usually 
only displaying long slender blood stream form (BSF) cells.  The VSG switching 
frequency of this strain is 10-6-10-7 switches per cell per generation (Lamont et 
al., 1986; Turner, 1997).  For RNAi experiments, the 2T1 strain, derived from 
the Lister 427 strain, was used (Alsford et al., 2005b). 
HMI-9 medium (Hirumi & Hirumi, 1989) was used for in vitro growth of BSF Lister 
427 trypanosomes.  Pre-formulated HMI-9 powder (Gibco, cat. no. 07490915N) 
was supplemented with 3% w/v NaHCO3 and 200 µM β-mercaptoethanol to 
produce ‘incomplete’ HMI-medium.  Incomplete HMI-9 medium was filter 
sterilized using a 0.22 µM bottle top filter unit (Millipore, cat. no. SCGPS05RE) 
and stored at 4˚C.  For use, HMI-9 was completed with 20% v/v foetal bovine 
serum (FBS) (Sigma, cat. no. F9665) to produce ‘complete’ HMI-9.  For I-SceI cell 
lines, tetracycline-free FBS was used (Invitrogen, cat no. 10270-106) and for 
RNAi lines incomplete HMI-9 was supplemented with 10% v/v tetracycline-free 
FBS to produce ‘complete’ HMI-11.  After addition of FBS, media was re-filtered 
before use and stored at 37˚C for no longer than one month.  VSG switching 
analysis experiments were performed using thymidine-free media (see 2.2.4.1).  
Where appropriate, medium was supplemented with antibiotics at the point of 
culture preparation at the following concentrations: Hygromycin (Invivogen, cat. 
no. ant-hg-5b) 5 µg.mL-1 for I-SceI lines and 1 µg.mL-1 for RNAi lines, G418 
(Invivogen, cat. no. ant-gn-5b) 5 µg.mL-1, blasticidin (Invivogen, cat. no. 
ant-bl-5b) 10 µg.mL-1, puromycin (Invivogen, cat. no. ant-pr-5b) 0.2 µg.mL-1, 
phleomycin (Invivogen, cat. no. ant-ph-5b) 2 µg.mL-1 and 0.5 µg.mL-1 for RNAi 
lines.  For culture of double knockout cell lines, half of the above concentration 
of blasticidin and neomycin were used, based on experience of our laboratory. 
In vitro growth of trypanosomes in HMI-9 or HMI-11 media was carried out at 
37°C in a humidified 5% CO2 incubator.  The population doubling time of the 
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Lister 427 strain is eight hours (Proudfoot & McCulloch, 2006).  Cultures were 
subcultured regularly to avoid overgrowth and maintained at a maximum of    
2.5 x 106 cells.mL-1 in tissue culture plates or vented flasks laid flat.  Culture 
density was monitored using a haemocytometer whereby 10 µL of a culture of 
parasites under a 1 mM square area was counted and multiplied by 104 to obtain 
the number of cells.mL-1 in the culture. 
2.1.2 Stabilate preparation and retrieval 
Trypanosome cultures were grown to a density of approx 1 x 106 cells.mL-1 were 
used to prepare stabilates for long term storage.  Two hundred microlitres of a 
50:50 solution of HMI-9 or HMI-11 media was added to 800 µL of trypanosome 
culture in a 1.8 mL cryovial (Alpha Laboratories cat. no. LW3534).  Stabilates 
were wrapped in cotton wool and stored at -80˚C for 24 hours before transfer to 
liquid nitrogen storage.  For retrieval, stabilates were thawed at room 
temperature and added to nine millilitres of drug-free HMI-9 or HMI-11.  
Appropriate selective drugs were added the following day and cells were 
passaged as normal. 
2.1.3 Transfection of trypanosomes 
Transfection of trypanosomes was performed using the Human T-Cell 
Nucleofector® Kit (Amaxa cat. no. VAPA-1002).  Trypanosome cultures were 
grown to a density of ~1 x 106 cells.mL-1 and 30 x 106 were harvested by 
centrifugation at 1620 x g for 10 minutes.  Cell pellets were resuspended in 
transfection buffer (supplied with kit), transferred to an electroporation cuvette 
(supplied with kit) and DNA to be transfected was added.  Electroporation was 
performed using the Amaxa Human T Cell Nucleofector® Kit (Amaxa, cat. no. 
VPA-1002) and the electroporated cells added to 30 mL of drug-free HMI-9 
medium.  Two serial 1:10 dilutions of this cell-medium solution were made and 
each of the three dilutions was distributed in one millilitre aliquots into 24-well 
plates. Transfected cells were allowed to recover for 24 hours before being 
subjected to antibiotic selection. 
Selective antibiotic concentrations were as follows: blasticidin 10 µg.ml-1, 
G418 5 µg.mL-1, hygromycin 10 µg.mL-1 unless otherwise stated.  For second-
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round transfection of knockout constructs into heterozygous lines, the blasticidin 
and neomycin concentrations were halved, based on our laboratory’s 
experience. 
Transformants were counted after 7-10 days by examining the plates under a 
light microscope and counting the number of wells containing live parasites.  
Each well containing live cells can be considered clonal if the number of positive 
wells on that plate is <80% (Wickstead et al., 2003).  Six wells were usually 
expanded for further analysis. 
2.1.4 Preparation of trypanosomes for molecular biology 
procedures 
The required number of trypanosomes (as described below) was harvested by 
centrifugation at 1620 xg for five minutes at room temperature.  Cell pellets 
were washed once with one millilitre of 1x PBS (phosphate buffered saline) then 
processed or stored for extraction of genomic DNA, RNA or protein as outlined 
below. 
2.2 Analysis of trypanosome phenotypes 
2.2.1 Cell cycle analysis 
For cell cycle analysis, trypanosomes were prepared for microscopy and stained 
with DAPI (4, 6-diamidino-2-phenylindole) (SouthernBiotech, cat no 0100-20) 
(section 2.11.1).  Differential interface contrast (DIC) was used to visualise 
whole cells and UV to visualise DAPI.  Images were acquired using Volocity 
(Perkin Elmer) and images analysed using ImageJ.  Cells were counted according 
to the number of nuclei and kinetoplasts they contained.  Cells in the G1 phase 
of the cell cycle contain one nucleus and one kinetoplast (1N1K).  Kinetoplast 
division precedes nuclear division, thus cells in the S phase of the cell cycle 
contain one nucleus and two kinetoplasts (1N2K).  After nuclear division, G2 
phase cells contain two nuclei and two kinetoplasts (2N2K).  Any cells not 
conforming to 1N1K, 1N2K or 2N2K were classified as ‘other’. 
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2.2.2 Analysis of trypanosome in vitro growth 
In vitro growth analysis was performed by inoculating 5 mL of medium with 
cells, to a final density of 1 x 104 cells.mL-1 or 5 x 104 cells.mL-1.  The inoculating 
cultures were previously grown to a maximum of 1 x 106 cells.mL-1.  Cell density 
was counted at 24, 48, 72 and 96 hours.  Growth analysis was repeated at least 
three times for each cell line and results plotted on a semi-logarithmic scale. 
2.2.3 Analysis of DNA damage sensitivity 
Analysis of DNA damage sensitivity was performed using three DNA damaging 
agents: methyl methansulfonate (MMS) (Sigma cat. no. M4016), phleomycin 
(Invivogen cat. no. ant-ph-5b) and hydroxyurea (Sigma cat. no. H8627).  DNA 
damaging agents were used as described for each procedure and in all cases 
were added to the culture for chronic exposure and not washed off. 
MMS is an alkylating agent that methylates purines at the 7’ position of 
guanosine residues and the 3’ position of adenine residues (Brookes & Lawley, 
1961; Reiter et al., 1972).  Phleomycin is an antibiotic that blocks the activity of 
DNA polymerase, inhibiting DNA synthesis, resulting in formation of single and 
double strand DNA breaks (SSBs and DSBs, respectively), though primarily double 
strand breaks (Falaschi & Kornberg, 1964; Reiter et al., 1972).  Hydroxyurea 
inhibits ribonucleotide reductase, an enzyme involved in dNTP synthesis.  This 
results in a depletion of the cellular dNTP pool and causes stalling of DNA 
replication (Bianchi et al., 1986). 
2.2.3.1 DNA damage growth curve analysis 
Growth curves were set up from cultures grown to a density not exceeding 
1 x 106 cells.mL-1.  The day prior to set up of the growth curve, all cultures were 
passaged into medium without selective antibiotics.  Assays were set up and 
analysed as in Section 2.2.2 with the modification that after preparation of 
starting cultures, the culture was aliquoted and the appropriate DNA damaging 
agent added to the appropriate final concentration as follows.  MMS: untreated, 
0.0002%, 0.0003% and 0.0004%.  Phleomycin: 0.05 µg.ml-1, 0.075 µg.mL-1 and 0.1 
µg.mL-1.  Hydroxyurea: 0.01 mM, 0.02 mM and 0.03 mM.  Culture density was 
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counted at 24, 48 and 72 hours and DNA damaging agent added again to the 
same final concentration if cultures required dilution (where specified). 
2.2.3.2 DNA damage clonal survival assays 
The day prior to set up of the clonal survival assays all cultures were passaged 
into drug-free medium.  When setting up the assay, cultures were diluted to 
1 cell/200 µL (0.5 x 101 cells.mL-1) and distributed in 200 µl aliquots among 
three 96 well culture plates after adding phleomycin, hydroxyurea or MMS at the 
appropriate concentration, or left untreated.  Concentrations of DNA damaging 
agents used were: MMS 0.0001%, 0.0002%, 0.0003% and 0.0004%; hydroxyurea: 
0.01 mM, 0.02 mM and 0.03 mM; phleomycin: 0.1 µg.ml-1, 0.2 µg.mL-1 and 
0.3 µg.mL-1or 0.05 µg.mL-1, 0.10 µg.mL-1 and 0.15 µg.mL-1. 
After ~10 days incubation, or when cultures were saturated, the number of 
surviving clones was counted on each plate and the mean survival (of the three 
96 well plates) for each damaging agent concentration was calculated.  Positive 
wells (with live cells) were determined by the colour of the medium: HMI 
medium turns yellow at high cell density.  This was graphed as percentage 
survival relative to untreated cells.  The mean of the relative percentage 
survival was calculated from multiple experiments and used to present combined 
data from multiple experiments. 
2.2.3.3 I-SceI double strand break survival assays 
Assays were carried out as in (Glover et al., 2013a).  Cultures were diluted at 
sub-clonal dilution (HR1 cell lines: 0.15 x 101 cells.mL-1, HRES cell lines: 
0.26 x 101 cells.mL-1), divided into two aliquots then tetracycline (Calbiochem 
cat. no. 583411) added to one (final concentration 2 µg.mL-1) to induce I-SceI 
expression.  Cultures were distributed in 200 µL aliquots into 96 well plates (four 
plates each of uninduced and induced cells).  After 7-10 days incubation (before 
cultures were saturated) the number of surviving clones was counted and 
survival was normalised to un-induced cultures.  Positive wells (with live cells) 
were determined by the colour of the medium: HMI medium turns yellow at high 
cell density. 
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From each uninduced cell line, six surviving clones were expanded for 
subsequent analysis.  Twenty-five surviving induced HR1 and all surviving 
induced HRES clones were expanded.  Selected clones were tested for puromycin 
sensitivity (final concentration 1 µg.mL-1) and genomic DNA was extracted for 
PCR analysis.  HR1 cell lines were assayed using PCR for MMEJ by amplification 
across the RFP:PURO cassette and HRES cell lines were assayed by PCR for 
VSG221 (primers #90 and #91, 955 bp product) and ESAG1 (primers #92 and #93, 
328 bp product) loss.  Primer sequences are listed in Appendix 7.1.  Genomic 
DNA preparations were also assayed to check the presence of amplifiable 
genomic DNA by amplification of a gene not knocked out in that cell line.  This 
positive control gene was different depending on the knockout cell line and is 
specified (along with PCR primers used) in each experiment. 
2.2.4 VSG switching analysis 
2.2.4.1 Preparation of media for the culture of VSG switching cell 
GFP221hygTK 
The bloodstream form T. brucei cell line generated for analysis of VSG switching 
(GFP221hygTK) was cultured in thymidine-free medium.  This consisted of 
Isocove’s Modified Dulbecco’s Medium (Invitrogen, cat no. 21980-065) 
supplemented with 20% FBS (Sigma, cat. no. F9665), 1 mM hypoxanthine (Sigma, 
cat no. H9377), 0.05 mM bathocuproine disulphonic acid (Sigma, cat no. B1125), 
1 mM sodium pyruvate (Sigma, cat no. P5280), 1.5 mM L-cysteine (Sigma-Aldrich, 
cat no. C7352) and 200 µM β-mercaptoethanol.  Media was filter sterilised prior 
to use. 
2.2.4.2 Analysis of VSG switching frequency and mechanism 
Mutants were generated in the GFP221hygTK cell line to analyse VSG switching 
frequency and mechanism.  This cell line contains two constructs integrated into 
the active VSG BES (MiTat 1.2); eGFP and puromycin are integrated downstream 
of the promoter and a hygromycin resistance gene fused to the thymidine kinase 
(TK) gene is integrated between the 70 bp array and the active VSG.  Negative 
selection against thymidine kinase using ganciclovir allows selection of cells that 
no longer express the TK gene, either through a VSG switching event or 
thymidine kinase point mutation. 
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Cells were passaged to a density of 1 x 104 cells.mL-1 either in the presence or 
absence of puromycin (0.2 µg.mL-1) and incubated for 48 hours to allow them to 
switch VSG.  After 48 hours cultures were diluted to 1.25 x 104  cells.mL-1 in the 
presence of 4 µg.mL-1 ganciclovir (Sigma-Aldrich, cat. no. G2536) and plated in 
200 µl aliquots over three 96 well plates, resulting in 2.5 x 103 cells per well. 
After one week, surviving clones (in all experiments apart from the first RECQ2 
VSG switching experiment: 20 each from wild type and heterozygote (+/-) lines 
and 30 from double knockout (-/-) cell lines) were selected on a random basis to 
expand in thymidine- and drug-free medium for further analysis.  Plates were 
incubated for a further week before the number of surviving clones on each 
plate was counted. Cells were collected for genomic DNA extraction for PCR 
analysis and for SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) for western blot analysis. 
To calculate the VSG switching frequency the number of surviving clones in total 
(all three 96 well plates) was divided by the total number of cells plated to 
obtain the number of switching events per cell.  This number was then divided 
by the number of generations in the 48 hour incubation prior to plating the cells 
to obtain the VSG switching rate per cell per generation.  The number of 
generations was calculated for each cell line in the presence and absence of 
puromycin using the cell density measured at the 48 hour time point.  To 
determine the number of generations, the number of cell doublings per hour was 
calculated.  The doubling time was then calculated and was then used to 
calculate the number of generations during the 48 hour incubation.  These 
formulae are shown in Figure 2-1.  In the formula in Fig. 2-1 the number 0.301 is 
used because this is the log of two and division occurs by binary fission, 
therefore each division results in a doubling of the population size. 
 
Figure 2-1 Formulae used to calculate the number of generations in VSG switching 
experiments 
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These formulae were used to calculate the number of cell doublings per hour, time taken to 
double the population and the number of generations during the 48 hour VSG switching 
period.  The number of generations was then used to calculate the VSG switching 
frequency, as described in the text. 
SDS-PAGE gels were loaded with 2.5 x 106 cells per lane.  SDS-PAGE was 
performed as outlined in Section 2.5.2 and western blotting was performed as 
outlined in Section 1.6.  Blots were probed with rabbit anti-VSG221 antisera 
(Gift, David Horn, (Glover et al., 2013a)) at a 1:20,000 dilution and rabbit anti-
GFP antisera (Abcam, cat. no. ab290) at a 1:5000 dilution.  Goat anti-rabbit HRP 
conjugated antisera (Molecular Probes, cat. no. G-21234) was used as secondary 
antisera.  Genomic DNA was assayed for the presence of VSG221 and GFP by PCR 
using primer pairs #156 & #157 (522 bp product) and #160 & #161 (361 bp 
product), respectively.  As a positive control to test the presence of amplifiable 
genomic DNA, a 453 bp region of RNA polymerase I was amplified using primer 
pairs #158 & #159. 
2.3 Trypanosome RNA interference (RNAi) 
2.3.1 Cloning of RECQ1 RNAi plasmid using Gateway® system 
The modified pRPaISL plasmid, pGL2084, developed by Jones et al. (2014) was 
used to clone plasmids for RNAi.  The pGL2084 plasmid contains two sets of 
inverted Gateway donor sites (containing attP sites).  Each pair of Gateway 
donor sites flank a ccdB counter selectable marker.  The two sets of Gateway 
donor sites are separated by 150 bp of the lacZ gene.  The RECQ1 RNAi target 
sequence was determined using the TrypanoFAN: RNAit programme (Redmond, 
2003).  Primers #67 & #68 incorporated attB1 and attB2 sites to facilitate 
recombination with the pGL2084 attP sites.  The resultant PCR product was 
cloned into pGL2084 in a BP recombinase reaction (Invitrogen, cat. no. 
11789013) and propagated using Max Efficiency DH5α Competent Cells (Life 
Technologies, cat. no. 18258012).  Prior to transformation into 2T1 cells (Alsford 
et al., 2005a), the RECQ1 RNAi plasmid was linearised by digestion with the 
restriction enzyme PacI. 
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2.4 Isolation of material from trypanosomes 
2.4.1 Isolation of genomic DNA 
Cell pellets obtained as described above (approximately 3 x 106 cells per sample) 
were frozen at -20˚C prior to genomic DNA extraction.  DNA was extracted using 
the Qiagen DNeasy Blood and Tissue kit (Qiagen cat. No. 69606) following the 
manufacturer’s instructions.  DNA concentration was determined 
photospectrometrically using a Nanodrop 1000 (Thermo Scientific). 
2.4.2 Isolation of total RNA 
Cell pellets obtained as above (approximately 2 x 107 cells per sample) were 
frozen at -80˚C prior to RNA extraction.  RNA was extracted using the Qiagen 
RNeasy kit (Qiagen cat. no. 74106).  DNase digestion was performed after RNA 
extraction using the Qiagen RNase-Free DNase Set (Qiagen cat. no. 79254) and 
RNA clean up performed afterwards using the Qiagen RNeasy kit, following the 
manufacturer’s instructions.  Total RNA preparations were stored at -80˚C. 
2.5 Electrophoresis 
2.5.1 DNA electrophoresis 
Separation of DNA fragments for routine analysis was achieved by loading on 
1.2% (w/v) agarose gels (Invitrogen, Paisley, UK, cat. No. 15510-027) run at 100V 
in 1 x TAE buffer (40 mM Tris, 19 mM acetic acid, 1 mM EDTA).  SYBR-Safe DNA 
Stain (Life Technologies, cat. no. S33102) was used at a 1:20,000 dilution to 
visualise DNA under ultraviolet light.  Gels were imaged using Bio-Rad GelDoc 
(BioRad) and images captured using Quantity One (Bio-Rad). 
2.5.2 Protein electrophoresis 
SDS-PAGE was used for separation of proteins in crude cell lysates using pre-cast 
NuPAGE® Novex® 3-8% Tris-acetate gels (Life Technologies, cat. no. 
EA0375BOX).  Trypanosome cell pellets were frozen at -80˚C until ready to be 
electrophoresed.  Cell pellets were resuspended in protein loading buffer (1x 
Life Technologies NuPAGE® LDS sample buffer cat. no. NP0007, 2.5% β-
mercaptoethanol, 2x Roche cOmplete Mini protease inhibitor cocktail tablets 
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cat. no. 04693124001), mixed well and boiled at 100˚C for five minutes.  
Approximately 5 x 106 cell equivalents were loaded per lane and gels were run at 
100V for 50 minutes.  For estimation of protein molecular weight, 10 µL of 
HiMark™ Pre-stained Protein Standard (Life Technologies, cat. no LC5699) was 
also loaded. 
2.6 Blotting 
2.6.1 Western blot transfer 
Western blotting of SDS-PAGE gels was carried out using the Mini Trans-Blot® 
Cell (Bio-Rad).  Gels, Hybond ECL nitrocellulose membrane (Amersham, cat. no. 
RPN303D), foam and filter paper (Bio-Rad) were equilibrated in transfer buffer 
(25 mM Tris pH 8.3, 192 mM Glycine, and 20% (v/v) methanol)) prior to 
assembling the gel sandwich.  The gel sandwich comprised the gel and 
nitrocellulose membrane, surrounded by filter paper and foam, sandwiched into 
a plastic cassette.  An ice block was placed next to the cassette to prevent 
overheating.  The transfer gel sandwich was electrophoresed at 400 mA for one 
hour followed by transfer at 90 mA overnight at 4˚C.  The success of transfer 
was determined by incubation of the membrane in ponceau solution (Sigma-
Aldrich, cat. no. P7170) for 10 minutes and visualised using Bio-Rad GelDoc 
(BioRad) and images captured using Quantity One (Bio-Rad). 
2.6.2 Western blot detection 
2.6.3 Hybridisation and detection of antibodies 
Western blot membranes were washed once in 1x PBS then incubated in blocking 
solution (1x PBS, 5% Milk (Marvel), 0.1% Tween-20 (Sigma-Aldrich cat. no. 
P1379)) for one hour or overnight at 4˚C, on a rocker.  Membranes were then 
placed in blocking buffer containing primary antisera (Table 2-1) for one hour.  
Membranes were rinsed twice in PBST (PBS, 0.1% Tween-20 (Sigma)) for 10 
minutes, then placed in blocking buffer containing the secondary antisera 
(Table 2-1) for one hour.  Secondary antisera were horseradish peroxidase 
conjugated.  Membranes were washed three times in PBST for 10 minutes each 
before applying SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, cat. no. 34078).  Membranes were incubated in the dark for one 
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minute after application of the substrate, then exposed to an X-ray film (Kodak) 
for 10 minutes to overnight.  X-ray films were visualized by developing in a 
Kodak M-25-M X-omat processor. 
2.6.4 Stripping western blots 
Nitrocellulose membranes were stripped by incubating in Restore Western Blot 
Stripping Buffer (Thermo Scientific, cat. no. 21059) on a rocker for 
10-20 minutes.  Membranes were washed in PBST before re-probing. 
  
Ta
bl
e 
2-
1 
Li
st
 o
f a
nt
is
er
a 
us
ed
 in
 th
is
 th
es
is
 
Th
e 
ta
bl
e 
lis
ts
 th
e 
an
tis
er
a 
ut
ili
se
d 
in
 th
is
 w
or
k 
an
d 
th
e 
di
lu
tio
ns
 a
t w
hi
ch
 th
ey
 w
er
e 
us
ed
.  
H
or
n,
 D
av
id
 H
or
n;
 M
at
th
ew
s,
 K
ei
th
 M
at
th
ew
s;
 M
cC
ul
lo
ch
, 
R
ic
ha
rd
 M
cC
ul
lo
ch
; M
ot
tr
am
, J
er
em
y 
M
ot
tr
am
.  
W
B
, w
es
te
rn
 b
lo
t; 
IF
A
, i
m
m
un
of
lu
or
es
ce
nc
e.
 
Chapter 2 77 
Chapter 2   78 
2.7 Molecular biology techniques 
2.7.1 Polymerase chain reaction (PCR) 
For diagnostic PCR reactions Taq DNA polymerase (New England Biolabs (NEB) 
cat. no. M0273S) was used.  A typical 20 µL reaction contained 0.1 µM 5’ primer, 
0.1 µM 3’ primer, 1x ThermoPol Buffer (NEB, cat no M0273S), 0.2 mM dNTPs (NEB 
cat. no. N0446S), 0.2 units Taq polymerase and dH2O made up to 25 µL.  PCRs 
were performed with typical conditions of 95°C for five minutes, followed by 30-
35 cycles of 95°C for one minute, 50-60°C for one minute, 72°C for one minute 
per 1 Kb of expected product and a final cycle of 72°C for five to ten minutes. 
Phusion DNA polymerase (NEB cat. no. M0530S) was used for PCRs where a low 
error rate was required.  A typical 50 µL reaction contained 0.1 µM 5’ primer, 
0.1 µM 3’ primer, 1x Phusion High fidelity (HF) buffer (supplied with Phusion 
polymerase), 0.2 µM dNTPs (NEB cat. no. N0446S), 1 unit of Phusion DNA 
polymerase and dH2O to 50 µL.  PCRs were performed with typical conditions 
similar to those for Taq polymerase above, with the modification that the 
denaturation temperature was 98°C. 
2.7.2 DNA fragment gel extraction 
When separated DNA was to be extracted from an agarose gel, a clean scalpel 
was used to excise the DNA fragment, which was then placed in a sterile 
microfuge tube.  DNA was extracted from gel fragments using the Qiagen Gel 
Extraction Kit (Qiagen cat. no. 28706) following the manufacturer’s instructions. 
2.7.3 cDNA synthesis 
RNA was used as the template for cDNA synthesis.  cDNA synthesis was 
performed using the Primer Design Precision nanoScript Reverse Transcription kit 
(Primer Design cat. no. RT-nanoScript) according to manufacturer’s instructions.  
Random primers (supplied by manufacturer) were used for cDNA synthesis.  A 
negative control, to which no reverse transcriptase enzyme was added, was also 
performed in order to determine whether DNase digestion performed during RNA 
extraction was complete. 
Chapter 2   79 
 
2.7.4 Restriction enzyme analysis of DNA 
All restriction enzyme digestions were performed using enzymes supplied by New 
England Biolabs in buffers recommended by the manufacturer.  In a typical 
digestion, 10 units of enzyme were added per microgram of DNA and incubated 
at 37°C for one hour, or overnight in the case of digesting plasmids, prior to 
trypanosome transformation. 
2.7.5 Primer design 
T. brucei gene sequences were downloaded from TriTrypDB (www.tritrypdb.org) 
using the gene accession number.  Sequences were viewed in CLC Genomics 
Workbench 6 (CLC Bio).  Primers were designed using CLC Genomics Workbench 
6 and the web-based programme Primer3 (http://frodo.wi.mit.edu/primer3/).  
Restriction sites were added to the 5’ end of primers with additional bases at 
the 5’ terminus for efficient restriction enzyme digest of PCR products. 
Start and stop codons were added or removed as necessary and it was verified 
that the resulting products would be in-frame with fusion tags.  All 
oligonucleotides in this thesis were synthesised by Eurofins MWG Operon 
(www.eurofinsdna.com) and are listed in Appendix 7.1, Table 7-1. 
2.7.6 Plasmid sequencing 
All sequencing was performed by MWG Eurofins Operon (Ebersburg, Germany). 
2.7.7 Concentration of digested DNA 
Plasmids digested prior to trypanosome transfection were concentrated using 
the Zymogen DNA Clean and Concentrator Kit (Zymogen cat. no. D4005 & D4003) 
following the manufacturer’s instructions. 
2.8 Cloning 
2.8.1 T4 DNA ligase 
DNA ligation was used to insert digested PCR products into plasmids.  A typical 
20 µL reaction contained: 2.5 units of T4- DNA ligase (NEB, cat. no. M0202), 
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molar ratios of vector to insert was typically 1:3 (typically 50 ng linearised 
vector: 150 ng digested insert DNA), 2 µL of 10x ligation buffer (supplied with T4 
DNA ligase) and dH2O to a final volume of 20 µL.  The ligation mix was incubated 
at room temperature overnight. 
2.9 Transformation of E. coli and plasmid retrieval 
2.9.1 Transformation of E. coli 
For general transformations, chemically competent DH5-α cells were used.  Cells 
stored at -80°C were thawed on ice and 5-10 µL of ligation reaction or 50–300 ng 
of purified plasmid was added to 50 µL of cells in a sterile microfuge tube.  
Transformations were incubated on ice for 30 minutes before being heat shocked 
at 42°C for 30 seconds.  The cells were left to recover on ice for five minutes 
before 1 mL of SOC medium (5 g yeast extract, 20 g tryptone, 0.5 g NaCl, 10 mL 
1M MgCl2, 10 mL 2M glucose, 10 mL 1M MgSO4 in 1 L) added and the microfuge 
tube was incubated at 37°C for one hour.  Recovered cells were spread on Luria-
Bertani broth (LB; 5 g yeast extract (Formedium), 10 g tryptone (Formedium), 
10 g NaCl in 1 L dH2O pH 7.0 (NaOH)] and 20 g agar (Formedium)) agar plates 
containing 100 µg.mL-1 ampicillin (Sigma-Aldrich cat. no. A9518) and incubated 
overnight at 37°C. 
For transformation of plasmids (221GP1 and HYG-TK) used to construct the VSG 
switching lines GFP221hygTK XL-10 Gold Supercompetent Cells (Agilent 
Technologies cat. no. 200314) were used.  Transformations were performed 
following the manufacturer’s instruction and cultured using ZYM-5 agar and 
medium (see Section 2.9.1.1).  Transformation of BP plasmids (for constructing 
the RNAi cell line) were performed into MAX Efficiency® DH5α Competent Cells 
(Life Technologies cat. no. 18258-012) following the manufacturer’s instructions. 
2.9.1.1 Preparation of ZYM-5 medium 
ZYM medium and agar was used to propagate plasmids used to generate the VSG 
switching cell line GFP221hygTK.  ZYM-5 medium: 10 g.L-1 trypton, 5 g.L-1 yeast 
extract, 5 g.L-1 glycerol.  Medium was autoclaved and, prior to use, the 
appropriate volume of autoclaved 50x “stock M” and 500x “stock Mg” was 
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added.  50x “stock M”: 1.25 M Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl.  500x 
“stock Mg”: 1M MgSO4. 
2.9.2 Extraction of plasmid DNA from E. coli 
Colonies containing the desired plasmid were inoculated into overnight 5 mL 
cultures of Luria Bertani broth.  Approximately 18 hours later, cultures were 
centrifuged at 2000x g for 10 minutes then processed using the QIAprep Spin 
Miniprep Kit (Qiagen cat. no. 27104) following the manufacturer’s instructions.  
DNA concentration was determined photospectrometrically using a 
Nanodrop 1000 (Thermo Scientific). 
2.10 Microscopy 
2.10.1 DAPI staining 
Cells were harvested by centrifugation at 405 x g for 10 minutes and the cell 
pellet washed once with 1x vPBS (NaCl 8 g/L, KCl 2.2 g/L, Na2HPO4 22.7 g/L, 
KH2PO4 4.4 g/L, 15.7 gL sucrose, 1.8 g/L glucose, pH 7.4).  The pellet was 
resuspended and 20 µL (containing 2 x 106 cells) was pipetted onto one well of a 
12-well glass slide (Menzel-Gläser, cat. no. X2XER202W) pre-treated with poly-L-
lysine (Sigma, cat. no. P8920) and a mini PAP pen (Life Technologies, cat no. 00-
8877) was used to create a barrier between wells.  Cells were allowed to settle 
for five minutes, most of the liquid removed with a pipette and 20 µL of 3.7% 
paraformalydehyde (PFA) added to fix cells.  PFA was removed after four 
minutes.  Cells were permeabilised by adding 25 µL Triton X-100 (Thermo 
Scientific, cat. no. 85112) in PBS for 10 minutes.  Fifty microlitres of 100 mM 
glycine was added and incubated for five minutes and repeated to neutralise 
free aldehyde groups.  Wells were washed twice with 50 µL 1x PBS for five 
minutes.  Five microlitres of DAPI (SouthernBiotech, cat no. 0100-20) was added 
to every well and incubated for three minutes at room temperature before 
addition of a coverslip and sealing with nail varnish.  Slides were stored at 4°C in 
the dark.  All solutions used were filter sterilsed. 
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2.10.2 Immunofluorescence microscopy 
Cells were prepared as in Section 2.11.1, modified thus:  Instead of adding DAPI, 
25 µL of blocking solution (1% BSA (Sigma, cat. no. A2153-50G), 0.2% Tween-20 
in PBS) was added to the well and incubated for one hour in a moist chamber.  
Blocking solution was removed, 25 µL primary antisera in blocking buffer added 
and incubated for one hour in a moist chamber.  Primary antisera was removed, 
25 µL of secondary antisera in blocking buffer added and incubated as before.  
The well was washed twice with 50 µL PBS and DAPI added and slides sealed as 
in Section 2.11.1.  Antibodies used and their dilutions are listed in Table 2-1.  
Slides were stored at 4°C in the dark.  All solutions were filter sterilsed. 
DIC was used to visualise whole cells and UV was used to visualise DAPI.  A 
fluorescein isothiocyanate (FITC) (520 nm) filter was used to visualise Alexa 
Fluor 488 conjugated antibodies and a rhodamine (673 nm) filter was used to 
visualise Alexa Fluor 594 conjugated antibodies.  Slides were imaged using a 
Zeiss Axioskop microscope and images acquired using the Volocity software 
package (Elmer Perkin).  Acquired images were analysed using ImageJ image 
processing software. 
2.11 Bioinformatics 
Kinetoplastid sequences were downloaded from TripTrypDB (TripTrypDB.org) and 
all other gene and protein sequences were downloaded from NCBI.  All 
sequences were viewed in CLC Genomics Workbench 6.  Protein BLAST (P-BLAST) 
analysis of kinetoplastid genomes was carried out on TriTrypDB.org and P-BLAST 
analysis of all other organisms was performed on NCBI.  P-BLAST is a protein 
sequence similarity search method that compares the input (query) protein 
sequence to protein sequences in the chosen database (non-redundant protein 
database based here).  The result is the identification of regions of local 
alignment between the query and database sequences.  Results include the 
aligned sequence, alignment score and length of the aligned region.  PSI-BLAST 
is a protein sequence profile search that utilises the alignment generated in an 
initial BLAST search.  PSI-BLAST then generates a multiple sequence alignment 
based on the results of the BLAST search and calculates a position-specific score 
matrix (PSSM).  A PSSM describes the sequence conservation of the multiple 
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sequence alignment, giving higher scores to more highly conserved residues.  
The P-BLAST search is then repeated using the PSSM as the input sequence and 
the results of this search are used to refine the PSSM.  This process is repeated 
until no new sequences are detected, known as convergence.  Iterative 
searching using a PSSM enables PSI-BLAST to detect more distantly related 
sequences than P-BLAST and is therefore beneficial when the input sequence is 
highly divergent and P-BLAST is insufficient to detect similar proteins.  Protein 
domain prediction was performed using InterProScan sequence search 
(http://www.ebi.ac.uk/interpro/search/sequence-search).  InterProScan brings 
together a number of other databases that contain information about known 
proteins’ function, including the protein families, domains and functional sites.  
This permits predictive functional characterisation of the user’s input sequence. 
ClustalX and BoxShade were used to construct multiple sequence alignments 
(except for alignments used to produce trees).  Clustal works by calculating all 
pairwise alignments and recording the score for each pair of sequences in a 
distance matrix.  A tree using the neighbour joining method is then constructed 
using this distance matrix, identifying the two most closely related sequences.  
These two sequences are aligned and the consensus is calculated.  The next two 
most closely related sequences are added to the alignment, the consensus is 
calculated again and the process is repeated until all sequences are aligned.  
Construction of trees was performed using CLC Genomics Workbench 6.  A 
multiple sequence alignment was constructed using the entire amino acid 
sequence of each protein and a tree generated using the neighbour-joining (NJ) 
method.  This tree construction method was chosen as it does not assume a 
molecular clock and is appropriate when the evolutionary relationship between 
all sequences is unknown.  For this reason, the NJ method was chosen over the 
unweighted pair group with arithmetic mean (UPGMA) method, which assumes a 
randomised molecular clock.  The NJ method constructs a tree by finding pairs 
of sequences (neighbours) that result in the minimum total branch length at 
each stage of the tree construction, therefore producing a tree with the 
minimum evolutionary distance.  It is therefore a ‘bottom-up’ clustering 
method. 
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3 Analysis of the roles in general DNA repair of 
RECQ2, PIF6 and MUS81 
3.1 Introduction 
Many proteins with functions in DNA break repair have been identified in 
T. brucei, notably RAD51 and RAD51 paralogues, BRCA2 and MRE11.  However, 
only some of the proteins involved in DNA repair been demonstrated to function 
in VSG switching.  These include RAD51 (McCulloch & Barry, 1999), the RAD51-3 
paralogue (Dobson et al., 2011; Proudfoot & McCulloch, 2005), BRCA2 (Hartley & 
McCulloch, 2008), the topoisomerase TOPO3α (Kim & Cross, 2010) and RMI1 (Kim 
& Cross, 2011). 
This chapter provides evidence for repair functions for three further proteins, 
which were identified in the T. brucei genome through P-BLAST searches using 
eukaryotic homologue protein sequences: RECQ2, one of two RecQ-like helicases 
in the T. brucei, MUS81, a structure specific endonuclease and PIF6, one of eight 
Pif1-like helicases encoded by T. brucei.   
The aim of this chapter was to analyse RECQ2, MUS81 and PIF6 to determine 
whether they act in DNA damage repair in BSF T. brucei, before continuing in 
the next chapter to analyse specifically their role in DSB repair and VSG 
switching. 
3.2 Sequence analysis of putative DNA repair factors 
TbRECQ2, TbPIF6 and TbMUS81 were identified and selected for analysis through 
P-BLAST searches using eukaryotic homologues of each protein, searching against 
the T. brucei Lister 427 proteome on tritrypdb.org.  However, as T. brucei is a 
highly diverged eukaryote, further sequence analysis was undertaken to confirm 
the identity of the T. brucei proteins and investigate their similarity to 
characterised eukaryotic homologues. 
3.2.1 T. brucei RECQ2 is a RecQ helicase homologue 
To identify TbRECQ1, NCBI protein-BLAST (P-BLAST) searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi; NCBI nr November 2014) were 
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performed (data not shown), using 18 different RecQ protein sequences from 
Homo sapiens, Mus musculus, Arabidopsis thaliana, Caenorhabditis elegans and 
Saccharomyces cerevisiae as the query sequence and using only the T. brucei 
Lister 427 strain as the target organism (http://tritrypdb.org; Version 8.1).  
TbRECQ2 (TriTrypDB accession number Tb427.08.6690) and TbRECQ1 (TriTrypDB 
accession number Tb427.06.3580) were consistently the only protein sequences 
retrieved.  TbRECQ1 is discussed in Chapter 5.  To begin to test the putative 
function and orthology of TbRECQ2, the predicted protein sequence was used for 
P-BLAST analysis. 
P-BLAST searches using the T. brucei RECQ2 amino acid sequence as the query 
sequence were also performed to ensure that searches returned RecQ helicases.  
The hits with the highest scores and lowest E values were all RecQ helicases.  
The top 11 hits against RECQ2 were Trypanosoma spp and Leishmania spp RecQ-
like proteins, with an expectancy value of 0.  A number of plant and mammalian 
RecQ-like proteins were retrieved as good alignments for RECQ2, with E values in 
the range of 10-120 to 10-110.  These were primarily mammalian BLM homologues, 
in addition to several RECQ4A and RECQ4B homologues. 
Protein domain analysis using InterProScan sequence search 
(http://www.ebi.ac.uk/interpro/search/sequence-search/ (Hunter et al., 2012)) 
was used to predict the domains present in RECQ2.  RECQ2 contains a 
DEAD/DEAH box helicase domain (approximately aa460-666), involved in ATP and 
nucleic acid binding, and a C-terminal helicase domain (approximately aa674-
825) (RQC domain), which are found in helicases of multiple families (Linder, 
2006) (Fig. 3-1).  Also present is an HRDC (helicase and RNaseD C-terminal) 
domain (approximately aa1207-1283).  In contrast to the other domains present, 
the HRDC domain is only in some RecQ helicases.  For example, three human 
RecQ helicases contain an HRDC domain (WRN, BLM and RECQ1), but it is absent 
in human RECQ4 and RECQ5 (Bernstein et al., 2010).  It is also present in some 
RNase D homologues (Morozov et al., 1997) and is probably involved in DNA 
binding (Bachrati & Hickson, 2003).  Some RecQ helicases also contain an RQC 
(RecQ C-terminal) domain found only in this family.  The RQC domain has been 
suggested to be involved in protein-protein interactions (Bernstein et al., 2010), 
as well as to bind and unwind dsDNA at branch points (Kitano et al., 2010).  
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However, it is absent from or highly diverged in some members (Bachrati & 
Hickson, 2003). 
 
Figure 3-1 Representation of predicted protein domains in TbRECQ2 
Protein domains predicted from the predicted amino acid sequence of TbRECQ2 using 
InterProScan 5 and comparison with those of E. coli and S. cerevisiae RecQ proteins.  
Sequence length is indicated on the right.  Not to scale. 
A multiple sequence alignment of the RECQ2 sequence and other eukaryotic 
RecQ proteins was performed (ClustalX 2.0).  Figure 3-2 shows this alignment, 
with only the central conserved protein core shown for reasons of space.  The 
RecQ protein family, as in all SF2 helicases, is characterised by seven highly 
conserved protein motifs (I, Ia and II-VI) (Bachrati & Hickson, 2003; Guo et al., 
2007).  As shown in Fig.3-2, all of these motifs are present in TbRECQ2, which 
along with P-BLAST searches and domain identification dicussed above, confirms 
that it is a RecQ helicase family member. 
P-BLAST searches described above, which returned mainly BLM homologues, 
suggested that TbRECQ2 is more closely related to eukaryotic BLM homologues.  
To investigate this further, a multiple sequence alignment was performed of 
TbRECQ2 and RECQ proteins from a range of organisms and a phylogenetic tree 
was constructed from the resulting alignment, shown in Figure 3-3 (using CLC 
Genomics Workbench 6).  As would be expected, TbRECQ2 groups closely with 
other kinetoplastid RecQ proteins.  T. brucei, T. cruzi and L. major each contain 
two predicted RecQ helicases and TbRECQ2 clusters with one RecQ-like helicase 
from L. major and T. cruzi.  Beyond this, TbRECQ2 clusters with BLM homologues 
from several eukaryotes (including SGS1, the Saccharoymyces cerevisiae BLM 
homologue).  This phylogenetic analysis appears to confirm that TbRecQ2 is 
closely evolutionarily related to SGS1/BLM.  In addition, it indicates that 
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TbRECQ2 is more similar to SGS1/BLM than the other RecQ-like protein in 
T.  brucei, TbRecQ1, which is discussed in Chapter 5. 
Figure 3-2 Multiple sequence alignment of RecQ-like helicases. 
The protein sequences of eukaryotic RecQ-like helicases were aligned generated using 
ClustalX (2.0) (clustal.org/clustal2/) and shaded using BoxShade 
(ch.embnet.org/software/BOX_form.html) and the central conserved helicase core is shown 
(region indicated by residue numers on the left).  The seven highly conserved SF2 helicase 
motifs in the helicase domain are indicated.  Black background indicates conserved 
residues and a grey background indicates similar residues.  Tb, T. brucei; Hs, Homo 
sapiens; Sc, S. cerevisiae; Sp, S. pombe.  Accession numbers for sequences can be found 
in Appendix 7.2. 
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Figure 3-3 Neighbour-joining tree of eukaryotic RecQ-like helicases 
Protein sequences from multiple eukaryotic RecQ-like proteins were aligned and a tree 
generated from this alignment using CLC Genomics Workbench 6, using the neighbour 
joining method.  Hs, H. sapiens; Sc, S. cerevisiae; Tb, T. brucei; Sp, S. pombe; At, 
Arabidopsis thaliana; Lm, Leishmania major; Tc, Trypanosoma cruzi.  Accession numbers 
for sequences can be found in Appendix 7.2. 
3.2.2 Sequence analysis of T. brucei MUS81 
Initial identification of TbMUS81 was through P-BLAST analysis (NCBI nr 
November 2014) using the S. cerevisiae MUS81 sequence against the T. brucei 
Lister 427 proteome (using tritrypdb.org; Version 8.1), which returned only the 
TbMUS81 sequence (TriTrypDB accession number Tb427.08.6740), though with an 
expectancy value of only 0.094.  Further analysis was therefore required to 
confirm the identity of the putative TbMUS81. 
As for TbRECQ2, protein P-BLAST analysis using the predicted sequence of 
TbMUS81 as the query was performed to investigate the similarity of TbMUS81 to 
other eukaryotic MUS81 proteins.  The top hits were DNA repair and hypothetical 
proteins from Trypanosoma and other kinetoplastid species, including 
Trypanosoma vivax, T. cruzi, Leishmania mexicana, Leishmania infantum, 
L. major and Phytomonas spp.  Non-Trypanosoma spp.  Hits retrieved were 
dominated by fungal, parasitic and plant hypothetical proteins, some of which 
were annotated as MUS81-like.  Upon restricting the search to S. cerevisiae or 
H. sapiens, MUS81 proteins from both species were returned, with expectancy 
values of 0.52 and 10-4, respectively.  Protein domain analysis using InterProScan 
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sequence search (http://www.ebi.ac.uk/interpro/search/sequence-search 
(Hunter et al., 2012)) was used to analyse the domains present in MUS81, which 
are shown in Figure 3-4.  This revealed a predicted ERCC4 domain 
(approximately aa329-523), with an expectancy value of 0.02.  ERCC4 domains 
are involved in nucleic acid binding and are found in a number of DNA repair 
proteins, including RAD1 and XPF, as well as in MUS81 and another crossover 
junction endonuclease, EME1 (Ciccia et al., 2008).  Additionally, a SAP (SAF-A/B, 
Acinus and PIAS) domain was predicted near the N terminus of TbMUS8 (aa164-
198).  It has been proposed that SAP domains are involved in DNA binding 
(Aravind & Koonin, 2000), though they are not found in other characterised 
eukaryotic MUS81 proteins such as in M. musculus and H. sapiens. 
 
Figure 3-4 Representation of protein domains predicted in TbMUS81 
Protein domains predicted from the predicted amino acid sequence of TbMUS81 using 
InterProScan 5.  Sequence length is indicated on the right.  Not to scale. 
The low similarity of TbMUS81 to other characterised eukaryotic MUS81 proteins, 
the lower expectancy value for the MUS81-characteristic ERCC4 domain and the 
unusual SAP domain was the reason for then using PSI-BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) search to attempt to confirm the 
identity of Tb427.08.6740 as encoding TbMUS81.  TbMUS81 was used as the 
query sequence and convergence was reached on the 16th iteration.  The top 10 
hits were primarily fungal MUS81 and putative MUS81 homologues, ERCC4 
domain-containing proteins and endonuclease proteins.  Additionally, P- BLAST 
searches using Mus81 sequences from eukaryotes including H. sapiens and 
Arabidopsis thaliana as the query against the T. brucei genome (data not shown) 
(http://tritrypdb.org) retrieved T. brucei MUS81 as the only significant 
alignment in the T. brucei genome. 
A multiple sequence alignment was performed (ClustalX 2.0) of TbMUS81 and 
eukaryotic MUS81 homologues to further investigate the similarity of TbMUS81 to 
these proteins (Fig. 3-5).  Overall, the average sequence identity of MUS81 to 
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the MUS81 sequences in Figure 3-5 is only 11.5%, though it is higher (17.2%) 
within the ERCC4 domain.  MUS81 proteins contain an ERKx3D motif in the ERCC4 
domain (Chang et al., 2008), which is also present in TbMUS81 (Fig. 3-5). 
Figure 3-5 Multiple sequence alignment of MUS81 proteins 
The protein sequences of multiple eukaryotic MUS81 proteins were generated using 
ClustalX (2.0) (clustal.org/clustal2/) and shaded using BoxShade 
(ch.embnet.org/software/BOX_form.html).  Black background indicates conserved residues 
and a grey background indicates similar residues.  Tb, T. brucei; Hs, Homo sapiens; Sp, 
S. pombe; YEAST, S. cerevisiae.  Accession numbers for sequences can be found in 
Appendix 7.2. 
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ERCC4 domains are present in a number of DNA repair nucleases in addition to 
MUS81, including XPF, RAD1 and EME1/MMS4.  To confirm that TbMUS81 is a 
MUS81 homologue rather than another ERCC4-containing protein, its similarity to 
other ERCC4 proteins was analysed.  An alignment of eukaryotic MUS81, 
EME1/MMS4 and XPF proteins was generated and used to construct a tree using 
CLC Genomics Workbench 6 (Fig. 3-6).  Unsurprisingly, TbMUS81 groups closely 
with other kinetoplastid (predicted) MUS81 proteins.  However, all of these 
MUS81 proteins group more closely with EME1/MMS4 and XPF proteins than to 
other eukaryotic MUS81 proteins.  It appears therefore that T. brucei MUS81, 
along with other kinetoplastid MUS81 proteins, is much diverged from yeast and 
human MUS81 proteins. 
 
Figure 3-6 Neighbor-joining tree of eukaryotic ERCC4-containing proteins. 
Protein sequences from multiple eukaryotic EME1/MMS4, RAD1, MUS81, and XPF proteins 
were aligned and a tree generated from this alignment using CLC Genomics Workbench 6, 
using the neighbour joining method.  Hs, H. sapiens; Sc, S. cerevisiae; Tb, T. brucei; Sp, 
S. pombe; Li, Leishmania infantum; Lm, Leishmania major; Tc, Trypanosoma cruzi.  
Accession numbers for sequences can be found in Appendix 7.2. 
Taken together, these analyses indicate that TbMUS81 appears to be a MUS81 
homologue, though as with many kinetoplastid proteins, very much diverged 
from other eukaryotes. 
3.2.3 TbPIF6 is a member of the PIF1-like helicase family 
Searches conducted using P-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi; 
NCBI nr November 2014) with T. brucei Lister 427 PIF6 (TriTrypDB accession 
number Tb427.10.910) (Liu et al., 2009a) as the query retrieved known Pif1-
family helicases as good matches, including PIF1 helicases of H. sapiens, M. 
musculus and Xenopus laevis at expectancy values of approximately 10-70.  The 
top hits however, excluding kinetoplastids, were predicted PIF1-like proteins 
from Anopheles spp. and a number of vertebrate species. 
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Additionally, reciprocal P-BLAST searches on tritrypdb.org (Version 8.1) using 
these sequences as the query sequences retrieved all TbPIF1 helicases including 
PIF6.  Protein domain analysis using InterProScan sequence search 
(http://www.ebi.ac.uk/interpro/search/sequence-search/(Hunter et al., 2012) 
revealed TbPIF6 to contain an AAA+ ATPase domain (approximately aa236-388) 
(Fig. 3-7).  Other PIF1 proteins contain at least one of these domains or another 
domain of the P-loop NTPase (nucleotide triphosphatase) family involved in 
nucleotide binding.  Additionally, the TbPIF6 sequence was identified by 
InterProScan as a PIF1-like helicase. 
 
Figure 3-7 Representation of protein domains predicted in TbPIF6 
Protein domains predicted from the predicted amino acid sequence of TbPIF6 using 
InterProScan 5.  Approximate position (from the N-terminus) is shown underneath the 
diagram.  Not to scale. 
A multiple protein sequence alignment was constructed of TbPIF6 with Pif1-like 
helicases from a number of eukaryotic species including other kinetoplastids 
(Fig. 3-8).  TbPIF6 is well aligned with other Pif1-like family helicases, though 
the N and C termini of the sequences are less well aligned and are not shown in 
the alignment in Figure 3-8.  TbPIF6 contains all of the seven SF1s (I, Ia, II-VI) 
motifs (Fig. 3-8), as well as the putative Pif1-like family signature, located 
between motifs II and III, identified by Bochman et al. (2010) in their analysis of 
Pif1-family helicases. 
Figure 3-8 Multiple sequence alignment of Pif1 family helicases 
The protein sequences of multiple eukaryotic Pif1 family helicases were aligned and a tree 
generated using ClustalX (2.0) (clustal.org/clustal2/) and shaded using BoxShade 
(ch.embnet.org/software/BOX_form.html).  Black background indicates conserved residues 
and a grey background indicates similar residues.  The conserved helicase core is shown 
and the seven SF1 helicase motifs (grey arrows and the putative Pif1 family signature 
(orange arrow) are shown.  Sc, S. cerevisiae; Sp, S. pombe; Hs, Homo sapiens; Tb, T. 
brucei.  Locations for helicase motifs I-VI and putative Pif1 helicase family signature are 
indicated.  Accession numbers for sequences can be found in Appendix 7.2. 
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Unsurprisingly, a phylogenetic tree generated from the alignment in Figure 3-8 
(using CLC Genomics Workbench 6) shows T. brucei, T. cruzi and L. major PIF6 
proteins to be much diverged from the other PIF1-like proteins analysed (Fig. 3-
9), even from other kinetoplastid PIF1-like proteins in the alignment.  This may 
be because it has been proposed that the expansion of the T. brucei Pif1 
helicase family is due to requirements for kDNA maintenance, whereas TbPIF6 
has been proposed to be nuclear (Liu et al., 2009a).  These analyses of TbPIF6 
clearly demonstrate that TbPIF6 is a PIF1-like helicase, though highly diverged 
from other characterised eukaryotic, including kinetoplastid, PIF1-helicases 
analysed.  Note this alignment excludes the large number of predicted PIF1-like 
proteins that were highly scoring hits in P-BLAST analysis. 
 
Figure 3-9 Neighbour-joining tree of eukaryotic Pif1 family helicases 
A phylogenetic tree was constructed (using the neighbour joining method) from a multiple 
sequence alignment of alignment of Pif1 helicase family proteins (each constructed using 
CLC Genomics Workbench 6).  TbPIF6 is highlighted in yellow.  ARATH, Arabidopsis 
thaliana; Lm, Leishmania major; Tb, T. brucei; Tc, Trypanosoma cruzi; Sc, S. cerevisiae; Sp, 
S.pombe; Hs, H. sapiens.  Accession numbers for sequences can be found in Appendix 7.2. 
3.3 Generation of knockout mutants 
3.3.1 Knockout strategy 
Heterozygous (+/-) and homozygous (-/-) knockout mutants for each gene were 
generated in Lister 427 T. brucei by deleting the entire ORF as shown in Figure 
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3-10A.  All mutant cell lines were generated using the same vector backbone, 
ΔORF::BSD and ΔORF::NEO (BSD, blasticidin; NEO, neomycin), and examples of 
the knockout construct used are shown in Figure 3-10B (gift, Marko Prorocic).  
These constructs contain regions homologous to the 5’ and 3’ ends of the 
targeted gene flanking an antibiotic resistance cassette.  These 5’ and 3’ regions 
were used as the targeting sequence to facilitate homologous recombination and 
replacement of the target ORF. 
A ~500-800 bp region of the target gene’s 5’ ORF/5’ UTR and a ~500-800 bp 
region of the target gene’s 3’ ORF/3’ UTR were amplified by PCR and cloned 
into the knockout construct, flanking a BSD or NEO resistance cassette.  The 5’ 
UTR of the target gene was amplified by PCR using a forward primer that 
contained a NotI restriction site at the 5’ end of the primer, followed by a 
HindIII restriction site and a reverse primer that contained an XbaI restriction 
site at the 5’ end of the primer.  The PCR amplified product was therefore 5’-
NotI-HindIII-gene specific sequence-XbaI-3’.  The 3’ UTR of the target gene was 
amplified by PCR similarly, with the modification that the NotI restriction site 
was at the 3’ end of the amplified product.  The PCR amplified product was 
therefore 5’-SacI-gene specific sequence-ClaI-NotI-3’.  The regions PCR 
amplified for each construct are shown in Figure 3-10A, which in most cases 
included sequence from the target gene ORF as well as UTR sequence.  The 3’ 
targeting region PCR amplified in the MUS81 knockout construct included the 
first 190 bp of the ORF of the gene immediately downstream of MUS81 
(Tb427.08.6730).  PCR-specific details are listed in Figure 3-10.  Integration of 
the knockout cassette however should not result in loss of or disruption to 
Tb427.08.6730 sequence.   
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Figure 3-10 Schematic of knockout constructs and targeting strategy 
(A) PCR was used to amplify a 5’ and a 3’ region (blue arrows) of the target gene, in most 
cases including part of the ORF (orange arrow) and UTR of the target gene.  These PCR 
products were the ‘targeting regions’ cloned into the knockout plasmid (see (b)).  In the 
case of MUS81, the amplified 3’ targeting region included the 3’ 190 bp of the downstream 
gene (Tb427.08.6730).  The primers used to generate the targeting regions were:  RECQ2: 5’ 
primers #30 & #31, 3’ primers #32 & #33.  MUS81: 5’ primers #34 & #35, 3’ primers #36 & #37.  
PIF6: 5’ primers #38 & #39, 3’ #40 & #41.  Primer sequences can be found in Appendix 7.1.  
(B) Generalised schematic of the knockout constructs.  3’ and 5’ targeting regions of the 
target gene (blue) flank the resistance cassette containing a NEO or BSD resistance gene 
(pink).  NotI (as indicated) was used to linearise the constructs and restriction enzyme sites 
are indicated.  Sizes shown (bp), length of the 5’ and 3’ targeting fragment lengths were 
specific to the gene targeted.  (C) Knockout strategy used to generate heterozygous (+/-) 
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and knockout (-/-) mutants.  Generalised representation of the linearised knockout BSD and 
NEO resistance constructs (bottom) relative to the targeted gene (ORF, orange) and its 
flanking regions (black line).  The 5’ and 3’ targeting regions in the constructs correspond to 
the 5’-most or 3’-most regions of the targeted ORF and its flanking regions. β/α tub, β/a 
tubulin; actin IR, actin intergenic region; BSD, blasticidin resistance; NEO, neomycin 
resistance.  Not to scale. 
A generalised schematic of the knockout plasmids used is shown in Figure 3-10B, 
though the size of the targeting fragments differed depending on the gene 
targeted.  To allow selection of successful T. brucei transformants, a BSD or NEO 
resistance cassette was cloned between the UTR flanks.  In each construct the 
resistance gene is flanked upstream by a beta-alpha tubulin intergenic sequence 
and downstream by an actin intergenic sequence, to allow trans-splicing and 
polyadenylation respectively, and to generate antibiotic resistance ORF-
containing mRNAs. 
In a four-fragment ligation reaction the HindIII/XbaI digested 5’ and ClaI/SacI 
digested 3’ targeting fragment PCR products were ligated to the resistance 
cassette, which had been cut with XbaI (5’) and SacI (3’), and to the plasmid 
backbone, which had been cut with ClaI and HindIII.  This ligation produced a 
final plasmid that contained the resistance cassette, flanked 5’ by the 5’ region 
of the target gene and 3’ by the 3’ region of the target gene.  This region, the 
knockout cassette, could be excised from the plasmid by digestion with NotI 
utilising the NotI restriction sites from the gene targeting PCR products.  All 
plasmids were checked using restriction digest pattern analysis and sequencing.  
Approximately 10 µg of plasmid DNA was digested and concentrated using a 
Zymogen Clean and Concentrate DNA concentrator kit prior to transformation, as 
described in Section 2.8.8. 
Knockout constructs were linearised using NotI.  Integration into the genome and 
replacement of the targeted gene was facilitated by the 5’ and 3’ targeting 
regions of the linearised knockout plasmid (Fig. 3-10C). 
3.3.2 Generation of knockout mutants in the Lister 427 cell line 
Wild type BSF Lister 427 cells were transformed (as described in Section 2.1.3) 
with ΔRECQ2::BSD, ΔMUS81::BSD or ΔPIF6::BSD constructs to attempt to 
generate recq2+/-, mus81+/- or pif6+/- cell lines respectively.  In all cases, 
antibiotic resistant clones were selected using 10 µg.mL-1 blasticidin.  However, 
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no surviving clones were obtained from the ΔMUS81::BSD transformation, and so 
it was attempted to generate mus81+/- cells by transforming the ΔMUS81::NEO 
construct; selection with 5 µg.mL-1 G418 allowed a number of surviving clones to 
be obtained.  Sequencing of the ΔMUS81::BSD construct revealed a non-
synonymous mutation in the blasticidin resistance gene.  The blasticidin 
resistance cassette ΔMUS81::BSD was subsequently replaced and the plasmid 
sequenced to confirm the absence of mutations. 
The generation of -/- mutants was confirmed by PCR analysis (see Section 3.1.3 
below) performed on genomic DNA extracted from six different heterozygous 
clones for each gene, all of which contained the knockout construct integrated 
at the correct locus as expected.  One confirmed +/- clone was transformed with 
the Δgene of interest::NEO construct (or blasticidin construct in the case of 
mus81+/-) and antibiotic resistant clones selected with 5 µg.mL-1 blasticidin and 
2.5 µg.mL-1 neomycin. 
3.3.3 Confirmation of knockout mutants by PCR 
The generation of +/- and -/- mutants was confirmed by PCR performed on 
genomic DNA extracted from putative +/- (BSD; RECQ2 and PIF6), +/- (NEO; 
MUS81) and -/-(BSD+NEO) transformant clones.  Three different PCRs were used, 
as shown in Figure 3-11, to confirm the correct integration of the BSD and NEO 
knockout cassettes relative to the target gene (“NEO” and “BSD” PCRs) and the 
presence of the targeted gene ORF. 
 
Figure 3-11 Diagnostic PCRs to confirm knockout of target genes 
A ~500 bp region of the open reading frame was amplified (“ORF PCR”) and a ~1000 bp 
region was amplified using a forward primer lying upstream of the 5’ UTR region present in 
the knockout construct and a reverse primer specific to the BSD or NEO gene (“BSD PCR” 
and “NEO PCR”) respectively.  RECQ2 “ORF PCR” primers #44 and #45, 498 bp; “BSD PCR” 
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primers #51 and #154, 1365 bp; “NEO PCR” primers #51 and #155, 1008 bp.  MUS81”ORF 
PCR” primers #46 and #47, 494 bp; “BSD PCR” primers #52 and #154; 1331 bp, “NEO PCR” 
primers #52 and #155, 974 bp.  PIF6 “ORF PCR” primers #48 and #49, 500 bp; “BSD PCR” 
primers #53 and #154, 1255 bp;  “NEO PCR” primers #53 and #155, 898 bp.  Sequences of all 
primers are in Appendix 7.1.  Black arrows indicate primer binding sites.  Not to scale. 
The agarose gel in Figure 3-12 shows confirmation, using the above PCRs, of the 
integration of the knockout cassettes in each cell line and the removal of the 
cognate ORFs after the second round of transformation.  Only one knockout 
cassette could be PCR amplified (“BSD/NEO PCR”) in each heterozygote line, 
whereas both cassettes could be PCR amplified in the double knockout cell lines.  
Furthermore, the ORF of the targeted gene could no longer be PCR amplified in 
double knockout cell lines, indicating successful knockout of each gene. 
 
Figure 3-12 Confirmation by PCR of knockout of RECQ2, MUS81 and PIF6 
Agarose gels of PCR products generated from genomic extracted from DNA wild type and 
recq2, mus81 and pif6 mutant cells.  A 500 bp region of the open reading frame was 
amplified (“ORF PCR”) and a ~1000 bp region was amplified using a forward primer lying 
upstream of the 5’ UTR region present in the knockout construct and a reverse primer 
specific to the BSD or NEO gene (“BSD PCR” and “NEO PCR”) respectively.  These primers 
are described in Figure 3-11 and their sequences can be found in Appendix 7.1 
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3.3.4 Confirmation of knockout mutants by RT-PCR 
Reverse transcription PCR (RT-PCR) was used to confirm absence of expression of 
the knocked-out gene in each -/- cell line.  RNA extracted from wild type, +/- 
and -/- cell lines was reverse transcribed (as described in sections 2.4.2 and 
2.8.3).  During reverse transcription, a no reverse transcriptase (-RT) control was 
performed to assay for complete genomic DNA digestion.  A region of the ORF of 
the deleted gene was amplified from the cDNA template, as well as a region of 
the ORF of another gene (RECQ2 or pif6-/- mutants or PIF6 for recq2-/- mutants) 
that was not targeted, as a positive control to confirm the presence of cDNA in 
the sample.  This control PCR was not performed for MUS81, therefore the 
quality of the cDNA in mus81-/- preparations was uncertain.  Sequences of all 
primers can be found in Appendix 7.1 and gene-specific PCR details are 
described in the legend of Figure 3-13. 
The agarose gel in Figure 3-13 shows that the segment of the ORF of RECQ2, 
MUS81 and PIF6 could not be PCR amplified in their respective knockout cell 
lines, but that PCR amplification of the control gene was successful in the case 
of recq2 and pif6 mutants.  In contrast, the expected PCR products were 
generated in the different +/- cells and in the untransformed wild type cells.  
There was faint PCR amplification in some –RT control samples, indicating DNA 
contamination in those RNA preparations.  However, the ORF PCR for the 
targeted gene failed in knockout cell lines in both the +RT and –RT samples, 
confirming that knockout of the targeted genes was successful. 
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Figure 3-13 RT-PCR confirmation of recq2, mus81 and pif6 mutants 
cDNA was synthesised from RNA extracted from wild type, recq2, mus81 and pif6 mutant 
cells.  (A) A 245 bp region of the PIF6 ORF (primers #81/#82) and 232 bp region of the 
RECQ2 ORF (primers #77/#78) was PCR amplified from cDNA of wild type cells, recq2 
mutants and pif6 mutants (+RT), as well as from samples in which no reverse transcriptase 
had been added (-RT).  Distilled water was used as a negative control (-).  (B) A 
494 bp region of the MUS81 ORF (primers #46/#47) was PCR amplified from cDNA of wild 
type cells and mus81 mutants (+RT), as well as from RNA used to synthesise the cDNA 
(RNA).  Distilled water was used as a negative control.  Dashes lined indicate different 
images aligned in this figure.  Sizes shown, ladder (bp). 
3.4 Phenotypic analysis of knockout mutants 
3.4.1 Analysis of in vitro growth 
In order to understand if any of the gene knockouts had an effect on cell 
survival, the in vitro growth of recq2, pif6 and mus81 +/- and -/- mutants was 
compared to wild type cells by incubation of 1 mL cultures at a density of 1 x 104 
cells.mL-1 in the absence of selective drugs and the density counted every 24 
hours up to a maximum of 96 hours using a haemocytometer.  Cultures were not 
diluted during the growth curve.  All growth curves were repeated three times 
and the average and standard error of the mean (SEM) of these counts were 
plotted logarithmically (Fig. 3-14).   
A growth defect was observed for recq2-/- mutants compared to wild type cells 
(Fig. 3-14A), which was statistically significant at 24 and 48 hours (p=0.018 and 
p=0.037 respectively, using a 2 sample t-test).  In addition, there appeared to be 
Chapter 3     107 
 
a minor effect on growth in the req2+/- mutants, perhaps suggesting some 
impediment after loss of one allele.  A growth defect similar to the recq2-/- 
mutants was also observed in mus81-/- mutants (Fig. 3-14B), though this was only 
significant at the 24 hour time point (p=0.005 using a 2 sample t-test). For these 
mutant series there was, however, no obvious growth impediment in the 
mus81+/- cells, suggesting any effects are only manifest after both alleles are 
deleted.  No defect in growth was found to be statistically significant for either 
pif6 mutant (Fig. 3-14C), though the growth curves suggest a minor growth 
impediment that is of the same magnitude in both the +/- and -/- cells.  
Interestingly, this appears to correlate with several further assays (below), 
which suggest that loss of one pif6 allele has phenotypic consequences that are 
not increased further after loss of the second allele. 
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Figure 3-14 In vitro growth analysis of recq2, mus81 and pif6 mutants  
The cell density of wild type and recq2 mutants (A), mus81 mutants (B) and pif6 mutants (C). 
Cultures were counted every 24 hours up to a maximum of 96 hours using a 
haemocytometer starting from a cell density of 1 x 104 cells.mL-1.  Growth curves were 
repeated three times and the mean cell density and standard error of the mean (SEM) are 
plotted logarithmically.  For clarity, in vitro growth of wild type, +/- and -/- mutants is plotted 
on the left and the growth of wild type and -/- cells only is plotted on the right.  Significant 
differences between the means are indicated by * and were calculated using Student’s t-
test; * p= 0.018; ** p=0.037; *** p=0.005. 
3.4.2 Cell cycle analysis 
To investigate if the growth impediments (above) can be explained by delay in 
completion of the cell cycle, it was examined whether there were detectable 
cell cycle alterations in recq2, mus81 and pif6 mutants.  For this purpose, cells 
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were fixed, stained with DAPI and scored by cell cycle stage.  Cells in the G1 and 
S phases of the cell cycle contain one nucleus and one kinetoplast (1N1K).  
Kinetoplast division occurs before nuclear division and thus cells in the G2 phase 
contain one nucleus and two kinetoplasts (1N2K) and cells with two nuclei and 
two kinetoplasts are in M phase (2N2K).  Following M phase, cytokinesis results in 
two 1N1K cells (Woodward & Gull, 1990).  The expected distribution of 
detectable cell cycle phases in wild type blood stream form cells is: ~80% 1N1K, 
~10% 1N2K, ~5% 2N2K (Benmerzouga et al., 2013). 
Figure 3-15 shows cell cycle analysis of mus81, pif6 and recq2 mutants.  The 
distribution of cell cycle stages in all of the +/- or -/- cell lines was similar to 
the expected distribution, indicating no detectable defects in the cell cycle 
using this method.  Therefore, although in vitro growth analysis showed that at 
least the recq2-/- and mus81-/- mutants have a growth defect, this is not 
accompanied by changes in progression through the cell cycle. 
 
Figure 3-15 Cell cycle analysis of recq2, mus81 and pif6 mutants 
Logarithmically growing wild type and mutant cells were fixed and stained with DAPI to 
visualise the nucleus and kinetoplast.  Cells in captured images were counted (using Fuji 
ImageJ) and categorised as 1N1K, 1N2K, 2N2K or ‘other’ for cells that did not conform to 
these categories.  N, nucleus, K, kinetoplast.  The number of cells counted is indicated 
above each bar (N). 
3.4.3 Analysis of DNA damage sensitivity 
The three genes under investigation have each been shown to act in genome 
repair in other eukaryotes.  To ask if they also act in similar pathways of repair 
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in T. brucei, analysis of the growth and clonal survival of cells following 
exogenous DNA damage was performed, assessing the DNA damage sensitivity of 
the mutants.  Three DNA damaging agents with different modes of action and 
resultant damage were used: hydroxyurea (HU), methyl methanesulfonate (MMS) 
and phleomycin.  HU depletes the cellular dNTP pool (Bianchi et al., 1986), 
resulting in replication stalling.  Stalled replication forks can subsequently 
collapse, resulting in DNA breaks.  MMS is an alkylating agent, which methylates 
purines at the 7’ position of guanosine residues and the 3’ position of adenine 
residues (Brookes & Lawley, 1961).  MMS causes DNA breaks, though it is not 
clear whether it produces these directly or whether DNA breaks are formed 
through activities resulting from DNA alkylation (Lundin et al., 2005; Wyatt & 
Pittman, 2006).  MMS also perturbs replication, slowing the progression of the 
replication fork due to alkylated nucleotides physically blocking replication fork 
elongation (Groth et al., 2010; Tercero & Diffley, 2001).  Phleomycin blocks the 
activity of DNA polymerase, inhibiting DNA synthesis and resulting in formation 
of single and double strand DNA breaks, primarily the latter (Falaschi & 
Kornberg, 1964; Reiter et al., 1972). 
The sensitivity of recq2, pif6 and mus81 mutants to these damaging agents was 
assayed using clonal survival assays and measuring the outgrowth of a single cell 
in the presence of a damaging agent.  Prior to this and in order to determine the 
appropriate concentrations of each damaging agent, in vitro growth was assayed 
by growth curve analysis in the presence of a damaging agent. 
3.4.3.1 Analysis of in vitro growth after DNA damage 
To determine the appropriate concentrations to use in subsequent clonal survival 
assays, growth curve analysis of pif6 and recq2 mutants was performed.  The 
same analysis was not performed for mus81 mutants. 
The initial concentrations of MMS chosen for in vitro growth analysis were 
0.0002%, 0.0003% and 0.0004%, based on our lab’s previous experience.  The 
growth of untreated cells is shown in Figure 3-16A for comparison.  Following 
MMS treatment, wild type cells exhibited slower growth as expected, which was 
detectable at 0.0002% and became more pronounced at 0.0003% and 0.0004%.  
The very slow growth of recq2-/- mutants displayed an increased impairment in 
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growth relative to wild type cells and recq2+/- mutants at all concentrations of 
MMS tested (Fig. 3-16B), suggesting that null mutants are more sensitive to MMS-
induced DNA damage.  No cells were counted in 0.0003% and 0.0004% MMS 
treated wild type cultures at 72 hours.  This is most likely due to technical error 
in passage of cultures at 48 hours.  The very slow growth of recq2-/- at even the 
lowest concentration of MMS (0.0002%) suggested that an additional, lower 
concentration (0.0001%) of MMS should be used in subsequent clonal survival 
assays (see below).  The growth of pif6+/- and pif6-/- cells was similar to wild 
type cells after MMS treatment (Fig. 3-16B).  These data suggested that pif6 
mutants have no difference in MMS-induced damage sensitivity or alternatively, 
any phenotype is not detectable in this assay. 
The HU concentrations used in the analysis of in vitro growth were 0.01 mM, 
0.02 mM and 0.03 mM, based on Kim & Cross (2010).  Following HU treatment, 
no obvious effect on growth was observed for wild type cells (Fig. 3-16C).  
recq2+/- mutants grew similarly to wild type cells under HU treatment but req2-/- 
mutants appeared to grow more slowly in the presence of HU.  In addition, there 
was a minor growth defect in both pif6+/- and pif6-/- mutants.  These data 
suggested that the HU concentration range should be increased to attempt to 
observe a more obvious phenotype in pif6 mutants. 
Little effect on the growth of wild type or recq2+/- cells was observed during 
growth in the presence of phleomycin (Fig. 3-16D).  However, the growth of 
phleomycin treated recq2-/- cells was slower compared to untreated recq2-/- 
cells and wild type phleomycin treated cells.  Interestingly, phleomycin-treated 
pif6+/- cells appeared to grow faster than untreated cells, although this effect 
was only observed at 72 hours.  In contrast, no effect on growth was observed 
for pif6-/- phleomycin-treated cells.  The absence of an observable phleomycin 
treated growth phenotype in most of the cell lines suggested that the 
phleomycin concentration range should be increased in subsequent clonal 
survival assays. 
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Figure 3-16 In vitro growth of recq2 and pif6 mutants in the presence of DNA damaging 
agents 
Wild type, recq2 mutant and pif6 mutant cells at a starting density of 1 x 104 cells.mL-1 were 
incubated for 72 hours in the presence of (A) no damaging agents, (B) varying 
concentrations of MMS, (C) varying concentrations of hydroxyurea (HU) or (D) varying 
concentrations of phleomycin.  The cell density was counted every 24 hours using a 
haemocytometer.  Cumulative growth is plotted logarithmically. 
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3.4.3.2 Analysis of clonal survival after DNA damage 
In order to analyse the clonal survival of recq2, mus81 and pif6 mutants, treated 
and untreated cultures were diluted to one cell per well and the number of wells 
on a 96 well plate with live cells was counted after ~10 days incubation (see 
Section 2.2.3.2 for more details). 
MMS concentrations used (0.0001%, 0.0002%, 0.0003% and 0.0004%) were 
determined from previous in vitro growth curve analysis (Section 3.4.3.1).  The 
survival of wild type cultures decreased with increasing MMS concentration 
(Fig. 3-17).  At MMS concentrations at and above 0.0002%, recq2+/- survival was 
lower than wild type and recq2-/- cells displayed a severe sensitivity to MMS, 
though not statistically significant using a Mann-Whitney U test.  These data 
indicate that recq2-/- mutants are more sensitive to MMS and that mild MMS 
sensitivity is caused by loss of even one allele, indicating that RECQ2 is involved 
in the T. brucei response to MMS-induced damage.  MMS sensitivity has 
previously been reported in RecQ helicase mutants.  S. cerevisiae SGS1 mutants 
(Mullen et al., 2000) as well as human blm-/- (Wang et al., 2000) and chicken 
DT40 cells (Imamura et al., 2001) are hypersensitive to MMS. 
No change in MMS sensitivity was seen in mus81+/- cells relative to wild type (Fig. 
3-17).  At higher concentrations of MMS (0.0003% and 0.0004% MMS), mus81-/- 
displayed approximately three-fold reduced survival relative to wild type using a 
Mann-Whitney U test (0.0003% MMS: P=0.0286, WT n=4 median=79.05, mus81-/- 
n=4 median=33.05; 0.0004%: P=0.0286, WT n=4 median=47.65, mus81-/- n=4 
median=13.25).  These survival data indicate that MUS81 also acts in the 
response to MMS damage, though the reduced sensitivity of mus81-/- mutants 
relative to recq2-/- mutants suggests a greater role for the latter factor. 
Following incubation with MMS, the survival of both pif6+/- and pif6-/- mutants 
appeared higher relative to wild type cultures, a quite different effect of these 
mutations to that of mus81 and recq2.  It is also notable that the effect of a 
single pif6 allele knockout appeared the same as removing both alleles, 
consistent with the equivalent minor growth defects (Figure 3-14C).  Despite this 
trend, there was considerable variation in survival of the pif6 mutants in each 
individual experiment performed (Fig. 3-17) and there was no statistical 
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difference detected (Mann-Whitney U test) between wild type cells and pif6 
mutants.  In fact, it was noted that assays conducted using pif6 mutants that 
had been in culture for a longer period of time showed an increased MMS 
sensitivity than when pif6 mutant cell lines were used after only a short period 
in culture (Appendix 7.2, Fig. 7-1).  The basis for this variation is unclear, 
though it is possible that loss of PIF6 results in the selection for unknown, 
secondary mutations.  Irrespective, it is clear that PIF6 does not play the same 
role in response to MMS damage as either RECQ2 or MUS81, and its absence may 
be beneficial in this circumstance. 
 
Figure 3-17 Clonal survival of recq2, mus81 and pif6 mutants in the presence of MMS 
Wild type and recq2 (A), mus81 (B), and pif6 (C) mutants were diluted to the equivalent of 
one cell per well over three 96 well plates in the presence of varying concentrations of MMS.  
Plates were incubated for 10 days or until wells were clearly positive or negative by colour 
(saturated cultures are indicated by yellow media).  Positive wells were counted and the 
survival of MMS-treated cultures was calculated relative to untreated.  Assays were 
repeated three times for recq2 mutants, four times for mus81 mutants and three times for 
pif6 mutants.  Mean survival (%) relative to untreated cells is plotted; bars represent 
standard error of the mean (SEM).  Significant differences between the relative survival of 
different cell lines are indicated (Mann-Whitney U test - 0.0003% MMS: P=0.0286, WT n=4, 
median=79.05; mus81-/- n=4, median=33.05; 0.0004%: P=0.0286, WT n=4 median=47.65, 
mus81-/- n=4 median=13.25). 
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Initial clonal survival experiments were conducted using phleomycin at 
0.1 µg.mL-1, 0.2 µg.mL-1 and 0.3 µg.mL-1, estimated from the lack of strong 
growth effects in the growth curve analysis (Section 3.4.3.1).  However, these 
concentrations were found to be too high, as no cell line survived at 
concentrations higher than 0.1 µg.mL-1 phleomycin (data not shown).  The 
concentrations were thus lowered to 0.05 µg.mL—1, 0.075 µg.mL-1 and 
0.10 µg.mL-1, the same concentrations used in the growth curve. 
The clonal survival of recq2 mutants in the presence of phleomycin treatment 
was assayed twice and in each of these experiments, recq2-/- mutants displayed 
reduced survival relative to wild type cells (Fig. 3-18), suggesting a role for 
RECQ2 in responding to phleomycin-induced damage.  However, there was a high 
variation in the survival rate in the two repeats. 
Survival of mus81+/- cells was similar to wild type at all concentrations of 
phleomycin treatment (Fig. 3-18).  However, at 0.075 µg.mL-1 and 0.10 µg.mL-1 
phleomycin mus81-/- survival was significantly lower than wild type using a Mann-
Whitney U test (0.075 µg.mL-1: P=0.0152, WT n=6 median=86.2, mus81-/- n=6 
median=29.9; 0.10 µg.mL-1: P=0.0087, WT n=6 median=62.36, mus81-/- n=6 
median=1.10).  These data demonstrate that mus81-/-, but not mus81+/-, mutants 
have an increased sensitivity to phleomycin-induced damage and indicate that 
MUS81 is involved in the response to phleomycin damage. 
No difference in sensitivity to phleomycin was observed in either pif6 mutant 
compared to wild type cells (Fig. 3-18), suggesting PIF6 does not play a role in 
the response to phleomycin-induced damage and again indicating a distinct role 
to that of RECQ2 and MUS81. 
Hydroxyurea concentrations used (0.02 mM, 0.03 mM and 0.04 mM) were 
determined from previous in vitro growth curve analysis.  No effect on survival 
was observed after HU treatment of either wild type or recq2+/- cells 
(Fig. 3-19A).  In contrast, recq2-/- cells displayed reduced survival compared to 
both cells at all concentrations of HU, with survival of recq2-/- at 0.04 mM 
approximately five-fold lower than wild type cells.  These data suggest that 
RECQ2 acts in the T. brucei BSF cell response to HU damage. 
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Sensitivity of mus81 mutants to HU was assayed twice and when data from the 
two assays were combined (Fig. 3-19B) no obvious change in sensitivity to HU 
was observed in mus81 mutants.  When these two assays are examined 
separately (Fig. 3-19D), mus81-/- cells displayed ~20% reduced survival compared 
to wild type at the highest HU concentration tested (0.04 mM) in only one of the 
experiments.  These data suggest that MUS81 does not play a role in the 
response to HU, or at least has a very minor role. 
 
Figure 3-18 Clonal survival of recq2, mus81 and pif6 mutants following treatment with 
phleomycin 
Wild type and recq2 (A), mus81 (B), and pif6 (C) mutants were diluted to the equivalent of 
one cell per well over three 96 well plates in the presence of varying concentrations of 
phleomycin.  Plates were incubated for 10 days or until wells were clearly positive or 
negative by colour (saturated cultures are indicated by yellow media).  Positive wells were 
counted and the survival of phleomycin-treated cultures was calculated relative to 
untreated.  Assays were repeated twice for recq2 mutants, six times for mus81 mutants and 
twice for pif6 mutants.  Mean survival (%) relative to untreated cells is plotted; bars 
represent standard error of the mean (SEM).  Significant differences between the relative 
survival of different cell lines are indicated (Mann-Whitney U test 0.075 µg.mL-1: P=0.0152, 
WT n=6 median=86.2, mus81-/- n=6 median=29.9; 0.10 µg.mL-1: P=0.0087, WT n=6 
median=62.36, mus81-/- n=6 median=1.10). 
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A mild increase in HU sensitivity was observed in pif6 mutants (Fig. 3-19C), 
survival of which was approximately 15% lower than wild type at 0.04 mM HU.  
Notably, and in common with the MMS data (Figure 3-17), both the pif6+/- and 
pif6-/- mutants displayed the same effect.  Although these data are from only 
two repeats of this assay, and are perhaps surprising in that sensitivity increases 
with HU concentration (in contrast to recq2-/-), they suggest that PIF6 
contributes to the response to HU.  This contrasts with the lack of a detectable 
repair role against either MMS or phleomycin damage. 
Taken together these data show that each of the knockout mutants displays a 
different DNA damage sensitivity phenotype.  recq2-/- mutants displayed 
pronounced increased sensitivity to the DNA damaging agents MMS and 
hydroxyurea, and some evidence for increased sensitivity to phleomycin, 
suggesting RECQ2 acts in a broad range of repair roles.  Though not as dramatic 
as in recq2-/- mutants, mus81-/- mutants also display an increased sensitivity to 
MMS compared to wild type and mus81+/- cells.  mus81-/- cells were more 
sensitive than wild type or mus81+/- cells to phleomycin and, in this case, the 
sensitivity was similar to that of recq2-/- cells.  Only weak evidence was found 
for a change in sensitivity to HU in mus81-/- cells.  Thus, in total, MUS81 appears 
to display a similar broad range of repair activities to RECQ2, but for two forms 
of damage this role is substantially weaker and only for phleomycin damage does 
the putative endonuclease appear to compare in importance.  In contrast to 
both mus81-/- and recq2-/- mutants, pif6 mutants showed no increase in MMS or 
phleomycin sensitivity compared to wild type cells (indeed, if anything, pif6 
mutants displayed improved survival in response to MMS); instead, pif6 mutant 
cells exhibited an increased sensitivity only to HU.  Moreover, pif6 mutants were 
notable for displaying no discernible difference in phenotypes between the +/- 
and -/- mutation configuration.  PIF6 appears to provide a narrower DNA repair 
role in T. brucei than MUS81 or RECQ2. 
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Figure 3-19 Clonal survival of recq2, mus81 and pif6 mutants in the presence of 
hydroxyurea 
Wild type and recq2 (A), mus81 (B), and pif6 (C) mutants were diluted to the equivalent of 
one cell per well over three 96 well plates, in the presence of varying concentrations of 
hydroxyurea (HU).  Plates were incubated for 10 days or until wells were clearly positive or 
negative by colour (saturated cultures are indicated by yellow media).  Positive wells were 
counted and the survival of HU-treated cultures was calculated relative to untreated.  
Assays were repeated twice.  The two individual repeats assaying mus81 mutants are 
shown in (D).  Mean survival (%) relative to untreated cells is plotted; bars represent 
standard error of the mean (SEM). 
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3.5 Generation of re-expresser cell lines 
3.5.1 Generation of re-expresser constructs 
After confirming the viability and assaying the DNA damage phenotype of the 
recq2, mus81 and pif6 mutants, it was necessary to re-express the genes in the 
mutant backgrounds to confirm that the phenotype was due to the knockout of 
the gene and not as a result of secondary effects.  To achieve this the entire 
ORF of each gene was amplified (primers RECQ2 #151/#126; MUS81 #152/#128; 
PIF6 #153/#130, see Appendix 7.1 for sequences) by PCR and cloned, using NheI 
and XbaI restriction sites, into a modified version of the pGL2070 vector (Gift, 
Jeremy Mottram).  pGL2070 contains a blasticidin resistance cassette, flanked 
upstream with a βα-tubulin intergenic region and downstream with an actin 
intergenic region (βα-BSD-act).  The re-expressed ORF is placed downstream of 
the actin intergenic region and is followed immediately downstream by a 6HA 
tag and an αβ-tubulin intergenic region (βα-BSD-act-ORF-6HA-αβ).  pGL2070 was 
modified by replacing the blasticidin resistance gene with hygromycin (using 
cloning primers #108/#109, see Appendix 7.1), followed by removal of the 6HA 
tag and replacement with an oligonucleotide (oligos #116/#117, see Appendix 
7.1) containing multiple restriction sites, including NheI and XbaI, which were 
used to attempt to clone in the RECQ2, MUS81 and PIF6 ORFs.  Due to the 
compatibility of NheI and XbaI digested DNA ends, plasmids were screened by 
restriction enzyme digestion prior to sequencing in order to exclude clones in 
which the ORF had ligated in the reverse orientation. 
A representation of the expected final plasmids used to generate the re-
expresser cell lines is shown in Figure 3-20.  The plasmid contains a hygromycin 
resistance cassette for selection and the untagged gene ORF.  This construct can 
be integrated into the βα tubulin locus of T. brucei after digestion with PacI and 
transformation.  Recombination occurs on the βα and αβ targeting regions, 
integrating the construct into the βα-tubulin array replacing an α tubulin ORF 
and allowing expression of the ORF mRNA through the flanking non-endogenous 
intergenic sequences. 
It was not possible to generate a RECQ2 re-expresser plasmid; the successfully 
amplified ORF did not successfully ligate into the construct.  The MUS81 and PIF6 
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re-expresser constructs RXP-MUS81 (re-expresser MUS81) and RXP-PIF6 (re-
expresser PIF6) were digested with PacI and transformed into either the pif6-/- 
or mus81-/- cell lines and selected for using 2.5 µg.mL-1 G418, 5 µg.mL-1 
blasticidin and 10 µg.mL-1 hygromycin. 
 
Figure 3-20 Schematic of re-expresser construct 
The MUS81 and PIF6 re-expresser constructs used to generate the re-expresser lines in 
mus81-/- and pif6-/- backgrounds contain the MUS81 (1845 bp) or PIF6 ORF (2391 bp) 
(orange), cloned using NheI and XbaI restriction enzyme sites (RECQ2 primers #151 and 
#126; MUS81 primers #152 and #128; PIF6 primers #153 and #130).  Antibiotic selection is 
enabled by a hygromycin resistance gene (pink).  The construct is linearised by digestion 
with PacI (sites indicated) and integration into the tubulin array for expression of the 
resistance gene and re-expressed ORF is facilitated by tubulin sequences flanking the 
construct.  Tubulin and actin sequences present provide transplicing and polyadenylation 
signals for hygromycin and the re-expressed ORF.  Sizes shown (bp) vary by gene ORF. 
Two of the three mus81-/-/+ transformation tissue cultures plates contained too 
many positive wells to be clonal.  However, the third and most dilute plate 
contained six wells with live cells.  These were all taken for analysis and PCR 
amplification showed all six clones contained the MUS81-RXP cassette, as 
discussed below.  Two of the three pif6-/-/+ transformation tissue cultures plates 
contained too many positive wells to be clonal.  However, the third and most 
dilute plate contained nine wells with live cells.  Six were taken for analysis and 
PCR amplification showed all six clones contained the PIF6-RXP cassette, as 
discussed below. 
3.5.2 Confirmation of re-expresser cell lines by PCR and RT-PCR 
Possible MUS81 and PIF6 re-expresser clones following transformation of mus81-/- 
and pif6-/- cell lines with the RXP-MUS81 or RXP-PIF6 re-expresser constructs 
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respectively (βα-HYG-Act-ORF-αβ) were screened using PCR primers that bind to 
the actin IR (primer #OL4038, see Appendix 7.1) and within the gene ORF 
(primer #80, MUS81 (1603 bp product); and #82, PIF6 (1165 bp PCR product); see 
Appendix 7.1).  Figure 3-21A shows the PCR screening strategy.  The re-
expresser construct was amplified in the MUS81 and PIF6 re-expresser cell lines 
(Fig. 3-21B), demonstrating the successful integration of the re-expresser 
constructs into the mus81-/- and pif6-/- cell lines.  The putative re-expresser cells 
were designated mus81-/-/+ and pif6-/-/+. 
 
Figure 3-21 PCR confirmation of MUS81 and PIF6 re-expresser cell lines 
(A) Integration of the RXP-MUS81 and RXP-PIF6 constructs was confirmed by PCR 
amplification of the construct using a forward primer binding in the acting intergenic region 
(primer #OL4038) and reverse primer binding in the MUS81 (primer #80, 1603 bp product) of 
PIF6 (primer #82, 1165 bp product) ORF.  (B) PCR amplification of the re-expresser 
construct was performed as described above, using genomic DNA extracted from mus81-/-/+ 
and pif6-/-/+ cells.  Distilled water was used as a negative control.  Sizes are shown (bp). 
PCR analysis of cDNA from putative mus81-/-/+ and wild type cells was 
undertaken to test for re-expression of MUS81.  A ~200 bp region of the MUS81 
ORF was PCR amplified (primers #79/#80, see Appendix 7.1).  A negative reverse 
transcriptase (-RT) control reaction, which contained no enzyme, was performed 
to test whether PCR products generated arose from cDNA and not from 
contaminating genomic DNA.  In wild type, mus81+/- and mus81-/-/+ both MUS81 
and RNA PolI PCR products were amplified (Fig. 3-22) confirming that cDNA is 
present in all samples and that MUS81 is expressed in all four cell lines.  Absence 
of PCR amplification of either PCR product in the minus RT samples of mus81-/-/+ 
confirms the absence of detectable genomic DNA contamination in the RNA 
sample used for cDNA synthesis.  However, amplification in the -RT sample of 
wild type cells indicates some genomic DNA contamination in the RNA sample 
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used for cDNA synthesis.  RT-PCR analysis was not undertaken for the putative 
pif6-/-/+ line. 
 
Figure 3-22 RT-PCR confirmation of MUS81 re-expresser cell lines 
cDNA was synthesised from RNA extracted from wild type, mus81-/- and mus81-/-/+ cells 
(+RT).  A 214 bp region of the MUS81 ORF was amplified by PCR using primers #79 and #80, 
and a 453 bp region of RNA polymerase I (RNA polI) was PCR amplified to test for the 
presence of cDNA in all samples.  PCR amplification was also carried out on samples from a 
reaction in which reverse transcriptase (-RT) was absent.  Distilled water was used as a 
negative control (-).  Size and markers are shown (ladder, bp). 
3.6 Analysis of re-expresser cell lines 
3.6.1 Analysis of in vitro growth of re-expresser cell lines 
Analysis of in vitro growth of re-expresser lines was performed as described in 
Section 3.4.1.  The growth of mus81-/-/+ cells showed growth similar to that of 
wild type (Fig. 3-23A), indicating a rescue of the growth defect of mus81-/- cells.  
In vitro growth of pif6-/-/+ cells was indistinguishable from pif6-/- cells (Fig. 3–
23B) with both showing some evidence of slowed, though not statistically 
significant, growth relative to wild type.  Whether this means that there is no 
re-expression of PIF6 is unclear since previous growth curves, as well as MMS and 
HU survival assays, suggest that pif6+/- cells are phenotypically equivalent to 
pif6-/- cells.  For this reason, re-introduction of a single copy of the PIF6 ORF 
may have little discernible effect. 
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Figure 3-23 In vitro growth of MUS81 and PIF6 re-expresser cell lines 
Wild type, mus81-/- and mus81-/-/+ cells were incubated for 96 hours at a starting density of 
1 x 104 cells.mL-1.  The cell density of cultures was counted every 24 hours using a 
haemocytometer.  Cultures were not diluted during incubation.  Growth curves were 
repeated three times and the mean cell density is plotted logarithmically.  Bars represent 
standard error of the mean (SEM).  Differences between the mean cell density of WT and 
mus81-/- cultures were calculated using Student’s t-test; *** p=0.005). 
3.6.2 Analysis of DNA damage sensitivity of re-expresser cell 
lines 
To test further for functionality of the re-expressed MUS81, rescue of the DNA 
damage phenotype using a clonal survival in the presence of phleomycin was 
investigated next.  This assay was chosen due to the strong increase in 
phleomycin sensitivity in mus81-/- mutants.  Re-expression of the MUS81 ORF in 
the mus81-/-/+ line clearly rescued the phleomycin sensitivity of mus81-/- mutants 
(Fig. 3-24A). 
Clonal survival in the presence of MMS was used to attempt to ascertain whether 
re-introduction of the PIF6 ORF showed phenotypic evidence.  However, as 
stated above, this was complicated by the fact that the observed increased 
resistance of pif6-/- mutants to MMS relative to wild type was also seen in pif6+/- 
cells (Fig. 3-17).  Even accepting these problems however, the results of the 
assay (Fig. 3-24B) were anomalous when compared with previous clonal survival 
assays of pif6 mutants in the presence of MMS; in this experiment pif6-/- mutants 
displayed substantially impaired survival compared with wild type and pif6+/- 
cells, casting doubt on the validity of the experiment.  The survival of pif6-/-/+ 
cells following MMS treatment was similar to wild type, though as discussed 
above, whether this suggests that the expressed PIF6 ORF in pif6-/-/+ rescues the 
phenotype of pif6-/- mutants is unclear. 
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The Pro742Ser mutation present in the re-expressed protein, combined with the 
absence of RT-PCR data to demonstrate re-expression of PIF6, mean it is not 
possible to determine whether PIF6 re-expression alters the DNA damage 
phenotype, if it has been rescued, or indeed whether it is expressed at all.  As 
the pif6 mutants showed statistically significant increased sensitivity to HU, it is 
possible that a clonal survival assay with this compound may be revealing, but 
again the pif6+/- and pif6-/- mutants appear phenotypically indistinguishable. 
 
Figure 3-24 Clonal survival of re-expresser lines in the presence of DNA damaging 
agents 
(A) Wild type (WT), mus81+/-, mus81-/- and mus81-/-/+ cells were diluted to the equivalent of 
one cell per well over three 96 well plates in the presence of 0/0.05/0.075/0.1 µg.mL-1 
phleomycin.  Plates were incubated for 10 days or until wells were clearly positive or 
negative by colour (saturated cultures are indicated by yellow media).  Positive wells were 
counted and the survival of phleomycin-treated cultures was calculated relative to 
untreated.  Mean survival (%) per plate relative to untreated cells is plotted; bars represent 
standard error of the mean (SEM) from the three plates, to indicate intra-experiment 
variation.  (B) Wild type, pif6+/-, pif6-/- and pif6-/-/+ cells were treated and analysed as in (A), 
with the exception that cells were treated with 0%, 0.0001%, 0.0002%, 0.0003% or 0.0004% 
MMS. 
3.7 Generation of endogenously tagged cell lines 
3.7.1 Generation of C-terminal myc-tagged MUS81 and PIF6 cell 
lines 
To date there are no antisera available against any of these three T. brucei 
repair proteins and so, in order to attempt to discern their subcellular 
localisation, attempts were made to express each of them as epitope tagged 
variants.  It was initially intended to endogenously tag all three factors at the C-
terminus using 12 copies of the myc epitope.  This vector (pNATx12myc, (Alsford & 
Horn, 2008)) has successfully been used to tag and localise proteins in T. brucei 
previously (Jones et al., 2014; Trenaman et al., 2013).  However, cloning to 
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generate a C-terminal RECQ2::12myc construct was unsuccessful and this protein 
was instead tagged at the N-terminus (see below). 
C-terminal tagging strategy and the C-terminal tagging constructs are shown in 
Figure 3-25.  The MUS81 ORF was targeted using the final 488 bp of the C-
terminal coding region of the gene containing a unique restriction site (EcoRV) in 
the MUS81::C-12myc construct (Gift, Catarina Marques), derived from the 
pNATx12myc construct (Alsford & Horn, 2008).  The PIF6 ORF was targeted using 
the final 743 bp of the C-terminal coding region of the gene containing a unique 
restriction site (BsiWI) in the PIF6::C-12myc construct, derived from the 
pNATx12myc construct (Alsford & Horn, 2008).  The PIF6 targeting region was PCR 
amplified from wild type genomic DNA using primers #19 and #20 (see Appendix 
7.1).  The unique restriction enzyme site was used to linearise the construct 
prior to transformation.  This C-terminal region includes sequence up to but not 
including the stop codon to allow translation to proceed through into the 12myc 
epitope tag, and was cloned into the construct using HindIII and XbaI restriction 
enzyme sites.  Selection of transformants is enabled by a blasticidin resistance 
gene, which is flanked by tubulin and actin processing sequences.  After 
integration the 3’ UTR of the tagged gene will no longer be endogenous 
sequence; instead, plasmid sequence is downstream and the blasticidin cassette 
provides polyadenylation signals for the tagged gene. 
Chapter 3     126 
 
 
Figure 3-25 Diagram of C-terminal 12myc tagging construct and strategy 
(A) Construct used to epitope tag MUS81 and PIF6 at the C-terminus with a 12myc tag.  As 
described in the text, the final 488 bp of MUS81 for the MUS81::C-12myc construct and final 
743 bp of PIF6 for the PIF6::C-12myc construct was cloned, excluding the stop codon (blue), 
immediately upstream of 12 repeats of the myc sequence (orange) using AscI and Xba 
restriction enzyme sites.  Antibiotic selection was provided by a blasticidin resistance gene 
(pink), flanked by tubulin and actin sequences for mRNA transplicing and polyadenylation 
(light grey).  The MUS81::C-12myc and PIF6::C-12myc constructs were linearised using a 
unique restriction enzyme linearisation site located in the cloned C-terminal region of the 
gene ORF (indicated on map), EcoRV for MUS81::C-12myc and BsiWI for PIF6::C-12myc.   
(B) C-terminal tagging strategy used.  Linearisation of the MUS81::C-12myc or BsiWI for 
PIF6::C-12myc construct within the cloned 3’ end of the ORF (blue dashed box) allows 
integration into the genome at the site of the targeted ORF (blue) by HR (dashed lines).  This 
produces the endogenous ORF fused with the C-terminal 12myc tag (orange).  Not to scale. 
3.7.2 Generation of N-terminal myc-tagged RECQ2 cell line 
The strategy used to generate the RECQ2 endogenous N-terminal 12myc-tagged 
lines and the constructs used are shown in Figure 3-26.  A 322 bp region of the 
RECQ2 ORF, starting after the start codon, was cloned into the construct 
immediately downstream and in frame of the 12myc tag.  The forward ORF 
primer (#24) contained a SpeI restriction enzyme site for ligation of the PCR 
product to the construct backbone, and the reverse primer (#25) contained a 
KpnI restriction enzyme site for ligation of the RECQ2 ORF PCR product to the 
RECQ2 UTR PCR product (see below).  The cloned RECQ2 ORF region is 
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immediately upstream of a 378 bp region of the RECQ2 5’ UTR, which includes 
the RECQ2 5’ UTR region up to but excluding the RECQ2 start codon.  The 
forward 5’ RECQ2 UTR primer (#22) contained a KpnI restriction enzyme site for 
ligation of the RECQ2 UTR PCR product to the RECQ2 ORF PCR product and the 
reverse primer (#23) contained a BamHI restriction enzyme site for ligation of 
the RECQ2 UTR PCR product to the construct backbone.  The sequences of all 
primers can be found in Appendix 7.1. 
The 5’ UTR and ORF regions facilitated targeting of RECQ2 through homologous 
recombination and integration into the genome.  The KpnI restriction site at the 
junction between the ORF and 5’ UTR was used for linearisation prior to 
transformation.  Selection of transformants is facilitated by a blasticidin 
resistance gene, flanked 5’ by an aldolase processing sequence and 3’ by an 
actin processing sequence.  After integration of the construct, the 5’ UTR of the 
12myc::RECQ2 gene is non-endogenous due to the use of the sequences of the 
upstream blasticidin resistance gene as RNA trans-splicing sequences. 
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Figure 3-26 RECQ2 N-terminal 12myc tagging construct and strategy 
(A) Construct used to epitope tag RECQ2 at the N-terminus with a 12myc tag.  As described 
in the text, the first 322 bp of the RECQ2 ORF, excluding the stop codon (blue), was cloned 
immediately downstream of 12 repeats of the myc sequence (orange) using SpeI and KpnI 
restriction enzyme sites.  Immediately downstream of the cloned RECQ2 ORF region is a 
378 bp region of the 5’ UTR (brown) of RECQ2 up to but not including the RECQ2 start 
codon, using restriction enzyme sites KpnI and BamHI.  The [12myc-RECQ2 ORF- 5’ UTR] 
cassette is flanked by aldolase 5’ and 3’ UTRs (grey) for mRNA transplicing and 
polyadenylation.  Antibiotic selection is enabled by a blasticidin resistance gene, flanked by 
actin sequences for transplicing and polyadenylation.  Restriction enzyme digestion using 
KpnI was used to linearise the construct prior to transformation.  Sizes shown (bp).           
(B) N-terminal tagging strategy used.  Linearisation (using KpnI) of the RECQ2-Nmyc 
construct allows integration into the genome at the site of the targeted ORF (blue) by HR 
(dashed lines).  This produces the endogenous ORF fused with the N-terminal 12myc tag 
(orange).  BSD, blasticidin; ALD, aldolase. Not to scale. 
3.7.3 Confirmation of in vivo myc-tagging by western blot 
analysis 
Wild type bloodstream Lister 427 cells were transformed with the linearised 
MUS81::12myc, PIF6::12myc and 12myc::RECQ2 constructs in order to generate a 
C-terminally 12myc tagged MUS81 and PIF6, and N-terminally 12myc tagged 
RECQ2 cell lines.  Antibiotic resistant transformants were selected using 
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10 µg.mL-1 blasticidin.  Six putative RECQ2 12myc clones were analysed by dot 
blot for myc expression, three of which expressed the myc epitope (data not 
shown).  Whole cell lysates were dotted onto nitrocellulose membrane and 
probed with rabbit anti-myc antiserum (1:7000 dilution, Life Technologies) and 
secondary anti-rabbit antiserum (1:5000, Life Technologies).  The clone selected 
for use in experiments was later analysed by western blot (Fig. 3-27) to test that 
the myc-tagged protein expressed matched the expected molecular weight of 
RECQ2 12myc.  Six putative PIF6 12myc clones were analysed by western blot, of 
which four expressed a myc-reactive protein matching the expected molecular 
weight of PIF6 12myc (data not shown).  Eighteen putative MUS81 12myc clones 
were analysed by PCR due to problems with dot and western blots at the time of 
clone screening.  This PCR used a forward primer (#52) binding within the MUS81 
ORF upstream of the unique restriction enzyme site and a reverse primer (#64) 
binding downstream of the 12myc tag, PCR amplifying a 1196 bp region to test 
integration of the MUS81 12myc construct.  Four of the eighteen putative 
MUS81 12myc clones were positive for this PCR (data not shown).  The clone 
selected for use in experiments was analysed by western blot (Fig. 3-27) to test 
that MUS81 12myc was expressed. 
Putative myc-tagged RECQ2, MUS81 and PIF6 transformant clones were screened 
by western blot to test expression of the tagged proteins.  Whole cell lysates 
were separated by SDS-PAGE on a 3-8% tris-acetate gel before western blotting 
and probing with rabbit anti-myc antiserum (1:7000 dilution, Millipore) and 
secondary anti-rabbit HRP-conjugated antiserum (1:5000 dilution, Life 
Technologies).  Figure 3-27 demonstrates that the putative myc-tagged clones 
expressed the expectd tagged protein.  The predicted molecular weight of 
12myc RECQ2 is 182 kDa (167.8 kDa (RECQ2) + 14.4 kDa (12myc)), and a single 
band was observed at approximately this molecular weight.  The predicted 
molecular weight of MUS81 12myc is 82.6 kDa (68.2 kDa (MUS81) + 14.4 kDa 
(12myc)) and a single band was observed at approximately this molecular 
weight.  The predicted molecular weight of PIF6 12myc is 102.7 kDa (88.3 kDa 
(PIF6) + 14.4 kDa (12myc)) and a single band was observed with an apparent 
molecular weight of approximately 117 kDa, larger than predicted.  Using a 10% 
bis-tris gel, the apparent molecular weight of PIF6 12myc was closer to the 
expected molecular weight, suggesting that the smaller size here is a running 
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artefact for PIF6 in 3-8% tris-acetate gels.  These myc-tagged clones were used 
in all subsequent experiments involving tagged RECQ2, MUS81 or PIF6. 
 
Figure 3-27 Western blot of 12myc-tagged RECQ2, MUS81 and PIF6 
Whole cell lysates (5 x 106 cell equivalents) of untagged wild type (WT), RECQ2 12 myc, 
MUS81 12myc and PIF6 12myc cultures were separated by SDS-PAGE on a 3-8% tris-acetate 
gel, western blotted and probed with rabbit anti-Myc antiserum (Millipore, 1:7000 dilution) 
and secondary anti-mouse HRP-conjugated antiserum (Life Technologies, 1:5000 dilution).  
The bands produced by RECQ2 12myc (182 kDa), MUS81 12myc 82.6 kDa) and PIF6 12myc 
(102.7 kDa) are indicated (*, ** and *** respectively) and size markers are shown (kDa). 
3.8 Testing the functionality of endogenously-tagged 
proteins 
3.8.1 Generation and validation of single-copy myc tagged cell 
lines 
As it had already been established that recq2, mus81 and pif6 null mutants are 
viable, the functionality of the tagged proteins in the 12myc lines could not be 
determined merely by showing that it is possible to knockout out the second, 
untagged allele of the genes.  Instead, for each tagged line, the second gene 
allele was knocked out and the DNA damage phenotype of the resulting cell lines 
was assayed. 
Because the myc tagging in all cases was selected for by blasticidin resistance, 
the second (untagged) allele was knocked out utilizing the three different 
neomycin knockout constructs used to generate the knockout cell lines (see 
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Section 3.3).  Each knockout construct was transformed into the cognate 12myc 
cell lines and transformants were selected with 5 µg.mL-1 blasticidin and 
2.5 µg.mL-1 G418.  Putative 12myc/- clones were screened using PCR and 
western blotting.  A PCR to confirm integration of the neomycin knockout 
cassette into the correct locus (“NEO PCR”) and a PCR reaction amplifying a 
~200 bp region of the targeted ORF (as a positive control; “ORF PCR”) (see 
Section 3.3.3) were both performed.  Figure 3-28 shows that all of the putative 
12myc/- clones analysed for each of RECQ2, MUS81 and PIF6 were positive for 
both of these PCRs, indicating correct integration of the neomycin knockout 
cassette in the clones. 
Two clones of each cell line, previously shown to be correct by PCR (as above), 
were screened by western blotting to confirm they still expressed the tagged 
protein.  Whole cell lysates were separated by SDS-PAGE on a 3-8% tris-acetate 
gel before western blotting and probing with anti-myc antiserum at a 1:7000 
dilution (Millipore).  As shown in Figure 3-28, all of the clones tested expressed 
the 12myc tagged protein for that line.  One clone from each cell line (indicated 
by * ) was selected for use in further experiments. 
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Figure 3-28 Confirmation of 12myc/- cells by western blot and PCR 
(A) Genomic DNA extracted from putative 12myc RECQ2/-, MUS81 12myc/- and PIF6 12myc/- 
clones and PCR amplification was used to confirm integration of the ::ΔNEO  knockout 
construct (NEO) and presence of the targeting gene ORF, as used previously to check 
integration of knockout cassettes.  NEO PCR: RECQ2, primers #51 and #155 1008 bp; 
MUS81, primers #52 and #155 974 bp; PIF6, primers #53 and #155 898 bp.  ORF PCR: 
RECQ2, primers #77 and #78 232 bp; MUS81, primers #79 and #80 214 bp; PIF6, primers #81 
and #82 245 bp.  Primer sequences can be found in Appendix 7.1.  Distilled water was used 
for negative controls for all PCRs (gels in dashed box).  Ladder and sizes indicated (bp).  
Dashed lines between gels indicate different gels aligned for this figure.  (B) Whole cell 
lysates (5 x 106 cell equivalents) of 12myc RECQ2/-, MUS81 12myc/- and PIF6 12myc/- 
cultures were separated by SDS-PAGE on a 3-8% tris-acetate gel, western blotted and 
probed with mouse anti-myc antiserum (Millipore, 1:7000 dilution) and secondary anti-
mouse HRP-conjugated antisera (Life Technologies, 1:5000 dilution).  The bands produced 
by RECQ2 12myc (182 kDa), MUS81 12myc (82.6 kDa) and PIF6 12myc (102.7 kDa) are 
indicated (*, ** and *** respectively) and size markers are shown (kDa). 
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3.8.2 Testing functionality using DNA damage sensitivity assays 
The functionality of the myc-tagged proteins was evaluated using a clonal 
survival assay in the presence of MMS.  MMS was the damaging agent of choice as 
previous data (Section 3.4.3.1) had indicated recq2-/-, mus81-/- and pif6-/- cells 
all exhibit an altered clonal survival phenotype in its presence; decreased 
survival in recq2-/- and mus81-/-, versus increased survival in pif6-/-. 
The clonal survival of the recq2 12myc/- cells was similar to wild type cells at all 
concentrations of MMS (Fig. 3-29A).  If the myc-tagged RECQ2 were non-
functional, the cell line would be expected to have the same strong sensitivity 
to MMS as recq2-/-.  As this is clearly not the case, these data demonstrate that 
12myc RECQ2 is functional in MMS repair.  It was apparent from previous assays 
that recq2+/- cells also display some increased MMS sensitivity relative to wild 
type cells.  Whether the greater comparability of the recq2 myc/- cells’ survival 
to that of wild type vs recq2+/- indicates some increased protein expression due 
to the tagging is not possible to test in the absence of antiserum against native 
RECQ2.  In addition, since the same effect was not seen in the cells in which one 
RECQ2 allele was tagged and the other unaltered (12myc RECQ2), it is possible 
that these data merely reflect the inherit variability in this assay.  Similarly, 
mus81 12myc/- cells did not display the same increased sensitivity to MMS as 
mus81-/- mutants (Fig. 3-29B), indicating that MUS81 12myc is also functional in 
MMS repair.  Interpretation of the data for PIF6, however, is more complex. 
As discussed earlier (Section 3.4.3.2), both pif6+/- and pif6-/- cells consistently 
exhibit a mild increase in MMS sensitivity at high concentrations (especially 
0.0004%) of MMS compared to wild type, though this difference is not 
statistically significant.  When assayed, pif6 12myc (with one tagged allele, and 
one functional untagged allele) cells exhibited survival similar to wild type at 
0.0004% MMS, while pif6 12myc/- survival was much higher than wild type and 
also higher than pif6+/- and pif6-/- (Fig. 3-29C).  Alone, increase in MMS 
resistance of pif6 12myc/- suggests that PIF6 12myc is non-functional as the 
phenotype is most similar to pif6+/- and pif6-/- mutants.  However, if this were 
the case, pif6 12myc would also be expected to exhibit the same increase in 
MMS resistance as pif6+/- and pif6-/- are both more resistant to MMS.  Since the 
data do not conform to this predicted result, it is not possible to conclude 
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whether PIF6 12myc is functional.  Using HU as the damaging agent in this 
experiment may be more appropriate given HU treatment results in a distinct 
phenotype in pif6-/- mutants. 
 
Figure 3-29 Clonal survival of myc/- cells following MMS treatment 
Wild type (WT) and +/-, -/-, 12myc and 12myc/- recq2 (A), mus81 (B) and pif6 (C) mutants 
were diluted to the equivalent of one cell per well over three 96 well plates in the presence 
of varying concentrations of phleomycin.  Plates were incubated for 10 days or until wells 
were clearly positive or negative by colour (saturated cultures are indicated by yellow 
media).  Positive wells were counted and the survival of MMS-treated cultures was 
calculated relative to untreated.  Mean survival (%) relative to untreated cells is plotted; bars 
represent standard error of the mean (SEM). 
3.9 Localisation of endogenously-tagged factors 
T. brucei cells generated expressing 12myc RECQ2, MUS81 12myc or PIF6 12myc  
at the endogenous locus (Sections 3.7-3.8) with the second allele untagged were 
used for microscopic protein localisation by indirect immunofluorescence.  DNA 
was stained with DAPI and visualised using a DAPI filter; 12myc-tagged proteins 
were immunolocalised using Alexa Fluor 488 conjugated anti-myc antiserum (Life 
Technologies, 1:2000 dilution) and visualised using a FITC filter.  Where co-
localisation with RAD51 was assessed, RAD51 was immunolocalised using an anti-
Rad51 antiserum (1:1000 dilution) and Alexa Fluor 594 conjugated anti-rabbit 
antiserum (Life Technologies, 1:2000 dilution), and visualised using a rhodamine 
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filter.  Whole cells were visualised using DIC microscopy.  See Materials and 
Methods, Section 2.10 for full details. 
3.9.1 Localisation of 12myc-RECQ2 
In the vast majority of cells, no signal could be detected for 12myc RECQ2 
(Fig.3-30F).  However, in a very small proportion (0.2%) of cells, discrete, 
punctate signals were seen in the nucleus (images not shown).  This pattern is 
reminiscent of the localisation described for T. brucei RAD51 (Dobson et al., 
2011; Glover et al., 2008; Hartley & McCulloch, 2008; Proudfoot & McCulloch, 
2005; Trenaman et al., 2013), which is normally not seen in the cell, but 
localises in what have been described as foci in a small number of cells in the 
absence of induced damage.  RAD51 foci are thought to be repair-related 
structures as their number increases after damage, both in T. brucei and in 
many other cells (Bergink et al., 2013; Da Ines et al., 2013; Haaf et al., 1995; 
Tarsounas et al., 2004).  Therefore, 12myc RECQ2 cells were also probed for 
RAD51 using anti-RAD51 antiserum (see Materials and Methods, Section 2.10 for 
full details) to examine RAD51/12myc RECQ2 co-localisation.  RAD51 foci were 
observed in ~2% of untreated cells (Fig. 3-30F), similar to previous studies 
(Dobson et al., 2011; Hartley & McCulloch, 2008; Proudfoot & McCulloch, 2005; 
Trenaman et al., 2013) and slightly higher than 12myc RECQ2 (~1% of untreated 
cells), though this may simply reflect the very small number of cells that display 
either localisation.  As a control, untagged wild type cells were probed with 
anti-myc antiserum.  No signal was observed in these control cells.  Untagged 
wild type cells were also probed with anti-rabbit Alexa Fluor 594 antiserum to 
test for cross-reactivity.  No signal was observed in these cells. 
To assess whether the 12mycRECQ2 signals might represent repair–related foci 
and, indeed, might be structurally associated with RAD51 foci, the cells were 
incubated for 18 hours with phleomycin at 1 µg.mL-1, which has been shown to 
generate a majority of cells with RAD51 foci (Dobson et al., 2011; Hartley & 
McCulloch, 2008; Trenaman et al., 2013).  In these conditions greatly increased 
numbers of both 12myc RECQ2 and RAD51 foci were observed; 47% of cells 
contained one or more 12myc RECQ2 foci and 44% of cells contained one or more 
RAD51 foci (377 cells analysed).  The relative proportion of cells with 
12myc RECQ2 and RAD51 foci were very similar, as was the pattern of foci 
Chapter 3     136 
 
accumulation: most cells contained a single focus of either protein, though some 
contained two or three discrete foci, while others had larger numbers (where it 
became difficult to count accurately).  Beyond this striking similarity in the 
behaviour of each factor, there was evidence for overlapping signals, though a 
number of different localisation patterns were seen, examples of which are 
shown in Figures 3-30B-E: cells containing a single RECQ2 12myc focus that co-
localised with a single RAD51 focus (Fig. 3-30B), a 12myc RECQ2 focus with no 
accompanying RAD51 focus (Fig. 3-30C); multiple 12myc RECQ2 and RAD51 foci 
that partially or fully co-localised (Fig. 3-30D); and one or more RAD51 foci with 
no 12myc RECQ2 foci (Fig. 3-30E).  Overall, ~50% of cells contained one or more 
12myc RECQ2 foci with most of these containing only one focus (Fig. 3-30G).  
The percentage of cells containing RAD51 foci and the number of foci per cell 
were similar to that of 12myc RECQ2 (Fig. 3-30H).  The majority of 12myc 
RECQ2/RAD51 foci co-localised fully (~60% of cells with both foci, Fig. 3-30H), 
though a smaller number localised only partially (~20% of cells with foci, Fig. 3-
30h).  In summary, there appears to be substantial, but not complete overlap in 
behaviour between 12myc RECQ2 and RAD51, especially after phleomycin- 
induced damage.  Whether the non-overlapping signals merely reflect 
incomplete resolution of one or other signal or tell us that the proteins act in 
subtly different manners (perhaps temporally or spatially) is unclear. 
Figure 3-30 Representative examples of 12myc RECQ2 localisation 
12myc RECQ2 cells were incubated for 18 hours in the presence or absence of phleomycin 
(1 µg.mL-1).  Cells were fixed and Alexa Fluor 488 antiserum was used to stain 
RECQ2 12myc; RAD51 was localised using anti-RAD51 antiserum and goat anti-rabbit Alexa 
Fluor 594 conjugated antiserum (Life Technologies). DAPI was used to visualise the DNA 
(DAPI) as described in the text.  Differential interference contrast was used to visualise 
whole cells (DIC). DAPI, 12myc RECQ2, RAD51 and merged (DAPI, 12myc RECQ2 and 
RAD51) images are shown.  (A-E) Representative images of different types of 12myc RECQ2 
and RAD51 localisation, as described in the text.  (F, G) The percentage of cells containing 
12myc RECQ2 and RAD51 foci and the number of foci, in the absence (G) and presence (H) 
of phleomycin, was counted using Fiji ImageJ.  (H) Cells containing 12myc RECQ2 and 
RAD51 foci following phleomycin treatment were categorised according to the degree of 
12myc RECQ2 and RAD51 foci co-localisation, represented as % of cells that contained both 
foci.  Bar, 13 µM. 
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Figure 3-30 
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3.9.2 Localisation of MUS81myc 
Similarly to 12myc RECQ2, <1% of cells contained detectable MUS81 nuclear 
signal in the absence of DNA damage (Fig. 3-31A) with the huge majority of cells 
showing no fluorescence.  Where signal was seen, it was again in discrete foci-
like structures.  Therefore, the cells were incubated with phleomycin using the 
same conditions.  In this case, however, only approximately 20% of cells 
contained MUS81 12myc foci (Fig. 3-31F), and in almost all cases the treated 
cells with MUS81 12myc foci contained just a single focus.  As this pattern of 
focal accumulation differs from 12mycRECQ2 and RAD51, no attempt at co-
localisation of MUS81 12myc with RAD51 was performed.  Instead, the 
distribution of localisation of the foci was analysed, revealing four different 
types of localisation, examples of which are shown in Figure 3-31B-E.  In the 
majority (73%) of cells (Fig. 3-31G), MUS81 12myc foci were located in the 
nuclear periphery (Fig. 3-31B).  A further 17% of cells (Fig. 3-31G) contained foci 
more centrally located in the nucleus, as shown in Figure 3-31C.  Fewer than 2% 
of cells (18 out of 998 cells counted) contained two nuclear foci, as shown in 
Figure 3-31D.  MUS81 12myc foci (Fig. 3-31E) were also infrequently observed 
(approximately 10% of cells with foci, Fig. 3-31G) that did not overlap with the 
DAPI.  Though these might be non-nuclear, it is also possible that these are in 
nuclear locations in which the chromatin has disassembled, perhaps due to the 
DNA damage. 
Chapter 3     139 
 
 
Figure 3-31 Representative examples of MUS81 12myc localisation 
MUS81 12myc cells were incubated for 18 hours in the presence or absence of phleomycin 
(+T/-T) (1 µg.mL-1).  Cells were fixed and anti-myc Alexa Fluor 488 (Millipore) antiserum was 
used to detect MUS81 12myc. DAPI was used to visualise the DNA (DAPI) as described in 
the text.  Differential interference contrast was used to visualise whole cells (DIC).  DAPI, 
MUS81 12myc and merged DAPI and MUS81 12myc images are shown.  (A-E) 
Representative images of different types of MUS81 12myc localisation as described in the 
text.  (F) Percentage of cells containing MUS81 12myc foci.  The number of foci present, in 
the absence and presence of phleomycin, was counted using Fiji ImageJ.  (G) Cells 
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containing MUS81 12myc foci following phleomycin treatment were categorised by sub-
cellular localisation, represented as % of cells that contained MUS81 12myc foci.  
Bar, 13 µM.  
3.9.3 Localisation of PIF6myc 
In contrast to 12myc RECQ2 and MUS81 12myc, PIF6 12myc signal was observed 
in the nucleus of approximately 65% of cells (Fig. 3-32E) in the absence of DNA 
damage.  An example of a PIF6 12myc positive cell is shown in Figure 3-32A, 
while Figure 3-32B shows a PIF6 12myc negative cell.  PIF6 12myc nuclear 
localisation is in agreement with the findings of Liu et al. (2009a), who reported 
nuclear localisation of GFP-tagged PIF6, albeit in procyclic form cells.  What 
distinguishes those BSF cells that display a nuclear PIF6 12myc signal from those 
that do is unclear.  Again, in contrast with 12myc RECQ2 and MUS81 12myc, foci 
of PIF6 12myc were not observed after incubation with the DNA damaging agent 
phleomycin using the same conditions.  However, the level of PIF6 12myc 
fluorescence appeared to be stronger after phleomycin (Fig. 3-32C) and the 
number of PIF6 12myc positive cells observed increased by 8% (Fig. 3-32E).  
Rarely, phleomycin-treated cells were observed with diffuse, grainy PIF6 12myc 
staining (Fig. 3-32D).  It is possible this is due to a high background level of 
immunofluorescence or the breakdown of the nucleus in dying cells. 
Given the perceived increase in nuclear PIF6 12myc fluorescence of phleomycin 
treated cells, nuclear fluorescence intensity was measured using ImageJ.  The 
mean fluorescence intensity was measured for each nucleus and the mean of all 
the cells then calculated.  The mean nuclear fluorescence intensity of untagged 
cells was used as a measure of the background level of fluorescence 
(autofluorescence).  The nuclear fluorescence intensity of PIF6 12myc cells was 
higher than that of untagged cells (Fig. 3-32F), suggesting that the signal is 
derived from PIF6 12myc.  Surprisingly, the mean fluorescence intensity of both 
PIF6 12myc nuclei and untagged nuclei was higher following phleomycin 
treatment (Fig. 3-32F).  It is unclear why phleomycin treatment would increase 
nuclear autofluorescence, though metabolic changes induced by phleomycin 
treatment could affect autofluorescence if they altered the levels of 
autofluorescent molecules such as NADH and NADPH (Monici, 2005).  However, 
after subtraction of background fluorescence (untagged nuclear fluorescence) 
the nuclear fluorescence intensity of phleomycin treated PIF6 12myc cells is 
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higher than that of untreated PIF6 12myc cells (Fig. 3-32G), appearing to 
confirm the damage-dependent change in PIF6 12myc signal.  The basis for such 
a change is unknown, but could reflect an increase in PIF6 expression in response 
to phleomycin damage, which might be consistent with a role for the factor in 
repair of such damage.  If so, why pif6 mutants do not display altered sensitivity 
to phleomycin relative to wild type cells is unclear.  
Since PIF6 12myc expression appeared not to be consistent in all nuclei, it was 
asked whether the expression of PIF6 12myc varied by the cell cycle stage.  Cell 
cycle dependent expression could suggest that the PIF6 is only involved in the 
repair of DNA at certain cell cycle stages.  The average nuclear fluorescence of 
untreated nuclei was measured as described above; nuclei were categorised by 
the cell cycle stage of the cell (1N1K, 1N2K or 2N2K) and plotted as a dot plot 
(Fig. 3-32H).  Error bars represent standard error of the mean (SEM).  The 
intensity of PIF6 12myc expression appeared to have no obvious correlation with 
the cell cycle stage, with the mean fluorescence 6.8 in 1N1K, 7.5 in 1N2K and 
5.6 in 2N2K.  The mean PIF6 12myc fluorescence was lowest in 2N2K cells and 
the spread of values also smaller, with no values exceeding 10, but this could be 
the result of the smaller number of 2N2K cells in the population compared to 
1N1K and 1N2K.  It should also be borne in mind when considering these data 
that, unlike for RECQ2 and MUS81, it remains unclear if the myc tagging of PIF6 
affects the function (and thus perhaps localisation) of the factor. 
Figure 3-32 Representative examples of PIF6 12myc localisation 
PIF6 12myc cells were incubated for 18 hours in the presence or absence of phleomycin 
(1 µg.mL-1).  Fixed cells were fixed and Alexa Fluor 488 (Millipore) was used to stain PIF6 
12myc. DAPI was used to visualise the DNA (DAPI) as described in the text.  Differential 
interference contrast was used to visualise whole cells (DIC).  DAPI, PIF6 12myc and 
merged DAPI and PIF6 12myc images are shown.  (A-D) Representative images of different 
types of PIF6 12myc localisation, as described in the text.  Bar, 13 µM.  (E) The percentage 
of cells containing nuclear PIF6 12myc nuclear signal, in the absence and presence of 
phleomycin, was counted using Fiji ImageJ.  (F) The average nuclear myc fluorescence 
intensity was measured in wild type untagged and PIF6 12myc cell lines in the absence of 
and following phleomycin treatment.  Fluorescence intensity was measured using Fiji 
ImageJ, arbitrary units.  (G) The nuclear myc fluorescence intensity of PIF6 12myc cells, 
with and without phleomycin treatment, above the background level.  The background level 
of fluorescence (fluorescence of untagged cell nuclei (F)) was subtracted from the tagged 
nuclei fluorescence (fluorescence of PIF6 12myc, (F)).  (H) Average nuclear PIF6 12myc 
fluorescence by cell cycle stage.  The average fluorescence intensity of nuclei was 
measured using ImageJ and plotted according to cell cycle stage (1N1K, 1N2K, 1N2K). 
Horizontal lines on H represent mean, and bars the standard error of the mean (SEM). 
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Figure 3-32 
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3.10 Summary 
3.10.1 Key findings of this chapter 
The data in this chapter has revealed at least two new factors that act in 
T. brucei genome repair:  RECQ2 and MUS81.  The data presented also suggest 
that a third factor, PIF6 may also be involved in the repair of DNA damage in 
T. brucei.  Analysis of gene mutants, as well as localisation of the myc-tagged 
factors by gene mutation and localisation, suggests differences in their function. 
3.10.1.1 T. brucei RECQ2 
Analysis of recq2 mutants revealed a range of defects in growth and sensitivity 
to DNA damaging agents.  recq2-/- mutants displayed impaired growth compared 
to wild type cells, as did recq2+/- to some extent, though the effect was much 
less pronounced.  In assays measuring sensitivity to DNA damaging agents a 
similar pattern was observed, with recq2+/- mutants behaving similarly to wild 
type.  In vitro growth analysis revealed pronounced sensitivity to MMS and some 
evidence for sensitivity to phleomycin in recq2-/- cells compared to wild type, 
both of which were also observed when clonal survival assays were used to 
assess DNA damaging agent sensitivity.  Each of these agents cause DNA breaks, 
predominantly DSBs in the case of phleomycin (Groth et al., 2010; Reiter et al., 
1972) and via nucleotide alkylation in the case of MMS (Groth et al., 2010; 
Tercero & Diffley, 2001).  These data suggest that RECQ2 has repair roles in 
response to these damaging agents. 
The increased sensitivity to MMS in recq2-/- mutants is consistent with the MMS 
treatment phenotype of other RecQ-like helicase mutants.  MMS sensitivity has 
previously been reported in other RecQ helicase mutants.  S. cerevisiae sgs1 
mutants (Mullen et al., 2000) as well as human blm-/- (Wang et al., 2000) and 
chicken DT40 cells (Imamura et al., 2001) are hypersensitive to MMS.  Human 
recql1-/- and recql5-/- cells however, do not show any difference in MMS 
sensitivity compared to wild type cells (Wang et al., 2003).  There was no 
information found in the current literature on the phleomycin sensitivity of 
other RecQ-like helicase mutants.  Therefore, comparison of these data with 
phleomycin sensitivity of other RecQ helicase mutants cannot be made. 
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A mild growth defect was observed in recq2-/- mutants following HU treatment 
and a strong sensitivity was seen in recq2-/- mutants in clonal survival assays.  HU 
depletes the cellular dNTP pool, resulting in replication stalling (Bianchi et al., 
1986), which can lead to DNA breaks if the replication is not successfully 
restarted.  This suggests that RECQ2 may have a role at the replication fork.  
Other RecQ helicases have been demonstrated to function at the replication 
fork: BLM and WRN contribute to normal replication fork progression, and 
treatment with HU in BLM and WRN mutants results in defects in replication fork 
recovery (Mao et al., 2010; Sidorova et al., 2013).  Additionally, BLM and WRN 
mutants accumulate a higher level of DNA damage than wild type cells following 
HU treatment, as measured by γH2A staining (Mao et al., 2010). 
Localisation of RECQ2 using a 12myc RECQ2 cell line and immunofluorescent 
microscopic analysis was unsuccessful.  This could be due to low expression of 
the protein.  However, following treatment with phleomycin, 12myc RECQ2 foci 
were observed.  This is reminiscent of RAD51, which is not normally seen but, 
following DNA damage, localises to discrete nuclear foci - thought to be repair-
related structures (Dobson et al., 2011; Hartley & McCulloch, 2008; Proudfoot & 
McCulloch, 2005; Trenaman et al., 2013).  Co-staining of 12myc RECQ2 and 
RAD51 following phleomycin damage revealed substantial but not complete 
overlap in RAD51 and 12myc RECQ2 following phleomycin damage, suggesting 
that 12myc RECQ2 foci are repair-related structures. 
RECQ2 has been proposed as the T. brucei homologue of BLM and the third 
component of the three-protein RTR (RecQ-Top3-Rmi1) complex (Kim & Cross, 
2011).  The complex is composed of a RecQ helicase (BLM in mammals, SGS1 in 
yeast), a topoisomerase III α and RMI1 (RecQ mediated genome instability 1; also 
known as BLAP75/18) (Johnson et al., 2000; Wu et al., 2000; Yin et al., 2005).  
The RTR complex is a major regulator of mitotic crossover in eukaryotes and 
resolves double HJs in a non-crossover manner (Bussen et al., 2007; Chelysheva 
et al., 2008; Raynard et al., 2008).  Kim and Cross identified the T. brucei RMI1 
and TOPO3α homologues, demonstrated that they interact and characterised 
null mutants (Kim & Cross, 2010; Kim & Cross, 2011), but the RecQ helicase 
component of the complex is yet to be identified and characterised.  T. brucei 
rmi1-/- and topo3α-/- mutants both display a mild growth impairment similar to 
that of recq2-/- mutants described here.  Also in common with recq2-/- mutants, 
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rmi1-/- and topo3α-/- mutants display increased HU sensitivity.  Furthermore, 
topo3a-/- mutants display markedly increased phleomycin sensitivity, which was 
likewise observed in recq2-/- mutants albeit not with as strong sensitivity. 
As discussed above (Section 3.2.1), the T. brucei genome encodes two RecQ-like 
helicases: TbRECQ2 (Tb427.08.6690) and TbRECQ1 (Tb427.06.3580), the latter of 
which is discussed in Chapter 5.  Protein domain prediction, multiple sequence 
alignment and phylogenetic analysis showed that RECQ2 has greater similarity to 
BLM and SGS1 homologues than RECQ1.  Combined with the similarity of the DNA 
damage and growth phenotypes of recq2-/- mutants to rmi1-/- and topo3α-/- 
mutants, the data presented in this chapter suggest that RECQ2 may be the 
RecQ helicase component of the RTR complex in T. brucei.  rmi1-/- and topo3α-/- 
mutants also display an elevated VSG switching rate and increased crossover 
switching events (Kim & Cross, 2010; Kim & Cross, 2011).  It was therefore 
decided to investigate the VSG switching profile of recq2 mutants, described in 
the next chapter (Chapter 4). 
3.10.1.2 T. brucei MUS81 
Generation and analysis of mus81+/- and mus81-/- mutants revealed that similar 
to recq2-/- mutants, mus81-/- mutants have a growth defect.  An increase in 
phleomycin and MMS sensitivity in mus81-/- mutants in clonal survival assays 
suggests that T. brucei MUS81 is involved in the response to both phleomycin and 
MMS damage.  Re-expression of the MUS81 ORF in mus81-/- cells from the tubulin 
locus (mus81-/-/+ cells) restored the phleomycin sensitivity to wild type levels.  In 
contrast to RECQ2 however, clonal survival data suggests that MUS81 plays little 
or no role in the response to HU. 
The DNA damage phenotype of mus81 mutants described in this chapter is 
consistent with reports of yeast MUS81.  Increased sensitivity of mus81-/- cells to 
MMS and phleomycin is consistent with observations in S. cerevisiae mus81Δ 
mutants (Blanco et al., 2010; Interthal & Heyer, 2000).  Furthermore, though 
following HU treatment in S. cerevisiae, MUS81 is required for recovery from 
replication fork collapse (which was not examined here), mutants do not have 
altered viability after HU treatment (Kai et al., 2005), nor altered survival in 
human cells (Nomura et al., 2007). 
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MUS81 12myc immunofluorescence signal was not observed in BSF T. brucei cells 
in the absence of phleomycin treatment.  However, following treatment with 
phleomycin, MUS81 12myc foci were observed (in ~90% of cases) in the nucleus.  
This is reminiscent of both the appearance of nuclear RAD51 (Dobson et al., 
2011; Hartley & McCulloch, 2008; Proudfoot & McCulloch, 2005; Trenaman et 
al., 2013) and 12myc RECQ2 foci (Section 3.9.1) following DNA damage and 
suggests that these MUS81 12myc foci are associated with DNA repair.  
Additionally, data indicated that MUS81 12myc is functional, as MUS81 12myc/- 
cells displayed MMS sensitivity similar to wild type rather than mus81-/- cells. 
Similar to BSF T. brucei MUS81, human MUS81 is predominantly nuclear, with 
super accumulation in nucleoli and co-localising with BLM and WRN RecQ-like 
helicases in nucleoli (Gao et al., 2003).  Yeast MUS81 also localises to the 
nucleus (Fu & Xiao, 2003).  Though no literature was available on the 
localisation of MUS81 in other eukaryotes following phleomycin treatment, 
human MUS81 is recruited to regions of UV damage in human S-phase cells, but 
not cells that have completed replication (Gao et al., 2003). 
In summary, the data presented in this chapter suggest that although primary 
amino acid sequence analysis indicated that T. brucei MUS81 appears to be 
somewhat diverged from other eukaryotic MUS81 homologues, it shares similar 
DNA damage sensitivity and localisation phenotypes with yeast and human MUS81 
endonucleases.  MUS81 appears to be involved in the response to phleomycin and 
MMS, though not HU, and further, MUS81 12myc forms what may be DNA repair-
related foci in response to phleomycin damage. 
3.10.1.3 T. brucei PIF6 
Analysis of pif6 mutants in this chapter revealed that unlike recq2-/- and mus81-/- 
mutants, neither pif6+/- nor pif6-/- mutants display a marked in vitro growth 
defect.  The DNA damage phenotype of pif6 mutants was markedly different to 
recq2 and mus81 mutants.  Though no defect was observed in the growth of pif6 
mutants following MMS treatment, both pif6+/- and pif6-/- mutants displayed an 
increase in MMS resistance in clonal survival assays.  The opposite effect was 
observed following HU treatment; pif6+/- and pif6-/- mutants displayed a mild 
growth defect and an increase in HU sensitivity in clonal survival assays.  PIF6 
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does not appear to be involved in the response to phleomycin, displaying only a 
minor growth defect in pif6+/- mutants.  Although a pif6-/-/+ line was generated, 
testing whether re-expression of the PIF6 ORF rescues the DNA damage 
phenotype of pif6-/- cells was unsuccessful.  A clonal survival assay testing the 
MMS sensitivity of pif6-/-/+ cells produced anomalous results and further testing 
using the HU sensitivity of pif6-/-/+ cells may be more appropriate as pif6 
mutants display a stronger HU survival phenotype. 
Immunolocalisation of PIF6 in BSF cells, using a PIF6 12myc tagged cell line, 
showed localisation to the nucleus by fluorescence microscopy.  This is 
consistent with Liu et al. (2009b) who reported that PIF6 localises to the nucleus 
of PCF cells.  Unlike 12myc RECQ2 and MUS81 12myc, PIF6 12myc did not form 
foci following phleomycin damage, though nuclear PIF6 12myc fluorescence did 
increase in intensity.  This nuclear localisation did not appear to be cell cycle 
dependent.  An attempt to test the functionality of PIF6 12myc by assaying the 
MMS sensitivity of PIF6 12myc/- cells produced inconclusive data and it was not 
possible to conclude whether PIF6 12myc is functional.  Repeating this assay 
using HU, which produces a more distinct phenotype in pif6 mutants, may reveal 
whether PIF6 12myc is functional. 
TbPIF6 is the only one of the eight T. brucei Pif1 helicases to have a nuclear 
function.  TbPIF1, 2, 5 and 8 are involved in kinetoplast replication (Liu et al., 
2009a; Liu et al., 2009b; Liu et al., 2010a; Wang et al., 2012).  Other eukaryotic 
Pif1 helicases have mitochondrial roles, such as S. cerevisiae ScPif1, which 
functions in repair, maintenance and recombination of mitochondrial DNA 
(Cheng et al., 2007; Lahaye et al., 1991; O'Rourke et al., 2002).  Pif1 helicases 
perform a wide range of nuclear functions, participating in almost all aspects of 
genomic DNA metabolism (reviewed in (Bochman et al., 2010)).  However, the 
phenotype of T. brucei mutants described here, particularly increased resistance 
to MMS, does not appear similar to any Pif1 helicase mutant described to date. 
PIF6 appears to play a distinct role in T. brucei DNA damage repair.  Unlike 
mus81 and recq2 mutants, pif6+/- mutants display a phenotype, indicating that 
loss of one PIF6 allele is sufficient to result in a change in the response to HU 
and MMS damage.  Also in contrast to mus81 and recq2 mutants, pif6 mutants 
displayed an enhanced ability to survive MMS damage.  pif6 mutant sensitivity to 
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HU is consistent with the increased sensitivity of S. pombe pfh1 (a Pif1 helicase) 
mutants to HU (Pinter et al., 2008).  More unusual is the MMS resistance of pif6 
mutants — the opposite phenotype to the MMS sensitivity exhibited by S. 
cerevisiae pif1Δ mutants (Budd et al., 2006).  A search of the available 
literature failed to return any reports of resistance to a DNA damaging agent in a 
Pif1 helicase mutant, suggesting that the increased MMS resistance of pif6 
mutants may be unique among Pif1 helicases.  Though increased MMS resistance 
following PIF1 knockout has not been observed in other organisms, deletion of 
pif1 suppresses the MMS sensitivity of dna2 mutants in S. cerevisiae (Budd et al., 
2006).  Increased resistance to DNA damage following knockout of a DNA repair 
factor is unusual, though has been reported for DNA ligase IV.  Loss of DNA ligase 
IV confers increased resistance to replication-associated DSBs in human cells 
(Kurosawa et al., 2013).  These authors found that repair of replication-
associated DSBs by NHEJ, in which DNA ligase IV is crucial, is detrimental to cell 
survival.  In the absence of DNA ligase IV, repair of replication DSBs by HR is not 
suppressed and HR-mediated repair is used, resulting in increased cell survival.  
If PIF6 expression leads to use of a repair pathway following MMS damage that is 
detrimental to cell survival, its loss and the subsequent use of a repair pathway 
resulting in higher cell survival could explain the increased MMS resistance of 
pif6 mutants and is an intriguing possibility requiring further study. 
In summary, PIF6 is a nuclear T. brucei repair factor with a role in DNA repair 
distinct to the two other factors described in this chapter, RECQ2 and MUS81.  
Its loss confers increased resistance to MMS, a phenotype not previously reported 
for a Pif1 helicase.  The exact role PIF6 plays in DNA repair and how loss of even 
a single allele leads to an increased ability to survive MMS damage, while 
conferring sensitivity to HU, will require further analysis.  Testing for rescue of 
the DNA damage phenotype of pif6 mutants is an important future experiment, 
along with further investigation of the MMS sensitivity of mutants, due to 
variability observed in experiments over time.  Examination of the repair 
products of pif6 mutants following damage and analysis of the integrity of the 
nuclear genome of pif6 mutants would be useful first steps in understanding the 
role PIF6 plays in DNA repair. 
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4 Analysis of the role in double strand break 
(DSB) DNA repair and VSG switching of RECQ2, 
PIF6 and MUS81 
4.1 Introduction 
In the previous chapter RECQ2, MUS81 and PIF6 heterozygous (+/-) and double 
knockout (-/-) mutants were generated in BSF T. brucei and their in vitro growth 
rate and sensitivity to the DNA damaging agents hydroxyurea, phleomycin and 
MMS of these mutants was analysed.  This revealed that recq2 and pif6 mutants, 
both heterozygous and homozygous, as well as mus81-/- mutants have a growth 
defect.  For RECQ2, it was shown that both +/- and -/- mutants have a striking 
increase in MMS sensitivity, and greater sensitivity to phleomycin and 
hydroxyurea (HU) was observed in recq2-/- mutants.  mus81-/- cells were more 
sensitive to both phleomycin and MMS, whilst pif6+/- and pif6-/- mutants 
displayed similar phenotypes to one another: both were more resistant to MMS 
and mildly more sensitive to HU.  Finally, immunolocalisation of the three 
proteins endogenously tagged with myc was described, which suggested that 
RECQ2 and MUS81 are involved in the response to phleomycin-induced DNA 
damage since both were shown to localise in damage-induced foci, with some 
co-localisation with the RAD51 recombinase. 
These data suggest that all three proteins are involved in the response to DNA 
damage, though act in diverse ways.  However, two of the damaging agents 
used, MMS and phleomycin, result in widespread DNA damage of a number of 
different types.  For example, phleomycin causes DSBs and SSBs (Reiter et al., 
1972).  The effects of MMS are diverse, including base alkylation, replication 
fork stalling due to dNTP pool depletion and DNA DSBs that may arise indirectly 
as a result of DNA alkylation (Bianchi et al., 1986; Brookes & Lawley, 1961; 
Lundin et al., 2005; Wyatt & Pittman, 2006).  The lack of specificity of damage 
makes it difficult to ascertain the type(s) of damage to which the proteins 
normally react to and how they function in repair.  This chapter will therefore 
next look specifically at whether RECQ2, MUS81 and PIF6 are involved in DSB 
repair. 
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It was chosen to look specifically at DSB repair due to the proposed role of DSBs 
in the current model for the initiation of VSG switching.  VSG switching by 
recombination necessitates that free DNA ends are available for recombination, 
thus requiring a DNA break to be formed to initiate switching.  The current 
hypothesis for the nature of this break is that DSBs occur in the active expression 
site, specifically in the region of the 70 bp repeats, initiating VSG 
recombination.  DSBs, or at least DNA breaks, have been detected by a ligation-
mediated PCR assay in the active VSG BES (Boothroyd et al., 2009; Glover et al., 
2013a) around the 70 bp repeats and telomeric VSG; such breaks appear to 
increase in abundance when telomere integrity is impaired (Jehi et al., 2014b). 
However, whether the putative DSBs are limited to the active expression site, as 
originally reported (Boothroyd et al., 2009) is unclear, since later studies did not 
detect this association with transcription status (Glover et al., 2013a). 
Nonetheless, both Boothroyd et al. (2009) and Glover et al. (2013a) utilised the 
inducible expression of a yeast meganuclease (I-SceI) to show that when DSBs 
are introduced into the active (but not inactive) expression site, the rate of VSG 
switching increases. 
This chapter describes the generation of recq2, mus81 and pif6 mutants in cell 
lines that allow the targeted investigation of the role of these factors in DSB 
repair and in VSG switching.  To investigate their role in DSB repair, I-SceI cell 
lines were used as in Glover et al. (2008, 2011 & 2013a), in which it is possible 
to induce a single, temporarily and spatially controlled DSB at the active VSG 
BES or at a chromosome internal location.  For examination of the proteins’ role 
in VSG switching, this chapter also describes the generation of mutants in a cell 
line that uses a thymidine kinase negative selection system, essentially as used 
previously (Povelones et al., 2012), to assay VSG switching rate and mechanism 
in vitro.  By examining the role of RECQ2, MUS81 and PIF6 in the repair of 
induced DSBs and comparing these data with that of their role in VSG switching, 
this chapter aims to build a more detailed picture of how these proteins function 
in DNA repair and VSG switching in T. brucei.  This chapter will also explore the 
contribution of DSB repair to VSG switching.  In examining DSB repair and VSG 
switching, the work tests the hypothesis that DSBs act as the initiating lesion for 
VSG switching. 
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4.2 Description of I-SceI cell lines used 
In order to investigate the role of RECQ2, MUS81 and PIF6 in DSB repair, we 
utilised two cell lines in which a single DSB could be induced, HR1 and HRES 
(Gift, David Horn).  The HR1 and HRES cell lines (Fig. 4-1) utilise the I-SceI 
meganuclease to cleave DNA to form a DSB.  I-SceI is a meganuclease encoded by 
a mitochondrial group I intron of S. cerevisiae that cleaves a specific 18 bp 
recognition sequence (Colleaux et al., 1988); this sequence does not appear 
naturally in the T. brucei genome.  Therefore, in T. brucei in which the I-SceI 
recognition sequence has been introduced, induction of I-SceI expression results 
in a single DSB at the I-Sce recognition site. 
Both HR1 and HRES cell lines contain the I-SceI recognition site, the I-SceI ORF 
under the control of a tet-on promoter and the tet repressor protein (TetR).  
The TetR is expressed from the tubulin locus and is maintained by the presence 
of the antibiotic resistance gene bleomycin (BLE) (Glover et al., 2007).  The      
I-SceI ORF is fused to an N-terminal SV40 nuclear localisation signal expressed 
from an RRNA spacer locus and maintained by the presence of the antibiotic 
resistance gene hygromycin (Glover et al., 2007).  This arrangement of I-SceI 
expression control by the TetR means that expression of I-SceI is induced by 
addition of tetracycline to the medium.  In the absence of tetracycline, I-SceI 
expression is repressed by the binding of the TetR to the tet operator.  Upon 
addition of tetracycline to the culture medium, tetracycline binds to the TetR, 
preventing it binding to the tet operator.  Repression of I-SceI expression is then 
relieved and I-SceI protein recognises and cleaves the I-SceI recognition 
sequence.  DSB induction is therefore controlled both temporarily by 
tetracycline, and spatially by a single I-SceI recognition site location (below). 
The I-SceI recognition site differs between the two cell lines.  In HR1, the I-SceI 
recognition site is located on chromosome 11 between genes Tb.11.02.2110 and 
Tb.11.02.2120 (genedb.org), and >1 Mbp from the nearest telomere (Glover et 
al., 2008).  Here, the I-SceI site is embedded within an RFP (red fluorescent 
protein):PUR (puromycin N-acetyl transferase) fusion gene (Glover et al., 2008).  
The RFP:PUR gene is flanked by tubulin sequences for mRNA transplicing and 
polyadenylation.  Thus, HR-directed repair after I-SceI-induced DSB formation 
could occur by recombination between chromosome 11a (containing the I-SceI 
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site) and its homologue (11b), but could also occur ectopically with chromosome 
1 (where the tubulin locus is found) using the short tubulin sequences on the 
RFP:PUR cassette.  Despite the presence of the RFP gene, Glover et al. (2008) 
reported that no fluorescence is detectable in HR1 cells.  We were also unable 
to detect any fluorescence in HR1 cells (data not shown).  In HRES, the I-SceI 
recognition site is located upstream of VSG221 in the active VSG BES on 
chromosome 6a, fused to a PUR gene (Glover et al., 2013a).  Here DSB induction 
has been proposed to mimic VSG switching by initiating HR through available 
homology (e.g. other VSGs, 70 bp repeats, telomere repeats, ESAGs).  In both 
HR1 and HRES, PUR gene presence at the I-SceI recognition site provides a means 
to assay for I-SceI cutting in induced cell cultures.  DNA end resection following 
I-SceI cutting results in puromycin sensitivity due to the proximity of the PUR 
gene to the I-SceI target sequence, meaning it must be degraded to access the 
flanking homology that drives DSB repair (Glover et al., 2008). 
I-SceI induction in the HR1 cell line allows the investigation of DSB repair at a 
chromosome-internal location.  In contrast, the HRES cell line enables study of 
DSB repair at a telomere and active expression site.  Both Boothroyd et al. 
(2009) and Glover et al. (2008 & 2013a) demonstrated, by Southern blot analysis, 
that I-SceI induction results in the formation of a DSB at the I-SceI recognition 
site.  Specifically, the I-SceI cleavage site is located in the region in which DNA 
breaks triggering VSG switching are hypothesised to occur and the experimental 
setup in the HRES is very similar to that described by Boothroyd et al. (2009).  
Both the HR1 and HRES cell lines have been used previously to investigate DSB 
repair in T. brucei; Glover et al. (2008) generated and used HR1 to investigate 
DSB repair, revealing the predicted HR events (above), as well as MMEJ, where 
repair normally occurs intrachromosomally based on very short flanking 
sequences and independent of HR (e.g. in the absence of RAD51) (Burton et al., 
2007; Conway et al., 2002b; Glover et al., 2011; Glover et al., 2008).  The HRES 
line was used by Glover et al. (2013a) (there referred to as VSGup), where they 
found that I-SceI induced breaks at the 70 bp repeats induced VSG switching, 
consistent with the findings of Boothroyd et al. (2009). 
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Figure 4-1 I-SceI target sequence organisation in HR1 and HRES cell lines 
As described in the text: (A) the HR1 cell line contains an I-SceI recognition site embedded 
within an RFP:PUR fusion gene (black), flanked by tubulin sequences (white), located 
between genes Tb.11.02.2110 and Tb.11.02.2020 on chromosome 11a; (B) the HRES cell line 
contains an I-SceI recognition site upstream of a PUR gene, flanked by tubulin sequences, 
located downstream of the 70 bp repeats of the active VSG221 expression site on 
chromosome 6. 
4.3 Generation of knockout mutants in I-SceI lines 
4.3.1 Generation of knockout lines 
It was attempted to generate heterozygous (+/-) and double knockout (-/-) 
mutants in HR1 and HRES I-SceI cell lines following the same procedure as used 
in the wild type BSF cells (described in Section 3.3.1).  Detailed explanation for 
the knockout strategy and the cloning procedure of the knockout plasmids is in 
Section 3.3.1. 
HR1 and HRES cell lines were first transformed with ΔRECQ2::BSD, ΔMUS81::BSD 
or ΔPIF6::BSD in an attempt to generate +/- cell lines.  In all cases, antibiotic 
resistant clones were selected using 10 µg.mL-1 blasticidin as well as 0.2 µg.mL-1 
puromycin, 5 µg.mL-1 hygromycin and 2 µg.mL-1 phleomycin to maintain the       
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I-SceI meganuclease recognition site, I-SceI meganuclease and tetracycline 
repressor constructs, respectively. 
PCR analysis was used to confirm the generation of heterozygous mutants (as 
described previously in wild type cells, see Section 3.3.3) using genomic DNA 
extracted from drug resistant transformant clones.  Six putative HR1 recq2-+/- 
clones and six HRES recq2+/- clones were tested, all of which were correct.  Six 
putative HR1 mus81+/- clones were tested, of which five were correct.  Five 
putative HRES mus81+/- clones were tested, all of which were correct.  Six 
putative HR1 pif6+/- clones and six HRES pif6+/- clones were tested, all of which 
were correct.  (In all cases, correct clones were defined by the blasticidin 
knockout construct having integrated as expected; data not shown, PCR 
described below.)  One confirmed +/- mutant from each of the ΔRECQ2::BSD, 
ΔMUS81::BSD and ΔPIF6::BSD transformants was chosen and transformed with 
the  ΔRECQ2::NEO, ΔMUS81::NEO or ΔPIF6::NEO construct, respectively.  
Transformants were selected with 5 µg.mL-1 blasticidin and 2.5 µg.mL-1 G418, in 
addition to 0.2 µg.mL-1 puromycin, 5 µg.mL-1 hygromycin and 2 µg.mL-1 
phleomycin (as in the first round of transformation).  A number of the clones 
recovered from the second round of transformation were tested by PCR (see 
below) to confirm knockout of the target gene.  Five putative HR1 recq2-/- clones 
were tested, of which four were correct, and three HRES recq2-/- clones were 
tested, of which two were correct and are shown in Figure 4-2.  Six putative HR1 
mus81-/- clones were tested, of which all were correct, and four HRES mus81-/- 
clones were tested, of which two were correct and are shown in Figure 4-3.  
Eight putative HR1 pif6-/- clones were tested, of which all were correct, and ten 
HRES pif6-/- clones were tested, of which eight were correct and two are shown 
in Figure 4-4. 
4.3.2 Confirmation of knockout mutants by PCR 
Demonstration of the generation of heterozygous (+/-) and homozygous (-/-) 
mutants of each gene in both the HR1 and HRES cells was confirmed by a number 
of PCRs. Figures 4-2, 4-3 and 4-4 show PCRs for the clones that were selected for 
further analysis.  Three different PCRs were performed (described in Section 
3.3.3) to confirm integration of the knockout cassettes in each cell line.  A 
region of the ORF was PCR-amplified (“ORF PCR”, (RECQ2 primers #44 & #45; 
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MUS81 primers #46 & #47; PIF6 primers #48 & #49)) to determine if the gene had 
been deleted.  In addition, a ~900-1300 bp region was PCR-amplified using a 
forward primer lying upstream of the 5’ UTR region present in the knockout 
construct (RECQ2 primer #51, MUS81 primer #52, PIF6 primer #53) and a reverse 
primer specific to the BSD or NEO gene (“BSD PCR” (primer #154) and “NEO PCR” 
(primer #155), respectively).  These resistance gene PCRs were designed to 
confirm the presence and correct integration location of the knockout cassette 
relative to the target gene.  Gene-specific PCR details are listed in the legend of 
Figures 4-2, 4-3 and 4-4 and sequences of all primers can be found in 
Appendix 7.1. 
The agarose gels in Figures 4-2, 4-3 and 4-4 show confirmation, using the PCRs 
described above, of the correct integration of the knockout cassettes in the HR1 
and HRES cell lines and absence of the cognate ORF in the different -/- clones.  
In all cases, two -/- mutants were examined in subsequent experiments to test 
for reproducibility of data.  Only the expected knockout cassette could be PCR-
amplified (“BSD PCR”) in each heterozygote line, whereas both cassettes could 
be amplified in homozygous knockout cell lines.  Furthermore, the ORF of the 
targeted gene could no longer be PCR-amplified in the double knockout cell 
lines, indicating successful deletion of each gene in HR1 and HRES backgrounds. 
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Figure 4-2 PCR confirmation of RECQ2 knockout in HR1 and HRES cell lines 
Agarose gels of PCR products generated from genomic DNA using primers described in the 
text.  A 498 bp region of the open reading frame (primers #44 & #45) was PCR amplified 
(“REQ2 ORF”).  Integration of the blasticidin knockout construct was tested by PCR 
amplification using primers #51 & #154 (1000 bp PCR product) that bind in the BSD 
resistance cassette and upstream of RECQ2 (“BSD”).  Integration of the NEO knockout 
construct was tested by PCR amplification using primers #51 and #155 (1008 bp PCR 
product) that bind in the NEO resistance gene and upstream of RECQ2 (“NEO”).  Primer 
sequences are listed in Appendix 7.1.  Gaps indicate that lanes have been aligned in this 
figure after excision from multiple gels or from disparate parts of the same gel; size markers 
are shown (ladder, bp). 
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Figure 4-3 PCR confirmation of MUS81 knockout in HR1 and HRES cell lines 
Agarose gels of PCR products generated from genomic DNA using primers described in the 
text.  A 494 bp region of the MUS81 open reading frame (primers #46 & #47) was PCR 
amplified (“MUS81 ORF”).  Integration of the blasticidin knockout construct was tested by 
PCR amplification using primers #52 & #154 (966 bp PCR product) that bind in the 
blasticidin resistance cassette and upstream of MUS81 (“BSD”).  Integration of the NEO 
knockout construct was tested by PCR amplification using primers #52 and #155 (974 bp 
PCR product) that bind in the NEO resistance gene and upstream of MUS81 (“NEO”).  Gaps 
indicate that lanes have been aligned in this figure after excision from multiple gels or from 
disparate parts of the same gel; size markers are shown (ladder, bp). 
Chapter 4  159 
 
Figure 4-4 Confirmation by PCR of PIF6 knockout in HR1 and HRES cell lines 
Agarose gels of PCR products generated from genomic DNA using primers described in the 
text.  A 245 bp region of the PIF6 open reading frame (primers #81 & #82) was PCR amplified 
(“PIF6 ORF”).  Integration of the blasticidin knockout construct was tested by PCR 
amplification using primers #53 & #154 (890 bp PCR product) that bind in the blasticidin 
resistance cassette and upstream of PIF6 (“BSD”).  Integration of the blasticidin knockout 
construct was tested by PCR amplification using primers #53 & #155 (898 bp PCR product) 
that bind in the NEO resistance gene and upstream of PIF6 (“NEO”).  Primer sequences can 
be found in Appendix 7.1.  Gaps indicate that lanes have been aligned in this figure after 
excision from multiple gels or from disparate parts of the same gel; size markers are shown 
(ladder, bp). 
4.3.3 Confirmation of recq2 and mus81 knockout lines by RT-PCR 
RT-PCR was used to confirm absence of expression of the deleted gene in each 
knockout (-/-) cell line.  A ~200 bp region of the targeted gene ORF was 
amplified from cDNA, as described in Section 3.3.4, using primers #77 & #78 
(RECQ2), #79 & #80 (MUS81) and #81 & #82 (PIF6).  In addition, PCR 
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amplification of a ~200 bp region of another gene (RECQ2, MUS81 or PIF6) that 
was not targeted, was used as a positive control to confirm the presence of 
cDNA in the sample.  Sequences of all primers can be found in Appendix 7.1 and 
gene-specific PCR details are described in the legend of Figure 4-5. 
The agarose gel in Figure 4-5 shows that the segment of the ORF of RECQ2 and 
MUS81 could not be PCR amplified in their respective knockout (-/-) cell lines, 
but that the control gene could be PCR amplified in each case.  Genomic DNA 
contamination was present in the RECQ2 samples, as indicated by PCR 
amplification of the control (PIF6) gene ORF in some –RT cDNA samples.  
However, the RECCQ2 ORF PCR only generated a product in untransformed HR1 
cells, which acted as a control, and generated no product in all the double 
knockout cell lines analysis in both the +RT and –RT preparations.  Thus, despite 
some contamination, expression of the both targeted genes in each -/- cell line 
could no longer be detected and knockout of these genes was successful in both 
HR1 and HRES cell line backgrounds. 
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Figure 4-5 Confirmation by RT-PCR of recq2 and mus81 knockout cells in HR1 and 
HRES cell lines 
cDNA was synthesised from RNA extracted from HR1 and HRES wild type and recq2 and 
mus81 HR1 and HRES mutants.  (A) RT-PCR check of recq2 mutants:  A 325 bp region of the 
RECQ2 ORF (primers #77/#78) and 245 bp region of the PIF6 ORF (primers #81/#82) was 
PCR amplified from cDNA of HR1 and HRES wild type cells and recq2 mutants (+RT), as well 
as from samples in which no reverse transcriptase had been added (-RT).  (B) A 
214 bp region of the MUS81 ORF (primers #79/#80) and a 214 bp region of the RECQ2 ORF 
(as described in (A)) was PCR amplified from cDNA of HR1 and HRES wild type cells and 
mus81 mutants (+RT), as well as from samples in which no reverse transcriptase had been 
added (-RT).  Distilled water was used as a negative control.  Gaps indicate different gels or 
portions of gels aligned in this figure.  Sizes shown, ladder (bp). 
 
4.4 Analysis of DSB repair at a chromosome internal 
location 
In order to understand if any of the gene knockouts had an effect on cell survival 
following induction of a chromosome-internal DSB, the clonal survival of I-SceI-
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induced recq2, mus81 and pif6 mutants in an HR1 background was assayed.  To 
survive, cells in which a DSB has been induced must repair the break.  Changes 
in the clonal survival following DSB induction in mutants can therefore reveal 
whether the knocked out gene is involved in DSB repair. 
The clonal survival assay was performed as in Glover et al. (2013a) (see 
Materials and Methods, Section 2.2.3.3).  Cells were cultured to mid-log phase 
(1 x 106 cells.mL-1) in the presence of phleomycin, puromycin and hygromycin to 
maintain the I-SceI genetic components in the cells prior to the assay.  
Additionally, the cells were grown in tetracycline-free HMI-9 to limit induction 
of I-SceI expression.  Mutant and non-mutant HR1 cultures were distributed at a 
sub-clonal dilution (0.26 cells per well) over four 96 well plates either with or 
without I-SceI induction.  I-SceI expression was induced by addition of 
tetracycline (Calbiochem) to the cultures to a final concentration of 2 µg.mL-1.  
Plates were incubated for seven to ten days and scored for survival (normalising 
to un-induced cultures).  HMI-9 medium, which in the absence of growing cells is 
red, becomes orange/yellow when saturated with live cells.  Therefore 
orange/yellow wells were scored as positive.  When there was doubt using this 
method, wells were examined microscopically to determine whether they 
contained live cells. 
For each cell line six I-SceI uninduced and up to 25 I-SceI induced surviving 
clones were selected for analysis.  Successful I-SceI induction and repair of the 
subsequent DSB should result in the puromycin resistance gene adjacent to the  
I-SceI site being deleted or truncated and thus surviving clones should be 
puromycin sensitive (Glover et al., 2008).  Therefore, clones taken for analysis 
were tested for puromycin resistance, using 1 µg.mL-1.  In addition, genomic DNA 
was extracted for PCR analysis to attempt to determine whether the induced 
DSB was repaired by HR or MMEJ.  Figure 4-6 shows this PCR.  Primers #86 and 
#87 were used (Glover et al., 2011), which PCR amplify a 1.4 kbp region of the 
RFP:PUR cassette.  Extensive DNA end resection that occurs in HR results in the 
loss of the primer binding sites.  Therefore, following repair of the I-SceI-
induced DSB, clones that had undergone repair by HR would not retain the 
primer binding sites and the PCR would fail in these clones.  Conversely, clones 
that had repaired the DSB by MMEJ would retain the primer binding sites, due to 
the requirement of MMEJ for little sequence identity, and assuming that this 
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microhomology is found within the cassette.  In these circumstances, this PCR in 
MMEJ-repaired clones results in a PCR product smaller than that from uninduced 
clones (1.4 kbp).  Glover et al. (2008) have previously shown that approximately 
85% of surviving HR1 clones repaired the DSB by HR.  This assay allows the 
comparison of the repair pathway profiles of wild type and recq2, mus81 and 
pif6 mutants and provides insight into whether RECQ2 is involved in HR or MMEJ 
in DSB repair in BSF T. brucei. 
 
Figure 4-6 Repair of I-SceI-induced DSB in HR1 cells 
As described in the text, repair of an I-SceI-induced DSB in HR1 cells (allele a) can be 
repaired via HR using sequence on the homologous chromosome (allele b) or the tubulin 
sequence on chromosome 1, both resulting in loss of the primer binding sites.  
Alternatively, repair can proceed via MMEJ, resulting in retention of primer binding sites but 
an altered PCR product length. 
4.4.1 Analysis of chromosome-internal DSB repair in recq2 
mutants 
To investigate whether RECQ2 is involved in DSB repair in T. brucei, clonal 
survival assays using recq2 mutants in the HR1 background were performed 
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twice.  The survival rate of HR1 wild type cells following I-SceI induction was 
61.8% (Fig. 4-7A), very similar to the survival rate of ~60% reported by Glover et 
al. (2008).  In the absence of RECQ2, the survival rate decreased by 50% 
compared to HR1 wild type, with survival rates of 30.8% and 29.5% in two HR1 
recq2-/- clones.  This indicates that recq2 mutants are less able to survive an 
induced DSB, and therefore that RECQ2 is involved in repair of DSBs in BSF 
T. brucei.  Previous data showed recq2 mutant sensitivity to the DNA damaging 
agents phleomycin and MMS (see Section 3.4.3).  When taken together with the 
finding that recq2 mutants are impaired in their ability to repair DSBs, these 
data suggest a wide role for RECQ2 in the repair of DNA damage. 
Analysis of the puromycin sensitivity of surviving clones (Fig. 4-7B) showed that 
all induced survivors were puromycin sensitive and that all un-induced clones 
were puromycin resistant, indicating that a functional PUR gene was lost in all 
induced clones and confirming successful DSB formation.  PCR analysis of clones 
was performed to attempt to analyse the mechanism of DSB repair in induced 
clones using the repair PCR described above (see Section 4.4).  Despite multiple 
attempts, PCR amplification was unsuccessful in all but two uninduced clones.  
This PCR should be successful in uninduced clones, as they have not undergone  
I-SceI induction and DSB formation.  I-SceI induction leads to DSB formation at 
the I-SceI recognition site and the majority of cells repair this DSB using HR, 
which results in loss of the primer binding sequences (Fig. 4-6) (Glover et al., 
2008).  Absence of I-SceI induction in the uninduced clones analysed means that 
they should all still contain the primer binding sites for this assay.  Why this PCR 
was so inefficient is unclear, but the lack of reproducible amplification in the 
uninduced controls means the findings are inconclusive and therefore these data 
are not presented here. 
The clonal survival of HR1 recq2 mutants was assayed a second time, selecting 
one of the HR1 recq2-/- mutants and this time assaying a HR1 recq2+/- mutant, to 
investigate the effect of loss of a single RECQ2 allele.  The results of this assay 
(Fig. 4-8A) contrast sharply with the first time the assay was performed.  
Although the survival of HR1 wild type cells was 43.3%, comparable with that 
observed previously, the survival of HR1 recq2-/- cells (48.6%) was higher than 
HR1 wild type, meaning that the survival rate was substantially higher than that 
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measured for the same clone previously, as well as higher than the other -/- 
clone (Fig. 4-7A). 
 
Figure 4-7 Clonal survival following I-SceI induction in HR1 recq2 mutants 
HR1 wild type and two HR1 recq2-/- clones were distributed in three 96 well plates at a 
concentration of 0.26 cells per well either in the absence (I-SceI uninduced) or presence (I-
SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells (clones) 
was counted after 7-10 days of incubation.  (A) Cell survival is shown as the average 
percentage of clonal survivors following I-SceI induction compared to survivors without I-
SceI induction.  Error bars represent standard error of the mean (SEM) between the three 96 
well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and uninduced clones, 
represented as the percentage of tested clones that grew in the presence (+) or absence (-) 
of 1 µg.mL-1 puromycin.  N, number of clones analysed. 
There are a number of difficulties in the interpretation of this second 
experiment.  Puromycin sensitivity testing was inconclusive (Fig.4-8B).  All 
uninduced survivors should be puromycin resistant and all induced survivors 
should be puromycin sensitive.  However, only 67% of HR1 recq2+/- and 50% of 
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HR1 recq2-/- uninduced survivors were puromycin resistant.  Furthermore, 100% 
of HR1 wild type induced survivors were puromycin resistant, suggesting that the 
‘induced’ HR1 wild type cells were not induced and DSBs did not form.  The 40% 
survival rate of the HR1 wild type cells appears to conflict with this 
interpretation, however, since it would be expected to be equal to un-induced 
cultures if DSB induction had not occurred.  However, a further difficulty in the 
interpretation of these data is that not all surviving clones grew well in the 
absence of puromycin despite the fact that all clones should be expected to 
survive whether or not they underwent DSB induction.  The reason for the 
differences between the first and second repeats of this experiment is unclear.  
However, the second experiment was conducted some time after the first and a 
possible explanation lays in background I-SceI expression leading to instability 
and uncharacterised changes over time in culture.  Though all of the I-SceI cell 
lines are cultured in ‘tetracycline-free’ medium, leaky expression of I-SceI would 
result in some background levels of DSB induction, which might cause loss of the 
I-SceI target sequence over time and puromycin sensitivity in these cells.  The 
nature of the changes selected by this background expression could be variable 
and this may explain why some clones that survive addition of tetracycline grow 
poorly even in the absence of puromycin.  Taken together, such putative 
changes may make the survival measurements unreliable.  These inconsistencies 
make this second repeat an unreliable source of data in determining whether 
RECQ2 plays a role in DSB repair in T. brucei.  By contrast, in the first 
experiment it was possible to confirm that all induced cultures underwent DSB 
induction from the puromycin resistance data, suggesting this experiment 
provides a more reliable assessment of RECQ2 function in DSB repair. 
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Figure 4-8 Repeat of clonal survival assay of HR1 recq2 mutants following I-SceI DSB 
induction 
(A) Cell survival is shown as the average percentage of clonal survivors following I-SceI 
induction compared to survivors without I-SceI induction.  Error bars represent standard 
error of the mean (SEM) between the three 96 well plates.  (B) Puromycin sensitivity of 
surviving I-SceI induced and uninduced clones represented as the percentage of tested 
clones that grew in the presence and absence of 1 µg.mL-1 puromycin.  N, number of clones 
analysed. 
4.4.2 Analysis of chromosome-internal DSB repair in mus81 
mutants 
The clonal survival of mus81 mutants in an HR1 background was assayed using 
the same protocol outlined above (see Section 4.4).  Figure 4-10a shows that the 
survival of HR1 wild type cells following DSB induction was 57.1%, similar to the 
survival rates obtained previously in this study (61.8%, see Section 4.4.1) and by 
Glover et al. (2008).  Loss of one MUS81 allele did not alter survival following 
DSB induction, with 56.9% of HR1 mus81+/- clones surviving.  However, loss of 
both MUS81 alleles resulted in an approximately two-fold decrease in survival 
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following I-SceI induction, with 30% and 22.4% survival rates seen in two 
different HR1 mus81-/- clones.  The puromycin sensitivity status of surviving 
clones confirmed that most of the cell lines underwent DSB induction (Fig. 4-
10B).  A small number (8%) of HR1 mus81-/- [clone 1] induced survivors were 
puromycin resistant, suggesting they were not induced.  However, the vast 
majority of HR1 mus81-/- [clone 1] survivors were puromycin sensitive as 
expected, and thus had undergone I-SceI cutting.  Though all uninduced survivors 
should be puromycin resistant, only 33% of uninduced HR1 wild type survivors 
were resistant to puromycin (Fig. 4-9B).  As discussed above (see Section 4.4.1), 
puromycin sensitivity in uninduced survivors could be due to leaky I-SceI 
expression leading to loss of the I-SceI recognition site and PUR in ‘uninduced’ 
cells.  If correct, the smaller percentage (~20%) of uninduced mus81+/- clones 
that were puromycin sensitive may also have lost PUR. 
These survival data of HR1 mus81 mutants following DSB induction indicate that 
loss of MUS81 impairs the repair of DSBs, though loss of one allele is insufficient 
to impair survival in this assay.  The absence of a DSB repair phenotype following 
loss of one MUS81 allele is consistent with clonal survival of mus81 mutants 
following treatment with MMS and phleomycin.  Furthermore, a role for MUS81 in 
the repair of DSBs is consistent with the increased sensitivity of mus81-/- mutants 
to phleomycin and MMS (see Section 3.4.3.2). 
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Figure 4-9 Clonal survival following I-SceI induction in HR1 mus81 mutants 
HR1 wild type, HR1 mus81+/- and two HR1 mus81-/- clones were distributed in three 96 well 
plates at a concentration of 0.26 cells per well either in the absence (I-SceI uninduced) or 
presence (I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells 
(clones) was counted after 7-10 days of incubation.  (A) Cell survival is shown as the 
average percentage of clonal survivors following I-SceI induction compared to survivors 
without I-SceI induction.  Error bars represent standard error of the mean (SEM) between 
the three 96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and 
uninduced clones, represented as the percentage of tested clones that grew in the presence 
and absence of 1 µg.mL-1 puromycin.  N, number of clones analysed. 
4.4.3 Analysis of chromosome-internal DSB repair in pif6 mutants 
To investigate whether PIF6 is involved in DSB repair in T. brucei, the clonal 
survival of pif6 mutants in the HR1 background was assayed and clones analysed 
by PCR to attempt to determine the repair pathway profile.  The clonal survival 
of HR1 wild type cells was 50% (Fig. 4-10A), again similar to that observed 
previously in this work.  Survival increased to 70% in the HR1 pif6+/- mutants but 
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decreased approximately five-fold in the two HR1 pif6-/- clones (9.6% and 
13.5%).  The puromycin sensitivity data for all survivors in this assay indicate 
that all ‘induced’ clones were puromycin sensitive and ‘uninduced’ clones were 
puromycin resistant as expected.  Furthermore, all clones grew in the absence of 
puromycin.  The puromycin sensitivity data therefore indicates that all ‘induced’ 
cultures were successfully induced (Fig. 4-10B). 
 
Figure 4-10 Clonal survival following I-SceI induction in HR1 pif6 mutants 
HR1 wild type, HR1 pif6+/- and two HR1 pif6-/- clones were distributed in three 96 well plates 
at a concentration of 0.26 cells per well either in the absence (I-SceI uninduced) or presence 
(I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells (clones) 
was counted after one week of incubation.  (A) Cell survival is shown as the average 
percentage of clonal survivors following I-SceI induction compared to survivors without      
I-SceI induction.  Error bars represent standard error of the mean (SEM) between the three 
96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and uninduced clones, 
represented as the percentage of tested clones that grew in the presence and absence of 
1 µg.mL-1 puromycin.  N, number of clones analysed. 
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The similarity in survival of HR1 wild type and HR1 pif6+/- mutants, compared 
with the reduced survival of the pif6-/- mutants, following a DSB is distinct from 
the survival profiles of these mutants following more general DNA damage.  In 
previous survival assays of pif6 mutants after treatment with the DNA damaging 
agents hydroxyurea (HU) and MMS, pif6+/- and pif6-/- displayed very similar or 
indistinguishable survival phenotypes (see Section 3.4.3.2).  Both mutants were 
more resistant to MMS, an inducer of DSBs, and less resistant to HU, primarily a 
replication-stalling agent.  It might therefore be predicted that both HR1 pif6+/- 
and HR1 pif6-/- mutants would display an increased resistance to DSB induction.  
In contrast, HR1 pif6+/- mutants were comparable with wild type and HR1 pif6-/- 
mutants displayed impaired survival, a different phenotype from the other cells. 
These data suggest that although the loss of one or both PIF6 alleles is sufficient 
to increase survival following MMS treatment, loss of a single PIF6 allele does not 
alter survival following a DSB at a chromosomal internal location.  Furthermore, 
whereas pif6-/- mutants are more resistant to ‘generalised’ DNA damage induced 
by MMS or hydroxyurea, the same null mutants are considerably impaired in their 
ability to repair an induced DSB at a chromosomal internal location.  Thus, the 
role of PIF6 in genome maintenance or repair may be quite different in response 
to different lesions. 
4.5 Analysis of DSB repair in the active VSG expression 
site 
The clonal survival of recq2, mus81 and pif6 mutants in an HRES background was 
next analysed in order to investigate whether these factors influence repair of 
DSBs upstream of the active VSG, the region in which DNA breaks initiating VSG 
switching are hypothesised to occur.  If mutants display an altered ability to 
survive a DSB in this location this can then be correlated with whether or not the 
same mutation also affects VSG switching, therefore testing whether DSBs play a 
role in VSG switching.  Such a correlation has been demonstrated for RAD51, 
mutants of which have a lower rate of VSG switching (McCulloch & Barry, 1999).  
Survival of HRES rad51-/- cells following I-SceI induction is also impaired 
compared to wild type HRES cells (Glover et al., 2013a).  In addition, this assay 
allows us to compare whether or not the same strategies for DSB repair are used 
in response to a DSB at the site hypothesised to initiate VSG switching relative to 
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a chromosome-internal DSB (in the HR1 background).  To date, different 
responses in these two locations have only been observed in mutants of a 
T. brucei histone acetyltransferase (HAT3) (Glover & Horn, 2014). 
In HRES cell lines a DSB adjacent to the 70 bp repeats has been demonstrated to 
induce VSG switching (Boothroyd et al., 2009; Glover et al., 2013a).  Surviving 
clones were therefore assayed by PCR for presence of VSG221 using primers #90 
and #91 (955 bp PCR product).  As VSG221 is lost in almost all switched survivors 
following I-SceI induction in the HRES line (Glover et al., 2013a), this PCR can 
therefore be used to confirm that surviving clones have switched.  Surviving 
clones were also assayed by PCR for presence of the ESAG1 present in and 
unique to the VSG221 active VSG BES using primers #92 and #93 (328 bp product) 
(Fig. 4-11).  ESAG1 is located upstream of the 70 bp repeats and its presence or 
absence in switched clones can be used to help determine the kind of switching 
event.  In most switched survivors ESAG1 is retained (Glover et al., 2013a), 
indicating that the VSG BES sequences upstream of the I-SceI site are still 
present and that recombination initiated in the region of the 70 bp repeats.  
ESAG1 absence indicates that recombination initiated upstream of the 70 bp 
repeats or switched through loss or replacement of the VSG BES.  The results of 
all PCR analyses on assays described below can be found in Appendix 7.1. 
 
Figure 4-11 Primer binding sites for PCR analysis of HRES I-SceI assay clones 
The VSG221 active BES is shown.  To test for presence of VSG221, a 328 bp PCR product 
was generated, using primers #90 and #91, which bind upstream of and within the VSG221 
ORF.  To test for presence of ESAG1, a 955 bp region of the ESAG1 ORF was PCR amplified, 
using primers #92 and #93.  Promoter (flag), red line indicates expression of the VSG BES, 
ESAGs (turquoise boxes), 70 bp repeats (hatched box), VSG221 (pink box), triangles 
(telomeric repeats).  Primer sequences can be found in Appendix 7.1.  Not to scale. 
Chapter 4  173 
4.5.1 Analysis of active VSG expression site DSB repair in recq2 
mutants 
It has previously been reported that survival of HRES wild type cells after I-SceI 
induction was extremely low at around 5% of uninduced cells and 10-fold lower 
than HR1 induced cells (Glover et al., 2013a).  Figure 4-12A shows that the 
survival of HRES wild type cells (23.8%) in this assay was two-fold lower than 
that of HR1 cells (see Section 4.4) and around four to five-fold higher than 
reported by Glover et al. (2013a).  This difference in survival could be due to 
differences in culturing conditions, such as the culture media used here 
containing a higher concentration of FBS (20% vs 10%).  Regardless, the survival 
rate of the two HRES recq2-/- clones (13% and 14.8%) was approximately half that 
of HRES wild type cells, suggesting absence of RECQ2 impaired survival (Fig. 4-
12A). 
The puromycin resistance data (Fig. 4-12B) indicate that not all cells were 
successfully induced.  A small proportion (3.8%) of HRES wild type clones 
recovered were puromycin resistant.  A higher frequency of resistance was seen 
in the mutants: 14% (one out of seven clones analysed) of HRES recq2-/- [clone 1] 
and 70% (seven out of ten clones analysed) of HRES recq2-/- [clone 1] survivors 
were puromycin resistant.  The increased incidence of puromycin–resistant cells 
in the mutants may reflect the impaired survival, meaning that a larger 
proportion of cells in the population not subjected to DSB induction were 
recovered on cloning.  These clones were excluded from the VSG221 and ESAG1 
PCR analysis of survivors shown in Figure 4-12C.  All other surviving induced 
clones lost VSG221 as expected and ESAG1 was retained in over 80% of HRES wild 
type survivors (25 clones analysed), consistent with Glover et al, (2013a).  ESAG1 
loss was higher in HRES recq2-/- [clone 1] survivors (~40%) but the total number 
of clones analysed was much lower (six).  ESAG1 was retained by all survivors of 
the second HRES recq2-/- clone analysed.  It is therefore not possible to draw 
firm conclusions regarding whether ESAG1 loss is greater in HRES recq2-/- 
mutants.  However, it seems likely that the profile of VSG221 loss and ESAG1 
retention is seen in both wild type and HRES recq2-/- mutants after I-SceI 
induction, despite the differing survival.  Details of the diagnostic PCRs and 
puromycin testing for each clone analysed can be found in Appendix 7.4. 
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The lowered survival of HRES recq2-/- mutants after induction of a DSB, relative 
to wild type HRES cells, suggests that RECQ2 is involved in the repair of DSBs in 
the active VSG BES.  However, the survival of recq2-/- mutants was not 
disproportionately lower in HRES than HR1 after I-SceI induction (a survival 
impairment of ~50% relative to wild type was seen in both cell lines), indicating 
that the role of RECQ2 in DSB repair is not specific to the active VSG BES.  A role 
for RECQ2 in the repair of DSBs at the active VSG BES is compatible with clonal 
survival assays (see Section 3.4.3.2), which showed that recq2 mutants are more 
sensitive to DNA damaging agents that cause DSBs, MMS and phleomycin.  In 
addition, it is compatible with the observation that myc-tagged RECQ2 
relocalises to detectable subnuclear foci after phleomycin treatment. 
As for the HR1 experiment, the survival of HRES recq2 mutants was assayed a 
second time (Fig. 4-13A), again with differing results to the first experiment.  
The survival rate of HRES wild type cells (13.1%) was lower than the first time 
the experiment was carried out, though similar to the survival rate in other 
repeats of this assay, described below (see Sections 4.5.2 and 4.5.3).  In addition 
to the HRES wild type and HRES recq2-/- cell lines assayed previously, the 
survival rate of HRES recq2+/- was also examined.  In contrast to the previous 
experiment, survival following I-SceI induction was not altered in HRES recq2-/- 
cells and furthermore, the survival rate of HRES recq2+/- cells was 24%, almost 
twice that of wild type HRES. 
These data are inconsistent with the impaired survival of HRES recq2 mutant 
survival in the first assay, impaired survival of HR1 recq2 mutants, and the 
sensitivity of recq2 mutants to a range of DNA damaging agents.  Furthermore, 
as seen with HR1, assessing the puromycin resistance data for the surviving 
clones of this experiment suggest the same difficulties as described for the HR1 
cells.  Figure 4-11B shows that 67% of uninduced HRES wild type and 33% of HRES 
recq2+/- survivors were puromycin sensitive, when previously no such cells were 
seen.  Additionally, puromycin resistant clones were seen for the induced HRES 
wild type and HRES recq2+/- cells, and nearly all of the HRES recq2-/- survivors 
were puromycin resistant, indicating that none of these cultures had a 100%      
I-SceI induction rate.  As before, this experiment was conducted after the first 
experiment, and after cells had been in culture for a longer period of time, 
providing further evidence that continued growth of either HR1 or HRES cells 
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leads to instability.  The problems with determining whether cultures were 
induced or not in this experiment, and lack of consistency with previous data on 
RECQ2, mean that this second assay cannot be relied upon. 
 
Figure 4-12 Clonal survival and ESAG1 and VSG221 loss following I-SceI induction in 
HRES recq2 mutants 
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HRES wild type and two HRES recq2-/- clones were distributed in three 96 well plates at a 
concentration of 0.56 cells per well either in the absence (I-SceI uninduced) or presence 
(I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells (clones) 
was counted after one week of incubation.  (A) Cell survival is shown as the average 
percentage of clonal survivors following I-SceI induction compared to survivors without 
I-SceI induction.  Error bars represent standard error of the mean (SEM) between the three 
96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and uninduced clones, 
represented as the percentage of tested clones that grew in the presence and absence of 
1 µg.mL-1 puromycin.  (C) Surviving I-SceI uninduced and induced clones from (B), 
excluding I-SceI induced clones that were puromycin resistant, were assayed for ESAG1 
and VSG221 presence by PCR.  N, number of clones analysed. 
 
 
Figure 4-13 Repeat of analysis of clonal survival following I-SceI induction in HRES 
recq2 mutants 
HRES wild type, HRES recq2+/- and HRES recq2-/- cells were distributed in three 96 well 
plates at a concentration of 0.56 cells per well either in the absence (I-SceI uninduced) or 
presence (I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells 
(clones) was counted after 7-10 days incubation.  (A) Cell survival is shown as the average 
percentage of clonal survivors following I-SceI induction compared to survivors without      
I-SceI induction.  Error bars represent standard error of the mean (SEM) between the three 
96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and uninduced clones, 
represented as the percentage of tested clones that grew in the presence and absence of 
1 µg.mL-1 puromycin.  N, number of clones analysed. 
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4.5.2 Analysis of active VSG expression site DSB repair in mus81 
mutants 
The ability of mus81 mutants to survive the induction of a DSB in the active VSG 
BES was next analysed, assaying an HRES mus81+/- mutant and two HRES mus81-/- 
mutants.  HRES mus81+/- mutants displayed a survival rate (30%) two-fold lower 
than HRES wild type cells (60%) (Fig. 4-14A).  This contrasts with the phenotype 
of HR1 mus81+/- mutants, which exhibited an unchanged survival rate from HR1 
wild type following I-SceI induction.  It is also different to the phenotype 
observed in mus81+/- mutants following treatment with phleomycin and MMS, 
both of which cause DSBs as well as other types of DNA damage.  HRES mus81-/- 
mutants had impaired survival following I-SceI-induced DSBs.  This was observed 
in both mus81-/- mutants analysed, with survival rates of 5.3% and 1.2% following 
I-SceI induction, respectively (Fig. 4-14A).  The puromycin sensitivity of surviving 
clones confirms that all ‘induced’ HRES wild type, HRES mus81+/- and HRES 
mus81-/- [clone 1] survivors underwent I-SceI induction.  Only a single induced 
HRES mus81-/- [clone 2] survivor was recovered in this experiment, and this was 
puromycin resistant, indicating that a DSB may not have been induced in that 
cell. 
PCR analysis of survivors revealed that all induced HRES wild type and HRES 
mus81-/- [clone 1] survivors lost VSG221, while a minority (12.5%) of HRES 
mus81+/- survivors retained VSG221 (Fig. 4-14B).  As all induced survivors were 
puromycin sensitive and therefore underwent I-SceI induction and DSB 
formation, it is possible that these VSG221 positive survivors underwent repair of 
the induced DSB through telomere exchange, meaning the VSG221 gene is 
located in another VSG BES.  However, this most likely reflects sampling 
variation rather than mutation of MUS81, as the same pattern was not seen in 
the mus81-/- mutants.  ESAG1 was retained by >80% of all induced survivors (Fig. 
4-14B), with no clear differences between wild type and mutants, indicating that 
recombination initiated downstream of ESAG1 in virtually all induced survivors.  
Genomic DNA was not recovered for the single induced HRES mus81-/- survivor in 
this assay and thus PCR analysis of ESAG1 and VSG221 presence was not possible. 
Decreased ability of mus81-/- cells to survive a DSB induced adjacent to the 
70 bp repeats suggests that MUS81 is involved in the repair of DSBs in this 
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location, in addition to playing a role in the repair of DSBs elsewhere in the 
chromosome and in repair of phleomycin and MMS-induced DNA damage. 
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Figure 4-14 Clonal survival and ESAG1 and VSG221 loss following I-SceI induction in 
HRES mus81 mutants 
HRES wild type, HRES mus81+/- and two HRES mus81-/- clones were distributed in three 96 
well plates at a concentration of 0.56 cells per well either in the absence (I-SceI uninduced) 
or presence (I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving 
cells (clones) was counted after one week of incubation.  (A) Cell survival is shown as the 
average percentage of clonal survivors following I-SceI induction compared to survivors 
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without I-SceI induction.  Error bars represent standard error of the mean (SEM) between 
the three 96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and 
uninduced clones, represented as the percentage of tested clones that grew in the presence 
and absence of 1 µg.mL-1 puromycin.  (C) Recovered clones from (B) were assayed for 
ESAG1 and VSG221 presence by PCR.  Genomic DNA was not recovered from one induced 
HRES wild type clone, one uninduced HRES mus81-/- [clone 1] and one induced HRES 
mus81-/- [clone 1] clone - these are excluded from the PCR analysis shown in (C).  The single 
induced HRES mus81-/- [clone 2] recovered was puromycin resistant and therefore HRES 
mus81-/- [clone 2] survivors were excluded from PCR analysis. N, number of clones 
analysed. 
4.5.3 Analysis of active expression site DSB repair in pif6 
mutants 
In contrast with the increased sensitivity of mus81 and recq2 mutants to induced 
DSBs in HRES, analysis of the survival of HRES pif6 mutants following I-SceI 
induction revealed a distinct phenotype.  The survival of induced HRES wild type 
cells was comparable with previous assays (8.1%) and loss of one PIF6 allele in 
the HRES pif6+/- cells did not alter the survival rate (8.6%) (Fig. 4-15A).  
However, there was a striking increase in survival in both HRES pif6-/- clones 
analysed.  Compared to HRES wild type, HRES pif6-/- [clone 1] survival increased 
six-fold (to 48%), while survival of the second clone increased over seven-fold (to 
62.1%), (Fig. 4-15A).  The puromycin resistance data (Fig. 4-16B) showed that all 
HRES wild type and HRES pif6+/- ‘induced’ clones were puromycin sensitive and 
thus underwent I-SceI cutting.  The high HRES pif6-/- survival was not due to 
inefficient I-SceI induction, as >95% of surviving HRES pif6-/- induced survivors 
were puromycin sensitive and thus were successfully induced.  This suggests that 
the increase in HRES pif6-/- survival was not a result of unforeseen alterations in 
the I-SceI target or gene.  To attempt to test this further, given the striking 
difference in this phenotype relative to the other mutants and to pif6-/- HR1 
mutants, PCR-amplification of the PUR gene was also attempted in order to 
investigate if it was removed by the DSB induction.  However, multiple 
attempts, including in the uninduced controls, produced inconsistent results, 
likely due to the high GC content of the PUR gene and therefore these data are 
not presented here.  Nonetheless, the increase in HRES pif6-/- survival is 
comparable with pif6 mutant survival following MMS damage, though differs in 
that pif6+/- mutants also displayed increased survival after MMS treatment.  A 
phenotypic separation between the two mutants was also seen in the I-SceI 
assays in HR1 cells, where pif6+/- mutants behaved more like wild type cells and 
were again different from pif6-/-. 
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Analysis of VSG221 and ESAG1 presence by PCR revealed a further unexpected 
result (Fig. 4-15C).  DSB induction near the 70 bp repeats causes loss of VSG221 
in almost all HRES survivors, as observed in assays described above (including for 
recq2 and mus81 mutants) and elsewhere (Glover et al., 2013a).  Though VSG221 
was lost from all induced HRES wild type and HRES pif6+/- survivors as predicted, 
it was retained in >98% of all induced HRES pif6-/- survivors.  Conversely, ESAG1 
was retained in all induced survivors.  Amplification of VSG221 by PCR showed 
that the gene is present but does not reveal its location.  For instance, induced 
survivors in which VSG221 was retained could have repaired the break and 
switched VSG via telomere exchange, thus the VSG221 gene would be in a 
different genomic location.  Alternatively, VSG221 may be retained in the VSG 
BES and may, indeed, continue to be expressed, meaning that in these cells 
induction of a DSB might not elicit a VSG switch.  It was therefore attempted to 
determine the genomic location of VSG221 in all survivors using PCR.  A pair of 
PCR primers was designed that amplified a region of the active VSG BES, the 
forward primer binding within a VSG pseudogene (accession number H25N7.32, 
tritrypdb.org) upstream of the 70 bp repeats, unique to the active VSG BES, and 
a reverse primer binding in VSG221.  Successful amplification of this PCR product 
(6.2 kbp in uninduced clones) would most likely indicate that VSG221 is located 
in the active VSG BES, whereas a negative result would suggest that VSG221 is in 
a different genomic location.  Multiple attempts at this PCR using a range of 
conditions and polymerases were unsuccessful and are not presented here.  This 
is most likely due to the length of the PCR product and the presence of the PUR 
gene. 
The clonal survival assay of HRES pif6 mutants was repeated an additional two 
times, selecting one of the HRES pif6-/- clones for analysis.  The results of these 
assays were very similar and are shown combined in Figure 4-17A.  Similar to the 
assay described above, following induction, the survival rate of HRES wild type 
cells was 15.6% and the survival of HRES pif6+/- cells was unchanged compared to 
wild type (15%).  However, the increase in induced HRES pif6-/- survival observed 
in the first experiment was not replicated.  The survival rate of induced HRES 
pif6-/- cells was similar to that of HRES wild type and HRES pif6+/- (18.5%). 
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Figure 4-15 Analysis of clonal survival and ESAG1 and VSG221 loss following I-SceI 
induction in HRES pif6 mutants 
HRES wild type, HRES pif6+/- and two HRES pif6-/- clones were distributed in three 96 well 
plates at a concentration of 0.56 cells per well either in the absence (I-SceI uninduced) or 
presence (I-SceI induced) of 2 µg.mL-1 tetracycline.  The number of wells with surviving cells 
(clones) was counted after one week of incubation.  (A) Cell survival is shown as the 
average percentage of clonal survivors following I-SceI induction compared to survivors 
without I-SceI induction.  Error bars represent standard error of the mean (SEM) between 
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the three 96 well plates.  (B) Puromycin sensitivity of surviving I-SceI induced and 
uninduced clones, represented as the percentage of tested clones that grew in the presence 
and absence of 1 µg.mL-1 puromycin.  (C) Clones from (B), excluding induced clones that 
were puromycin resistant or clones that were assayed for ESAG1 and VSG221 presence by 
PCR.  N, number of clones analysed. 
 
Figure 4-16 Attempt by PCR to analyse VSG221 genomic location 
A schematic of the VSG221 active VSG BES is shown.  Black arrows indicate primer binding 
locations.  PCR amplification to determine the genomic location of VSG221 was attempted 
using a primer (primer #94) that bound in the ORF of the VSG pseudogene (ΨVSG, yellow 
hatched box; H25N7.34, trytripdb.org) unique to the VSG221 BES and a primer that bound in 
the VSG221 ORF (primer #95), predicted product 6.2 kbp.  Sequences for primers can be 
found in Appendix 7.1.  Not to scale. 
However, the above combined dataset suffers from problems with the puromycin 
sensitivity data that have been described above and appear to be manifest when 
using more established cells.  In one experiment in this dataset, all uninduced 
survivors displayed puromycin resistance and only a small proportion (≤6%) of 
induced survivors were puromycin resistant, indicating that most cells in 
‘induced’ cultures were successfully induced (Fig. 4-17b).  However, the second 
experiment in this dataset (dataset 2) suffered from multiple problems in the 
puromycin resistance profile.  Some uninduced clones were not resistant to 
puromycin and some induced clones were resistant to puromycin (Fig. 4-17C).  
Only 33% of HRES pif6+/- uninduced clones and 50% of HRES pif6-/- uninduced 
clones were puromyin resistant.  In addition, 13% of HRES wild type induced 
clones were resistant to puromycin.  Even in the absence of puromycin, 33% of 
HRES pif6+/- uninduced survivors and 17% of HRES pif6-/- uninduced survivors did 
not grow. 
Due to the reasons outlined above, the combined data in the experimental 
repeats (Fig. 4-17) are less reliable than the first experiment (Fig. 4-15), almost 
certainly for the same reasons of I-SceI-induced instability seen in all such 
repeats.  Nonetheless, in considering the second combined dataset (Fig. 4-17), 
and although the increased HRES pif6-/- survival observed in the first experiment 
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was not replicated, loss of PIF6 did not result in impaired survival following       
I-SceI induction in HRES as was seen in recq2 and mus81 mutants.  
 
Figure 4-17 Combined data of two repeats of clonal survival following I-SceI induction in 
HRES pif6 mutants 
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HRES wild type, HRES pif6+/- and one of the HRES pif6-/- clones used in the previous assay 
(Fig. 4-15) were distributed in three 96 well plates at a concentration of 0.56 cells per well 
either in the absence (I-SceI uninduced) or presence (I-SceI induced) of 2 µg.mL-1 
tetracycline.  The number of wells with surviving cells (clones) was counted after one week 
of incubation.  (A) Cell survival is shown as the average percentage of clonal survivors 
following I-SceI induction compared to survivors without I-SceI induction.  Error bars 
represent standard error of the mean (SEM) of the two datasets.  (B & C) Puromycin 
sensitivity of surviving I-SceI induced and uninduced clones from dataset 1 (B) and dataset 
2 (C), represented as the percentage of tested clones that grew in the presence and absence 
of 1 µg.mL-1 puromycin.  N, number of clones analysed. 
The increase in pif6-/- survival following I-SceI induction in HRES in the first 
experiment (or the lack of impaired survival in the second experiment) is 
compatible with the observation that loss of PIF6 increases survival after MMS 
and phleomycin treatment.  If this correlation is correct, then it is unclear why 
increased survival was not observed in HR1 pif6-/- mutants and, instead, the 
opposite effect was observed.  Some PIF1 proteins in other eukaryotes have 
functions in telomere repair.  For example, S. cerevisiae PIF1 (ScPif1) inhibits 
the addition of telomeric repeats to DSBs and, in its absence, the rate of 
telomere addition to DSBs increases (Makovets & Blackburn, 2009; Schulz & 
Zakian, 1994).  Telomere addition to a telomere-proximal DSB (as in HRES) 
would result in loss of far fewer genes than telomere addition to a chromosome 
internal DSB (as in HR1).  Such a function for PIF6 could then explain the 
different survival phenotypes of pif6-/- mutants in HR1 and HRES.  However, 
telomere addition to DSBs does not seem compatible with retention of VSG221, 
which in theory would be lost if this repair mechanism were used in HRES. 
4.6 Analysis of cell cycle, VSG221 expression and H2Ax 
nuclear signal after DSB induction in pif6 mutants 
4.6.1 Analysis of cell cycle arrest following DSB induction in 
HRES and HR1 pif6 mutants 
DSB induction in HR1 and HRES cells has been demonstrated to cause cell cycle 
arrest at G2/M at 12 and 24 hours post tetracycline addition (Glover et al., 
2013a; Glover et al., 2008).  Given the potentially unusual profile of increased 
survival after I-SceI induction, the cell cycle profile of HRES wild type and HRES 
pif6 mutants was assayed to investigate whether loss of pif6 affected cell cycle 
arrest following DSB formation and perhaps, and suggest an explanation for how 
this helicase might be involved in the response to a DSB. 
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HRES wild type and pif6 mutant cells were induced with 2 µg.mL-1 tetracycline 
and cells were collected at 12 and 24 hours.  Cells were stained with DAPI to 
enable visualisation of nuclear and kinetoplast DNA and cells were categorised as 
either 1N1K (G1 phase), 1N2K (G2 phase), 2N2K (M phase), or ‘other’ for cells 
that were abnormal and corresponded to none of these categories.  See Section 
3.4.2 for a full explanation of the categorisation of visible cell cycle stages. 
The expected distribution of cell types for unperturbed BSF T. brucei is ~80% 
1N1K, ~10% 1N2K and ~5% 2N2K (Benmerzouga et al., 2013).  The cell cycle 
profile for uninduced HRES wild type and HRES pif6+/- cells was consistent with 
the expected distribution (Fig. 4-18A&B).  However, an increase in 1N2K (~G2 
phase) cells was observed in HRES pif6-/- uninduced cells at both 12 and 24 
hours, increasing from ~10% in both HRES wild type and HRES pif6+/- to ~16%.  
The proportion of 2N2K cells was also higher in uninduced HRES pif6-/- cells at 24 
hours (~9%) compared to HRES wild type and HRES pif6+/- cells (both ~5%).  
However, this was not apparent at the 12 hour time point and it is unclear why 
this would change without induction of I-SceI.  The higher proportion of 1N2K 
HRES pif6-/- cells suggests a cell cycle abnormality in HRES pif6-/- cells involving 
a delay in progression to M phase. 
Twelve hours after addition of tetracycline, an increase in 1N2K cells was 
observed in induced HRES wild type and HRES pif6+/- cultures, with the 
proportion of such cells increasing from ~10% (in the uninduced) to ~20%, which 
was accompanied by a decrease in 1N1K cells from ~80% (uninduced) to 70% (Fig. 
4-18A).  This is similar to the increase in G2 phase cells (to ~25%) observed by 
Glover et al. (2013a) after I-SceI induction in HRES cells.  In contrast, the 1N2K 
population of induced HRES pif6-/- cells did not increase above the 16% of 
uninduced cells at this time point. 
24 hours after I-SceI induction (Fig. 4-18B), the proportion of 1N2K cells 
remained elevated at ~20% in HRES wild type and HRES pif6+/- cells, accompanied 
by an increase in the proportion of 2N2K cells (from ~5% to ~10%), indicating a 
block in cytokinesis.  The proportion of 2N2K cells was already elevated in 
uninduced HRES pif6-/- cells at 24 hours (~10%) and did not increase above this 
level.  However, the proportion of 1N2K cells was elevated above the uninduced 
level (~16%), though only modestly (to ~22%). 
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One other feature was potentially seen following I-SceI induction:  a small but 
noticeable increase in the proportion of ‘other’ cells was observed in HRES   
pif6-/- mutants.  Such aberrant cells were not seen at all in any uninduced HRES 
populations and nor in the induced wild type, but were seen to a very limited 
extent in the pif6+/- cells, where their number appeared to increase from 12 to 
24 hours, though never reaching the levels in the pif6-/- mutants.  The ‘others’ 
were of several different categories, including zoid cells (0N1K), cells without 
kinetoplasts (e.g. 2N0K and 1N0K) and cells containing a fragmented nucleus 
that appeared to have begun to break down.  Examples are shown in Figure 4-18.  
Due to the low number of ‘other’ cells, their types were not sub-categorised 
during counting. 
The HRES wild type data above are consistent with the findings of Glover et al. 
(2013a), namely, that DSB induction in HRES wild type causes arrest at the G2/M 
cell cycle checkpoint and a cytokinesis block at 12 hours post-induction. I-SceI 
induction in HRES pif6+/- mutants results in the same cell cycle arrest profile as 
wild type HRES cells, though there may be a small indication that this is 
impaired, leading to aberrant cells.  In contrast, HRES pif6-/- cells appear to 
suffer from an intrinsic cell cycle block, reflected in an elevated proportion of 
1N2K cells in uninduced cultures, though induction of I-SceI can increase this 
phenotype (at least to some extent after 24 hrs). Again, the accumulation of 
aberrant cells after I-SceI induction may indicate some impediment to the cell’s 
response to DSB induction.  The intrinsic cell cycle phenotype (increased 1N2K 
cells) was not observed in pif6-/- mutants in a non-I-SceI background (see Section 
3.4.2), and it is therefore possible that this is a specific response to DSBs. For 
instance, expression of the I-SceI meganuclease may be leaky in the HRES cell 
line.  Alternatively, such leakiness may be specific to the clone examined here.  
It has also been suggested that DSBs occur more frequently at the 70 bp repeats 
of the active VSG BES (Boothroyd et al., 2009), though this has been contested 
by later studies (Glover et al., 2013a; Jehi et al., 2014b).  Additionally, 
introduction of the I-SceI/PUR construct itself, rather than I-SceI ‘leakiness’, 
may result in a higher rate of break formation by interfering with transcription 
or replication for example.  Finally, If PIF6 is important in repair of these 
breaks, this could also cause an increase in 1N2K cells in the absence of I-SceI 
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induction, as observed here.
 
Figure 4-18 DAPI cell cycle analysis of HRES pif6 mutants 
The DNA content of HRES wild type, HRES pif6+/- and HRES pif6-/- cells at 12 hours and 24 
hours post I-SceI induction (+T) was visualised by DAPI staining of fixed cells.  The number 
of cells with one nucleus and one kinetoplast (1N1K), one nucleus and two kinetoplasts 
(1N2K), two nuclei and two kinetoplasts (2N2K) and cells that did not fit into any of these 
categories (other) were counted using captured images.  The proportions of each of these 
cell types are represented as a percentage of the total cells counted (N).  Uninduced cells    
(-T) were also analysed as a control.  N, number of cells counted.  Examples of ‘other’ cells 
from the cell lines and times indicated are shown. 
To test the above data further, the cell cycle profile of HR1 wild type and HR1 
pif6-/- mutants was analysed (Fig. 4-19A&B).  In the absence of I-SceI induction, 
the cell cycle profile was normal for HR1 wild type and HR1 pif6-/-.  However, 
induction of I-SceI resulted in the accumulation of 1N2K cells in HR1 wild type 
and HR1 pif6-/- at 12 hours (Fig. 4-19A), indicating G2/M cell cycle arrest.  
Approximately 24% of HR1 and 17% of HR1 pif6-/- cells were 1N2K, similar to the 
accumulation of 1N2K cells found after I-SceI induction in HRES.  However, the 
G2/M cell cycle arrest observed in HR1 wild type and HR1 pif6-/- resolved more 
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rapidly than in HRES wild type and HRES pif6 mutants, with the proportion of 
1N2K cells returning to normal in induced cultures (~10%) at 24 hours (Fig. 4-
19B), perhaps suggesting that a DSB formed in the chromosomal internal location 
of HR1 is repaired more efficiently than the DSB formed at the 70 bp repeats in 
HRES.  These data are consistent with the G2/M cell cycle arrest and resolution 
observed by Glover et al. (2008) in HR1 following I-SceI induction, and that the 
altered cell cycle profiles in the pif6 mutants appear to be specific to HRES 
cells. 
 
Figure 4-19  Cell cycle analysis of HR1 pif6 mutants following I-SceI induction 
The DNA content of HRES wild type and HRES pif6-/- cells at 12 hours and 24 hours post I-
SceI induction (+T) was visualised by DAPI staining of fixed cells.  The number of cells with 
one nucleus and one kinetoplast (1N1K), one nucleus and two kinetoplasts (1N2K), two 
nuclei and two kinetoplasts (2N2K) and cells that did not fit into any of these categories 
(other) were counted using captured images.  The proportions of each of these cell types 
are represented as a percentage of the total cells counted (N).  Uninduced cells (-T) were 
also analysed as a control.  N, number of cells counted. 
4.6.2 Analysis of VSG221 expression after DSB induction in HRES 
pif6 mutants 
To investigate whether loss of PIF6 affects loss of VSG221 expression following 
DSB induction in an HRES background, as might be expected if a DSB drives VSG 
switching, immunolocalisation of VSG221 following I-SceI induction was carried 
out.  Cells were induced with 2 µg.mL-1 tetracycline and samples were collected 
for VSG221 immunolocalisation at 24 hours.  Rabbit anti-VSG221 antiserum 
(Glover et al., 2013a) was used at a 1:1000 dilution and a secondary anti-rabbit 
Alexa Fluor 594 conjugated antiserum (Life Technologies) was used at a 1:2000 
dilution to detect VSG221.  From previous work, the accumulation of 1N2K (G2) 
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cells has been shown to peak at 12 hours after I-SceI induction in HRES wild type 
cells, then return to uninduced levels by 24 hours (Glover et al., 2013a; Glover & 
Horn, 2014).  It was therefore expected that at 24 hours post-induction the 
proportion of VSG221-positive cells would decrease, due to an induced switch in 
expression to a different VSG.  However, Figure 4-20 shows that any reduction in 
the proportion of cells expressing VSG221 was negligible at this stage after 
induction, with only 0.5-1% of cells not displaying VSG221 signal.  It is possible 
that this is because in these experiments cell cycle arrest following DSB 
induction was still present 24 hours after induction (discussed above, Section 
4.6.1), in contrast to the reports by Glover and colleagues.  Why this arrest 
should be more prolonged here is not clear, but given a prolonged cell cycle 
arrest, it is perhaps not surprising that VSG221 on the cell surface has not been 
replaced by another VSG.  To explore whether loss of PIF6 affects loss of VSG221 
expression following DSB induction, cell samples would need be collected at 
time points beyond 24 hours in order to examine cells that have re-entered the 
cell cycle.  Alternatively, clonal dilution of surviving clones ~one week after 
induction would provide data on whether VSG221 expression is retained in pif6-/- 
mutants, since virtually all clonal wild type HRES survivors do not express 
VSG221 (Glover et al., 2013a; Glover & Horn, 2014).  However, the timing of a 
switch to expression of another VSG could not be examined using a clonal 
survival method. 
Figure 4-20  Analysis of VSG221 expression in HRES pif6 mutants following I-SceI 
induction 
VSG221 expression in HRES wild type, HRES pif6+/- and HRES pif6-/- cells at 24 hours post   
I-SceI induction (+T) was visualised by staining fixed cells with rabbit anti-VSG221 
antiserum (1:1000 dilution, (Glover et al., 2013a)) and secondary staining with goat anti-
rabbit Alexa Fluor 594-conjugated antiserum (1:2000, Life Technologies).  The proportion of 
cells expressing VSG221 on their surface at 24 hours post I-SceI induction (+T) or without   
I-SceI induction (-T) is represented as the percentage of total cells counted.  N, total number 
of cells counted. 
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4.6.3 Analysis of H2Ax nuclear signal after DSB induction in 
HRES and HR1 pif6 mutants 
One of the earliest markers of DNA damage in eukaryotes is γH2A(X).  In 
mammals, the variant histone H2AX is Ser139 phosphorylated (Rogakou et al., 
1998) and in S. cerevisiae (Downs et al., 2000; Redon et al., 2003) and S. pombe 
(Nakamura et al., 2004), γH2A is a Ser128/129 phosphorylated version of the core 
histone H2A.  γH2A(X), from here on referred to as γH2A, signals DNA damage 
and triggers the recruitment of DNA repair proteins (Canman, 2003; Polo & 
Jackson, 2011) including MDC1 (mediator of damage checkpoint 1) (Stucki et al., 
2005), which activates the G2/M and intra S-phase cell cycle checkpoints (Stucki 
& Jackson, 2006).  The T. brucei equivalent of γH2A has been identified and 
characterised by Glover et al. (2012), who showed that histone H2A is not 
phosphorylated on a C-terminal serine residue, but instead that Thr130 is 
phosphorylated to form γH2A, whose abundance increases after DNA damage, 
including at sites of I-SceI-induced DSBs, and becomes visible as subnuclear foci. 
To investigate whether loss of PIF6 affects accumulation of γH2A in response to 
DSB formation, the intensity of γH2A immunofluorescence was measured in wild 
type and pif6 mutant HR1 and HRES cells following I-SceI induction.  Cultures 
were induced with 2 µg.mL-1 tetracycline and cells collected at 12 and 24 hours 
post-induction.  Cells were fixed and stained for γH2A using rabbit anti-γH2A 
antiserum at a 1:1000 dilution (gift, Tiago D. Serafim, unpublished) and goat 
anti-rabbit Alexa Fluor 594-conjugated antiserum (Life Technologies) at a 1:2000 
dilution and slides were also stained with DAPI for visualisation of the nucleus 
and kinetoplast.  Although γH2A in trypanosomes has previously been analysed 
by looking at nuclear γH2A foci (Glover & Horn, 2012), the antiserum used here 
did not provide clear results using this method.  The staining obtained was 
general nuclear staining in the vast majority of cases, not γH2A foci (see 
examples in Figure 4-21B).  It was therefore decided to measure the nuclear 
γH2A intensity instead.  The intensity of γH2A signal in the nucleus was 
calculated by measuring the average intensity of all nuclei in captured images 
using ImageJ (imagej.nih.gov/ij) (Rasband, 1997-2014) and is presented in 
arbitrary units. 
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The average γH2A nuclear intensity in all HRES wild type and HRES pif6 mutant 
cultures at 12 and 24 hours following I-SceI induction was at least twice the 
background γH2A nuclear intensity, as determined by the average nuclear γH2A 
intensity of I-SceI uninduced cells (Fig. 4-21A).  All fluorescence intensity values 
cited below are the value above background fluorescence, taking the 
background value as zero.  At 12 hours following I-SceI induction the nuclear 
γH2A intensity was highest in HRES wild type (14.6 units above background) and 
remained almost unchanged (13.4 units above background) at 24 hours.  HRES 
pif6+/- γH2A intensity at 12 hours post-induction was ~50% lower (7.3 units above 
background) than HRES wild type and similarly did not decrease at 24 hours.  
Therefore, although the γH2A intensity was lower in HRES pif6+/- than HRES wild 
type, neither underwent a substantial change in fluorescence between 12 and 24 
hours.  The γH2A intensity profile of HRES pif6-/- cells however was very 
different.  The γH2A intensity of HRES pif6-/- at 12 hours post-induction (12.3 
units above background) was comparable to that of wild type HRES.  However, at 
24 hours post-induction there was a ~60% reduction in HRES pif6-/- γH2A intensity 
(5 units), a signal loss that was not seen in the two other cell lines. 
 
Figure 4-21 Analysis of γH2A expression in HRES pif6 mutants 
γH2A expression in HRES wild type, HRES pif6+/- and HRES pif6-/- cells at 12 and 24 hours 
post I-SceI induction was visualised by staining fixed cells with rabbit anti- γH2A antiserum 
(1:1000 dilution, gift, Tiago D Serafim (unpublished)) and secondary staining with goat anti-
rabbit Alexa Fluor 594-conjugated antiserum (1:2000, Life Technologies).  (A) The average 
nuclear intensity of γH2A expression was measured from captured images using ImageJ 
(imagej.nih.gov/ij) (Rasband, 1997-2014) and is expressed as the average nuclear intensity 
(arbitrary units) of all nuclei counted (N).  The average nuclear intensity of I-SceI uninduced 
cells was used as a background level (dashed line).  Bars represent standard error of the 
mean (SEM).  N, number of cells counted.  (B) Representative images of γH2A expression in 
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cells at 12 and 24 hours post induction.  –T, no tetracycline (control); +T, tetracycline added.  
Scale bar, 13 µM. 
 
Figure 4-21 continued 
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Figure 4-21 continued 
 
Glover et al. (2012) showed that γH2A foci appeared most frequently in S-phase 
and G2-phase cells.  Glover et al. (2013a & 2008) also found that I-SceI induction 
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in HRES cells results in a G2/M phase arrest, which peaks at 12 hours and is 
resolved by 24 hours (see Section 1.6.1).  The data here are largely consistent 
with this, with the exception that in our hands the G2/M arrest is more slowly 
resolved for reasons that are unclear.  If so, the γH2A intensity of HRES wild 
type and HRES pif6+/- may follow I-SceI induction.  At 24 hours the accumulation 
of 1N2K cells is still present at the same level, and thus it is likely that γH2A 
accumulation is still present at this stage; note that the timing of γH2A focal 
accumulation and resolution relative to G2/M arrest has not been reported for 
HRES.  However, there was also an elevated level of G2/M arrested HRES pif6-/- 
cells at 24 hours post induction.  It might therefore be expected that γH2A 
intensity would remain similarly elevated at 24 hours in HRES pif6-/-.  Recovery 
from cell cycle arrest and re-entry into the cell cycle in S. cerevisiae is 
contingent upon dephosphorylation of H2Ax (Bazzi et al., 2010; Keogh et al., 
2006; Nakada et al., 2008).  The lowered levels of γH2A staining at 24 hours 
might therefore suggest that HRES pif6-/- cells undergo H2AX dephosphorylation 
earlier than HRES wild type and HRES pif6+/- cells, but have not yet resumed the 
cell cycle at the time point examined. 
The nuclear γH2A signal intensity of HR1 wild type and HR1 pif6-/- cells was 
calculated in the same way as for HRES cells and cells were prepared identically.  
All values quoted are average fluorescence above the background level.  As in 
the HRES background (see Section 4.6.3), the γH2A signal intensity of HR1 wild 
type cells 12 hours post I-SceI induction (11.6 units) was similar to that of HR1 
pif6-/- (14.5 units) (Fig. 4-22).  However, whereas the γH2A signal remained high 
in HRES wild type cells at 24 hours post induction, the γH2A signal decreased 
substantially in both HR1 wild type and HR1 pif6-/- at 24 hours post I-SceI 
induction (~60% and ~80% respectively).  These data are consistent with the 
accumulation of 1N2K cells in HR1 wild type and HR1 pif6-/- 12 hours post I-SceI 
induction and the return to a normal cell cycle profile of both at 24 hours post-
induction (see Section 4.6.1).  This indicates that DSBs at the chromosomal 
internal location in HR1 cells are repaired more efficiently than DSBs at the 
70 bp repeats of the active VSG BES of HRES cells.  Furthermore, H2A 
phosphorylation following I-SceI induction in HR1, an important marker of DNA 
damage, is resolved as efficiently in HR1 pif6-/- cells as HR1 wild type cells. 
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Figure 4-22 Analysis of γH2A expression in HR1 pif6 mutants 
γH2A expression of HR1 wild type and HR1 pif6-/- cells at 12 and 24 hours post I-SceI 
induction was visualised by staining fixed cells with rabbit anti- γH2A antiserum (1:1000 
dilution, gift, Tiago D Serafim (unpublished)) and secondary staining with goat anti-rabbit 
Alexa Fluor 594-conjugated antiserum (1:2000, Life Technologies).  (A) The average nuclear 
intensity of γH2A expression was measured from captured images using ImageJ 
(imagej.nih.gov/ij) (Rasband, 1997-2014) and is expressed as the average nuclear intensity 
(arbitrary units) of all nuclei counted (N).  The average nuclear intensity of I-SceI uninduced 
cells was used as a background level (dashed line).  Bars represent standard error of the 
mean (SEM).  (B) Representative images of γH2A expression in cells at 12 and 24 hours post 
induction.  –T, no tetracycline (control); +T, tetracycline added.  Scale bar, 13 µM. 
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Figure 4-22 continued 
Chapter 4  199 
 
Figure 4-22 continued  
 
4.7 Analysis of VSG switching in knockout cell lines 
4.7.1 VSG switching assay strategy 
In order to analyse the effect of loss of RECQ2, MUS81 and PIF6 on VSG switching 
in vitro we adapted the strategy of Povelones et al. (2012), who used RNAi 
against histone H1 to examine the role of this factor in VSG switching.  In this 
strategy, a herpes simplex virus thymidine kinase (HSV-TK, here referred to as 
TK) gene is fused to a hygromycin resistance gene (HYG-TK) and inserted 
between the 70 bp repeats and VSG221 (427-2) in the active VSG BES (named 
BES1, as described by directed cloning in Hertz-Fowler et al. (2008) of T. brucei 
Lister 427 strain MITat1.2.  Additionally, enhanced GFP (eGFP) and a puromycin 
Chapter 4  200 
resistance gene are integrated downstream of the active VSG BES promoter (Fig. 
4-24).  This cell line is here referred to as GFP221hygTK. 
 
Figure 4-23 Cell line GFP221hygTK used for VSG switching experiments 
As discussed in the text, the GFP221hygTK cell line contains a puromycin resistance gene 
(PUR, purple) and eGFP gene (GFP, green) integrated immediately downstream of the 
VSG221 BES (active VSG BES) promoter (arrow) allowing monitoring of the activity status of 
the expression site, and a hygromycin-TK (Hyg-TK, orange-grey) fusion gene integrated 
between the 70 bp repeats (hatched) and VSG221 (pink), to permit negative selection of 
VSG221 in the active VSG BES. 
In this experimental approach to analyse VSG switching GFP221hygTK cells are 
maintained under puromycin and hygromycin selection in order to maintain 
transcription of the VSG221 BES and presence of VSG221 in the BES, 
respectively.  Thymidine kinase is widely used as a negative selection marker in 
mammalian systems: to enrich for correctly integrated DNA insertions (Mansour 
et al., 1988) and to eliminate certain cell types (Heyman et al., 1989).  
Thymidine kinase phosphorylates a range of nucleosides and nucleoside 
analogues, including ganciclovir, into toxic compounds that cause cell death. 
At the beginning of the VSG switching assay cells are passaged into medium not 
containing hygromycin, either in the presence or absence of puromycin 
(0.2 µg.mL-1).  The absence of hygromycin selection allows cells to lose or 
inactivate the HYG-TK fusion gene upstream of VSG221 in the active BES.  VSG 
switching can occur by a number of events within the VSG BES. Recombination 
reactions, which are most frequently gene conversions that delete sequences 
within the VSG BES, can involve the region upstream of VSG221 where the HYG-
TK fusion gene is located; such recombination can be variable, encompassing 
merely the VSG221 proximal region up to the 70 bp repeats, or can involve 
sequences upstream of the 70 bp repeats, such as the ESAGs or upstream of the 
promoter, in which case the PUR-GFP markers would be affected.  VSG BES 
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deletion events have also been described.  Finally, switching can occur by in situ 
(transcriptional) switching, inactivating the VSG221 BES and activating another 
VSG BES.  Puromycin selection forces cells to maintain transcription of the 
VSG221 BES, thus preventing in situ switching that would inactivate PUR-GFP 
expression and VSG BES deletion VSG switching events that remove the PUR-GFP 
markers.  After 48 hours of culture in the absence of antibiotic, during which 
switching can occur, the cells are then diluted in the same media but containing 
ganciclovir.  The assay utilises the toxic activity of TK on ganciclovir to eliminate 
from the population cells that have not inactivated the TK gene through a VSG 
switching event.  Thus, TK negative selection is used a proxy for VSG switching.  
Cells that have inactivated TK through point mutations rather than VSG 
switching will also be selected for in this assay.  However, these clones can be 
identified by their continued expression of VSG221, as revealed by western blot 
analysis. 
Analysis of the proportion of clones surviving ganciclovir selection permits the 
calculation of the VSG switching rate.  PCR analyses of VSG221 and eGFP 
presence and western blot analysis of VSG221 and eGFP expression allows the 
determination of the mechanism of VSG switching (Fig. 4-24).  In situ switchers 
are positive for VSG221 and eGFP by PCR but no longer express either.  Clones 
that have switched by VSG gene conversion downstream of PUR-GFP (VSG GC) 
retain eGFP in the active expression site and are thus positive for GFP by PCR 
and western blot analysis, but have lost VSG221 and are therefore are negative 
for the VSG221 gene by PCR and the protein by western blot analysis.  Telomere 
crossover switchers can also retain eGFP in the active expression site and thus 
are also eGFP positive by PCR and western blot analysis.  However, in this case, 
VSG221 is retained in the genome but no longer in the active expression site, 
and so are VSG221 positive by PCR but not by western blot analysis.  The final 
types of switch detectable in this system are gene conversions (GC) 
encompassing the whole expression site or in situ switch with expression site 
deletion (ES GC or in situ + ES del, respectively).  Both of these switching events 
result in the loss of the VSG BES and are indistinguishable in this assay.  They are 
negative for both GFP and VSG221 by PCR and express neither protein in western 
analysis. 
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A similar strategy to the one employed by Povelones et al. (2012), and adopted 
here, has been used previously to investigate VSG switching (Benmerzouga et 
al., 2013; Jehi et al., 2014a; Jehi et al., 2014b; Kim & Cross, 2010; Kim & Cross, 
2011).  The strategy used in these previous studies utilised the same principles 
as this work and Povelones et al. (2012), but differed in some technical details: 
by the absence of eGFP at the VSG221 BES promoter, the use of a blasticidin 
resistance instead of puromycin resistance cassette at the promoter, as well as 
the TK-fusion gene at the 70 bp repeat utilising a puromycin resistance cassette 
instead of hygromycin resistance.  It is also likely that differences exist in the 
precise locations of construct integrations within the VSG221 BES. 
Figure 4-24 Strategy for determining VSG switching mechanisms 
The active VSG BES of GFP221hygTK is shown, within which the PUR, GFP, HYG-TK and 
VSG221 genes are represented as in Figure 4-24.  In addition, one of the ~15 silent VSG 
BESs containing a distinct VSG (turquoise) is shown, as are multiple silent VSGs elsewhere 
in the genome (various colours; for convenience these are shown as an array, but could 
also be at the telomere of silent mini-chromosomes).  Upstream of all VSGs 70 bp repeats 
are denoted by hatched boxes.  After ganciclovir treatment, utilisation of different switching 
strategies results in different outcomes (boxes), distinguishable by analysis of VSG221 and 
GFP presence by PCR and expression by western blot (profiles detailed under each 
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mechanism).  Switching by in situ switching, telomere crossover (XO), VSG gene 
conversion (VSG GC), and BES gene conversion/in situ switch + BES deletion (ES GC/ in 
situ + ES del) are detectable using this strategy.  TK mutants can also be identified using 
these analyses.  Note, for VSG GC the silent grey array donor VSG gene is shown as being 
copied but the reaction could also use a BES VSG gene; in addition, in situ + ES del is 
shown and not ES GC, where all sequence of a silent BES is duplicated and replaces the 
VSG221 BES.  Figure inspired by Povelones et al. (2012). 
4.7.2 Generation of VSG switching cell line 
The GFP221hygTK line generated for analysis of VSG switching used the same 
constructs as in Povelones et al. (2012), kindly gifted by Gloria Rudenko.  It was 
necessary to construct the GFP221hygTK strain because the only strain available 
had been previously genetically modified for RNAi against histone H1.  The first 
of these constructs contained the eGFP-PUR (puromycin) construct, 221GP1 
(Sheader et al., 2004) (Fig. 4-25A).  221GP1 contains a puromycin resistance 
gene (PUR) flanked by tubulin intergenic sequences, providing splicing and 
polyadenylation sites.  The eGFP gene is located downstream of PUR and is 
flanked upstream by the same tubulin intergenic region used downstream of PUR 
and downstream by the VGS221 UTR, providing a polyadenylation signal.  The 
PUR-eGFP sequence is flanked by 221 BES targeting fragments and the whole 
construct is bounded 5’ by a NotI restriction site and 3’ by an XhoI restriction 
site.  Digestion of the 221GP1 construct with NotI and XhoI prior to 
transformation releases the targeting construct, which integrates 216 bp 
downstream of the VSG221 BES transcription start site. 
The second construct used to generate the VSG switching line contains the HYG-
TK gene and integrates downstream of the 70 bp repeats.  The construct (gift, 
G. Rudenko (Povelones et al., 2012)), here referred to as HYG-TK, contains the 
HYG-TK gene flanked upstream by a tubulin intergenic region, providing a 
splicing signal and downstream by an actin intergenic region, providing for 
polyadenylation (Fig. 4-25B).  This cassette is flanked upstream by a targeting 
sequence composed of a 2.5 kb region of the 70 bp repeats excised from the 
construct RM3173 (McCulloch et al., 1997) and downstream by a VSG221 BES 
targeting fragment, which is composed of the so-called ‘co-transposed region’ 
found upstream of all VSGs, in this case from the VSG221 BES between the 70 bp 
repeats and the VSG221 gene.  The construct was digested with NotI and HindIII 
prior to transformation.  Significant difficulty was encountered in attempting to 
propagate the HYG-TK construct.  Restriction digest of plasmid preparations 
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showed that much of the plasmid had been lost, most likely due to the presence 
of the 70 bp repeats, which may be unstable in E. coli.  Propagation of the 
correct, full length HYG-TK construct was ultimately successful using XL-10 Gold 
Cells (Stratagene) and ZYM-5 medium.  These cells contain a number of 
mutations in genes involved in DNA rearrangement to improve the stability of 
unstable clones.  Both constructs were checked using restriction enzyme digest 
prior to use in transformations. 
Before beginning generation of the GFP221hygTK cell line, it was confirmed by 
immunofluorescence that the wild type T. brucei Lister 427 MITat1.2 BSF cells 
expressed VSG221, using an anti-VSG221 antiserum (gift, K. Matthews), data not 
shown.  These cells were then transformed (as described in Section 2.1.3) with 
10 µg of the 221GP1 construct and selected using 0.2 µg.mL-1 puromycin.  Four 
clones were retrieved from this transformation.  The successful integration of 
the 221GP1 construct was confirmed by PCR analysis (“GFP PCR”) using primer 
#120, which binds in the eGFP ORF and primer #121, which binds downstream of 
the integration site within the ESAG7 ORF (Tb427.BES40.2) and produces a 
2.8 kbp amplified product (Fig.4-26).  Primer sequences can be found in 
Appendix 7.1.  Three of these clones were assayed using the above PCR, all of 
which were positive (data not shown).  These three clones were also assayed for 
eGFP and VSG221 expression by immunofluorescence.  VSG221 expression was 
detected using rabbit anti-VSG221 antiserum (Keith Matthews, used at 1:1000 
dilution) and an anti-rabbit Alexa Fluor 594 conjugated antiserum (Invitrogen, 
used at 1:2000 dilution); eGFP fluorescence was detected directly using a FITC 
filter.  All three clones were positive for both eGFP and VSG221 expression (data 
not shown). 
One of the above eGFP-PUR clones was taken forward for the second round of 
transformation.  The eGFP-PUR cell line was cultured in the presence of 
0.2 µg.mL-1 puromycin in medium lacking thymidine, transformed with 10 µg of 
the HYG-TK construct and selected using 0.2 µg.mL-1 puromycin and 10 µg.mL-1 
hygromycin.  Two surviving clones were obtained from this transformation.  
Successful integration of the HYG-TK construct was confirmed by PCR (“HYG-TK 
PCR”), using primers #131, which binds in the TK ORF and #133, which binds in 
the VSG221 ORF, producing a 2.2 kbp PCR product (data not shown).  Figure 4-26 
shows the primer binding locations of the HYG-TK and eGFP PCRs. 
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Figure 4-25 Constructs used in the generation of the GFP221hygTK VSG switching cell 
line 
(A) The 221GP1 construct (Sheader et al., 2004) contains the eGFP and PUR genes, both 
flanked by sequences for mRNA splicing and polyadenylation (dark grey).  Sequences from 
the VSG221 BES (221 BES upstream & 221 BES downstream) provide sequence identity for 
HR with, and integration into, the VSG221 BES immediately downstream of the promoter.  
Prior to transformation the construct was digested with XhoI and NotI.  (B) The HYG-TK 
construct (Povelones et al., 2012) contains a hygromycin resistance gene fused to a 
thymidine kinase gene (hyg-TK), flanked by sequences for mRNA splicing and 
polyadenylation (dark grey).  A region of the 70 bp repeats of the VSG221 BES and a region 
of the VSG221 co-transposed region (VSG221 CTR) provide sequence homology for HR and 
integration into the VSG221 BES between the 70 bp repeats and VSG221.  Prior to 
transformation the construct was digested with NotI and HindIII. 
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Figure 4-26 PCR primer binding sites of PCR confirm GFP221hygTK cell line 
The active VSG221 BES is shown.  Primers #120 and #121 bind in the eGFP and ESAG7 
ORFs respectively (“GFP PCR”) to confirm integration of the 221GP1 construct at the 
correct locus (2.8 kbp).  Primers #131 and #133 bind in TK and VSG221 ORFs respectively 
(“HYG-TK PCR”) to confirm integration of the HYG-TK construct at the correct locus 
(2.2 kbp product).  Primer sequences are listed in Appendix 7.1. 
Putative GFP221hygTK clones were also assayed by western blot analysis for 
eGFP and VSG221 expression and eGFP-PUR construct presence by PCR (“GFP 
PCR”), as previously.  Though both clones were positive for eGFP and VSG221 
expression, and 221GP1 and HYG-TK construct integration, only one clone was 
selected to use to attempt to generate recq2, mus81 and pif6 mutants. Western 
blot and PCR confirmation of the selected GFP221hygTK clone is shown in Figure 
4-7.  Data for the second clone is not shown. 
 
Figure 4-27 Confirmation of GFP221hygTK cell line by PCR and western blot 
(A) Genomic DNA was extracted from putative GFP221hygTK and wild type cells and 
integration of the 221GP1 (primers #120 and #121, 2.8 kbp PCR product) and HYG-TK 
(primers #131 and #133, 2.2 kbp PCR product) constructs was confirmed by PCR 
amplification.  Primer sequences can be found in Appendix 7.1.  Distilled water was used as 
a negative control.  Size markers (ladder, bp) are shown.  (B) Total protein extract of 
GFP221hygTK cells were separated by SDS-PAGE, western blotted and membranes were 
cut in two.  The upper half, containing proteins of the predicted molecular weight of VSG221 
(51 kDa), was probed with rabbit anti-VSG221 antiserum (1:20,000 dilution, (Glover et al., 
2013a)) and the other half, containing proteins of the predicted molecular weight of eGFP 
(27 kDa) was probed with rabbit anti-GFP antiserum (1:5000 dilution, abcam).  Both 
membranes were probed with goat HRP-conjugated anti-rabbit antiserum (Life 
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Technologies).  Size markers (kDa) are shown.  Gaps indicate lanes aligned in this figure 
after excision from multiple gels/membranes or from disparate parts of the same 
gel/membrane. 
After cells had been transformed with the HYG-TK construct, the resulting 
GFP221hygTK cells were maintained in culture for as little time as possible, with 
hygromycin and puromycin antibiotic selection, and always in thymidine-free 
medium.  This was done in order to attempt to minimise the number of cells 
acquiring inactivating mutations in the thymidine kinase gene, as it has 
previously been shown that T. brucei bloodstream form thymidine kinase 
expressing cells revert to a ganciclovir-resistant phenotype at a rate of 10-6 cells 
per generation (Valdes et al., 1996).  Additionally, the VSG switching strategy 
employed here has been demonstrated to be prone to the TK mutants (Povelones 
et al., 2012). 
4.7.3 Generation and confirmation of mutants in VSG switching 
cell line 
The plasmids to generate recq2, mus81 and pif6 mutants in the GFP221hygTK 
background were the same ones used for the generation of mutants in wild type 
(Section 3.3.2) and I-SceI (Section 4.3.1) backgrounds.  Detailed explanation for 
the cloning procedure of the knockout plasmids is in Section 3.3.1.  
GFP221hygTK cells were cultured in thymidine-free medium containing 
puromycin (0.2 µg.mL-1) and hygromycin (10 µg.mL-1) and transformed with 
ΔRECQ2::BSD, ΔMUS81::BSD or ΔPIF6::BSD in an attempt to generate 
heterozygous (+/-) cell lines.  In all cases, antibiotic resistant clones were 
selected using 10 µg.mL-1 blasticidin as well as 5 µg.mL-1 hygromycin.  
Hygromycin was used to prevent loss of the HYG-TK construct, which was 
considered a possibility due to the proximity of the integrated construct to the 
70 bp repeats and the suggestion that cells containing the HYG-TK construct can 
lose it during culture (G. Rudenko, personal communication), a suggestion that 
appeared to be confirmed upon further transformation (see below). 
Six putative recq2+/- (blasticidin resistant) clones were obtained, all of which 
were taken forward for analysis to confirm correct integration of the construct.  
A total of 29 blasticidin-resistant positive wells were obtained from the 
ΔMUS81::BSD transfection.  As 22 of these were on one 24 well plate, and thus 
were unlikely to be clonal, they were not taken forward for analysis.  Six of the 
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remaining wells (putative mus81+/- clones, blasticidin resisant) were taken 
forward for further analysis.  Thirteen putative pif6+/- clones (blasticidin 
resistant) were obtained from the ΔPIF6::BSD transformation, of which six were 
taken forward for analysis. 
Putative heterozygote clones were analysed by PCR (data not shown) similar to 
knockout cells generated in wild type and I-SceI backgrounds (see Sections 3.3.3 
and 4.3.2).  Briefly, a ~200 bp region of the open reading frame was PCR 
amplified to test for presence of the ORF of the targeted gene.  To check for 
integration of the blasticidin knockout construct a ~900 bp region was amplified 
using a forward primer lying upstream of the 5’ UTR region present in the 
knockout construct and a reverse primer specific to the BSD gene.  To check 
correct integration of the NEO knockout construct in subsequent analysis of 
putative knockout clones, a ~900 bp region was amplified using a forward primer 
lying upstream of the 5’ UTR region present in the knockout construct and a 
reverse primer specific to the NEO gene.  Gene-specific PCR details are listed in 
the legend of Figures 4-28, 4-29 and 4-30.  These resistance gene PCRs were 
designed to confirm the presence and correct integration location of the 
knockout cassette relative to the target gene.  Sequences of all primers can be 
found in Appendix 7.1. 
In addition to the above PCRs to check correct integration of the knockout 
construct, the “GFP PCR” and “HYG-TK PCR” (see Section 4.8.2) were performed 
to confirm the cell lines retained the 221GP1 and HYG-TK constructs, 
respectively.  Expression of eGFP and VSG221 was also assayed by 
immunofluorescence (as described above in Section 4.8.2).  These analyses 
showed all six putative GFP221hygTK recq2+/- clones to be correct (data not 
shown).  Four out of the six putative GFP221hygTK mus81+/- clones were correct, 
with PCR analyses indicating two clones did not contain the HYG-TK construct 
and one also lacked the 221GP1 construct (data not shown).  Three out of the six 
putative GFP221hygTK pif6+/- clones were correct; PCR analyses indicated that 
two clones lacked the HYG-TK construct and one clone did not contain the 
correctly integrated ΔPIF6::BSD cassette (data not shown).  One correct clone of 
each of GFP221hygTK recq2+/-, GFP221hygTK mus81+/- and GFP221hygTK pif6+/- 
was selected to use in subsequent experiments and for generation of knockout   
(-/-) clones. 
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To generate knockout mutants, GFP221hygTK recq2+/-, mus81+/- and pif6+/- cells 
were transformed with ΔRECQ2::NEO, ΔMUS81::NEO or ΔPIF6::NEO constructs, 
respectively.  Transformation of GFP221hygTK recq2+/- and antibiotic selection 
with 10 µg.mL-1 hygromycin, 5 µg.mL-1 blasticidin and 2.5  µg.mL-1 G418 resulted 
in one surviving putative GFP221hygTK recq2-/- clone.  Successful amplification 
of the “NEO”, “BSD”, “HYG-TK” and “GFP” PCR products in the putative 
GFP221hygTK recq2-/- clone (Fig. 4-29A) confirmed that the ΔRECQ2::NEO and 
ΔRECQ2::BSD cassettes were integrated correctly relative to RECQ2 and that the 
clone contained the HYG-TK and 221GP1 constructs.  Furthermore, the RECQ2 
ORF could no longer be PCR-amplified, indicating successful knockout of RECQ2.  
Additionally, western blot analysis (Fig. 4-28B) of VSG221 and eGFP expression 
confirmed that the GFP221hygTK recq2-/- clone still expressed VSG221 and eGFP. 
 
Figure 4-28 PCR and western blot analysis of GFP221hygTK recq2 mutants 
(A) Genomic DNA was extracted from GFP221hygTK recq2+/- and GFP221hygTK recq2-/- 
cells.  A 232 bp region of the ORF (primers #77 & #78) was PCR amplified (“RECQ2 ORF”) to 
test for presence of the RECQ2 ORF.  PCR amplification using primers #51 & #154 (1000 bp 
PCR product) that bind in the BSD resistance cassette and upstream of RECQ2 (“BSD”) was 
used to test for correct integration of the BSD knockout construct.  PCR amplification using 
primers #51 and #155 (1008 bp PCR product) that bind in the NEO resistance cassette and 
upstream of RECQ2 (“NEO”) was used to test for correct integration of the NEO knockout 
construct.  Presence of the 221GP1 construct was tested by PCR amplification using 
primers #120 and #120 (2.8 kbp PCR product, “221GP1”) and presence of the HYG-TK 
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construct was tested by PCR amplification using primers #131 and #133 (2.2 kbp PCR 
product, “HYG-TK”) constructs.  Primer sequences can be found in Appendix 7.1.  Size 
markers are shown (ladder, bp).  (B) Total protein extracts were separated by SDS-PAGE 
and western blotted.  Membranes were probed with rabbit anti-VSG221 antiserum (1:20,000 
dilution, (Glover et al., 2013a)) and rabbit anti-GFP antiserum (1:5000 dilution, abcam).  Both 
membranes were probed with goat HRP-conjugated anti-rabbit antiserum (Life 
Technologies).  Size markers (kDa) are shown.  Gaps indicate that lanes have been aligned 
in this figure after excision from multiple gels/membranes or from disparate parts of the 
same gel/membrane. 
Repeated transformations to generate putative GFP221hygTK mus81-/- clones 
were attempted, which upon PCR analysis were shown to retain the mus81 ORF.  
Multiple antibiotic drug concentrations in these transformations were used.  
Initial transformations used 10 µg.mL-1 hygromycin, 5 µg.mL-1 blasticidin and 
2.5  µg.mL-1 G418.  Puromycin was also used in subsequent transformations, at a 
concentration at 0.2 µg.mL-1, in addition to these antibiotics.  Again, antibiotic 
resistant clones were selected using higher concentrations of blasticidin and 
G418 than previous transformations: 10 µg.mL-1 hygromycin, 10 µg.mL-1 
blasticidin, 5 µg.mL-1 G418 and 0.2 µg.mL-1 puromycin.  The three 
transformations produced 21 putative GFP221hygTK mus81-/- clones, nine of 
which were analysed by PCR and all were correct. 
 
Figure 4-29 PCR and western blot analysis of GFP221hygTK mus81 mutants 
Genomic DNA was extracted from GFP221hygTK mus81+/- and GFP221hygTK mus81-/- cells.  
A 214 bp region of the ORF (primers #79 & #80) was PCR amplified (“MUS81 ORF”) to test 
for presence of the MUS81 ORF.  PCR amplification using primers #52 & #154 (966 bp PCR 
product) that bind in the BSD resistance cassette and upstream of MUS81 (“BSD”) was used 
to test for correct integration of the BSD knockout construct.  PCR amplification using 
primers #52 and #155 (974 bp PCR product) that bind in the NEO resistance cassette and 
upstream of MUS81 (“NEO”) was used to test for correct integration of the NEO knockout 
construct.  Presence of the 221GP1 construct was tested by PCR amplification using 
primers #120 and #120 (2.8 kbp PCR product, “221GP1”) and presence of the HYG-TK 
construct was tested by PCR amplification using primers #131 and #133 (2.2 kbp PCR 
product, “HYG-TK”) constructs.  Primer sequences can be found in Appendix 7.1.  Gaps 
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indicate that lanes have been aligned in this figure after excision from multiple gels or from 
disparate parts of the same gel; size markers are shown (ladder, bp). 
Multiple transformations of GFP221hygTK pif6+/- with ΔPIF6::NEO were 
attempted in order to successfully obtain a GFP221hygTK pif6-/- clone.  Initial 
transformation of GFP221hygTK pif6+/- with ΔPIF6::NEO used the following 
antibiotic drug concentrations: 5 µg.mL-1 hygromycin, 5 µg.mL-1 blasticidin and 
2.5 µg.mL-1 G418.  These concentrations were altered to 5 µg.mL-1 hygromycin, 
5 µg.mL-1 blasticidin, 2.5 µg.mL-1 G418 and 0.2 µg.mL-1 puromycin when a 
further transformation was attempted.  Putative GFP221hygTK pif6-/- clones 
obtained were shown by PCR analysis to retain the PIF6 ORF (data not shown).  
Upon increasing the selective antibiotic concentrations in the transformation to 
10 µg.mL-1 hygromycin, 5 µg.mL-1 blasticidin, 2.5 µg.mL-1 G418 and 0.2 µg.mL-1 
puromycin one putative GFP221hygTK pif6-/- clone was obtained.  As shown in 
Figure 4-30A, successful PCR amplification of the “NEO”, “BSD”, “HYG-TK” and 
“GFP” PCR products in the putative GFP221hygTK pif6-/- clone confirmed that 
the ΔPIF6::NEO and ΔPIF6::BSD cassettes were integrated correctly relative to 
PIF6 and that the clone contained the HYG-TK and 221GP1 constructs.  
Furthermore, the PIF6 ORF could no longer be PCR amplified, indicating 
successful knockout of PIF6.  Additionally, western blot analysis (Fig. 4-30B) of 
VSG221 and eGFP expression confirmed that the GFP221hygTK pif6-/- clone still 
expressed VSG221 and eGFP. 
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Figure 4-30 PCR and western blot analysis of GFP221hygTK pif6 mutants 
(A) Genomic DNA was extracted from GFP221hygTK, GFP221hygTK pif6+/- and 
GFP221hygTK pif6-/- cells.  A 245 bp region of the ORF (primers #81 & #82) was PCR 
amplified (“PIF6 ORF”) to test for presence of the RECQ2 ORF.  PCR amplification using 
primers #53 & #154 (890 bp PCR product) that bind in the BSD resistance cassette and 
upstream of RECQ2 (“BSD”) was used to test for correct integration of the BSD knockout 
construct.  PCR amplification using primers #53 and #155 (898 bp PCR product) that bind in 
the NEO resistance cassette and upstream of RECQ2 (“NEO”) was used to test for correct 
integration of the NEO knockout construct.  Presence of the 221GP1 construct was tested 
by PCR amplification using primers #120 and #120 (2.8 kbp PCR product, “221GP1”) and 
presence of the HYG-TK construct was tested by PCR amplification using primers #131 and 
#133 (2.2 kbp PCR product, “HYG-TK”) constructs.  Primer sequences can be found in 
Appendix 7.1.  Size markers are shown (ladder, bp).  (B) Total protein extracts were 
separated by SDS-PAGE and western blotted.  Membranes were probed with rabbit anti-
VSG221 antiserum (1:20,000 dilution, (Glover et al., 2013a)) and rabbit anti-GFP antiserum 
(1:5000 dilution, abcam).  Both membranes were probed with goat HRP-conjugated anti-
rabbit antiserum (Life Technologies).  Size markers (kDa) are shown.  Gaps indicate that 
lanes have been aligned in this figure after excision from multiple gels/membranes or from 
disparate parts of the same gel/membrane. 
4.7.4 VSG switching analysis 
To analyse VSG switching in recq2, mus81 and pif6 mutants, VSG switching 
assays were performed as described in Materials and Methods 2.2.4.  Cells were 
diluted to a density of 1 x 104 cells.mL-1, either in the presence or absence of 
puromycin (0.2 µg.mL-1) but otherwise free of antibiotics, and cultured for 
48 hours.  Absence of hygromycin selection allowed cells to switch VSG.  
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Puromycin selection was used in some cultures in order to eliminate switching 
events that result in the deletion of the VSG BES, a phenomenon frequently 
observed in in vitro switching experiments, and to select against in situ 
switching (Benmerzouga et al., 2013; Cross et al., 1998; Jehi et al., 2014b; Kim 
& Cross, 2010; Kim & Cross, 2011; Povelones et al., 2012; Rudenko et al., 1998).  
Following 48 hours of incubation, cultures were diluted to either 
5 x 103 cells.mL-1 or 2.5 x 103 cells.mL-1 and ganciclovir (Sigma) was added to a 
final concentration of 4 µg.mL-1.  The cell concentration used in each 
experiment is indicated in the appropriate sections below.  Cultures were then 
distributed across three 96 well plates, each well containing 200 µL of culture. 
After incubation for seven days, the number of surviving wells per plate was 
counted.  The VSG switching frequency was calculated as described in Materials 
and Methods, Section 2.2.4.2.  Briefly, the number of survivors (totaled from the 
three 96 well plates) was divided by the total number of cells plated to obtain 
the number of switching events per cell, as each surviving well is a proxy for one 
switching event.  The number of switching events per cell was then divided by 
the number of population doublings that had occurred in the 48 hour incubation 
period giving the number of switching events/cell/generation.  This was done to 
adjust the calculated VSG switching rate to account for the slower growth of 
some mutants in the GFP221hygTK background.  The number of population 
doublings was calculated for each culture in every experiment using the cell 
densities at the beginning and end of the 48 hour incubation period. 
A selection of surviving clones were then analysed to determine the different 
VSG switching mechanisms used, as described in Materials and Methods, Sections 
2.2.4.2 and 2.5.2.  VSG221 and eGFP expression were assayed by western 
blotting, using anti-VSG221 antiserum (gift, David Horn, (Glover et al., 2013a)) 
and an anti-GFP antiserum (abcam).  Ponceau staining of the nitrocellulose 
membrane was carried out to confirm that protein was present on the blot for 
clones that were VSG221- and eGFP-.  The presence or absence of the VSG221 
and eGFP genes was determined by PCR-amplification of a region of the ORF of 
each gene.  Primers #156 and #157 were used to amplify a 522 bp region of 
VSG221 and primers #160 and #161 were used to amplify a 361 bp region of 
eGFP.  A 453 bp region of the RNA polymerase I (RNA PolI) large subunit 
(Tb427.08.5090) was amplified by PCR, using primers #158 and #159, as a 
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positive control in all clones.  RNA PolI and VSG221 PCR primer sequences were 
those as used in Povelones et al. (2012).  The results obtained from the GFP PCR 
were inconclusive due to the poor efficiency of the PCR, and it was unclear 
whether clones contained the GFP gene using this PCR.  The GFP PCR data are 
therefore not discussed in the text, though the PCR gels are shown in Figure 4-32 
and Figure 4-35 and the results, based on the best estimation of the presence of 
amplification products in these gels, are included in the summaries in Tables    
4-2, 4-4 and 4-6. 
4.7.4.1 Analysis of VSG switching in recq2 mutants  
Two experiments were performed to investigate the effect of mutation of RECQ2 
on the rate of VSG switching and profile of switching events.  Experiments were 
performed as described above (see Section 4.8.4).  In the first experiment, cell 
lines were seeded in 96 well plates at a density of 5 x 103 cells.mL-1.  Table 4-1 
shows the number of survivors (wells with live cells) on each of the three 96 well 
plates for each cell line.  The total number of survivors from the three 96 well 
plates was then used to calculate the VSG switching rate for each cell line in the 
presence or absence of puromycin (Fig. 4-31A).  In the absence of puromycin, 
the switching rate of wild type cells was 1.03 x 10-5 events per cell per 
generation (events/cell/generation).  This switching rate is comparable with the 
switching rates for wild type cells found by other studies using a similar VSG 
switching assay strategy (Kim & Cross, 2010; Kim & Cross, 2011; Povelones et 
al., 2012), which were in the range 1.05 x 10-5 – 2.8 x 10-5.  However, the rate 
found in this experiment was considerably higher than the rate of ~5 x 10-6 found 
by Benmerzouga et al. (2013).  recq2+/- and recq2-/-  cells each had an elevated 
VSG switching rate of 2.35 x 10-5 and 2.93 x 10-5 events/cell/generation 
respectively.  The survival rate of each cell line (the percentage of wells 
containing live cells at the end of the incubation period) is shown in Table 4-1. 
In the presence of puromycin, the VSG switching rate would be expected to 
decrease compared to in the absence puromycin, since switching events 
involving the inactivation or loss of the VSG221 BES or in situ switching are 
suppressed.  This was the case for recq2+/- and recq2-/- mutants, the switching 
rates of which decreased by approximately three-fold and two-fold, 
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respectively.  However, the switching rate of wild type cells remained 
unchanged at 1.03 x 10-5 events/cell/generation. 
A small selection of surviving clones were analysed to determine the VSG 
switching profiles of wild type and recq2 mutant cell lines.  Three clones each 
from the +puromycin and –puromycin conditions for wild type and recq2+/- cells, 
and six each from the +puromycin and –puromycin conditions for recq2-/- cells 
were analysed.  Figure 4-31B shows the switching profile for wild type, recq2+/- 
and recq2-/- cells.  Figures 4-32 and 4-33 show the PCR and western blot analysis 
results for each clone analysed.  Table 4-2 is a summary of the analysis of all 
clones examined.  As observed in a previous study using this cell line (Povelones 
et al., 2012), and in other in vitro switching assays that relied upon immune 
selection in vivo (Bell & McCulloch, 2003; Hartley & McCulloch, 2008; McCulloch 
& Barry, 1999; Proudfoot & McCulloch, 2005), switching events involving deletion 
of the VSG BES (ES GC/in situ + ES del) predominated (two out of three clones 
analysed) in wild type cells in the absence of puromycin (Fig. 4-31B).  The third 
clone was determined to be a TK mutant and to have not switched VSG.  A high 
proportion of TK mutant survivors has been observed previously using this assay 
strategy (Povelones et al., 2012).  TK mutants were absent from the switching 
profile of analysed recq2+/- clones, where instead two out of three clones were 
in situ switchers, and the remainder VSG BES GC/in situ + ES deletion events.  
However, the switching profile of recq2-/- mutants was clearly different to that 
of wild type and recq2+/- cells.  Two thirds of analysed clones had undergone 
VSG GC and the remaining third had undergone telomere XO, neither of which 
was observed in wild type or recq2+/- mutants and both of which are 
recombination-mediated switching events. 
In the presence of puromycin, the switching profiles of wild type and recq2 
mutant cells were more similar to one another, and were altered relative to the 
profile seen in the absence of puromycin, despite the lack of detectable 
switching rate change in wild type cells (Fig. 4-31B).  In these conditions, VSG 
GC events accounted for two thirds of switching events, with TK mutants 
accounting for the remaining third.  Such a change is consistent with puromycin 
imposing a constraint on the assay by removing any processes in which PUR 
expression is lost.  In the recq2-/- mutants, much less change in switching was 
seen, with telomere XO and VSG GC events each comprising half of the reactions 
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analysed.  Thus, addition of puromycin altered the VSG switching profile of wild 
type and recq2+/- cells, but did not alter the switching profile of recq2-/- 
mutants, presumably because recq2-/- mutants preferentially underwent 
recombination-mediated switching events in the vicinity of VSG221, even in the 
absence of selection (by puromycin) for them. 
 
Table 4-1 Survival data from first RECQ2 VSG switching assay 
 
Figure 4-31 Switching rate and profile in first RECQ2 VSG switching assay. 
(A) The switching rate of GFP221hygTK wild type and GFP221hygTK recq2 mutants was 
calculated from the number of surviving clones as a proxy for VSG switching, following 
limiting dilution in the presence of ganciclovir and with (+) or without (-) puromycin.  (B) The 
switching profiles of survivors in both the presence and absence of puromycin, represented 
as a percentage of total clones analysed.  Switching events are as described in Figure 4-24.  
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VSG gene conversion (VSG GC), telomere crossover (telomere XO), VSG BES gene 
conversion / in situ switch + ES deletion (ES GC/in situ + ES del) 
 
Figure 4-32 PCR analysis of first RECQ2 VSG switching experiment 
Genomic DNA was extracted from a selection of surviving GFP221hygTK wild type and 
GFP221hygTK recq2 mutant clones.  A 453 bp region of the RNA polymerase I (RNA PolI) 
large subunit (Tb427.08.5090) was amplified by PCR using primers #158 and #159 as a 
positive control for the presence of genomic DNA.  Primers #156 and #157 were used to 
amplify a 522 bp region of VSG221 and primers #160 and #161 were used to amplify a 361 bp 
region of eGFP.  GFP221hygTK wild type genomic DNA (+) was used as a positive control in 
all PCRs.  Distilled water was used as a negative control (-).  –P, clones recovered from the 
assay conducted without puromycin selection; +P, clones recovered from the assay 
conducted with puromycin selection.  PCR primer sequences were those as used in 
(Povelones et al., 2012) and can be found in Appendix 7.1.  Size markers (bp, ladder) are 
shown.  Gaps indicate that lanes have been aligned in this figure after excision from 
multiple gels or from disparate parts of the same gel. 
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Figure 4-33  Western analysis of first RECQ2 VSG switching experiment 
(A) Western analysis of a selection of surviving GFP221hygTK wild type and GFP221hygTK 
recq2 mutant clones.  Total protein extracts were separated by SDS-PAGE and western 
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blotted. Membranes were probed with rabbit anti-VSG221 antiserum (1:20,000 dilution, 
(Glover et al., 2013a)) and rabbit anti-GFP antiserum (1:5000 dilution, abcam).  Both 
membranes were probed with goat HRP-conjugated anti-rabbit antiserum (Life 
Technologies).  (-). –P, clones recovered from the assay conducted without puromycin 
selection; +P, clones recovered from the assay conducted with puromycin selection.  
GFP221hygTK wild type cells were used as a positive control (+).  (B) Ponceau staining of 
the membranes shown in (A) after transfer.  Membranes were incubated in ponceau solution 
for 10 minutes, rinsed and imaged.  Size markers (kDa) are shown.  Gaps indicate that lanes 
have been aligned in this figure after excision from multiple gels/membranes or from 
disparate parts of the same gel/membrane. 
 
 
Table 4-2 Summary of the analysis of clones from first RECQ2 VSG switching 
experiment 
Summary of the data shown in Figures. 4-30 and 4-31.  PUR, puromycin (1 µg.mL-1); HYG, 
hygromycin (10 µg.mL-1).  Telomere XO, telomere crossover; VSG GC, VSG gene 
conversion.  Blue indicates a negative result, yellow indicates a positive result. 
The switching assay above was repeated as described, except that cells were 
diluted to a density of 2.5 x 103 cells.mL-1.  This was to attempt to ensure that 
recq2-/- survivors obtained were clonal, given the high number of positive wells 
in recq2-/- plates obtained from the higher cell density plating of                        
5 x 10-3 cells.mL-1 in the first experiment.  Table 4-3 shows the number of 
survivors (wells with live cells) for each cell line.  Additionally, as a control to 
ensure that the ganciclovir killed TK-positive cells, GFP221hygTK wild type, 
recq2+/- and recq2-/- cells that had been continuously cultured in the presence of 
hygromycin and puromycin were diluted and treated with ganciclovir in the same 
manner as switching assay cultures.  Following 10 days incubation there were no 
surviving wells (data not shown). 
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Table 4-3 Survival in a second RECQ2 VSG switching assay 
 
The VSG switching rate of wild type cells in the absence of puromycin was 
1.92 x 10-5 events/cell/generation (Fig. 4-34A), similar to the switching rate 
from the previous experiment (1.03 x 10-5).  The switching rate of recq2+/- and 
recq2-/- mutants was 1.02 x 10-5 events/cell/generation and 3.54 x 10-5 
events/cell/generation respectively.  Thus, only the switching rate of the +/- 
mutants differed substantially between the two experiments.  Whether this 
change simply reflects fluctuation, given the low absolute number of switching 
events, is unclear. 
In the presence of puromycin, the switching rate of wild type and recq2+/- cells 
was decreased approximately three-fold and two-fold, respectively (Fig. 4-34A).  
This is the expected result as, (1) puromycin suppresses in situ and VSG BES 
deletion switching events, and (2) the switching profiles of wild type and 
recq2+/- cells in the first experiment were dominated by these types of switching 
events.  However, this is different to the first experiment where the switching 
rate of wild type cells did not alter in the presence of puromycin.  Again, this 
may simply reflect fluctuation.  The switching rate of recq2-/- cells was 
essentially equivalent in the absence or presence of puromycin, increasing very 
slightly from 3.54 x 10-5 in the former conditions to 4.17x 10-5 
events/cell/generation in the latter (Fig. 4-34A).  This result is once again 
different to the first experiment, where the switching rate of recq2-/- mutants 
decreased two-fold in the presence of puromycin.  However, no change in the 
switching rate of recq2-/- cells in the presence of puromycin makes sense in the 
context of the switch profile of these cells in the first experiment, which 
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suggested a predominance of VSG-focussed recombination-based switches, 
rather than in situ or VSG BES deletion switches.  Irrespective, the rate of 
switching in the absence of puromycin was very comparable between the two 
experiments. 
A greater number of surviving clones were analysed to investigate the switching 
profiles than in the first experiment; 19 wild type, 19 recq2+/- and 30 recq2-/- 
clones were analysed, all from the non-puromycin condition.  No clones were 
analysed from the puromycin treated assays because the addition of puromycin 
did not alter the switching profile of recq2-/- mutants in the first experiment.  
The VSG switching profiles of all three cell lines is shown in Figure 4-34B.  In 
contrast to the first experiment, no TK mutants were recovered.  As in the first 
experiment, the VSG switching profile of wild type cells was predominated 
(57.9%) by switches involving deletion of the active VSG BES (ES GC/in situ + ES 
del) (Fig. 4-34B).  Analysis of a greater number of clones and the absence of TK 
mutants however, gives an expanded picture of the VSG switching profile.  
Approximately one third (31.6%) of wild type survivors had switched VSG by an in 
situ switch and the remaining 10.5% had switched VSG using VSG GC.  The VSG 
switching profile of recq2+/- mutants was very similar to wild type cells, with the 
majority of survivors (68.4%) undergoing VSG BES deletion events and similar 
proportions of survivors switching VSG by VSG GC (5.3%) and in situ (26.3%) 
switches.  Thus, the difference in switching profiles between these cells seen in 
the first experiment is most likely a consequence of the small number of clones 
examined. 
The VSG switching profile of recq2-/- cells was, as in the first experiment, 
markedly different to wild type and recq2+/- cells.  The switching profile was 
characterised by a dramatic increase in VSG switching events involving 
recombination, and a decrease in VSG BES deletion and in situ switching events.  
Approximately equal proportions of survivors underwent VSG GC (46.7%) and 
telomere XO (43.3%) events.  This proportion of VSG GC is a four-fold increase 
from the proportion in wild type cells and an almost nine-fold increase from the 
proportion in recq2+/- cells, whilst telomere crossovers were not observed at all 
in wild type or recq2+/- survivors.  The proportion of recq2-/- survivors that 
underwent in situ switching was 3.3% - nine-fold lower than that of wild type.  
Similarly, the proportion of recq2-/- survivors having undergone events involving 
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VSG BES deletion (ES GC/in situ + ES del) was 6.7%, an eight-fold reduction 
compared to wild type. 
 
Figure 4-34 Switching rate and profile of recq2 mutants in a second VSG switching 
experiment 
(A) The switching rate of GFP221hygTK wild type and GFP221hygTK recq2 mutants was 
calculated from the number of surviving clones, as a proxy for VSG switching, following 
treatment with ganciclovir after culture with or without puromycin.  (B) The switching 
profiles of survivors of the different cell lines in both the puromycin and the non-puromycin 
condition, represented as a percentage of total surviving clones analysed. 
The results of PCR analysis of each clone analysed in this experiment are shown 
in Figure 4-35 and the western analysis results are shown in Figure 4-36.  In 
addition, a summary of the data in Figs. 4-35 and 4-36, as well the growth of 
each clone in 10 µg.mL-1 hygromycin and 1 µg.mL-1 puromycin and VSG switching 
mechanism inferred from these analyses is shown in Table 4-4. 
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Figure 4-35  PCR analysis of second RECQ2 VSG switching experiment 
Genomic DNA was extracted from a selection of surviving GFP221hygTK wild type and 
GFP221hygTK recq2 mutant clones.  A 453 bp region of the RNA polymerase I (RNA PolI) 
large subunit (Tb427.08.5090) was amplified by PCR, using primers #158 and #159, as a 
positive control for the presence of genomic DNA.  Primers #156 and #157 were used to 
amplify a 522 bp region of VSG221 and primers #160 and #161 were used to amplify a 361 bp 
region of eGFP.  GFP221hygTK wild type genomic DNA (+) was used as a positive control in 
all PCRs.  Distilled water was used as a negative control (-).  –P, clones recovered from the 
assay conducted without puromycin selection; +P, clones recovered from the assay 
conducted with puromycin selection.  PCR primer sequences were those as used in 
(Povelones et al., 2012) and can be found in Appendix 7.1.  Size markers (bp, ladder) are 
shown.  Gaps indicate that lanes have been aligned in this figure after excision from 
multiple gels or from disparate parts of the same gel. 
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Figure 4-35 
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Figure 4-36 continued 
A) Western analysis of a selection of surviving GFP221hygTK wild type and GFP221hygTK 
recq2 mutant clones.  Total protein extracts were separated by SDS-PAGE and western 
blotted. Membranes were probed with rabbit anti-VSG221 antiserum (1:20,000 dilution, 
(Glover et al., 2013a)) and rabbit anti-GFP antiserum (1:5000 dilution, abcam).  Both 
membranes were probed with goat HRP-conjugated anti-rabbit antiserum (Life 
Technologies).  –P, clones recovered from the assay conducted without puromycin 
selection; +P, clones recovered from the assay conducted with puromycin selection.  
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GFP221hygTK wild type cells were used as a positive control (+).  (B) Ponceau staining of 
the membranes shown in (A) after transfer.  Membranes were incubated in ponceau 
solution for 10 minutes, washed and imaged.  Size markers (kDa) are shown.  Gaps 
indicate that lanes have been aligned in this figure after excision from multiple 
gels/membranes or from disparate parts of the same gel/membrane. 
C
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Table 4-4 Summary of analysis of clones from a second RECQ2 VSG switching 
experiment 
Summary of the data shown in Figs. 4-36 and 4-37, and growth in puromycin (1 µg.mL-1) and 
hygromycin (10 µg.mL-1).  PUR, puromycin (1 µg.mL-1); HYG, hygromycin (10 µg.mL-1).  
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Telomere XO, telomere crossover; VSG GC, VSG gene conversion.  Blue indicates a 
negative result, yellow indicates a positive result.  Completely white rows indicate clones 
that could not be analysed, either due to absence of genomic DNA in genomic DNA 
extractions or cell lysates in western blot analysis. 
The two repeats of this assay are broadly similar.  The VSG switching rates 
obtained for wild type cells, recq2+/- and recq2-/- in the absence of puromycin 
varied only a small amount between the two experiments.  In both experiments 
it was observed that some surviving clones grew more slowly than others.  This 
has been observed in other studies (Kim & Cross, 2010) but is currently not 
understood, though it has been suggested that slower growing clones may be 
switchers expressing ESAGs less advantageous for in vitro growth (Bitter et al., 
1998). 
Due to the overall similarity between the experiments, the two datasets were 
combined (Fig. 4-37), allowing variation to be taken into consideration.  Figure 
4-38A shows that the VSG switching rate of recq2-/- cells was higher than that of 
wild type by approximately two-fold and was approximately similarly higher than 
recq2+/- mutants.  The VSG switching rate of the recq2+/- cells showed greater 
variation between the two experiments and perhaps showed a trend towards a 
slight increase relative to wild type (which may be consistent with the minor 
growth impairment and MMS sensitivity phenotypes in these cells; Chapter 3), 
but this was not statistically significant.  In the presence of puromycin, the 
combined data show that the rate of VSG switching was decreased by 1.8- and 
2.7-fold in wild type and recq2+/- lines, respectively.  In contrast, the same 
pronounced reduction was not seen in the VSG switching rate of recq2-/- mutants 
in the presence of puromycin, though the variation in these data between the 
two experimental repeats makes it difficult to draw firm conclusions.  However, 
the high proportion of recombination-based switching events, which are not 
selected against in the puromycin-free switching profile of recq2-/- cells 
(discussed below), suggests that the second data set is accurate and that 
puromycin does not affect the VSG switching rate in recq2-/- cells. 
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Figure 4-37  Switching rate and switching profile of recq2 mutants from a combined 
dataset 
(A) The mean switching rate of GFP221hygTK wild type and GFP221hygTK recq2 mutants 
was calculated from the mean number of surviving from the two experiments, following 
treatment with ganciclovir after culture with or without puromycin.  Error bars represent 
standard error of the mean (SEM).  (B) The switching profiles of survivors of the different 
cell lines in the non-puromycin condition, represented as a percentage of total surviving 
clones analysed from the two datasets. 
The increase in VSG switching rate and VSG GC and crossover events in recq2-/- 
mutants is very similar to the phenotype described for topo3a and rmi1 mutants 
(Kim & Cross, 2010; Kim & Cross, 2011).  The increase in switching frequency 
observed in recq2-/- mutants (two to three-fold) was not as high as the elevated 
switching frequency reported in rmi1 and topo3α null mutants (four-fold and 10 
to 40-fold, respectively).  However, the proportion of VSG GC and telomere XO 
switchers in recq2-/- mutants (~50% and ~40% respectively) is similar to those of 
rm1i (70% and 25%, respectively) and topo3α (70% and 23%, respectively) 
mutants, as well as all of these mutants sharing an almost complete absence of 
events leading to VSG BES loss (Kim & Cross, 2010; Kim & Cross, 2011).  Although 
the switching rate of wild type cells in the Kim & Cross studies (2010; 2011) was 
broadly similar to the data presented here, the switching profile of wild type 
Chapter 4  231 
cells was somewhat different.  For example, in situ switchers were almost 
entirely absent (<2% of total switchers) in the Kim & Cross studies (Kim & Cross, 
2010; Kim & Cross, 2011), whereas they constituted ~27% of wild type switchers 
in this work.  Conversely, ~65% of wild type switchers recovered in Kim & Cross 
(2010) used VSG GC, as opposed to only ~10% here.  These differences may be a 
result of differences in the cell lines.  Although the strategies used are the 
same, the constructs used to generate the VSG switching lines were different.  
Small differences in the constructs, their expression levels and/or their 
integration into the active VSG BES may influence the VSG switching rate and 
switching profile.  Nonetheless, the similarity in the elevation of VSG-focused 
recombination in the switching profiles of recq2, topo3α and rmi1 null mutants 
is notable, given that has been suggested that a RECQ protein functions in a 
complex with RMI1 and TOPO3α, forming the T. brucei homologue of the RTR 
complex.  The RTR complex is composed of a RecQ helicase (BLM in mammals 
and SGS1 in S. cerevisiae, topoisomerase III α (Topo3α) and RMI1/2 (BLAP75/18 
in mammals) and resolves crossover intermediates such as HJs (Hickson & 
Mankouri, 2011; Singh et al., 2008).  Kim & Cross (2011) demonstrated that 
TbTOPO3α (Tb927.8.3810) and TbRMI1 (Tb927.3.1830) interact with one 
another, but did not reveal interaction with any helicase.  As RECQ1 is essential 
and may be involved in nuclear DNA replication (discussed in Chapter 5), the 
pronounced similarity of the phenotypes seen here suggest it is likely that RECQ2 
is the more probable candidate to interact in a putative T. brucei RTR complex.  
Confirmation of this hypothesis would require co-immunoprecipitation of RECQ2 
and RMI1/TOPO3α and analysis of the switching rate and phenotype of double 
mutants. 
4.7.4.2 Analysis of VSG switching in pif6 mutants 
VSG switching analysis of pif6 mutants was performed by the same approach as 
used in the second recq2 mutant VSG switching assay (see Section 4.7.4.1); cells 
were seeded in the presence of ganciclovir (4 µg.mL-1) at a density of 
2.5 x 103 cells.mL-1 and 20 wild type, 20 pif6+/- and 30 pif6-/- surviving clones 
were analysed. 
Table 4-5 shows the number of survivors on each of the three 96 well plates for 
wild type, pif6+/- and pif6-/- cell lines used to calculate the VSG switching rate 
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for each cell line (Fig. 4-38A).  The VSG switching rate of wild type cells was 
measured at 1.69 x 10-5 events/cell/generation, similar to the switching rate we 
found for wild type cells previously (1.03 x 10-5 – 1.92 x 10-5, see 
Section 4.8.4.1).  Deletion of one PIF6 allele did not alter the VSG switching 
frequency compared to wild type, which was measured at 1.55 x 10-5 
switches/cell/generation in pif6+/- cells.  However, deletion of the second PIF6 
allele in pif6-/- cells increased the VSG switching rate two-fold to 3.17 x 10-5 
switches/cell/generation, a similar elevation in VSG switching as was seen for 
recq2-/- mutants.  In the presence of puromycin, the switching rate decreased 
approximately four-fold in wild type cells (3.89 x 10-6) and approximately three-
fold in pif6+/- cells (4.63 x 10-6), as expected if VSG BES GC/deletion and in situ 
switching events predominate in these cells  and were suppressed (see below).  
By contrast, the switching rate of pif6-/- did not change (3.43 x 10-5) in the 
presence of puromycin. 
 
Table 4-5 Number of survivors and survival rate in PIF6 VSG switching assay 
 
Analysis of survivors was undertaken similarly to that of the second RECQ2 VSG 
switching experiment described above (Section 4.7.4.1), except that GFP PCR 
analysis was not performed due to difficulties with the PCR.  Clones were 
analysed by PCR for the presence of RNA PolI and VSG221 and by western blot 
analysis for GFP and VSG221 expression (Fig. 4-38B).  Twenty wild type, 20 
pif6+/- survivors and 30 pif6-/- survivors from the non-puromycin condition were 
analysed.  PCRs and western blots of these data are shown in Figures 4-39 and 
4—40 and a summary of the results for each clone is shown in Table 4-6. 
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In contrast to the previous VSG switching experiments described in Section 
4.7.4.1, no VSG switching events other than VSG BES loss and TK mutants were 
detected in wild type cells.  This may reflect inherent variability in the assay.  
One clone classified as a TK mutant was negative for VSG221 by PCR but this 
probably reflects a failure in the PCR reaction as the clone expressed VSG221 
and GFP by western blot analysis.  Loss of one PIF6 allele did not alter the VSG 
switching rate however, the profile of pif6+/- mutants was different to that of 
wild type cells.  Though the frequency of VSG BES loss events was high (50%), 
the remainder of VSG switching events detected were primarily telomere 
crossover and VSG GC (35% and 10% respectively), with a single in situ switching 
event detected (5%).  This switching profile greatly resembles that observed in 
wild type cells in the second RecQ2 VSG switching experiment in Section 4.7.4.1 
(Figure 4-34).  The VSG switching profile of pif6-/- cells was dominated by TK 
mutants (50%).  The majority of analysed clones that had switched VSG however 
had switched via a VSG BES loss event (30%), with the remainder of clones 
switching by VSG GC or telomere crossover (10% each). 
Analysis of these switching data for pif6 mutants is challenging for several 
reasons.  Though in this experiment the VSG switching profile of wild type and 
pif6+/- cells is quite different, and suggests an increase in recombination 
reactions near the active VSG, the profile of pif6+/- cells actually closely 
resembles that of wild type cells observed previously (Fig 4-34).  Secondly, the 
VSG switching profile of pif6-/- looks broadly similar to that of pif6+/- cells when 
the TK mutants are excluded.  The high frequency of TK mutants in pif6-/- 
survivors is also interesting.  These clones were classified as TK mutants because 
they retained the VSG221 gene and maintained expression of VSG221 and GFP.  
However, the high frequency of pif6-/- survivors here is reminiscent of the 
retention of VSG221 observed in HRES pif6-/- mutants (Section 4.5.3, Fig. 4-15).  
Presumably the only way this could occur is if DSB induction in HRES and the 
initiating lesion in VSG switching both get repaired by an end-joining mechanism 
(such as MMEJ) in pif6-/- cells, rather than by recombination.  However, given 
the relatively high percentage of TK mutants recovered in wild type cells in this 
experiment (20%), the 50% of TK mutants recovered in pif6-/- cells may simply 
reflect variability in TK mutant generation in this assay.  These data suggest 
therefore, that it would be advisable in future experiments to enrich for VSG221 
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non-expressers prior to plating cells.  This has previously been used successfully 
in VSG switching experiments done by magnetic activated cell sorting (MACS) 
(Boothroyd et al., 2009; Kim & Cross, 2010; Kim & Cross, 2011). 
 
Figure 4-38 Switching rate and switching profile of pif6 mutants 
(A) The switching rate of GFP221hygTK wild type and GFP221hygTK pif6 mutants was 
calculated from the mean number of surviving clones, following treatment with ganciclovir 
after culture with or without puromycin.  (B) The switching profiles of survivors of the 
different cell lines in the non-puromycin condition, represented as a percentage of total 
surviving clones analysed, determined using the PCRs and western blots described in the 
text.  +P, with puromycin (1 µg.mL-1); -P, without puromycin. 
 
The high frequency of TK mutant cells in the non-puromycin condition is also of 
interest with respect to the VSG switching rate.  The VSG switching rate of     
pif6-/- cells was elevated compared to wild type and remained elevated in the 
presence of puromycin (Fig. 4-38A).  Whilst in recq2-/- mutants this was 
explained by dramatic shift to recombination and crossover events near the 
active VSG, the likely explanation here is the high percentage of TK mutants.  
The VSG switching rate of pif6-/- cells is roughly two-fold higher than wild type 
and 50% of pif6-/- survivors were classified as TK mutants, proportional to the 
increase in switching rate.  These data suggest that the high percentage of TK 
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mutants generated in pif6-/- cells resulted in an apparent increase in the VSG 
switching rate.  Furthermore, the VSG switching rate of pif6-/- cells remained 
high in the presence of puromycin, suggesting there may have been a high 
percentage of TK mutants in these surviving clones.  It is known that these TK 
mutants were not present in the starting population (‘parental culture’) from 
which the + and – puromycin pif6-/- cultures were taken, because this parental 
culture was maintained in puromycin and hygromycin during the 48 hour 
switching period, was plated in in the same manner as the other cultures (with 
ganciclovir) and there were no surviving clones.  This might, therefore, suggest 
that pif6-/- cells have a higher propensity of TK mutant generation.  Repetition 
of the assay and analysis of both + and – puromycin clones would be necessary to 
test this hypothesis. 
 
Figure 4-39 PCR analysis of PIF6 VSG switching experiment 
Genomic DNA was extracted from a selection of surviving GFP221hygTK wild type and 
GFP221hygTK pif6 mutant clones.  A 453 bp region of the RNA polymerase I (RNA PolI) 
large subunit (Tb427.08.5090) was amplified by PCR, using primers #158 and #159, as a 
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positive control for the presence of genomic DNA.  Primers #156 and #157 were used to 
amplify a 522 bp region of VSG221.  GFP221hygTK wild type genomic DNA (+) was used as 
a positive control in all PCRs.  Distilled water was used as a negative control (-).  –P, clones 
recovered from the assay conducted without puromycin selection; +P, clones recovered 
from the assay conducted with puromycin selection.  PCR primer sequences were those as 
used in (Povelones et al., 2012) and can be found in Appendix 7.1.  Size markers (bp, ladder) 
are shown.  PCRs were performed by Craig Lapsley. 
 
Chapter 4  237 
Figure 4-40 Western analysis of PIF6 VSG switching experiment 
(A) Western analysis of a selection of surviving GFP221hygTK wild type and GFP221hygTK 
pif6 mutant clones.  Total protein extracts were separated by SDS-PAGE and western 
blotted. Membranes were probed with rabbit anti-VSG221 antiserum (1:20,000 dilution, 
(Glover et al., 2013a)) and rabbit anti-GFP antiserum (1:5000 dilution, abcam).  Both 
membranes were probed with goat HRP-conjugated anti-rabbit antiserum (Life 
Technologies).  –P, clones recovered from the assay conducted without puromycin 
selection; +P, clones recovered from the assay conducted with puromycin selection.  
GFP221hygTK wild type cells were used as a positive control (+).  (B) Ponceau staining of 
the membranes shown in (A) after transfer.  Membranes were incubated in ponceau solution 
for 10 minutes, washed and imaged.  Size markers (kDa) are shown.  Gaps and dashed lines 
indicate that lanes have been aligned in this figure after excision from multiple 
gels/membranes or from disparate parts of the same gel/membrane.  Western blots of wild 
type and pif6+/- clones were performed by Craig Lapsley. 
 
Figure 4-40 continued 
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Figure 4-40 continued 
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Figure 4-40 continued 
Chapter 4  240 
 
Table 4-6 Summary of the analysis of clones from PIF6 VSG switching experiment. 
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Summary of the data shown in Figs. 4-40 and 4-41.  Telomere XO, telomere crossover; VSG 
GC, VSG gene conversion.  Blue indicates a negative result, yellow indicates a positive 
result. 
4.8 Summary 
4.8.1 RECQ2 is involved in DSB repair and suppresses VSG 
switching 
The clonal survival data presented here for recq2-/- mutants following I-SceI 
induction and DSB formation at the 70 bp repeats (HRES) and at a chromosomal 
internal location (HR1) showed that loss of this putative helicase resulted in  
~50% lower survival than wild type, suggesting that RECQ2 is involved in DSB 
repair at both of these genomic locations.  Repeats of these experiments did not 
replicate these data but analyses suggest these later data are less robust and 
that DSBs were not efficiently induced in these experiments, possibly due to loss 
of the I-SceI target sequence during culture.  Further analysis of these cell lines 
to determine the presence or absence of the I-SceI recognition site would be 
necessary to confirm this.  Additionally, these later repeats compromised 
analysis of the effect of deletion of a single RECQ2 allele (recq2+/- cells). 
A role for RECQ2 in DSB repair is consistent with proposed DNA repair roles seen 
in the context of increased sensitivity of T. brucei recq2 mutants to phleomycin 
and MMS damage (see Section 3.4.3), both of which cause DSBs, the observed 
localisation of RECQ2 12myc to subnuclear foci after phleomycin treatment (see 
Section 3.9.1), and the role of other eukaryotic RecQ proteins in DSB repair.  
Efficient resection of DSB DNA ends has been demonstrated to require RECQ, in 
complex with DNA2 (Zhu et al., 2008).  For example, the mammalian RecQ 
protein BLM and S. cerevisiae SGS1 are required for normal DSB resection and 
mutants have increased sensitivity to DNA damaging agents and impaired HR-
mediated repair (Gravel et al., 2008; Langland et al., 2002; Zhu et al., 2008).  
RecQ proteins have been demonstrated to act at more than one point in HR; BLM 
plays an early role in DSB repair through DNA end resection and a later role in 
resolving recombination intermediates arising from HR-mediated repair (Mimitou 
& Symington, 2008).  Sgs1 unwinds DNA at yeast DSBs, acting with the nuclease 
Dna2 and the ssDNA binding protein RPA, to resect DNA (Cejka et al., 2010).  
Additionally, human RECQL4 mutants are less efficient in DSB repair in 
fibroblasts (Singh et al., 2010). 
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Analysis of the VSG switching phenotype of recq2 mutants demonstrated a two 
to three-fold increase in the VSG switching rate of recq2-/- mutants relative to 
wild type and recq2+/- cells, which was accounted for by a striking shift in the 
VSG switching profile of recq2-/- cells from ~60% VSG BES loss/GC events to ~90% 
VSG GC and telomere crossover switches.  It seems likely that RECQ2 acts to 
suppress VSG switching by limiting crossover events, some of which may be 
associated with GC, in the active VSG BES, as has been proposed for TOPO3a and 
RMI1.  Though topo3α and rmi1 mutants have been reported to exhibit a greater 
elevation in VSG switching rate (10-40-fold and four-fold, respectively) than we 
see here for recq2-/-, the shift to a switching profile dominated by VSG GC and 
telomere crossover events (Kim & Cross, 2010; Kim & Cross, 2011) is strikingly 
similar. 
Other RecQ proteins have been demonstrated to be important in suppressing 
hyper-recombination, including BLM and WRN (Prince et al., 2001; Yamagata et 
al., 1998).  Suppression of mitotic hyper-recombination and resolution of 
recombination intermediates (double HJs, dHJ) to produce non-crossover 
products are functions also performed by the RTR complex in multiple eukaryotic 
organisms (Hartung et al., 2008; Ira et al., 2003; Raynard et al., 2006; Wu & 
Hickson, 2003).  Hyper-recombination is a phenotype of mutants of all three 
components of the RTR complex; human blm cells, S. cerevisiae sgs1, top3 and 
rmi1 mutants and S. pombe rqh1 mutants all display hyper-recombination 
(Mullen et al., 2005; Myung et al., 2001; Stewart et al., 1997; Traverso et al., 
2003; Ui et al., 2001; Wallis et al., 1989).  Additionally, and as already 
discussed, T. brucei rmi1 and topo3 mutants also have elevated levels of 
recombination and crossover (Kim & Cross, 2010; Kim & Cross, 2011).  The 
multiple functions RecQ proteins play in HR, dHJ resolution, Rad51 filament 
inhibition and D-loop formation, as well as DSB processing, are distinct 
(Bernstein et al., 2010). 
Taken together, the available data suggest that RECQ2 may function with RMI1 
and TOPO3α as the RTR complex to suppress events in the vicinity of the VSG in 
the active expression site, limiting crossover events as well as gene conversions, 
and hence suppressing overall VSG switching rate.  RMI1 and TOPO3α have been 
demonstrated to interact with one another (Kim & Cross, 2011) and co-
immunoprecipitation of RECQ2 and RMI1/Topo3α and analysis of the VSG 
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switching phenotype of double mutants would enable this hypothesis to be 
tested. 
The phenotypes observed above - impairment of recq2 mutants in DSB repair at 
the 70 bp repeats of the active VSG BES, and their elevated VSG switching rate 
and altered profile – provide further insight into VSG switching.  The data 
collected in this work are not consistent with the hypothesis that DSBs at the 
70 bp repeats directly initiate VSG switching.  As recq2-/- mutants are deficient 
in repair of DSBs at the 70 bp repeats of the active VSG BES (as well as in the 
interior of chromosome 11), it would be expected that the mutants would have a 
lower rate of VSG switching due to an inability to repair DSBs that form in this 
location (and whose repair would lead to VSG switching).  Instead, the switching 
rate of recq2-/- mutants was two to three-fold higher than wild type, not lower.  
These genetic data suggest that the initiation of VSG switching cannot be 
accounted for by the direct formation of a DSB at the 70 bp repeats.  Thus, 
although VSG switching is increasingly being modeled by I-SceI-directed DSB 
formation (Boothroyd et al., 2009; Glover et al., 2013a; Glover & Horn, 2014), 
this experimental model may be flawed.  Though it is clear that induction of a 
DSB can elicit VSG switching, the analysis of RECQ2 function suggests this does 
not accurately mimic the natural route of switch initiation. Direct DSB formation 
in the active VSG BES may drive a distinct route of recombination than that 
normally used in VSG switching.  Alternatively, it is possible that the formation 
of a DSB in the active VSG BES merely imposes selection for switchers through 
killing of cells that have not removed the I-SceI target sequence, since it is clear 
that the survival rate after DSB formation in this location is very low (such as 
compared with HR1).  If so, this may suggest that DSBs are poorly recognised by 
the HR machinery in the VSG BES, perhaps explaining why no detectable RAD51 
foci form in HRES cells (David Horn, personal communication) after I-SceI 
induction, but do so in HR1 (Glover et al., 2008).  Alternatively, homology 
searching, e.g. by RAD51, may be inefficient for breaks in the VSG BES.  
Breaks, which are believed to be DSBs, have been detected in the active VSG 
BES (Boothroyd et al., 2009; Glover et al., 2013a).  How these breaks arise and 
whether they are associated with VSG switching is not fully understood.  One 
possibility for the source of these breaks is direct DSB formation via a site-
specific endonuclease.  For example, S. cerevisiae mating type switching uses 
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the HO endonuclease for formation of DSBs to initiate switching, reviewed in 
(Haber, 1998).  However, cleavage by an endonuclease seems incompatible with 
the I-SceI data and furthermore, no such endonuclease has been identified and 
would have to be regulated such that it did not cleave the many other stretches 
of 70 bp repeats in locations other than active VSG BESs. 
Replication stalling within the active VSG BES has also been proposed as the 
cause of breaks found in the active VSG BES (Kim & Cross, 2010; Kim & Cross, 
2011).  To date though, there is no evidence for replication in the active VSG 
BES, including the direction of replication or occurrence of replication stalling.  
RNAi knockdown of the replication factor ORC1/CDC6 (origin recognition 
complex 1/cell division cycle 6) causes an increase in VSG switching but this is 
primarily through VSG BES instability and in situ switches rather than 
recombination (Benmerzouga et al., 2013).  Inhibition of replication in T. brucei 
by treatment with HU causes an increase in the VSG switching rate (Sheader et 
al., 2004).  The possible involvement of replication stalling in the formation of 
breaks in the active VSG BES and VSG switching remains to be directly explored.  
To this end, single molecule analysis of replicated DNA (SMARD) would be a 
useful tool in attempting to determine of the direction of replication through 
the active VSG BES and whether replication regularly stalls in the region. 
Several other hypotheses for the causes of DNA breaks in the active VSG BES 
have been proposed.  Transcription-associated instability initiates 
immunoglobulin class switch recombination, whereby transcription directs the 
formation of breaks to initiate NHEJ, and ultimately affect class switching, 
reviewed by Stavnezer et al. (2008).  The formation of unusual DNA structures 
has also been demonstrated to cause DNA breaks.  The formation of a DNA/RNA 
hybrid at the Neisseria gonorrhoeae PilE (pilin expression) locus is necessary for 
the formation of a G4 DNA structure required for homologous recombination, 
leading to pilin antigenic variation (Cahoon & Seifert, 2013).  Finally, pausing of 
the replication fork at the S. pombe mat1 locus results in the formation of a DNA 
break and mating type switching by HR (Dalgaard & Klar, 2000; Kaykov et al., 
2004). 
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4.8.2  mus81 mutants are deficient in DSB repair 
The data presented here show that mus81-/- mutants are deficient in DSB repair 
both when such breaks are generated adjacent to the 70 bp repeats in the active 
VSG BES and at a chromosome internal location.  As for RECQ2, this observation 
is consistent with the finding that mus81-/- mutants are hypersensitive to MMS, 
which causes replication stalling and DSBs, and phleomycin, which causes DNA 
SSBs and DSBs (see Section 3.4.3).  Similar to TbMUS81, mitotic mus81 mutants 
in S. cerevisiae and S. pombe are sensitive to MMS, though they are also 
sensitive to HU, to which TbMUS81 does not appear sensitive (Bastin-Shanower 
et al., 2003; Chang et al., 2002; Doe et al., 2004; Interthal & Heyer, 2000).  
Mus81 is not however required for DSB repair in vegetative yeast cells, as mus81 
mutants are not sensitive to bleomycin and ionizing radiation, both of which 
cause DSBs (Boddy et al., 2000; Interthal & Heyer, 2000). 
Mus81 acts as a heterodimer with Mms4 (methyl methanesulfonate sensitivity 4) 
in S. cerevisiae and Eme1 (essential meiotic structure-specific endonuclease 1) 
in S. pombe (Boddy et al., 2001; Kaliraman et al., 2001).  The human partner 
protein for MUS81 is known as both Eme1 and Mms4 (Ciccia et al., 2003; Ogrunc 
& Sancar, 2003).  For simplicity, these MUS81-partner protein heterodimers are 
here referred to as MUS81*, specifying the relevant organism(s). 
MUS81* plays a role in the completion of HR as a heterodimer with Eme1 
(essential meiotic structure-specific endonuclease 1) in S. pombe and mammals, 
known as Mms4 in S. cerevisiae, to resolve recombination intermediates arising 
during replication (Boddy et al., 2001; Interthal & Heyer, 2000; Kikuchi et al., 
2013) and is important in replication fork restart (Hanada et al., 2007; Pepe & 
West).  Mus81* plays an essential role in meiosis in S. pombe and S. cerevisiae, 
resolving meiotic recombination intermediates to produce crossover products; 
mus81 mutants display a lower rate of meiotic crossover (Boddy et al., 2001; 
Kaliraman et al., 2001; Osman et al., 2003).  There is evidence that MUS81* acts 
on HJs and 3’ flaps (Gaillard et al., 2003) but MUS81/MMS4 shows a much 
greater activity with 3’ flaps and replication structures than with HJs (Doe et 
al., 2002; Kaliraman et al., 2001; Pepe & West, 2014b) and the question of 
whether MUS81/MMS4 resolves intact HJs in S. cerevisiae has been a matter of 
debate, reviewed in Hollingsworth & Brill (2004). 
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The complicated picture of Mus81* function in other eukaryotes makes it 
challenging to compare with the data on TbMus81 in this chapter.  TbMus81 may 
be acting to resolve recombination intermediates arising from processes such as 
repair of DNA damage and replication fork restart.  Failure to resolve these 
recombination intermediates in mus81-/- mutants may then cause the 
hypersensitivity to DSBs and DNA damaging agents.  mus81 mutants are 
synthetically lethal with an sgs1 mutant in yeast, (Boddy et al., 2000; Mullen et 
al., 2001), suggesting that Mus81* acts upon recombination intermediates 
generated by Sgs1 (Bastin-Shanower et al., 2003).  Analysis of whether a recq2-/-
/mus81-/- double mutant is also lethal in T. brucei would be useful in 
determining whether TbMus81 performs a similar function in T. brucei.  Given 
the strong phenotypes seen for mus81 mutants in general repair, in DSB directed 
repair and in the localisation of the myc tagged protein to foci after damage, it 
will be interesting to see if and how it might contribute to VSG switching.  This 
experiment was not performed in this thesis but the cell lines to conduct this 
experiment were generated (Section 4.7.3). 
4.8.3 PIF6: a complicated factor in T. brucei nuclear DNA repair 
Similar to the data for RECQ2, the I-SceI survival data for PIF6 mutants gave 
inconsistent results upon repetition, though it has been argued that later repeats 
of the assay were less robust as it was unclear whether DSBs had been efficiently 
induced.  It is possible that as with RECQ2, there was progressive loss of the      
I-SceI recognition sequence during culture.  If we accept the data from the 
initial, and arguably most robust experiment, this suggest that whilst pif6-/- 
mutants are hypersensitive to DSBs at a chromosomal-internal location (HR1 cell 
line), they exhibit enhanced survival after DSB formation at the 70 bp repeats of 
the active VSG BES (HRES cell line), a response that is unexpectedly associated 
with retention of VSG221.  If we rely on the later repeats of the clonal survival 
assays of pif6 mutants following DSB induction in HRES, then loss of PIF6 does 
not cause an increase in pif6-/- survival compared to wild type.  Nonetheless, 
pif6-/- survival was at least equivalent to wild type, indicating no impairment in 
DSB repair in the active VSG BES in pif6-/- mutants, a markedly different 
response to the strongly impaired survival after DSB formation at a chromosome-
internal location. 
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The dramatically different response of pif6-/- mutants to DSB induction in these 
locations could be a result of how absence of PIF6 influences repair.  
S. cerevisiae PIF1 suppresses telomere addition to DSBs and in its absence, DSBs 
are repaired by telomere addition and natural telomeres lengthen (Li et al., 
2014; Makovets & Blackburn, 2009; Schulz & Zakian, 1994).  This repair 
mechanism would be advantageous to breaks in the vicinity of the 70 bp repeats 
of the active VSG BES due to fact that breaks here are telomere-proximal.  Thus, 
only the VSG downstream of the DSB is lost – an effect that can be offset by VSG 
switching.  In contrast, repair of a DSB located in the interior of chromosome 11 
by addition of telomere repeats would create haploidy for many genes, which 
may be problematic.  It would be interesting to investigate whether such 
processes occur in pif6-/-mutants, such as by measuring telomere length.  This 
possibility does not fully explain the data, however, since retention of VSG221 
was seen in survivors following DSB formation in HRES, an outcome that is 
incompatible with addition of a telomere at the break site.  The expression and 
genomic location of VSG221 in these survivors is not known, however, which 
would be useful information in future experiments in order to determine how 
the DSB was repaired.  Continued expression of and location of VSG221 in the 
same active VSG BES in the DSB survivors could, for example, suggest that MMEJ 
had been utilised to repair the break, limiting sequence loss to the region 
around the I-SceI site (including PUR).  In contrast, VSG221 location in another 
expression site, and absence of expression, would indicate telomere crossover 
had been utilised.  The altered survival of pif6-/- mutants after DSB formation in 
the nuclear genome is consistent with the phleomycin-induced localisation of 
PIF6 12myc, suggesting that the helicase acts in the nucleus.  The putative 
increased survival of pif6-/- mutants in response to HRES breaks is also 
compatible with the observed improved survival of the same mutants in the 
presence of MMS.  But what feature of the damage inflicted by MMS compared 
with a DSB in the VSG BES, and why no such altered repair phenotype is seen 
with phleomycin or HU damage, is unclear. 
Following DSB induction, HR1 and HRES pif6-/- mutants undergo a G2/M cell cycle 
arrest, similar to wild type cells and as observed previously (Glover et al., 
2013a; Glover et al., 2008).  However, data presented here suggest some 
HRES pif6-/- cells may be in cell cycle arrest prior to I-SceI induction, possibly 
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due to leaky I-SceI expression.  Furthermore, nuclear γH2A accumulation, a 
marker of DNA damage (Canman, 2003; Glover & Horn, 2012; Polo & Jackson, 
2011), appears to disappear more rapidly in HRES pif6-/- mutants than HRES wild 
type cells, suggesting that pif6-/- may repair the DSB more efficiently or 
alternatively, ignore the DNA damage and prematurely re-enter the cell cycle.  
The latter suggestion is supported by a slight increase in aberrant cells observed 
in HRES pif6-/- mutants at 24 hours post DSB induction, compared to virtually 
none in wild type.  γH2A expression and cell cycle analysis suggest that DSBs in a 
chromosome internal location (HR1) are repaired more efficiently; γH2A 
expression decreased and cell cycle profiles returned to normal in wild type cells 
and pif6 mutants at 24 hours.  Again, these differences in HR1 and HRES suggest 
different roles of PIF6 in different genomic environments, but reconciling all the 
data is problematic. 
The discussion above presents a complex picture of the role of PIF6 in T. brucei 
DSB repair, though it is clear that the helicase does provide a nuclear repair-
associated function.  The complexity of phenotypes is further added to by 
examining the effect of loss of PIF6 on VSG switching.  The data generated in 
analysis of the VSG switching phenotype of pif6 mutants was challenging to 
interpret due to the high rate of TK mutants generated and unusual switching 
profile of wild type cells compared to previous experiments.  The switching rate 
of pif6-/- cells was higher than wild type but data suggested that this might be 
accounted for by the high rate of TK mutants generated in this experiment.  To 
understand the role, if any, PIF6 has in VSG switching, it will be necessary to 
repeat this experiment, enriching for VSG221 non-expressers in order to exclude 
TK mutants from downstream analysis.  The possibility that absence of PIF6 
results in a higher rate of TK mutant generation could also be explored by 
analysis of survivors from both the + and – puromycin conditions.  In summary, 
further work will be needed to try and understand how this enigmatic protein 
acts in T. brucei and to understand how the various repair and VSG switching 
phenotypes describe in pif6 mutants (above) can be explained. 
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5 Analysis of the role of T. brucei RECQ1 in DNA 
repair 
5.1 Introduction 
As discussed in Chapter 3, T. brucei encodes two RecQ like helicases, RECQ2 
(Tb427.08.6690) and TbRECQ1 (Tb427.06.3580).  The functions of the former in 
DNA repair and VSG switching were discussed in Chapters 3 and 4, which showed 
that TbRECQ2 is involved in both processes.  TbRECQ2 plays a role in survival 
following induction of DSBs and following phleomycin or MMS treatment, as well 
as suppressing VSG switching by reducing crossover and VSG gene conversion 
events.  In this chapter, the role of TbRECQ1 in DNA repair in T. brucei is 
investigated. 
Mutations in the RecQ proteins WRN, BLM and RECQ4 are all associated with 
different disease syndromes in humans (reviewed in Croteau et al. (2014)), 
indicating specialisation of function among RecQ proteins in multicellular 
organisms containing more than one RecQ helicase.  As TbRECQ1 and TbRECQ2 
have so far not been characterised, it was unknown before starting this work 
whether they have overlapping or distinct functions.  We therefore aimed to 
ascertain whether, like TbRECQ2, TbRECQ1 has a DNA repair function. 
5.2 Sequence analysis of TbRECQ1 
As described in Chapter 3 (Section 3.2) TbRECQ1 (Tb427.06.3580) was identified 
and selected for analysis through BLAST searches using the protein sequences of 
eukaryotic RecQ-like proteins, searching against the T. brucei Lister 427 
proteome on tritrypdb.org (Version 8.1).  To begin to test the putative function 
and orthology of TbRECQ1, the predicted protein sequence was used for BLAST 
analysis. 
5.2.1 Identification of TbRECQ1 
BLAST analysis, using NCBI standard P-BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi; NCBI nr September 2014), was 
undertaken using the TbRECQ1 predicted amino acid sequence as the query 
sequence.  The hits with the highest scores and lowest E values were all RecQ 
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helicases (Table 5-1).  The top 16 hits were all Trypanosoma spp and Leishmania 
spp predicted RecQ-like proteins with expectancy values of 0.  A number of 
bacterial RecQ-like proteins were retrieved as significant alignments with 
TbRECQ1, with E values in the range of 10-167 – 10-44.  In contrast to RECQ2, for 
which significant alignments with mammalian RecQ homologues were retrieved 
(Section 3.2.1), RECQ1 produced no strong alignments with mammalian RecQ 
proteins; significant alignments were almost exclusively bacterial (Table 5-1).  
BLAST searches were also performed (data not shown) using RecQ protein 
sequences from H. sapiens, A. thaliana, C. elegans and S. cerevisiae as the 
query sequences and using only T. brucei Lister 427 as the target organism 
(http://tritryp.org).  TbRECQ1 (Tb427.06.3580) and TbRECQ2 (Tb427.08.6690) 
were consistently the only protein sequences retrieved with significant 
alignments.  Additionally, several of the significant non-kinetoplastid TbRECQ1 
BLAST results were used as query sequences in BLAST searches against T. brucei 
Lister 427 (http://tritrypdb.org).  These non-kinetoplastid sequences were 
RecQ-like helicase sequences from Haemophilus sputorum, Anditalea andensis 
and Vibrio brasiliensis (protein sequences WP_007523284.1, WP_035071022.1 
and WP_006878004.1 respectively – http://www.ncbi.nlm.nih.gov/protein), and 
all returned TbRECQ1 and TbRECQ2 as the highest scoring sequences.  In each of 
these searches, TbRECQ2 returned a stronger alignment than TbRECQ1. 
Protein domain analysis searching InterproScan sequence search 
(http://www.ebi.ac.uk/interpro/search/sequence-search) (Hunter et al., 2012) 
was used to predict the domains present in TbRECQ1.  TbRECQ1 is predicted to 
contain a DEAD/DEAH box helicase domain (approximately aa159-358) involved 
in nucleic acid and ATP binding, and a C-terminal helicase (RQC) domain 
(approximately aa407-602) found in helicases of multiple families (Linder, 2006) 
(Fig. 5-1).  RQC domains are involved in protein-protein interactions (Bernstein 
et al., 2010).  Not predicted is an HRDC (helicase and RNaseD C-terminal) 
domain, found only in RecQ helicases, as well as RNaseD homologues.  HRDC 
domains are thought to be involved in DNA binding (Bernstein et al., 2010; 
Morozov et al., 1997).  Though HRDC domains are not present in all RecQ 
proteins (Bachrati & Hickson, 2003), the absence an HRDC domain in TbRECQ1 
and its presence in TbRECQ2 suggests that TbRECQ1 may be more diverged from 
eukaryotic RecQ helicases than TbRECQ2. 
Chapter 5  252 
 
Figure 5-1 Representation of TbRECQ1 protein sequence 
The predicted polypeptide sequence of TbRECQ1 (Tb427.06.3580) and comparison with that 
of TbRECQ2, E. coli RecQ and S. cerevisiae Sgs1.  TbRECQ1 domains were predicted using 
InterproScan 5.  Amino acid sequence length is shown on the right.  Not to scale 
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5.2.2 Phylogenetic analysis 
A multiple sequence alignment of the complete predicted sequences of TbRECQ1 
and TbRECQ2 with other eukaryotic RecQ proteins in Chapter 3 (Section 3.2.1) 
showed that TbRECQ2 is more similar to eukaryotic RecQ proteins than 
TbRECQ1.  For this reason, and the finding above that most of the TbRECQ1 
BLAST results were bacterial RecQ helicases, TbRECQ1 was aligned with 
bacterial RecQ helicases in addition to eukaryotic RecQ helicases and a 
phylogenetic tree was constructed from this alignment using CLC Genomics 
Workbench 6. 
This tree (Fig. 5-2) shows that despite the dominance of bacterial RecQ-like 
proteins retrieved in BLAST analysis, TbRECQ1 aligns more closely to eukaryotic 
RecQ-like proteins.  The retrieval of predominantly bacterial RecQ-like proteins 
in BLAST analysis is therefore most likely due to (1) TbRECQ1 being more 
diverged from eukaryotic RecQ-like proteins, hence aligning to RecQ helicases 
from a wider range of organisms and (2) the large number of bacterial genomes 
present in the NCBI protein database. 
TbRECQ1 groups with other RecQ-like proteins, demonstrating together with the 
BLAST analysis that TbRECQ1 is a RecQ-like protein.  However, TbRECQ1 clusters 
separately from most eukaryotic RecQ-like proteins, whereas TbRECQ2 groups 
more closely with eukaryotic RecQ-like proteins.  This indicates that TbRECQ1 is 
more diverged from most eukaryotic RecQ-like helicases than TbRECQ2.  
TbRECQ1 also groups very closely with one of the two putative RecQ-like 
proteins from each of T. cruzi and L. major, while the second putative RecQ-like 
helicase from each of these three kinetoplastids groups with the eukaryotic 
helicases (yeast SGS1 and mammalian BLM homologues) (Fig. 5-2).  This again 
suggests that TbRECQ1 may be more diverged from most eukaryotic RecQ-like 
proteins, perhaps due to evolving to perform a specialised, kinetoplastid-specific 
function.  If so, such a specialised function might be shared by the L. major and 
T. cruzi putative RecQ-like proteins that group with TbRECQ1. 
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Figure 5-2 Neighbour-joining tree of TbRECQ1 and other RecQ-like helicases 
A tree was constructed from the alignment of TbRECQ1, eukaryotic and bacterial RecQ-like 
helicase protein sequences using CLC Genomics Workbench 6.  At, A. thaliana; Dd, 
Dictyostelium discoideum; Mm, Mus musculus; Ce, C. elegans; Sc, S. cerevisiae; Dm, 
D. melanogaster; Tc, T. cruzi; Tb, T. brucei; Lm, L. major; Tt, Tetrahymena thermophilus; Hs, 
H. sapiens; Gi, Giardia intestinalis; Pf, P. falciparum.  The two putative RecQ-like helicases 
in T. cruzi and L. major are indicated by (1) and (2) in the sequence name, assigned 
arbitrarily, while the T. brucei RecQ-like proteins follow the nomenclature used in this thesis 
(TbRECQ1 and TbRECQ2).  See Appendix 7.2 for gene accession numbers for sequences 
used. 
5.3 Generation of a RECQ1 RNAi cell line 
5.3.1 Attempts at generating a RECQ1 knockout cell line 
To investigate the function of TbRECQ1 and specifically whether it is involved in 
DNA repair, it was aimed to generate RECQ1 heterozygous (+/-) and homozygous 
(-/-) mutants.  The knockout constructs used in the attempt to generate recq1+/- 
and recq1-/- mutants used the same plasmid backbone and strategy as that used 
to generate recq2, mus81 and pif6 mutants (see Section 3.3).  A 580 bp region of 
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the 5’ end of the RECQ1 ORF and 544 bp region of the 3’ end of the RECQ1 ORF 
and the 3’ UTR, depicted in Figure 5-3A, were amplified by PCR and cloned into 
the knockout construct, flanking a blasticidin (BSD) or neomycin (NEO) resistance 
cassette.  PCR-specific details are listed in Figure 5-3.  A generalised schematic 
of the knockout plasmids used is shown in Figure 5-3B.  Knockout constructs 
were linearised using NotI and integration into the genome and replacement of 
the targeted gene was facilitated by the 5’ and 3’ targeting regions of the 
linearised knockout plasmid (Fig. 5-3C). 
 
Figure 5-3 Schematic of RECQ1 knockout constructs and knockout strategy 
(A) A 580 bp region (blue) of the 5’ end of the RECQ1 ORF (orange) and 544 bp region (blue) 
of the 3’ end of the RECQ1 ORF and the RECQ1 3’ UTR was amplified by PCR.  These were 
the targeting regions in the knockout constructs to knockout RECQ1.   PCR primer 
sequences: RECQ1 5’ targeting region primers #26 & #27, RECQ1 3’ targeting region 
primers #28 & #29.  Primer sequences can be found in Appendix 7.1.  (B) Schematic of the 
knockout constructs.  3’ and 5’ targeting regions of RECQ1 (blue) flank the resistance 
cassette containing a neomycin (NEO) or blasticidin (BSD) resistance gene (pink).  NotI (as 
indicated) was used to linearise the constructs and restriction enzyme sites are indicated.  
Sizes shown (bp), length of the 5’ and 3’ targeting fragments were specific to the gene 
targeted.  (C) Knockout strategy used to generate heterozygous (+/-) and knockout (-/-) 
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mutants.  Generalised representation of the linearised knockout BSD and NEO resistance 
constructs (bottom) relative to the targeted gene (ORF, orange) and its flanking regions 
(black line).  The 5’ and 3’ targeting regions in the constructs correspond to the 5’-most or 
3’-most regions of the RECQ1 ORF and its flanking regions.  β/α tub, β/a tubulin; actin IR, 
actin intergenic region; BSD, blasticidin resistance; NEO, G418 resistance.  Not to scale. 
The same PCRs as used in Chapters 3 and 4 (see Sections 3.3.3 and 4.3.2) were 
used to test for successful integration of these constructs in transformed clones.  
Briefly, three PCRs were used.  The first, “RECQ1 ORF”, amplified a 
226 bp region of the RECQ1 ORF to test absence of the RECQ1 ORF in putative 
recq1-/- clones (primers #75 and #76).  The second PCR amplified a region using a 
forward primer lying upstream of the 5’ targeting fragment present in the 
knockout constructs (primer #50) and a reverse primer lying in the BSD (primer 
#154) or NEO ORFs (primer #155), 1077 bp for BSD and 1085 bp for NEO.  The 
“BSD” and “NEO” PCRs confirmed the integration of the respective knockout 
constructs in the correct location, due to the forward primer (#50) binding 
upstream of the 5’ UTR region present in the construct. 
Wild type Lister 427 cells transformed with the RECQ1::ΔBSD construct 
successfully generated recq1+/- clones following selection with 10 µg.mL-1 
blasticidin, confirmed by PCR as described above (data not shown).  However, 
repeated attempts at generation of recq1-/- cells by transformation of recq1+/- 
with the ΔRECQ1::NEO construct and selection using 5 µg.mL-1 blasticidin and 
2.5 µg.mL-1 G418 were unsuccessful.  Surviving clones were shown not to be 
recq1-/- using the diagnostic PCRs described above (data not shown).  In some 
cases, no double resistant clones were recovered, whereas in others cases 
double resistant clones retained the RECQ1 ORF. 
The above data, in contrast to the efficiency with which recq2-/- mutants were 
generated, suggested that RECQ1 may be essential in BSF T. brucei.  However, 
the transformations were repeated in reverse, transforming the ΔRECQ1::NEO 
construct first, followed by the ΔRECQ1::BSD construct, to ensure that the 
ΔRECQ1::BSD construct could be integrated into wild type cells.  Altered 
selective drug concentrations were also used (described below).  Wild type 
Lister 427 cells were transformed with the ΔRECQ1::NEO construct and antibiotic 
resistant clones were selected with 5 µg.mL-1 G418.  Fifteen putative recq1+/- 
clones were obtained, of which 13 were shown to contain the correctly 
integrated ΔRECQ1::NEO construct (data not shown).  One of these clones (Fig. 
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5-4A) was taken forward for transformation of the ΔRECQ1::BSD construct.  
Given the failure to obtain antibiotic recq1-/- clones in previous attempts, 
antibiotic resistant cells were selected using two different conditions: 5 µg,mL-1 
blasticidin and 2.5 µg.mL-1 G418, or 10 µg.mL-1 blasticidin alone.  No surviving 
clones were obtained following selection with G418 and blasticidin.  Eighteen 
putative recq1-/- clones were obtained following selection with blasticidin only, 
all of which still contained the RECQ1 ORF (Fig. 5-4B) indicating that none of 
these clones were recq1-/- mutants.  In all of these clones, the BSD knockout 
construct had integrated correctly but the NEO knockout construct had been lost 
(Fig. 5-4B).  As deletion of the RECQ1 ORF was unsuccessful, this provided 
further evidence that RECQ1 is essential in BSF T. brucei. 
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5.3.2 Generation of a RECQ1 RNAi construct 
The inability to successfully obtain recq1-/- cells suggested that RECQ1 is 
essential in BSF form T. brucei.  To test this and to investigate the role of 
RECQ1, it was next aimed to generate an inducible RECQ1 RNAi line. 
5.3.2.1  RNAi in T. brucei  
RNAi, first reported by Fire et al. (1998), is a process whereby double stranded 
RNA (dsRNA) molecules are cleaved to generate short interference RNA (siRNA) 
molecules, which after processing, bind to their target mRNAs, leading to 
destruction of the target mRNA and subsequent inhibition of synthesis of the 
corresponding protein. 
T. brucei was the first protozoan parasite demonstrated to possess a functional 
RNAi system (Ngo et al., 1998).  RNAi has since been successfully developed and 
widely utilised as an experimental tool to study gene function in T. brucei, 
reviewed in Kolev et al. (2011).  Sense and anti-sense RNA transcripts are 
processed by two Dicer-like enzymes, TbDCL1 and TbDCL2, located in the 
cytoplasm and nucleus respectively, into dsRNA siRNA molecules 20-30 
nucleotides in length (Patrick et al., 2009; Shi et al., 2006).  siRNAs are loaded 
into the TbAGO1, the single T. brucei  Argonaute protein (Durand-Dubief & 
Bastin, 2003; Shi et al., 2004), to form the RNAi induced silencing complex 
(RISC).  TbAGO1, together with TbRIF4 and TbRIF5 (RNA interference factor) 
processes siRNA duplexes into the mature, single stranded form (Barnes et al., 
2012).  One strand of the duplex is removed (known as the passenger strand) and 
the remaining strand (known as the guide strand) interacts directly with 
Argonaute to target the mRNA, base pairing with it, which leads to mRNA 
cleavage and consequent down regulation of the corresponding protein. 
5.3.2.2 Gateway RNAi system and cloning of RECQ1 RNAi construct 
A number of genetic tools have been developed to take advantage of the T. 
brucei RNAi system.  Inducible expression of dsRNA molecules homologous to a 
target gene results in degradation of mRNA and down regulation of synthesis of 
the target gene’s corresponding protein.  The system employed here is the same 
as that developed by Jones et al. (2014).  This system uses the 2T1 T. brucei BSF 
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cell line, developed by Alsford et al. (Alsford et al., 2005b).  The 2T1 cell line 
(Fig. 5-6B) expresses TetR (tetracycline repressor) from the pHD1313 cassette 
integrated at the tubulin locus; see (Alibu et al., 2005).  Additionally, the 2T1 
cell line contains a 3’ hygromycin (HYG) resistance gene fragment driven by an 
EP1 procyclin promoter upstream of a puromycin resistance (PUR) ORF driven by 
a regulated ribosomal RNA (RRNA) promoter, integrated at a ribosomal spacer 
locus on chromosome 2a.  The 3’ HYG and RRNA sequences, which flank the PUR 
gene, create sequence homology to facilitate integration of linearised constructs 
flanked by the same sequences. 
2T1 cells are puromycin resistant and hygromycin sensitive.  Transformation of 
2T1 cells with a pRPa construct (Alsford et al., 2005b), which contains RNAi 
targeting sequences flanked by a 5’ HYG ORF and RRNA sequence, results in 
stable integration of the construct at the tagged RRNA spacer locus, loss of PUR 
and reconstitution of the HYG ORF.  Transformed cells should thus be puromycin 
sensitive and hygromycin and phleomycin resistant (phleomycin resistance being 
conferred by the TetR expression construct). 
The RNAi system used by Jones et al. (2014) utilises a modified version of the 
pRPaISL construct (Alsford & Horn, 2008), pGL2084 (Fig. 5-5), to transform 2T1 
cells.  pGL2084 contains a Gateway recombination cassette located between the 
HYG 5’-RRNA promoter and RRNA targeting sequences.  This cassette consists of 
two pairs of inverted AttP sites from the Gateway cloning system (Life 
Technologies).  In a Gateway reaction, AttB sites recombine with AttP sites, 
catalysed by a “BP clonase” enzyme, such that a single PCR product flanked by 
AttB sites is recombined into the pGL2084 plasmid at the site of the AttP 
sequences, forming an inverted tandem repeat. 
A 150 bp stuffer fragment is located between the pairs of AttP repeats, which 
allows the formation of a hairpin between the inverted PCR sequences once the 
construct is transcribed into RNA.  pGL2084 also contains the ccdB gene between 
both sets of AttP repeats.  The product of the ccdB gene is lethal in bacteria.  
However, upon successful recombination of the AttB-flanked PCR product into 
pGL2084, both ccdB sequences are lost and the plasmid can be propagated.  
pGL2084 also contains the TetO (Tet operator) sequence, as in pRPISL, which 
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results in the repression of transcription of the sequences downstream in the 
absence of tetracycline. 
 
Figure 5-5 Schematic of RNAi plasmid pGL2084 
pGL2084 contains a the 5’ region of the hygromycin (HYG) ORF and an RRNA targeting 
region (blue) for targeting integration of the construct into an RRNA spacer locus on 
chromosome 2a.  Flanked by these targeting regions is an RRNA promoter, under the 
control of the Tet operator (dark grey), and two pairs of AttP sites (orange) for 
recombination of AttB-flanked PCR products.  The pairs of AttP sites are linked by a 150 bp 
stuffer fragment (green), and flank a ccdB ‘suicide gene’ (light grey) for negative selection 
of improperly recombined plasmids after the Gateway reaction.  Linearisation of the 
construct (after Gateway recombination) is by AscI, which is indicated.  Sizes are shown 
(bp). 
The RECQ1 RNAi targeting sequence was designed using RNAit (Redmond et al., 
2003).  RNAit is an automated online tool for the selection of RNAi targets and 
primer sequences in T. brucei.  Through NCBI BLAST analysis of the predicted 
PCR product against the T. brucei genome, RNAit is designed to exclude RNAi 
targeting fragments that target genes other than the gene of interest.  A 425 bp 
RECQ1 RNAi targeting sequence was designed (primers #67 and #68), which 
included the 29 nt AttB sequence at either end of the final PCR product.  Primer 
sequences can be found in Appendix 7.1.  A BP Gateway reaction was used to 
recombine two copies of the AttB-flanked RECQ1 RNAi targeting fragment into 
pGL2084 in opposite directions (Fig 5-6A). 
A schematic of a 2T1 cell line successfully transformed with a pGL2084-derived 
RNAi vector is shown in Figure 5-6B.  The EP procyclin promoter drives 
expression of the HYG gene and the RRNA promoter drives transcription of the 
RNAi cassette, under the control of TetO.  Absence of tetracycline represses 
transcription and addition of tetracycline induces transcription (2 µg.mL-1 in 
these experiments).  Transcription of the two inverted RECQ1 RNAi targeting 
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fragments and the stuffer generates a dsRNA structure connected by a 150 bp 
hairpin.  This molecule should be recognised by the RNAi machinery and through 
the processes described above, target RECQ1 mRNA for destruction, thus 
resulting in inhibition of RECQ1 protein synthesis. 
 
Figure 5-6 Schematic of RECQ1 RNAi construct, Gateway cloning and 2T1 
transformation 
(A) The RECQ1 RNAi plasmid was generated from Gateway recombination of RECQ1 RNAi 
targeting fragments (pink) and the pGL2084 construct shown in Figure 5-5.  Restriction sites 
used for confirmation of the RECQ1 RNAi construct by restriction enzyme digest are 
indicated.  Sizes are shown (bp).  (B) The Gateway cloning process used to generate the 
RECQ1 RNAi plasmid and its integration into 2T1 cells.  A 425 bp region of the RECQ1 ORF 
was amplified by PCR (primers #67 and #68), using primers that contained the 29 nt AttB 
sequence.  The purified PCR product was recombined into the pGL2084 plasmid in a 
Gateway “BP clonase” reaction (Life Technologies), using the AttP recombination sites in 
pGL2084.  The inverted orientation of the pair of AttP sites results in the integration of two 
PCR products in opposite orientations (indicated by black arrow).  The pGL2084-derived 
RECQ1 plasmid was digested with AscI prior to transformation into 2T1 cells.  Integration of 
the construct into the tagged RRNA spacer locus on chromosome 2a reconstitutes a 
complete hygromycin (HYG) ORF and removes the PAC gene (“puromycin”).  Transcription 
of the HYG resistance gene is driven by an EP procyclin promoter (black arrow) and 
transcription of the RNAi cassette is driven by an RRNA promoter (black arrow), producing 
a dsRNA structure linked by the stuffer sequence (black box), which forms a hairpin.  Figure 
reproduced from Catarina Marques, PhD Thesis (2015). 
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Figure 5-6 continued 
 
Multiple restriction enzyme digests were used to confirm that the RECQ1 RNAi 
construct (Fig. 5-6A) was correct and the results of these digests indicated 
incorrect recombination of the PCR products (data not shown).  After multiple 
attempts, a correct plasmid was obtained.  Figure 5-7 shows confirmation by 
restriction digest that the RECQ1 RNAi plasmid was correct.  One restriction 
enzyme digest, ClaI, produced products in addition to the predicted ones.  This 
was most likely due to the methylation sensitivity of ClaI, or star activity in 
these conditions.  As the ClaI digest also produced the expected ~5.8 kb and 
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~600 bp digest products, and all of the other restriction enzyme digests 
produced the predicted products, the plasmid was considered to be correct and 
therefore used to transform 2T1 cells. 
 
Figure 5-7 Confirmation of RECQ1 RNAi plasmid 
(A) The RECQ1 RNAi plasmid was tested for integration of the RNAi PCR product by 
restriction enzyme digestion using enzymes shown in (B).  White dots indicate digestion 
products in addition to those predicted.  Sizes shown (ladder, bp).  (B) Predicted sizes (bp) 
of products resulting from digestion of the empty pGL2084 vector and RECQ1 RNAi 
plasmid. 
5.3.3 Generation of RECQ1 RNAi cell line 
2T1 cells were transformed with the AscI-linearised RECQ1 RNAi construct and 
antibiotic resistant clones were selected with 2.5 µg.mL-1 hygromycin and 
0.5 µg.mL-1 phleomycin.  Six putative RECQ1 RNAi clones were obtained from the 
transformation.  An additional 19 wells from the transformation contained live 
cells but as all 19 wells were on a single 24 well plate, they were unlikely to be 
clonal and therefore discarded.  The puromycin sensitivity of the seven putative 
RECQ1 RNAi clones was tested by assaying whether clones grew in the presence 
of 0.2 µg.mL-1 puromycin.  Clones in which the RNAi construct has integrated 
correctly are puromycin sensitive however, clones that are puromycin resistant 
but contain the RNAi construct can also be obtained (Alsford & Horn, 2008; 
Jones, 2013) and have presumably integrated the construct at a different locus.  
Four out of six putative RECQ1 RNAi clones were puromycin sensitive and these 
were taken forward for phenotype analysis, as puromycin resistant clones have 
previously been demonstrated to give less consistent and stable RNAi phenotypes 
(Jones, 2013). 
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Preliminary analysis of in vitro growth of each of the four putative RECQ1 RNAi 
clones was performed by induction of RNAi using 2 µg.mL-1 tetracycline.  The 
cell density was then counted every 24 hours using a haemocytometer, up to a 
maximum of 120 hours.  Cultures were diluted when appropriate to maintain a 
cell density of <1 x 106 cells.mL-1 and the cumulative cell density was 
calculated.  All four clones showed a very similar phenotype (discussed below, 
Section 5.4) and two were selected for more detailed analysis. 
5.3.4 Confirmation of RECQ1 RNAi cell line by PCR 
The presence of the RECQ1 RNAi cassette in the transformants was confirmed by 
PCR.  Primers #OL4161 and #OL4212, which bind in the AttL sites formed by 
recombination of the RECQ1 PCR product AttB and pGL2084 AttP sites, were 
used to amplify the RECQ1 RNAi fragment (425 bp), as shown in Figure 5-8A.  
Figure 5-8B shows that both RECQ1 RNAi clones used in experiments produced a 
PCR product of the expected size, suggesting they had integrated the RECQ1 
RNAi cassette. 
 
Figure 5-8 PCR of RECQ1 RNAi cassette integration in 2T1 cells 
(A) PCR primers #OL4161 and #OL4212 (black arrows under sequence) bind in the AttL sites 
of the RNAi cassettes (orange), amplifying the RECQ1 RNAi targeting fragment (pink) to 
produce a 485 bp PCR product.  (B) Genomic DNA from RECQ1 RNAi Clone 1 and Clone 2 
cells was analysed by PCR with primers #OL4161 and #OL4212 (see Appendix 7.1 for primer 
sequences).  Distilled water was used as a negative control (-).  Gaps indicate that lanes 
have been aligned in this figure after excision from multiple gels or from disparate parts of 
the same gel; size markers are shown (ladder, bp). 
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5.4 Phenotypic analysis of RECQ1 RNAi 
5.4.1 Effect of RECQ1 RNAi knockdown on growth 
To analyse the in vitro growth of BSF T. brucei following RECQ1 loss, RNAi was 
induced in cultures (2 µg.mL-1 tetracycline) at a density of 1 x 104 cells.mL-1.  
The cell density of cultures was counted every 24 hours up to 96 hours using a 
haemocytometer and cultures were not diluted during the time course.  Growth 
curves were performed three times for both RECQ1 RNAi clones.  Induction of 
RECQ1 RNAi resulted in a growth defect apparent from 48 hours post-induction, 
after which cessation of growth was seen in both RECQ1 RNAi clones (Fig. 5-9); 
indeed, some evidence of cell death was seen in clone 2 from 48-72 hrs, as the 
cell density reduced. A slight increase in cell density was seen from 72-96 hours, 
which may result from the outgrowth of altered cells that no longer induce RNAi, 
though this was not examined in detail. These data appear consistent with the 
inability to generate a recq1-/- cell line (Section 5.3.1), and suggest that RECQ1 
is essential for BSF growth. 
 
Figure 5-9 In vitro growth following RECQ1 RNAi induction 
Mean cell counts of BSF T. brucei 2T1 cells following RECQ1 RNAi induction by addition of 
2 µg.mL-1 tetracycline (broken line, +Tet) or without RNAi induction (solid line, -Tet) in two 
clones.  Error bars indicate standard error of the mean (SEM). 
5.4.2 Analysis of cell cycle 
To investigate if the impaired growth following RNAi induction was associated 
with altered cell cycle distribution, quantification was performed by DAPI 
staining and analysing the proportion of 1N1K, 1N2K, 2N2K and abnormal cells by 
visualisation of the nucleus (N) and kinetoplast (K) (see Section 2.2.1).  The 
number of nuclei and kinetoplasts correspond to different cell cycle stages in T. 
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brucei, providing a tool to examine progress through the cell cycle (see Section 
3.4.2 for detailed explanation). 
As mentioned previously (Section 4.6.1), the expected distribution of cell cycle 
phases in wild type BSF cells is: ~80% 1N1K, ~10% 1N2K, ~5% 2N2K (Benmerzouga 
et al., 2013).  In both clones, RNAi uninduced cells had a cell cycle distribution 
profile similar to this at all time points (Fig. 5-10A).  In contrast, RECQ1 RNAi 
induction severely altered this pattern.  Within the first 48 hours post-RNAi 
induction, an increase in the proportion of 1N2K cells was seen in both clones, 
accompanied by a decrease in the 1N1K population.  1N2K cells represented  
~30% of the total cell population 24 hours after induction, which suggests RECQ1 
knockdown results in a G2/M cell cycle arrest.  However, at 48 hours post RNAi 
induction there was a high proportion (~40% in both clones) of aberrant ‘other’ 
cells.  The proportion of 1N1K cells decreased further to ~30% at 48 hours post-
induction, but the proportion of 1N2K cells remained similar (~20-25%) to 24 
hours post-induction.  At 48 hrs post-induction, the number of 2N2K cells 
appeared reduced, but the small number of such cells in the absence of RNAi 
makes this uncertain. 
A number of different N-K configurations were observed at 48 hours post RNA-
induction (Fig 5-10A).  To examine these cell types, and the cell cycle 
perturbation after RECQ1 RNAi further, the cell cycle analysis was extended to 
72 hours in a further experiment using only RECQ1 RNAi Clone 2 (chosen at 
random), sub-categorising the N-K configurations of ‘other’ cells (Fig. 5-11B).  As 
observed in the first experiment, the proportion of 1N2K cells at 24 and 48 hours 
post-induction was similarly increased (~30% of the cell population, Fig. 5-11A), 
though appeared to reduce somewhat at 72 hours.  Analysing the RNAi until 
72 hours appeared to confirm the reduction in 2N2K cells, as these were barely 
detected at this time point after induction.  At 48 hours post RECQ1 RNAi 
induction, the proportion of aberrant cells was ~20% of the population (slightly 
lower than seen in the first analysis), and these were mainly comprised of 
1N >2K cells, indicating perturbation of nuclear division.  Extension of the time 
course to 72 hours of RNAi induction revealed the appearance of cells lacking a 
nucleus (0N1K, zoid cells), and an increase in ‘others’ relative to 48 hours (>40% 
of the population).  The proportion of zoid and 1N >2K cells was approximately 
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equal at 72 hours (17% and 18% respectively), with a smaller proportion being 
difficult to classify. 
 
Figure 5-10 Cell types observed 48 hours post RECQ1 RNAi induction 
RNAi was induced in RECQ1 RNAi [Clone 1 and Clone 2] cells by addition of tetracycline 
(2 µg.mL-1) and cell samples taken at 0, 24 and 48 hours post-induction.  Cells were stained 
with DAPI to visualise the nucleus and the number of each cell type.  Examples are shown 
of normal (1N1K, 1N2K and 2N2K) and aberrant cell types observed after 48 hours of RECQ1 
RNAi induction.  N, nucleus; K, kinetoplast. 
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These data suggest that RECQ1 may play a role in nuclear DNA replication.  
Knockdown of RECQ1 results in an accumulation of 1N2K cells, indicating cell 
G2/M cycle arrest followed by the appearance of aberrant cells, the vast 
majority of which are zoids or 1N >2K.  Taken together, these observations 
suggest that RECQ1 RNAi induces a checkpoint due to problems with nuclear 
replication or division, but that this is not absolute and cells emerge in which 
the nuclei is lost (zoids) or in which the kinetoplast continues to replicate 
without associated nuclear replication and division (1N >2K).  Further analysis of 
the DNA content of cells by FACS following RECQ1 knockdown would be 
necessary to confirm this hypothesis, as would a directed experiment to assess 
DNA synthesis, such as measuring nucleotide analogue incorporation. 
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Figure 5-11 Cell cycle analysis following RECQ1 RNAi induction 
(A) RNAi was induced in RECQ1 RNAi [Clone 1 and Clone 2] cells by addition of tetracycline 
(2 µg.mL-1) and cell samples taken at 0, 24 and 48 hours post-induction.  Cells were stained 
with DAPI to visualise the nucleus and the number of each cell type (1N1K, 1N2K, 2N2K & 
other) was counted and is represented as a percentage of cells counted.  The number of 
cells counted is indicated (N).  (B) RECQ1 RNAi induction and DAPI analysis was repeated 
in Clone 2, additionally analysing cells at 72 hours post induction.  Aberrant cells were 
classified as 1N >2K, zoid, and other. The number of cells counted is indicated (N). 
5.4.3 Analysis of methyl methanesulfonate damage sensitivity 
after RNAi 
To investigate whether RECQ1 plays a role in DNA repair, the sensitivity of BSF 
T. brucei to the DNA damaging agent MMS following RECQ1 RNAi knockdown was 
analysed.  This was performed by measurement of in vitro growth following RNAi 
induction in the presence of 0.0002% and 0.0003% MMS and compared with 
growth of uninduced cells after MMS treatment. 
RECQ1 RNAi was induced in 1 mL cultures at a density of 1 x 104 cells.mL-1 by 
addition of 2 µg.mL-1 tetracycline and MMS was added to the appropriate final 
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concentrations.  The cell density was counted using a haemocytometer every 24 
hours up to 96 hours without dilution of the culture.  All growth curves were 
repeated three times.  MMS appeared to have little effect on the growth of 
uninduced cells (Fig. 5-12).  Induction of RNAi again arrested the growth of both 
clones and, in these conditions, the addition of MMS at either concentration 
further impaired the cells’ growth, an effect that was most marked in Clone 2 at 
0.0003% MMS at 96 hours, where most cells were dead and therefore the cell 
density was too low to measure using a haemocytometer.  From these data it 
would seem that RNAi knockdown of RECQ1 results in slightly increased MMS 
sensitivity of BSF T. brucei, though whether this represents evidence for a role 
in damage repair or exaggeration of the growth defect caused by RNAi is 
unclear. 
 
Figure 5-12 Cell cycle analysis following RECQ1 RNAi induction 
RNAi was induced in RECQ1 RNAi [Clone 1 and Clone 2] cells by addition of tetracycline 
(2 µg.mL-1) at a cell density of 1 x 104 cells.mL-1 and MMS was added to a final concentration 
of 0%, 0.0003% or 0.0004%.  The cell density was measured using a haemocytometer every 
24 hours up to 96 hours.  The mean cell density of three independent cultures are shown, 
with bars representing standard error of the mean (SEM). 
5.4.4 Analysis of γH2A intensity following RECQ1 RNAi 
As discussed in Chapter 4 (see Section 4.6.3) phosphorylated variant histone H2A 
(γH2A) is an early marker of DNA damage in eukaryotes (Canman, 2003; Polo & 
Jackson, 2011).  It is also detectable in BSF T. brucei following treatment with 
DNA damaging agents or induction of DSBs (Glover et al., 2013a; Glover & Horn, 
2012).  To investigate whether knockdown of RECQ1 results in an increased level 
of endogenous DNA damage, the γH2A level in cells was quantified by 
immunolocalisation of γH2A and measurement of nuclear fluorescence intensity. 
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RNAi was induced in cultures at 5 x 104 cells.mL-1 by addition of 2 µg.mL-1 
tetracycline and cell samples were taken at 0, 24 and 48 hours.  A higher 
starting cell density was used in order to collect enough RNAi induced cells for 
analysis at 48 hours.  Cells were fixed on glass slides and stained for γH2A using 
rabbit anti-γH2A antiserum (gift; Tiago D Serafim, unpublished; 1:1000 dilution) 
and secondary Alexa Fluor 594-conjugated anti-rabbit antiserum (Life 
Technologies, 1:2000 dilution).  All slides were stained at the same time using 
the same antisera working solutions.  The intensity of γH2A signal in the nucleus 
was calculated by measuring the average intensity of all nuclei in captured 
images using ImageJ (imagej.nih.gov/ij) (Rasband, 1997-2014), and is presented 
in arbitrary units.  The background level of γΗ2Α fluorescence was calculated as 
the average γH2A nuclear intensity in uninduced cells for both clones and all 
time points. 
In Clone 1 the nuclear γH2A fluorescence of cells at 24 hours post RECQ1 RNAi 
induction was unchanged from the background level of nuclear γH2A 
fluorescence in the uninduced cells (Fig 5-13).  At the 24 hour time point it was 
not possible to analyse RNAi induced Clone 2 cells due to malfunctions in capture 
of these images. Nevertheless, at 48 hours post RNAi induction, the nuclear 
γH2A intensity of both RNAi induced cells was four to five-fold higher than 
background levels in both clones, indicating an increase in γH2A in the nucleus.  
This suggests that knockdown of RECQ1 results in an increased level of DNA 
damage apparent at 48 hours, the same time point at which a pronounced 
growth defect is first observed (Fig 5-9). 
γH2A expression has previously been shown to increase following knockdown of a 
RecQ protein.  Knockdown of the human RECQ1 protein, which renders cells 
more sensitive to DNA damage, results in spontaneous γH2A formation (Sharma & 
Brosh, 2007).  As previously discussed, phosphorylation of variant histone H2A 
occurs following DNA damage.  DNA damage can be incurred from multiple 
sources, exogenous and endogenous.  RecQ helicases play multiple roles in 
maintaining genome integrity, including replication fork integrity and recovery, 
and in repair of DNA damage.  If RECQ1 plays a role in replication, for example 
maintaining recovering stalled forks to prevent DNA lesions as some other RecQ 
helicases do (Berti et al., 2013; Zeman & Cimprich, 2014), knockdown of RECQ1 
would result in an increase in DNA lesions from collapsed replication forks, 
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triggering H2AX phosphorylation.  RecQ helicases also function in the repair of 
non-replicative damage, such as DSB repair by the yeast SGS1 RecQ helicase 
(Mimitou & Symington, 2008).  A similar role for RECQ1 would also lead to an 
increase in γH2A expression.  Analysis of RECQ1 expression through the cell cycle 
would be useful in investigating whether RECQ1 plays a role in nuclear DNA 
replication or the repair of replicative damage.  Cell cycle dependent expression 
is not necessary for, but would be consistent with, a role in either of these 
processes. 
 
Figure 5-13 Immunofluorescent analysis of nuclear γH2A intensity following RECQ1 
RNAi induction 
RNAi was induced in RECQ1 RNAi Clone 1 and Clone 2 cells at 5 x 104 cells.mL-1 (2 µg.mL-1 
tetracycline).  Samples were taken at 0, 24 and 48 hours post induction, fixed, stained for 
γH2A using rabbit anti-γH2A antiserum (gift; Tiago D Serafim, unpublished; 1:1000 dilution) 
and secondary Alexa Fluor 594-conjugated anti-rabbit antiserum (Life Technologies, 1:2000) 
and DNA visualised using DAPI.  The γH2A fluorescence intensity is represented as the 
average nuclear γH2A fluorescence of cells counted (N, number of cells counted), 
calculated using ImageJ (arbitrary units).  Background fluorescence is the average γH2A 
nuclear intensity of all uninduced cells.  No cells were counted at the 24 hour time point for 
Clone 2 (*). 
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Figure 5-13 continued 
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5.4.5 Confirmation of RECQ1 knockdown by western blot analysis 
In order to confirm knockdown of RECQ1 in both RECQ1 RNAi clones, one allele 
of RECQ1 was endogenously tagged with a 12myc epitope.  The same backbone 
construct (pNAT x12myc) as used to epitope tag MUS81 and PIF6 was used to tag 
RECQ1 (see Section 3.7 for detailed explanation).  The construct (Fig. 5-14) 
contains the final 1.1 kb of the RECQ1 coding sequence, excluding the STOP 
codon, cloned upstream of and in frame with a 12myc coding sequence.  The 
cloned RECQ1 region contained a unique restriction enzyme site (XhoI) for 
linearisation of the construct prior to transformation.  The RECQ1 region was 
cloned into the construct using AscI (5’) and XbaI (3’) restriction enzyme sites, 
and confirmed by restriction digestion and sequencing.  Selection of 
transformants is enabled by a blasticidin resistance gene, flanked by tubulin and 
actin processing sequences.  The blasticidin cassette provides polyadenylation 
signals for RECQ1 12myc, making the 3’ UTR of RECQ1 12myc non-endogenous. 
 
Figure 5-14 Schematic of the RECQ1 12myc plasmid 
The RECQ1 12myc plasmid contains 1.1 kb of the 3’ RECQ1 ORF up to but not including the 
stop codon (orange), followed by 12 copies of the myc epitope sequence (blue).  The unique 
restriction enzyme site (XhoI) used to linearise the construct is indicated.  The blasticidin 
resistance cassette is shown (pink) flanked by βα tubulin and actin intergenic sequences 
(light grey).  Ampicillin resistance gene (AmpR, dark grey) and the ColE1 origin (green) are 
also shown.  Sizes shown (bp). 
Both RECQ1 RNAi clones were transformed with the RECQ1 12myc construct, 
linearised using XhoI, and antibiotic resistant transformants were selected using 
10 µg.mL-1 blasticidin.  Blasticidin-resistant clones were screened by western 
blot and PCR to check that they expressed myc-tagged RECQ1 and retained the 
RECQ1 RNAi cassette (Fig 5-15).  Whole cell lysates were separated by SDS-PAGE 
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on a 3-8% tris-acetate gel, western blotted and probed with mouse anti-myc 
antiserum (Millipore, 1:7000) and secondary anti-rabbit HRP-conjugated 
antiserum (Life Technologies, 1:5000).  The presence of the RNAi cassette was 
confirmed by PCR amplification of a 485 bp region of the cassette (#OL4161 and 
#OL4212, sequences in Appendix 7.1).  All putative RECQ1-myc RNAi clones 
retained the RNAi cassette, but only seven out of 10 RECQ1-12myc RNAi clones 
in the RECQ1 RNAi Clone 1 and eight out of twelve clones in the RECQ1 RNAi 
Clone 2 background expressed a protein of the expected size of RECQ1 12myc 
(116.2 kDa).  Figure 5-15 shows the western blot and PCR analysis of the RECQ1-
myc RNAi clones used in the experiments described below. 
To test for knockdown of RECQ1 at the protein level, RECQ1 12myc expression 
following RNAi induction in RECQ1myc RNAi was assayed by western blot.  RNAi 
was induced in both RECQ1myc RNAi clones by addition of tetracycline 
(2 µg.mL-1) to cultures at a density of 1 x 105 cells.mL-1.  Cells were collected at 
0, 24, 48 and 72 hours after induction or in non-induced controls. A higher 
starting cell density was used to enable collection of enough cells for western 
blot analysis in RNAi induced cultures at later time points.  RNAi uninduced 
cultures were diluted to 1 x 105 cells.mL-1 at 24 and 48 hours to prevent cultures 
entering stationary phase.  At these time points, RNAi induced cultures were 
resuspended in fresh medium to the cell density measured at that time point 
and fresh tetracycline added (final 2 µg.mL-1).  Whole cell lysates were 
separated by SDS-PAGE on a 3-8% tris-acetate gel, with the same number of cell 
equivalents loaded in each lane.  Gels were western blotted and probed with 
mouse anti-myc antiserum and secondary anti-mouse HRP-conjugated antiserum 
to detect RECQ1 12myc, and mouse anti-EF1α and anti-mouse HRP-conjugated 
antisera as a loading control. 
Figure 5-16 shows RECQ1 12myc is not detectable in the RECQ1 RNAi Clone 1 or 
the RECQ1 RNAi Clone 2 background at 24 hours post RNAi-induction, or at any 
point thereafter.  Similar expression of EF1α in all samples confirms similar 
protein loading in all samples.  Both RECQ1 RNAi Clone 1 and Clone 2, therefore, 
exhibited a strong knockdown of RECQ1 protein upon induction by the addition 
of tetracycline. 
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Figure 5-15 Western blot confirmation of RECQ1-12myc expression in RECQ1 12myc 
RNAi clones 
Genomic DNA from RECQ1-myc RNAi clones was assayed by PCR for the presence of the 
RNAi cassette (primers #OL4161 and #OL4212; 485 bp PCR product).  Dashed lines indicate 
that lanes have been aligned in this figure after excision from multiple gels or from 
disparate parts of the same gel; size markers are shown (ladder, bp).  Total protein extract 
from RECQ1 12myc RNAi cells was separated by SDS-PAGE on a 3-8% tris-acetate gel, 
western blotted and probed with mouse anti-myc antiserum (Millipore, 1:7000 dilution) and 
secondary anti-rabbit HRP-conjugated antiserum (Life Technologies, 1:5000 dilution).  
Predicted size of RECQ1 12myc (116.2 kDa; RECQ1 101.8 kDa + 12myc 14.4 kDa).  Size 
markers are shown (kDa). 
 
Figure 5-16 Confirmation of RECQ1 knockdown by western blot analysis 
Whole cell lysates (5 x 106 cell equivalents) of RNAi induced (+T) and uninduced (-T) 
cultures were separated by SDS-PAGE on a 3-8% tris-acetate gel, western blotted and 
probed with mouse anti-myc antiserum (Millipore, 1:7000 dilution) and secondary anti-
mouse HRP-conjugated antiserum (Life Technologies, 1:5000) to detect RECQ1 12myc, and 
mouse anti-EF1α antiserum (Millipore, 1:25,000 dilution) and anti-mouse HRP-conjugated 
antieserum (Life Technologies, 1:5000 dilution) as a loading control.  –T, no tetracycline 
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added (control); +T, tetracycline added to 2 µg.mL-1; clone 1, RECQ1 RNAi clone 1 
background; clone 2, RECQ1 RNAi clone 2 background.  Size markers are shown (kDa). 
5.5 Immunolocalisation of RECQ1 
Immunolocalisation of RECQ1 and co-immunolocalisation with RAD51 was carried 
out following DNA damage in order to investigate the cellular localisation of 
RECQ1 before and after the induction of DNA damage and test whether it co-
localises with RAD51.  This was achieved using endogenously C-terminal 12myc 
epitope tagged RECQ1 and anti-RAD51 antiserum.  This strategy has previously 
been successfully used to tag and localise proteins in T. brucei (Trenaman et al., 
2013).  As discussed previously, RAD51 catalyses DNA strand exchange during 
DNA repair and T. brucei cells in which DNA damage has been induced form 
subnuclear RAD51 foci (Hartley & McCulloch, 2008; Proudfoot & McCulloch, 
2005).  The DNA repair factor BRCA2 has been demonstrated to co-localise with 
these RAD51 foci in a limited form (Trenaman et al., 2013).  RECQ2 also co-
localises with RAD51 repair foci, as discussed in Chapter 3 (see Section 3.9.1).  
Co-localisation of RECQ1 with RAD51 foci following DNA damage would suggest 
that RECQ1 plays a role in the repair of DNA damage. 
5.5.1 Generation of an endogenously myc-tagged RECQ1 cell line 
The RECQ1 12myc construct used previously to myc-tag RECQ1 in RECQ1 RNAi 
cell lines (see Section 5.4.5) was used to myc-tag RECQ1 in wild type Lister 427 
cells.  See Section 5.4.5 for details of the RECQ1 12myc construct. 
5.5.2 Confirmation of myc-tagged line by western blot analysis 
Wild type BSF Lister 427 cells were transformed with the linearised 
RECQ1 12myc construct in order to generate a C-terminal 12myc tagged RECQ1 
cell line.  Antibiotic resistant transformants were selected using 10 µg.mL-1 
blasticidin.  Antibiotic resistant clones obtained from this transformation were 
screened by western blot performed on total protein extracts.  Total protein 
extracts were separated by SDS-PAGE on a 3-8% tris-acetate gel before western 
blotting and probing with mouse anti-myc antiserum (Millipore, 1:7000 dilution) 
and HRP-conjugated anti-mouse secondary antiserum (Life Technologies, 1:5000 
dilution).  All of the four putative clones tested expressed a protein of the 
expected size of RECQ1 12myc (116.2 kDa; RECQ1 101.8 kDa + 12myc 14.4 kDa).  
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Western blot analysis of the clone taken forward for use in all experiments 
described below is shown in Figure 5-17. 
 
Figure 5-17 Confirmation of RECQ1 12myc expression by western blot 
Total protein extract from putative RECQ1 12myc cells was separated by SDS-PAGE on a 
3-8% tris-acetate gel, western blotted and probed with mouse anti-myc antiserum (Millipore, 
1:7000 dilution) and secondary anti-mouse HRP-conjugated antiserum (Life Technologies, 
1:5000 dilution).  A band of the size expected for RECQ1 12myc (116.2 kDa; RECQ1 
101.8 kDa + 12myc 14.4 kDa) is indicated (*).  Size markers are shown (kDa). 
5.5.3 Testing the functionality of endogenously-tagged RECQ1 
To test whether RECQ1 12myc is functional, the second (untagged) RECQ1 allele 
was knocked out, replacing the ORF with a NEO resistance cassette, as 
performed when testing the functionality of RECQ2myc, MUS81myc and PIF6myc 
in Chapter 3 (see Section 3.8).  As described above (Section 5.3), RECQ1 is 
essential.  Therefore, if RECQ1 12myc is functional, successful generation of 
RECQ1 12myc/ΔRECQ1::NEO cells should be possible. In contrast, if it is non-
functional, attempts at generating RECQ1 12myc/ΔRECQ1::NEO cells should fail. 
The construct used to knockout the untagged RECQ1 allele, ΔRECQ1::NEO, was 
the same construct as that used in the attempt to generate recq1-/- mutants 
(Section 5.3.1).  RECQ1 12myc cells were transformed with the linearised 
ΔRECQ1::NEO construct.  Antibiotic resistant cells were selected with 5 µg.mL-1 
blasticidin and 2.5 µg.mL-1 G418.  Four putative RECQ1 12myc/ΔRECQ1::NEO  
clones were screened by PCR for integration of the ΔRECQ1::NEO construct 
(“NEO”, primers #50 and #155) using the same PCR strategy as described in 
Section 3.3.3 and a ~200 bp region of the RECQ1 ORF was amplified as a control 
(“RECQ1 ORF”, primers #75 and #76).  Clones were additionally screened by 
western blot analysis, where whole cell lysates were separated by SDS-PAGE on a 
3-8% tris-acetate gel, western blotted and probed with mouse anti-myc 
antiserum (Millipore, 1:7000 dilution) followed by anti-mouse HRP-conjugated 
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antiserum (Life Technologies, 1:5000 dilution).  PCR and western blot analysis 
showed that three out of four putative RECQ1 12myc/ΔRECQ1::NEO clones had 
integrated the knockout cassette at the correct locus and still expressed 
RECQ1 12myc (Fig. 5-18).  As RECQ1 is essential, the successful generation of 
RECQ1 12myc/ΔRECQ1::NEO cells suggests that RECQ1 12myc is functional.  
However, it is possible that an ‘extra’ wild type RECQ1 allele has been formed 
following integration of the NEO knockout construct, as the PCR tests outlined 
above did not test for this. 
 
Figure 5-18 Confirmation of successful RECQ1 12myc/ΔRECQ1 by PCR and western blot 
analysis 
(A) PCR amplification of a region of RECQ1 (226 bp, primers #75 and #76) and PCR 
amplification using primers #50 & #155 (1085 bp) that bind in the NEO resistance cassette 
and upstream of RECQ1.  Primer sequences can be found in Appendix 7.1.  Sizes are shown 
(bp).  (B) Total protein extracts were separated by SDS-PAGE, western blotted and probed 
with mouse anti-myc antiserum (Millipore, 1:7000 dilution) and anti-mouse HRP-conjugated 
antisera (Life Technologies, 1:5000 dilution).  A band of the expected size of RECQ1 12myc 
is indicated by (*).  Size markers are shown (kDa). 
5.5.4 Localisation of RECQ1myc 
Immunolocalisation of RECQ1 12myc and co-localisation with RAD51 was carried 
out as previously described (see Sections 3.9 and 2.10).  RECQ1 12myc cultures 
(1 x 106 cells.mL-1) were incubated for 18 hours in the presence or absence of 
1 µg.mL-1 phleomycin.  Cells were fixed and stained with anti-myc Alexa Fluor 
488-conjugated antiserum (Millipore, 1:2000 dilution) and co-stained with rabbit 
anti-RAD51 antiserum (Proudfoot & McCulloch, 2005) (1:500 dilution) and anti-
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rabbit Alexa Fluor 594 conjugated antiserum (Life Technologies, 1:7000 
dilution).  DNA was stained with DAPI for visualisation of the kinetoplast and 
nucleus. 
As shown in Figure 5-19, RECQ1 12myc signal was not observed in any cells either 
in the presence or absence of phleomycin. In contrast, in these conditions, 
visible RAD51 subnuclear foci were seen, as described previously.  The absence 
of detectable subcellular RECQ1 12myc signal is not due to absence of 
RECQ1 12myc expression, as western analysis confirms that RECQ1 12myc is 
expressed in this cell line (see Figure 5-16, Section 5.5.2).  Nor is it a problem 
with the staining procedure, as slides to localise 12myc RECQ2, MUS81 12myc 
and PIF6 12myc were prepared using the same solutions and signal was observed 
in these (see Figures 3-30 to 3-32, Section 3.9). 
 
Figure 5-19 Representative examples of attempts at RECQ1 12myc immunolocalisation 
RECQ1 12myc cells were incubated for 18 hours in the presence or absence of phleomycin 
(1 µg.mL-1).  Alexa Fluor 488 antiserum was used to stain RECQ1 12myc (RECQ1myc), 
RAD51 was localised using anti-RAD51 antiserum (RAD51) and goat anti-rabbit Alexa Fluor 
594 conjugated antiserum, DAPI was used to visualise the DNA (DAPI) as described in the 
text.  Differential interference contrast was used to visualise whole cells (DIC).  Merged DAPI 
and RAD51 images are also shown (merge).  Scale, 13 µM. 
The absence of RECQ1 12myc signal could be due to low expression of 
RECQ1 12myc to a level not detectable by this method.  The absence of 
RECQ1 12myc foci following phleomycin damage, unlike RAD51 and BRCA2 
(Proudfoot & McCulloch, 2005; Trenaman et al., 2013), suggests that 
RECQ1 12myc is not involved in the response to phleomycin-induced DNA 
damage.  In comparison with the strong cell cycle defects after RECQ1 RNAi, the 
lack of detectable subnuclear localisation after phleomycin treatment and the 
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limited sensitivity to MMS suggest that any role for RECQ1 in repair is subservient 
to a function in genome duplication. 
5.6 Summary 
The aim of this chapter was to investigate the function of TbRECQ1, in particular 
to ask whether it plays a role in DNA repair.  This was initially attempted using a 
gene knockout approach but, due to an inability to obtain a recq1-/- mutant, an 
RNAi approach was adopted.  Analysis of the growth, cell cycle profile, MMS 
sensitivity and γH2A expression following TbRECQ1 RNAi induction was 
undertaken.  Additionally, localisation of TbRECQ1 was attempted using 
endogenous myc tagging, which was successful but did not reveal any subcellular 
signal using immunofluorescence.  To conclude this chapter, the data from 
analysis of the phenotype of BSF T. brucei following RECQ1 knockdown and 
hypotheses for the possible function(s) of TbRECQ1 will be discussed. 
5.6.1 TbRECQ1 is a diverged RecQ-like helicase 
Analysis of the predicted protein sequence of TbRECQ1 showed that it is 
predicted to contain some but not all of the protein domains usually found in 
RecQ-like helicases.  TbRECQ1 lacks both an HRDC domain, usually found in 
RecQ-like helicases.  Phylogenetic analysis of TbRECQ1 and a number of other 
bacterial and eukaryotic RecQ-like helicases was undertaken.  This showed that 
TbRECQ1, along with some other kinetoplastid RecQ-like proteins, groups more 
distantly from most RecQ-like helicases than TbRECQ2, indicating that TbRECQ1 
is a diverged RecQ-like helicase (or at least more so than TbRECQ2).  T. brucei 
and other kinetoplastids are unusual among unicellular organisms by their 
possession of more than one predicted RecQ-like helicase.  TbRECQ2), and its 
orthologues in L. major and T. cruzi, grouped relatively closely with the 
majority of eukaryotic RecQ helicases (such as BLM and WRN), whereas the 
RECQ1 orthologues clustered more distantly from most eukaryotic RecQ-
helicases.  Taken together, these data were considered suggestive that TbRECQ1 
may have a kinetoplastid-specific function. 
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5.6.2 TbRECQ1 is essential in bloodstream form T. brucei  
Inability to generate a homozygous recq1 knockout (recq1-/-) mutant, despite 
repeated attempts, and analysis of growth following RECQ1 RNAi induction 
strongly indicate that TbRECQ1 is essential in bloodstream form T. brucei.  
RECQ1 RNAi resulted in cessation of growth by 48 hours post induction.  Analysis 
of endogenously myc-tagged RECQ1 protein levels by western blot showed strong 
knockdown from 24 hours post induction, with no protein detectable by western 
blot. 
An essential role for RECQ1 is unusual among RecQ proteins.  In all single celled 
organisms thus far examined, the single RecQ protein can be deleted and the 
cells are viable, as we have seen for recq2-/- mutants in T. brucei.  Indeed, even 
in mutlicellular organisms, most RecQ proteins are not essential for viability, 
perhaps due to the ability of other RecQ proteins to partially or completely 
compensate for the loss of one RecQ protein (Chakraverty & Hickson, 1999; Cobb 
& Bjergbaek, 2006; Hickson, 2003). 
The inability of TbRECQ2 to compensate for the knockdown of TbRECQ1 suggests 
that TbRECQ1 has one or more functions sufficiently specialised as to make 
TbRECQ2 unable to compensate for its loss.  Though unusual, essentiality of at 
least one RecQ-like helicase has been demonstrated: RECQ4 is essential for 
viability in chicken cells (Abe et al., 2011), and RECQL4 is essential for 
Drosophila viability (Capp et al., 2009).  Thus, the sequence conservation of 
kinetoplastid RECQ1 with mammalian RecQ4 may have functional significance 
5.6.3 RNAi suggests TbRECQ1 has a nuclear function 
Knockdown of TbRECQ1 by RNAi resulted in an accumulation of 1N2K cells at 24 
hours, indicating cell cycle arrest, followed by accumulation of abnormal cells.  
1N >2K cells accumulated in RNAi induced cells at 48 hours, followed by the 
generation of zoid cells, suggesting a nuclear defect.  It is possible that TbRECQ1 
plays a role in nuclear DNA replication whereby RNAi induced cells that have not 
successfully completed nuclear DNA replication proceed through cytokinesis, 
albeit after some arrest at G2/M, and one of the daughter cells is a zoid.  Zoids 
form as a result of incomplete nuclear DNA replication and consequently, the 
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nucleus cannot be segregated.  FACS analysis of the DNA content of cells and 
analysis of the proportion of cells undergoing nuclear DNA replication would be 
useful in testing this hypothesis.  Analysis of the incorporation of a thymidine 
analogue (BrdU or EdU) by fluorescence microscopy is an established technique 
(Benmerzouga et al., 2013; Wang et al., 2012) for determining whether cells are 
replicating their DNA. 
Further evidence for a nuclear RECQ1 function was seen in that RNAi induction 
also caused a four to five-fold increase in nuclear γH2A intensity, as measured 
by immunofluorescence, indicating an increase in nuclear DNA damage.  The 
nature and source of this damage is unknown, as γH2A is a general marker of 
DNA damage and there are multiple sources of DNA damage, such as replication-
associated, reactive oxygen species and transcription-associated damage.  Cell 
cycle analysis suggested that RECQ1 may play a role in nuclear DNA replication; 
RecQ-like helicases in other organisms play roles in all stages of replication and 
also function in replication-associated events (Croteau et al., 2014).  For 
example, yeast SGS1 (Cobb et al., 2003) interacts with DNA replication proteins 
and RECQ1 RECQ4/RECQL4 proteins from several organisms play a role in the 
initiation of replication  (Abe et al., 2011; Xu et al., 2009a).  RecQ proteins also 
function in replication fork recovery and stabilization of the replication fork 
(Sidorova et al., 2013).  If TbRECQ1 has a function at any stage of replication or 
replication-associated repair, DNA lesions resulting from TbRECQ1 knockdown 
would lead to the observed increase in γH2A. 
Alternatively, TbRECQ1 may not play a role in replication and the source of 
increased γH2A expression following TbRECQ1 knockdown is not directly 
associated with a replication defect.  As discussed, RecQ helicases perform a 
wide range of nucleic acid functions to contribute to genome stability, including 
DNA repair, recombination and transcription and further investigation is required 
to dissect the function of TbRECQ1.  Many RecQ helicases are involved in the 
response to induced DNA damage.  For example, both BLM and WRN function in 
the repair of DSBs (Karmakar et al., 2006; Lan et al., 2005).  MMS and 
phleomycin both induce DSBs but knockdown of TbRECQ1 led to no pronounced 
change in MMS sensitivity, nor was myc epitope-tagged TbRECQ1 observed to 
form DNA damage foci.  Other inducers of DSBs and forms of DNA damage other 
than DSBs may shed more light on this, but the presented in this chapter do not 
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suggest that TbRECQ1 plays a profound role in DNA repair.  An important 
consideration, however, in the interpretation of the phleomycin treatment data 
is that it was not possible to localise TbRECQ1 12myc at all, despite confirming 
its expression by western blot and its functionality by deletion of the second 
untagged TbRECQ1 allele.  Further attempts to localise TbRECQ1 would be 
advantageous, as it would enable co-localisation studies with, for instance, 
repair associated RAD51 and the DNA damage marker γH2A, shedding further 
light on its function.  This would determine whether TbRECQ1 is recruited to 
sites of DNA damage, and therefore whether or not these are replication or 
repair-associated.  It is possible that the 12myc tag used here may be 
insufficient for IFA localisation and use of an alternative epitope tag such as 
GFP, HA or FLAG could be attempted. Alternatively, it may be valuable to 
overexpress RECQ1. 
An important further experiment to carry out is transfection of a recoded 
version of TbRECQ1 not targeted by the RECQ1 RNAi fragment.  In this recoded 
cell line, absence of all of the RNAi-associated phenotypes presented in this 
chapter when RNAi was induced would demonstrate that targeting of TbRECQ1 
specifically was the cause of these defects. 
Based on the evidence presented in this chapter, we conclude that TbRECQ1 
(Tb427.06.3580) is an essential, diverged RecQ-like helicase that likely carries 
out a nuclear repair or replication function.  Further experiments to explore 
both of these possible roles for TbRECQ1 are necessary. 
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6 Discussion 
6.1 Introduction 
The aim of this project was to analyse whether TbRECQ1, TbRECQ2, TbMUS81 
and TbPIF6 are involved in DNA repair in T. brucei.  Homologues of these genes 
in other eukaryotes are involved in DNA repair and as some T. brucei DNA repair 
factors are involved in VSG switching, such as RAD51 and BRCA2 (Hartley & 
McCulloch, 2008; McCulloch & Barry, 1999), it was also aimed to investigate 
whether these factors are involved in VSG switching.  Furthermore, it was aimed 
to test the prediction that this reaction is initiated by DNA DSBs. 
To analyse the functions of the above proteins, it was attempted to generate 
heterozygote (+/-) and knockout (-/-) mutants for each gene.  This was 
unsuccessful for TbRECQ1 and so the function of this factor was analysed using 
an inducible RNAi line.  The function of the three remaining factors was 
performed comparing the  +/- and -/- cells with wild type T. brucei, including in 
cell lines allowing the induction of DSBs using I-SceI and containing constructs to 
assay VSG switching.  In the latter case, negative selection against a hygromycin 
thymidine kinase (HYG-TK) gene integrated upstream of the active VSG BES 
acted as a proxy for VSG switching, in which new VSG coat variants are normally 
selected for via host immune recognition and killing.  Though to date the roles 
of TbRECQ1 and TbMUS81 in VSG switching have not been examined, Tbmus81 
mutants in the VSG switching assay cell line were generated and confirmed by 
PCR (see Section 4.7.3) and could be used in future work to investigate whether 
TbMUS81 has a role in VSG switching.  In addition, a modified RNAi approach 
could be considered to test for a role for TbRECQ1, as has been described for 
other essential factors, such as histone H1, ORC1 (origin recognition complex 1) 
and TRF (Benmerzouga et al., 2013; Jehi et al., 2014a; Povelones et al., 2012).  
A summary of the data presented in this thesis and described below is shown in 
Table 6-1. 
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Table 6-1 Summary of the data presented recq2, mus81 and pif6 mutants and recq1 
RNAi cells 
Arrows indicate increase (!) or decrease (") in value of assayed phenotype;  -, experiment 
not performed; WT, wild type; ?, data unclear; -/-, double knockout mutant. 
 
6.2 TbRECQ2 is a DNA repair helicase that suppresses 
VSG switching 
Sequence analyses (see Section 3.2) suggested that TbRECQ2 is a RecQ-like 
helicase, diverged from other eukaryotic RecQ-like helicases but grouping with 
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homologues of the H. sapiens BLM and its yeast homologue SGS1 in phylogenetic 
analysis.  Phylogenetic analysis also showed that TbRECQ2 is more similar to 
eukaryotic RecQ-like proteins than the other RecQ-like helicase examined in this 
thesis, TbRECQ1 (see Chapter 5). 
Analysis of recq2 mutants showed that recq2-/-, and to some extent recq2+/- 
mutants, have a growth defect (see Section 3.4.1).  A range of DNA repair 
defects was also evident in recq2-/- mutants (see Section 3.4.3), including a 
striking sensitivity to MMS and HU and some sensitivity to phleomycin when 
analysed in clonal survival assays, suggesting the involvement of TbRECQ2 in the 
response and or DNA repair of damage induced by these agents.  HU depletes the 
dNTP pool, leading to replication stalling (Bianchi et al., 1986), which can lead 
to the formation of DNA breaks.  MMS causes widespread damage, stalling 
replication and resulting in the formation of DSBs (Brookes & Lawley, 1961; 
Lundin et al., 2005; Wyatt & Pittman, 2006), while phleomycin results in the 
formation of single and double strand DNA breaks, primarily the latter (Falaschi 
& Kornberg, 1964; Reiter et al., 1972). 
The increased MMS and HU sensitivity observed here in recq2-/- mutants is 
consistent with RecQ-like helicases mutants in other organisms.  S. cerevisiae 
sgs1 and human blm-/- mutants are hypersensitive to MMS (Mullen et al., 2000; 
Wang et al., 2003), while human blm-/- and wrn-/- mutants are involved in 
replication fork progression and suffer higher levels of DNA damage following HU 
treatment (Mao et al., 2010; Sidorova et al., 2013).  These analyses suggest that 
TbRECQ2 may localise to replication forks and TbRECQ2 absence, treatment with 
agents that stall replication (MMS and HU) leads to impaired survival.  Analysis of 
the progression of the replication fork in recq2-/- mutants following HU or MMS 
treatment could be used to investigate this further.  This could be accomplished 
using SMARD (single molecular analysis of replicated DNA), for which techniques 
in trypanosomes have very recently been developed (Calderano et al., 2015). 
Endogenously tagged 12myc TbRECQ2 was observed to localise to discrete 
subnuclear foci following phleomycin treatment, with substantial co-localisation 
with the HR factor RAD51 (Section 3.9.1).  RAD51 foci, not normally observed in 
the absence of damage, are thought to be repair-related structures (Dobson et 
al., 2011; Hartley & McCulloch, 2008; Proudfoot & McCulloch, 2005; Trenaman 
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et al., 2013), suggesting that 12myc RECQ2 is recruited to repair foci in response 
to phleomycin-induced DNA damage. 
It was chosen to look specifically at the role of TbRECQ2 in DSB repair due to the 
proposed role of DSBs in the current model for the initiation of VSG switching, 
namely that DSBs in the region of the 70 bp repeats of the active expression site 
are thought to be the breaks that initiate VSG switching by recombination 
(Boothroyd et al., 2009; Glover et al., 2013a).  To look specifically at the role of 
TbRECQ2 in the repair of DSBs, the I-SceI meganuclease system was used (see 
Section 4.2).  Analysis of recq2 mutant survival following the induction of DSBs 
specifically adjacent to the 70 bp repeats of the active VSG BES and at 
achromosomal internal location, showed that recq2-/- mutants are hypersensitive 
to DSBs at both of these locations.  In both DSB locations, the survival of recq2-/- 
cells was ~50% that of wild type, indicating that recq2-/- mutants are deficient in 
DSB repair.  Importantly, this deficiency also exists when DSBs are induced at 
the genomic location currently hypothesised as the site for breaks initiating 
switching. 
Analysis of the role of TbRECQ2 in VSG switching, using an in vitro VSG switching 
assay (see Section 4.7), revealed that recq2-/- mutants exhibit an elevated VSG 
switching rate.  Additionally, there was a dramatic shift in the VSG switching 
profile of recq2-/- mutants.  The switching profile in wild type cells was 
dominated by events resulting in the loss of the active VSG BES (~60%) and in 
situ switching events, whereas 90% of surviving recq2-/- clones underwent VSG 
gene conversion or telomere crossover events.  It seems likely therefore, that 
TbRECQ2 acts to suppress VSG switching by limiting crossover events.  This is 
markedly similar to the VSG switching phenotype observed in topo3α and rmi1 
mutants (Kim & Cross, 2010; Kim & Cross, 2011).  Both topo3α and rmi1 mutants 
display an elevated switching rate, though exceeding that of TbRECQ2 (10-40 
and four-fold, respectively), accompanied by an increase in crossover VSG 
switching events similar to TbRECQ2.  Suppressing hyper-recombination is a 
function of other RecQ-like helicases, such as BLM and WRN (Prince et al., 2001; 
Yamagata et al., 1998). 
These data suggest that TbRECQ2 may be the RecQ helicase component of the 
RTR (RecQ-Top3-Rmi1) complex, the other two members of which are proposed 
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by Kim and Cross (2010, 2011) to be Topo3α and RMI1.  A role for TbRECQ2 in the 
RTR complex seems much more likely than for TbRECQ1, which analysis suggests 
is more diverged from other eukaryotic RecQ-like helicases than TbRECQ2 and 
has a nuclear replication rather than DNA repair role (Chapter 5).  The RTR 
complex is a major regulator of crossover in eukaryotes, resolving dHJs to 
produce non-crossovers (Bussen et al., 2007; Chelysheva et al., 2008; Raynard et 
al., 2008) and mutants in all three RTR proteins in multiple eukaryotes (human 
Bloom syndrome cells, S. cerevisiae sgs1, top3 and rmi1 mutants and S. pombe 
rqh) display hyper-recombination (Mullen et al., 2005; Myung et al., 2001; 
Stewart et al., 1997; Traverso et al., 2003; Ui et al., 2001; Wallis et al., 1989).  
These data suggest that TbRECQ2 may act with RMI1 and TOPO3α as the RTR 
complex to suppress the VSG switching rate by limiting crossover events near the 
VSG in the active VSG BES, suppressing VSG gene conversions and telomere 
crossover events.  T. brucei Topo3α and RMI1 have been demonstrated to 
interact (Kim & Cross, 2011) and testing for interaction of TbRECQ2 with each of 
these factors, such as by isolation of an TbRECQ2-Topo3α-RMI1 complex by co-
immunoprecipitation and VSG switching analysis of TbRECQ2 and RMI1 or Topo3α 
double mutants would enable this hypothesis to be tested. 
The data presented in this thesis on the function of TbRECQ2 in DNA repair and 
VSG switching also provide new insight into the process of VSG switching by 
recombination.  The DSB repair and VSG switching phenotypes of recq2-/- 
mutants described here are not compatible with the hypothesis that the direct 
formation of DSBs at the 70 bp repeats initiates VSG switching.  recq2-/- mutants 
are deficient in repair of DSBs induced adjacent to the 70 bp repeats at the 
active VSG BES, displaying lower survival following DSB induction.  That a direct 
role in the repair of DSBs is a key function of TbRECQ2 is evidenced by the 
observation that the same reduced survival is seen after I-SceI DSB formation in 
the interior of chromosome 11.  Indeed, the formation of TbRECQ2 foci 
formation after phleomycin treatment (and known cause of DSBs) suggests that 
the helicase localises to DSBs, consistent with the I-SceI survival data.  If DSBs in 
the VSG BES directly initiate the VSG switching process, it would be expected 
that recq2-/- mutants would display a lower VSG switching rate, as they would be 
less able to execute the reaction.  Instead, the opposite was observed when the 
VSG switching phenotype of recq2-/- cells was analysed, since the VSG switching 
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rate of recq2-/- cells was two-three-fold higher than wild type cells and occurred 
by a different route.  These data suggest that direct formation of DSBs in the 
region of the 70 bp repeats is not an adequate explanation for the initiation of 
VSG switching.  Indeed, though the I-SceI system is increasingly being used to 
study VSG switching (Boothroyd et al., 2009; Glover et al., 2013a; Glover & 
Horn, 2014), the data presented here suggest that this may not be an accurate 
mimic of the natural route for initiation of VSG switching. 
If DSBs adjacent to the 70 bp repeats are not an accurate model for the 
initiation of VSG switching, what then is the cause of the lesions detected in the 
active VSG BES?  Several possibilities exist, including replication stalling, 
transcription-associated instability and the formation of unusual DNA structures 
(possibly at the 70 bp repeats).  Replication stalling within the active VSG BES 
has been proposed by Kim and Cross (2010 & 2011) as the cause of breaks found 
in the active VSG BES.  However, there is currently no data available on 
replication dynamics through the active or inactive VSG BESs; for instance, no 
analysis has been performed to ask if replication forks stall around the VSG, 
including on the 70 bp repeats.  However, this hypothesis is consistent with the 
role of RecQ-like helicases at the replication fork and in recovery after 
replication arrest in other organisms (Mao et al., 2010; Sidorova et al., 2013), as 
well as the sensitivity to the replication stalling agent HU observed in recq2-/- 
mutants (see Section 3.4.3.2) and therefore merits further investigation.  
Increased replication stalling or poorer recovery of the replication fork after 
replication stalling in the active VSG BES in recq2-/- mutants, and subsequent 
formation of lesions, might explain the increased VSG switching rate in recq2-/- 
cells.  Analysis of replication direction and rate through the active VSG BES using 
SMARD (single molecule analysis of replicated DNA) could be used to investigate 
whether replication stalls are seen more often in the active VSG BES than 
elsewhere in the genome and to compare stalling frequency in wild type cells 
and recq2-/- mutants. 
6.2.1 Summary 
The data presented in this thesis demonstrate a clear DNA repair function for 
TbRECQ2.  In addition to sensitivity to MMS and HU, mutants are also sensitive to 
induced DSBs.  VSG switching assays also showed that TbRECQ2 plays a role in 
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VSG switching, where it appears to suppress the VSG switching rate and inhibit 
crossovers near the active VSG.  The elevated switching rate observed in recq2-/- 
mutants, which are also deficient in DSB repair, calls into question the 
hypothesis that DSBs directly initiate VSG switching by recombination and points 
to a need to continue to investigate the event and lesion initiating VSG switching 
by recombination. 
6.3 TbMUS81 is a DNA repair factor acting in DSB repair 
Amino acid sequence analysis (Section 3.2.2) of TbMUS81 confirmed that it is a 
MUS81 endonuclease, though somewhat diverged from eukaryotic MUS81 
homologues.  TbMUS81 contains a predicted ERCC4 domain typical of MUS81 
proteins and, in addition, a predicted SAP domain.  SAP domains are involved in 
DNA binding (Aravind & Koonin, 2000) and not found in other eukaryotic MUS81 
proteins, suggesting TbMUS81 could possess functions atypical of a MUS81 
protein. 
Analysis of mus81 mutants revealed that mus81-/-, but not mus81+/- cells, display 
a minor growth defect (see Section 3.4.1) and analysis of the DNA damage 
sensitivity of mutants revealed a range of repair defects (see Section 3.4.3).  
mus81-/- mutants were more sensitive to MMS and phleomycin, similar to T. 
brucei recq2-/- mutants and consistent with MMS sensitivity in S. cerevisiae 
mus81Δ cells (Blanco et al., 2010; Interthal & Heyer, 2000).  In contrast with T. 
brucei recq2-/- mutants, and to S. pombe and S. cerevisiae mus81Δ mutants 
(Boddy et al., 2000; Doe et al., 2002; Doe & Whitby, 2004), T. brucei mus81-/- 
cells display at most a minor sensitivity to HU.  However, MUS81 has been shown 
to not be vital for the viability of S. pombe mus81Δ cells under acute (as 
opposed to chronic) HU treatment (Kai et al., 2005) and human mus81-/- cells 
are not hypersensitive to HU (Nomura et al., 2007).  The HU sensitivity of mus81 
mutant cells may therefore differ by species and by treatment duration, 
complicating comparison of TbMUS81 with eukaryotic homologues.  It would 
however, be interesting to investigate whether replication fork recovery is 
impaired in T. brucei mus81-/- cells, as Mus81 is required for recovery from 
replication fork collapse in S. cerevisiae (which HU-induced dNTP depletion can 
cause, Petermann et al. (2010)). 
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In addition to a substantial increase in phleomycin sensitivity in mus81-/- cells, 
endogenously tagged MUS81 12myc was observed to localise as discrete nuclear 
foci following phleomycin treatment (see Section 3.9.2), which induces primarily 
DSBs (Groth et al., 2010; Reiter et al., 1972).  These foci are reminiscent of 
RAD51 DNA repair foci observed in T. brucei RAD51 (Dobson et al., 2011; Hartley 
& McCulloch, 2008; Proudfoot & McCulloch, 2005; Trenaman et al., 2013), 
suggesting that TbMUS81 is recruited to sites of phleomycin-induced DNA 
damage.  However, the extent of overlap with RAD51 foci was not as striking as 
that seen for TbRECQ2, for reasons that remain unclear.  Nonetheless, together 
with increased sensitivity in mus81-/- mutants to phleomycin and MMS, these 
data suggest that TbMUS81 may be recruited to DSBs and play a role in their 
repair.  Further evidence for a role of TbMUS81 in the repair of DSBs comes from 
the analysis of cell survival following induced DSBs, using the I-SceI system (see 
Sections 4.4.2 & 4.5.2).  mus81-/- cells are deficient in DSB repair for DSBs 
induced at a chromosome-internal location (HR1 cells) and DSBs induced 
adjacent to the 70 bp repeats of the active VSG BES. 
In other eukaryotes, some aspects of MUS81 function and MUS81 substrates are 
unclear or debated, making comparison with the data on TbMUS81 challenging.  
MUS81 resolves recombination intermediates arising during replication, 
replication fork restart and meiosis (Boddy et al., 2001; Hanada et al., 2007; 
Interthal & Heyer, 2000; Kikuchi et al., 2013; Pepe & West, 2014a), acting on 3’ 
flaps, replication structures and possibly intact HJs (Gaillard et al., 2003; 
Hollingsworth & Brill, 2004).  Failure to repair these endogenously generated 
recombination intermediates in mus81-/- mutants could lead to the growth 
defect observed, and to sensitivity to DNA damaging agents, which lead to an 
increase in the structures on which TbMUS81 acts.  However, further study is 
required to investigate on which structures TbMUS81 acts.  Examination of the 
repair products following DSB induction in TbMUS81 mutant HR1 and HRES cells 
would be informative in understanding the function of TbMUS81 in resolving 
recombination intermediates in T. brucei. 
The VSG switching rate and profile of mus81 mutants will be a valuable next 
experiment to perform.  As MUS81 is involved in recovery following replication 
fork collapse in S. pombe (Kai et al., 2005), and given the hypothesised role of 
replication stalling in the active VSG BES as the initiator of VSG switching, 
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TbMUS81 may be a key initiator factor, unlike TbRECQ2.  As discussed above, 
MUS81 is also involved in resolving recombination intermediates and therefore 
mus81-/- mutants might also be expected to display an altered switching profile 
as a result of changes in how intermediates are resolved in the absence of 
MUS81. 
6.3.1 Summary 
The data presented in this thesis suggest that TbMUS81 is involved in the repair 
of damage induced by phleomycin, MMS and to some extent HU, agents with a 
wide variety of effects, including replication stalling and DSBs.  Further analysis 
showed TbMUS81 to be important for the repair of DSBs.  Review of the 
literature of MUS81 function in other eukaryotes suggests that TbMUS81 may be 
acting on recombination intermediates arising from the repair of DNA damage.  
However, further experiments that examine how DNA lesions and are repaired in 
T. brucei mus81-/- mutants and whether TbMUS81 is important in replication fork 
recovery would be informative in understanding how TbMUS81 functions. 
6.4 TbPIF6 is an enigmatic DNA repair factor 
Of the four factors examined in this thesis, TbPIF6 is the most challenging to 
understand.  Unlike recq2-/- and mus81-/- mutants, and cells following TbRECQ1 
RNAi knockdown, pif6-/- mutants do not display an in vitro growth defect (see 
Section 3.4.1).  Also contrasting with recq2-/- and mus81-/- cells, which show 
increased sensitivity to MMS, pif6+/- and pif6-/- mutants display an increase in 
MMS resistance (Section 3.4.3).  This increase in MMS resistance in pif6 mutants 
does not appear to have been described in any other Pif1 helicase mutant 
described to date.  In fact, other Pif1 helicase mutants, such as in S. cerevisiae, 
are more sensitive to MMS than wild type (Budd et al., 2006), suggesting TbPif6 
may be unusual in this respect.  In contrast, pif6+/- and pif6-/- cell 
hypersensitivity to HU (Section 3.4.3) is more typical of the phenotype of other 
Pif1 helicase mutants, such as S. pombe Pfh1p mutants (Pinter et al., 2008).  It 
is unusual that the pif6+/- and pif6-/- cells displayed similar phenotypes, as this 
suggests that loss of a single allele is a significant as loss of both alleles, a 
genetic outcome that has not been observable for other genes in T. brucei (no 
examples were found when conducting a literature search).  What this might 
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mean in terms of the role or abundance of TbPIF6 remains unclear.  
TbPIF6 12myc was observed to localise to the nucleus, with an increase in 
fluorescence intensity following phleomycin damage, consistent with a nuclear 
repair function.  However, it did not form subnuclear foci reminiscent of DNA 
repair factors such as RAD51, or TbRECQ2 (described above) (see Section 3.9.3).  
Again then, in what way TbPIF6 contributes to maintenance of the T. brucei 
genome is elusive. 
The response to induced DSBs in pif6 mutants, analysed using the I-SceI system, 
produced a challenging set of data to interpret, primarily due to inconsistent 
results upon repetition.  Inconsistent results could be due to problems with 
instability of the I-SceI cell lines, which requires further investigation.  However, 
based upon the initial experiments, which were judged to be more robust, pif6 
mutants are more resistant to DSBs induced adjacent to the 70 bp repeats of the 
active VSG BES (HRES cells; see Section 4.5.3), which was associated with 
unexpected retention of VSG221.  In contrast, pif6 mutant were more sensitive 
to DSBs induced at a chromosomal internal location (HR1 cells; see Section 
4.4.3), suggesting that TbPIF6 may function differently depending on the 
genomic environment.  Taking subsequent experiments into consideration, 
however, would suggest that pif6 mutants have at least equivalent survival to 
wild type when DSBs are induced in the active VSG BES.  At the very least then, 
pif6-/- mutants are not more sensitive to DSBs than wild type cells.  DAPI analysis 
of HRES cells suggested that γH2A expression, an early marker of DNA damage, 
dissipates more rapidly following DSB induction in HRES pif6-/- cells compared to 
HRES wild type cells (see Section 4.6.3).  This could be due to more rapid repair 
of the DSB or, alternatively, that the cells ignore the damage and prematurely 
re-enter the cell cycle.  Ligation mediated PCR and DNA sequencing could be 
used to assess whether (and how) the DSB is repaired in HRES pif6-/- cells.  No 
such rapid decrease in γH2A compared to wild type was observed in HR1 pif6-/- 
cells, again suggesting differences in TbPIF6 function in different genomic 
environments. 
Differences for TbPIF6 DSB repair function at the telomere (HRES) and internal 
to the chromosome (HR1) could be accounted for if TbPIF6 suppresses telomere 
addition, similar to activities described for S. cerevisiae PIF1.  S. cerevisiae 
pif1Δ mutants have lengthened telomeres and DSBs are repaired by telomere 
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addition (Li et al., 2014; Makovets & Blackburn, 2009; Schulz & Zakian, 1994).  
Telomere addition to repair DSBs in HRES cells would be advantageous due to 
the small amount of sequence lost, but deleterious in HR1 cells due to the large 
portion of the chromosome that would be lost.  Examining the telomere length 
of pif6 mutants and investigating whether DSBs are repaired by telomeric 
addition would determine whether or not TbPIF6 shares this function in S. 
cerevisiae PIF1. 
Analysis of the VSG switching phenotype of pif6 mutants produced an unclear set 
of data to interpret (see Section 4.7.4.2).  The calculated VSG switching rate of    
pif6-/- cells was higher than that of wild type and pif6+/- cells, though it is 
possible that this was due to a high frequency (50%) of TK mutants in surviving 
pif6-/- clones analysed.  The switching profile of wild type cells in this 
experiment was also unusual compared to results obtained in the RECQ2 VSG 
switching experiments.  These aspects of the data made it difficult to analyse of 
the VSG switching rates and profiles of Tbpif6 mutants.  Further work is 
therefore necessary to try to understand the role of TbPIF6 in VSG switching.  To 
attempt to test for the elevated rate of TK mutants, , further TbPIF6 VSG 
switching assays should enrich for non-VSG221 expressers following the 48 hour 
switching period.  This could be achieved using a technique such as magnetic 
activated cell sorting (MACS) utilising an anti-VSG221 antisera, which has been 
successfully used elsewhere (Boothroyd et al., 2009; Kim & Cross, 2010; Kim & 
Cross, 2011), or testing for switching rates in immunised mice.  Alternatively, 
sequencing could be sued to ask if the ‘switchers’ really are TK mutants, since it 
remains possible that the elevated rate of ‘switching’ merely reflects altered 
repair dynamics in PIF6 mutants that affect the HYG-TK cassette but do not 
elicit a change in expressed VSG. 
6.4.1 Summary 
Interpreting the data on the function of TbPIF6 presented in this thesis is 
challenging.  It is clear that TbPIF6 provides a nuclear DNA repair function and 
that this function is quite different from that of TbMUS81 and TbRECQ2.  TbPIF6 
appears to be involved in the response to HU treatment, but knockout of TbPIF6 
improves survival following MMS treatment and genomic context may be 
important in the role of TbPIF6 in DSB repair.  Whether TbPIF6 plays a role in 
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VSG switching was unclear, complicated by a high frequency of unswitched cells.  
Establishing the DSB survival phenotype of Tbpif6 mutants using several robust 
experiments would lead to a better understanding of TbPIF6 DSB repair, while 
further VSG switching experiments that attempt to remove unswitched cells 
from analysis would help determine whether TbPIF6 has a role in VSG switching. 
6.5 TbRECQ1 is an essential RecQ helicase in blood 
stream form cells, with a possible nuclear function 
Analysis of TbRECQ1 suggests that it is an essential gene in BSF T. brucei.  
Multiple attempts to generate recq1-/- mutants (see Section 5.3.1) were 
unsuccessful after multiple attempts and the analysis of a RECQ1 RNAi cell line 
showed an arrest in growth at 48 hours post RNAi induction (see Section 5.4.1).  
TbRECQ1 RNAi knockdown was shown to be strong, as measured by decrease in 
TbRECQ1 12myc by western blot (Section 5.4.5).  An essential role for TbRECQ1 
is unusual among RecQ-like helicases.  Most multicellular eukaryotes contain 
multiple helicases and the loss of one can usually be compensated for by another 
RecQ helicase (Chakraverty & Hickson, 1999; Cobb & Bjergbaek, 2006; Hickson, 
2003), though RECQL4 is essential in chicken DT40 cells (Abe et al., 2011). 
A possible nuclear role for TbRECQ1 was suggested by analysis of cells following 
TbRECQ1 RNAi induction by DAPI staining for cell cycle analysis, and 
immunolocalisation (see Sections 5.4.2 & 5.4.4) for investigation of levels of the 
DNA damage marker γH2A.  These analyses revealed an increase in the 1N2K cell 
population at 24 hours post RNAi induction, the appearance of 1N >2K cells at 48 
hours, followed by the generation of zoid cells.  TbRECQ1 RNAi induction 
resulted in a five-fold increase in γH2A intensity, indicating higher levels of DNA 
damage following TbRECQ1 knockdown.  TbRECQ1 may therefore play a role in 
nuclear DNA replication, indicated by the accumulation of 1N2K cells followed 
by cells that have not completed nuclear DNA replication (1N >2K and zoid 
cells).  Defects in nuclear replication, such as stalled replication forks, single 
strand breaks (SSBs) and DSBs may result in the formation of γH2A, signaling DNA 
damage.  Unfortunately, it was not possible to visualise TbRECQ1 12myc 
localisation in order to test whether RECQ1 is present in the nucleus (see Section 
5.5.4).  It is also possible that TbRECQ1 is not involved in nuclear DNA 
replication and that there is a different cause for the increase in γH2A 
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expression following TbRECQ1 RNAi knockdown.  Analysis of the growth of cells 
following TbRECQ1 RNAi knockdown in the presence of MMS, revealed no 
detectable phenotype, suggesting that TbRECQ1 does not play a role in the 
response to MMS-induced DNA damage.  A role in the response to other DNA 
damaging agents cannot be ruled out however. 
The essentiality and nuclear defect of TbRECQ1 is reminiscent of several other 
T. brucei DNA repair factors that are essential but not core to replication.  
PrimPol (primase-polymerase) is a human protein with both primase, to 
synthesise RNA primers to prime DNA synthesis, and DNA polymerase activities 
and acts in translesion DNA synthesis (García-Gómez et al., 2013).  Translesion 
DNA synthesis permits replication through replication fork-blocking DNA lesions.  
T. brucei encodes two PrimPol-like (PPL) proteins, PPL1 and PPL2, of which PPL2 
is essential in BSF T. brucei (Rudd et al., 2013).  RNAi knockdown of PPL2 results 
in G2 cell cycle arrest following DNA synthesis, accumulation of γH2A and Rad51 
foci (Rudd et al., 2013).  From these data, Rudd et al. (2013) concluded that 
PPL2 has an essential role in the post-replication tolerance of endogenous DNA 
damage.  Thus, PPL2 while being an essential factor involved in DNA repair, is 
not a core replication protein.  Similarly, the T. brucei nucleotide excision 
repair (NER) genes XPC (xeroderma pigmentosum group C) and DDB (DNA-damage 
binding) are essential by RNAi knockdown, but are not core replication proteins 
(Machado et al., 2014).  These examples illustrate that it is possible that 
TbRECQ1 could act in a replication-related but unknown genome maintenance 
function. 
Several lines of investigation suggest that TbRECQ1 could play a kinetplastid-
specific role.  Firstly, primary amino acid sequence analysis (see Section 5.2) 
showed that T. brucei, L. major and T. cruzi each contain two predicted RecQ-
like helicases, whereas most unicellular eukaryotes posses a single RecQ-like 
helicase.  In these organisms, one RecQ-like helicase (including TbRECQ2) 
clusters with eukaryotic BLM/SGS1 orthologues and the other groups more 
distantly, with TbRECQ1.  Primary amino acid sequence analysis also showed 
that TbRECQ1 appears to be substantially diverged from other eukaryotic RecQ 
helicases, and more so than TbRECQ2, possessing fewer of the domains typically 
found in RecQ-like helicases.  Whether TbRECQ1 carries out an essential function 
specific to kinetoplastids requires further study however.  Important to this is 
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that the RecQ-like helicases predicted in other kinetoplastids have not been 
studied.  Establishing whether the phenotype of the TbRECQ1 homologues in 
other kinetoplastids are similar to that in T. brucei would be useful in 
determining whether TbRECQ1 carries out a kinetoplastid-specific function. 
Though the data presented in this thesis suggest an essential nuclear role for 
TbRECQ1, possibly in DNA replication, further work is required to establish the 
role of TbRECQ1 in T. brucei.  To draw a more detailed picture of the cell cycle 
profile of TbRECQ1 RNAi induced cells, FACS analysis could be used and 
measurement of the incorporation of a thymidine analogue (e.g. BrdU or EdU) 
could be measured by immunofluorescence to determine whether cells continue 
to replicate their nuclear DNA following TbRECQ1 RNAi induction.  Use of 
another epitope tag to immunolocalise TbRECQ1, such as HA, may be more 
successful than the 12myc tag used in Chapter 5 (see Section 5.5.4) and 
localisation of TbRECQ1 to the nucleus and testing whether localisation changes 
in response to replication stalling (e.g. by HU treatment) or by cell cycle stage 
would be informative in establishing a nuclear replication role for TbRECQ1. 
One of the aims at the outset of this thesis was to investigate whether the four 
factors examined play a role in VSG switching.  This was not examined for 
TbRECQ1, but if TbRECQ1 is involved in replication it does not preclude its 
involvement in VSG switching.  RNAi knockdown of the replication factor 
ORC1/CDC6 in BSF T. brucei results in an increase in the VSG switching rate and 
de-repression of VSGs in inactive VSG BESs, due to VSG BES instability 
(Benmerzouga et al., 2013).  Another possible mechanism by which a TbRECQ1 
could contribute to VSG switching, through a replicative function, is via 
replication stalling.  Replication stalling within the active VSG BES has been 
hypothesised as the cause of breaks found in the active VSG BES that are thought 
to initiate VSG switching (Kim & Cross, 2010; Kim & Cross, 2011).  Therefore, if 
TbRECQ1 RNAi knockdown were to cause increased replication stalling, this 
might affect the VSG switching rate.  However, no direct evidence exists for 
replication stalling in the active VSG BES and as discussed above, more work is 
needed to understand what, if any, role TbRECQ1 plays in DNA replication. 
It is also possible that TbRECQ1 may not play a role in replication and that 
increased γH2A expression observed following TbRECQ1 RNAi is not related to a 
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replication defect.  RecQ helicases perform a range of functions in the genome 
in addition to replication, including recombination, transcription and DNA repair.  
Growth curve analysis of MMS-treated TbRECQ1 RNAi induced cells did not result 
in a detectable phenotype but this does not exclude the possibility that cells 
may be sensitive to other forms of DNA damage following TbRECQ1 RNAi 
knockdown.  Some DNA repair proteins are recruited to sites of DNA damage.  As 
such, successful localisation of TbRECQ1 would be advantageous in this respect, 
as it would allow the investigation of whether it too is recruited to sites of DNA 
damage induced by various agents such as MMS and phleomycin. 
6.5.1 Summary 
The data presented here on the function of TbRECQ1 show a diverged RecQ-like 
helicase, unusual due to its apparent essentiality in an organism with more than 
one RecQ helicase and with an interesting nuclear phenotype.  More work is 
required to dissect its role in T. brucei: as a first step, the hypothesis that it is 
involved in nuclear DNA replication can be tested by measuring replication in 
using thymidine analogue incorporation and more detailed analysis of the cell 
cycle stage distribution of TbRECQ1 RNAi induced cells. 
6.6 Conclusion 
This work has explored the functions in DNA repair of four previously 
uncharacterised proteins in bloodstream form T. brucei.  Three of these, 
TbRECQ2, TbMUS81 and TbPIF6 are DNA repair factor whereas the fourth, 
TbRECQ1, is essential appears to be involved in nuclear DNA replication.  Though 
all involved in DNA repair, probing of their functions using a range of DNA 
damaging agents and induced DSBs reveal that TbRECQ2, TbMUS81 and TbPIF6 all 
play different roles; while Tbrecq2 and Tbmus81 mutants are sensitive to several 
DNA damaging agents including MMS and are sensitive to induced DSBs, Tbpif6 
mutants are resistant to MMS-induced DNA damage and display no increased 
sensitivity to DSB repair.  It was also found that TbRECQ2 plays a role in VSG 
switching, suppressing VSG switching events in the active VSG BES, a finding that 
cannot easily be reconciled with the hypothesis that DSBs in the active VSG BES 
initiate VSG switching.  Further studies to investigate the role in DSB repair and 
VSG switching of TbRECQ2, and utilising the cell lines developed in the course of 
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this work to investigate VSG switching in Tbmus81 mutants, would be valuable in 
furthering our understanding of this process.  TbPIF6 provides an intriguing 
avenue for further study, as an MMS-resistant phenotype has not been observed 
previously in PIF1-like helicase mutant.  Unfortunately, experiments here were 
unable to determine whether TbPIF6 plays a role in VSG switching but 
refinements to experiment as discussed above would be expected to yield 
improved results on this.  As demonstrated by data presented here for the role 
of TbRECQ2 in DNA repair and VSG switching, the investigation of VSG switching 
by recombination in T. brucei would benefit from both examining DSB repair in 
the active VSG BES in addition to a non-directed approach, in order to continue 
to assess the hypothesis that DNA breaks in the active VSG BES initiate the 
process. 
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7 Appendices 
7.1 Oligonucleotide sequences 
 
Table 7-1 List of oligonucleotides used in this thesis 
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Table 7-1 continued 
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7.2 Protein accession numbers 
 
Table 7-2 Accession numbers for sequences used in sequence analysis 
Appendices  309 
 
Table 7-2 continued 
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Table 7-2 continued 
 
7.3 Individual pif6 mutant MMS clonal survival assays 
The three individual pif6 mutant clonal survival assays following MMS damage, 
used to calculate the mean relative survival of pif6 mutants shown in Figure 3-17 
(Section 3.4.3.2), are shown in Figure 7-1.  Also shown is an additional assay 
(Fig. 7-1(graph 4)) where pif6-/- survival was substantially lower than initial 
assays.  This experiment was not included in data shown in Figure 3-7 as it was 
discounted as an anomaly due to the dissimilar phenotype of pif6+/- and pif6-/- 
mutants.  pif6+/- and pif6-/- exhibited similar phenotypes in all previous MMS 
assays conducted.  As described in Section 3.4.3.2, pif6 mutant survival 
following MMS treatment appeared to decrease in experiments conducted after 
cells had been in culture for a longer period of time. 
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Figure 7-1 Individual pif6 mutant MMS clonal survival assays 
Individual assays of wild type cells and pif6 mutant survival following MMS damage are 
shown in chronological order (i.e. 1, first assay; 4, final assay).  Assays 1-3 were used to 
calculate the mean relative survival of wild type and pif6 mutants shown in Figure 3-17 
(Section 3.4.3.2). 
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7.4 HRES recq2 I-SceI assay PCRs 
The results of the diagnostic PCRs to test for PIF6 (as a positive control), VSG221 
and ESAG1 in survivors from the first RECQ2 HRES I-SceI assay (Section 4.5.1) are 
shown in Figure 7-2. 
A summary of the analysis of survivors from the first RECQ2 HRES I-SceI survival 
assay is shown in Figure 7-2.  Clones determined to not be induced, due to 
puromycin resistance and presence of both VSG221 and ESAG1.  Several clones 
were possibly uninduced, due to puromycin resistance.  Both clones classed as 
‘uninduced’ and ‘possibly uninduced’ were excluded from calculation of the 
percentage of cells that retained VSG221 and ESAG1 (see Figure 4-12). 
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Figure 7-2 Diagnostic PCRs from first RECQ2 HRES I-SceI assay 
Genomic DNA was extracted from HRES wild type and HRES recq2+/- and HRES recq2-/- 
surviving clones from the first RECQ2 HRES I-SceI assay (Section 4.5.1).  The presence of 
genomic DNA was tested using PCR amplification of a region of PIF6 using primers using 
primers #81 & #82 (245 bp product).  Presence of VSG221 was tested by PCR amplification 
using primers #90 and #91 (955 bp product) and presence of ESAG1 was tested by PCR 
amplification using primers #92 and #93 (328 bp product).  Distilled water (-) was used as a 
negative control.  WT, wild type (positive control).  –T, survivors from non-tetracycline (I-
SceI non-induced) condition; +T, survivors from with tetracycline (I-SceI induced) condition.  
Numbers indicate clone numbers.  Gaps indicate that lanes have been aligned in this figure 
after excision from multiple gels/membranes or from disparate parts of the same 
gel/membrane.  Sizes shown (ladder, bp). 
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Figure 7-2 continued 
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Table 7-3 Summary of analysis of first RECQ2 HRES I-SceI assay 
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Summary of survivors from first RECQ2 HRES I-SceI assay (see Section 4.5 and Figure 7-2).  
Puromycin resistance was determined by testing growth in 1 µg.mL-1 puromycin (PUR).  
Details of PCR analyses can be found in Figure 7-2 and Section 4.5.1.  Grey shaded clones 
were not included in calculation of VSG221 and ESAG1 frequency (Fig. 4-12) due to: *, clone 
not induced; §, clone likely not induced; #, no PCR data.  Yellow, positive result; blue, 
negative result.  Blue hatching, clones tested by PCR but no amplifiable genomic DNA 
(gDNA) recovered. 
 
Table 7-3 continued 
 
7.5 HRES mus81 I-SceI assay PCRs 
The results of the diagnostic PCRs to test for RECQ2 (as a positive control), 
VSG221 and ESAG1 in survivors from the MUS81 HRES I-SceI assay discussed in 
Section 4.5.2 are shown in Figure 7-3.  Several clones determined to not be 
induced, due to puromycin resistance and presence of both VSG221 and ESAG1, 
are marked in Figure 7-3.  For several clones, genomic DNA was not recovered or 
cells not recovered for puromycin sensitivity – marked in Table 7-4.  Clones 
classed as uninduced, or for which there was missing data were excluded from 
calculation of the percentage of cells that retained VSG221 and ESAG1 (see 
Figure 4-14). 
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Figure 7-3 Diagnostic PCRs of survivors from MUS81 HRES I-SceI assay 
Genomic DNA was extracted from HRES wild type and HRES mus81+/- and HRES mus81-/- 
surviving clones from the MUS81 HRES I-SceI assay detailed in Section 4.5.2.  The presence 
of genomic DNA was tested using PCR amplification of a region of RECQ2 using primers 
using primers #77 & #78 (232 bp product).  Presence of VSG221 was tested by PCR 
amplification using primers #90 and #91 (955 bp product) and presence of ESAG1 was 
tested by PCR amplification using primers #92 and #93 (328 bp product).  Distilled water (-) 
was used as a negative control.  WT, wild type (positive control).  –T, survivors from non-
tetracycline (I-SceI non-induced) condition; +T, survivors from with tetracycline (I-SceI 
induced) condition.  Numbers indicate clone numbers.  Gaps indicate that lanes have been 
aligned in this figure after excision from multiple gels/membranes or from disparate parts of 
the same gel/membrane.  Sizes shown, (ladder, bp). 
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Table 7-4 Summary of analysis of first MUS81 HRES I-SceI assay 
Summary of survivors from MUS81 HRES I-SceI assay (see Section 4.5.2 and Figure 7-3).  
Puromycin resistance was determined by testing growth in 1 µg.mL-1 puromycin (PUR).  
Details of PCR analyses can be found in Figure 7-3 and Section 4.5.  Grey shaded clones 
were not included in calculation of VSG221 and ESAG1 frequency (Fig. 4-15c) due to: *, 
clone not induced; #, no PCR data.  Yellow, positive result; blue, negative result; blank box, 
cells not recovered for puromycin (PURO) testing; blue hatching, clones tested by PCR but 
not amplifiable genomic DNA (gDNA) recovered. 
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Table 7-4 continued 
 
7.6 HRES pif6 I-SceI assay PCR 
The results of the diagnostic PCRs to test for RECQ2 (as a positive control), 
VSG221 and ESAG1, in survivors from the MUS81 HRES I-SceI assay discussed in 
Section 4.5.3 are shown in Figure 7-4.  Clones determined to not be induced, 
due to puromycin resistance and presence of both VSG221 and ESAG1, are 
marked in Figure 7-4.  For several clones, genomic DNA was not recovered or 
cells were not recovered for puromycin sensitivity testing – marked in Table 7-5.  
Clones classed as uninduced, or for which there was missing data (marked in 
Table 7-5) were excluded from calculation of the percentage of cells that 
retained VSG221 and ESAG1 (see Figure 4-15). 
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Figure 7-4 Diagnostic PCRs of survivors from first PIF6 HRES I-SceI assay 
Genomic DNA was extracted from HRES wild type and HRES pif6+/- and HRES pif6-/- 
surviving clones from the PIF6 HRES I-SceI assay detailed in Section 4.5.3.  The presence of 
genomic DNA was tested using PCR amplification of a region of RECQ2 using primers using 
primers #77 & #78 (232 bp product).  Presence of VSG221 was tested by PCR amplification 
using primers #90 and #91 (955 bp product) and presence of ESAG1 was tested by PCR 
amplification using primers #92 and #93 (328 bp product).  Distilled water (-) was used as a 
negative control.  WT, wild type (positive control).  –T, survivors from non-tetracycline (I-
SceI non-induced) condition; +T, survivors from with tetracycline (I-SceI induced) condition.  
Numbers indicate clone numbers.  Gaps indicate that lanes have been aligned in this figure 
after excision from multiple gels/membranes or from disparate parts of the same 
gel/membrane.  Sizes shown, (ladder, bp). 
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Figure 7-4 continued 
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Figure 7-4 continued 
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Table 7-5 Summary of analysis of survivors from first PIF6 HRES I-SceI assay 
Summary of survivors from MUS81 HRES I-SceI assay (see Section 4.5.3 and Figure 7-4).  
Puromycin resistance was determined by testing growth in 1 µg.mL-1 puromycin (PUR).  
Details of PCR analyses can be found in Figure 7-3 and Section 4.5.  Grey shaded clones 
were not included in calculation of VSG221 and ESAG1 frequency (Fig. 4-16C) due to *, 
clone not induced; #, no PCR data.  Yellow, positive result; blue, negative result; blank box, 
cells not recovered for puromycin (PURO) testing; blue hatching, clones tested by PCR but 
not amplifiable genomic DNA (gDNA) recovered; pink hatching, genomic DNA not obtained. 
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Table 7-5 continued 
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Table 7-5 continued 
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Table 7-5 continued 
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Table 7-5 continued 
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